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The tetrahydroisoquinoline (THIQ) core structure is explored as a steroidomimetic 
nucleus with attractive pharmaceutical properties. A  library was synthesised employing 
Pomeranz-Fritsch, Pictet-Spengler, Bischler-Napieralski strategies yielding 77 final 
targets, substituted at every position, for biological evaluation. Complementary 
strategies overcame synthetic difficulties, sometimes yielding two products in a single 
cyclisation. Three compounds were initially tested against a panel of 19 nuclear 
receptors (NRs) and exhibited broad substitution-dependent activity.  2-(4-
Chlorophenyl)-1-isopropyl-1,2,3,4-tetrahydroisoquinolin-6-ol fully inhibited every NR 
at 100 µM, confirming the THIQ as a lead for optimisation. Compounds were evaluated 
for cytotoxicity against 60 cell lines by the NCI (USA), exhibiting moderate to 
insignificant cytotoxicity. Three compounds showed ca. 30-90% of average growth 
inhibition and were selected for a five dose test. Off-target evaluation highlighted 
compounds with activity against glucagon-like peptide 1 secretion, calcitonin gene-
related peptide receptor antagonism and with >100% inhibition against the metabotropic 
glutamate receptor 2. Estrogen receptor-related receptor α (ERRα), a constitutively 
active orphan NR, is a hormone-dependent cancer target and diethylstilboestrol (DES), 
a known inverse agonist, possesses similarities to THIQs. THIQs tested against ERRα 
revealed no general SAR rules, but showed a lower degree of efficacy in a commercial 
TR-FRET assay, with 1-benzyl-2-(4-chlorophenyl)-4-methyl-1,2,3,4-
tetrahydroisoquinolin-6-ol showing 79% efficacy at 100 µM as an inverse agonist, 
being more active than DES (64% at 100 µM). Inhibition of steroidogenic enzymes like 
17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) is an emerging approach for the 
treatment of HDBC, compared to other current clinical strategies.  THIQs evaluated 
against 17β-HSD1 showed good activity in both whole cell and cell lysate assays, with 
the best inhibitor, 2-(4-chlorophenyl)-4-isopropyl-1,2,3,4-tetrahydroisoquinolin-6-ol, 
possessing an IC50 value of 336 nM. The value of THIQ as a drug-like steroidomimetic 
scaffold is thus established and this work reveals  straightforward strategies to optimise 
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17β-HSD1 17β-hydroxysteroid dehydrogenase type 1 
17β-HSD2 17β-hydroxysteroid dehydrogenase type 2 





AcOH Acetic acid 




bs Broad singlet (NMR spectra) 
CBZ Carboxybenzyl 
Conc. Concentrated 
CSM Charcoal stripped serum supplemented medium (biology) 
CSR Chiral Shift Reagent 
CYP Cytochrome P450 
d Doublet (NMR spectra) 
dd Double doublet (NMR spectra) 
ddd Double double doublet (NMR spectra) 
dt Double triplet (NMR spectra) 
DABAL Bis(trimethylaluminum)-1,4-diazabicyclo[2.2.2]octane adduct 











DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
E1 Estrone 
E1S Estrone sulphate 
E2 Estradiol 
E3 Estriol 
EC50 Concentration to activate 50% of the target (agonists); 




ER Estrogen receptor 
ER- Estrogen receptor negative 
ER+ Estrogen receptor positive 
ERE Estrogen response elements 
ERR Estrogen receptor-related receptor 




FRET Fluorescence Resonance Energy Transfer 
Glu Glutamate 
GST Glutathione S-transferase 
HER2 Human Epidermal Growth Factor Receptor 2 
HIF Hypoxia-Inducible factor 
His Histidine 
HPLC High Performance Liquid Chromatography 
HSQC Heteronuclear single quantum coherence spectroscopy 
Hz Hertz 
IC50 Concentration to inhibit 50% of the target activity 
i-Pr isopropyl 
J Coupling constant (NMR spectra) 
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KHMDS Potassium hexamethyldisilazane 
LBD Ligand Binding Domain 
LC-MS (HPLC-MS) High pressure liquid chromatography - Mass 
spectroscopy 
LDA Lactate dehydrogenase (enzyme) 
LDA Lithium diisoprylamine (chemical) 
Leu Leucine 
M Molar (concentration), Molecular ion (mass spectroscopy) 
m milli, multiplet (NMR spectra) 
Me Methyl 
mp Melting point 
MTS 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt 
MS 4Å molecular sieves 
NAD
+
 Nicotinamide Adenine Dinucleotide (oxidised) 
NADH Nicotinamide Adenine Dinucleotide (reduced) 
NADP
+
 Nicotinamide Adenine Dinucleotide Phosphate (oxidised) 
NADPH Nicotinamide Adenine Dinucleotide Phosphate (reduced) 
NCI National Cancer Institute of America 
NHR Nuclear Hormone Receptor 
NM Normal serum supplemented medium (biology) 
NMR Nuclear Magnetic Resonance 
NOESY Nuclear Overhauser Effect spectroscopy 
NR Nuclear Receptor 
OIDD Open Innovation Drug Discovery 
OXPHOS Oxidative phosphorylation 
PD
2 
Phenotypic Drug Discovery 
Pd/C Palladium on carbon 
PES Phenazine ethosulfate 
pet. ether Petroleum ether 40-60 °C  
PF Pomeranz-Fritsch 




ppm Parts per million 
PR Progesterone Receptor 
PS Pictet-Spengler 
PTSA para-Toluene sulphonic acid 
q Quartet (NMR spectra) 
rt Room temperature 
s Singlet (NMR spectra) 
SAR Structure activity relationship 
Ser Serine 
SERD Selective estrogen receptor down-regulator 
SERM Selective estrogen receptor modulator 
STS Steroid Sulphatase 
t Triplet (NMR spectra) 
TargetD
2 
Target Drug Discovery 
Tb Terbium 
TBAI Tetrabutylammonium iodide 
t-Bu tert-Butyl, tertiary butyl  
TCA Tricarboxylic acids 
TFA Trifluoroacetic acid 
TfOH Trifluoromethanesulphonic acid (triflic acid) 
THF Tetrahydrofuran 
THIQ 1,2,3,4-Tetrahydroisoquinoline 
TLC Thin layer chromatography 
TNBC Triple Negative Breast Cancer 
TR-FRET Time Resolved FRET 
Tyr Tyrosine 
Val Valine 
VEGF Vascular Endothelial Growth Factor 
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Around 309,500 new cases of cancer are diagnosed each year in the UK and between 
1979 and 2008 the incidence rates for cancer increased by 26%.
1
 Cancer occurs 
predominantly in older people with 75% of cases diagnosed in people aged 60 but one 
in ten of all cancer cases occur in adults aged 25-49 years. Breast cancer accounts for 
nearly half of all cancers diagnosed in the UK in women aged 29-49 years.
1
 Of the 
many types of cancer, breast, lung, colorectal and prostate are the four most commonly 
diagnosed. In addition, breast, prostate, ovarian and uterine cancers represent 32% of 





1.1. Breast cancer statistics 
Cancer incidence varies by sex and breast cancer, which is overall the most common 
in the UK with 48,034 new diagnoses in 2012, is quite rare in men for whom prostate 
cancer is the most common with 37,051 diagnoses.
1
 Between 1999-2001 and 2008-
2010, the incidence of breast cancer in women has increased by 6% but, in contrast, the 
mortality rate in the same time span has reduced by 19%.
1
 This reduction in mortality is 
connected to the increase in therapeutic options, better screening services and enhanced 
and more effective surgical techniques. Nevertheless, 12,047 deaths for breast cancer in 
only 2008 is still a frightening number.
1
 
Even though the exact cause of cancer is unknown, breast cancer is known to have 
some degree of heredity. In fact, mutation in the genes BRCA1 and BRCA2 are 
associated with a greater incidence of breast cancer. Together, BRCA1 and BRCA2 
mutations account for the 20-25% of hereditary breast cancer.
2
 These two genes are 
related to the expression of tumour suppressing proteins and therefore mutations might 




1.2. Current breast cancer treatments 
The best treatment options to undertake are decided after the status of the cancer has 
been identified (e.g. type, size, stage and grade of breast cancer) and depending on other 
2 
 




Surgery is generally the first line treatment and is often coupled with radiotherapy to 
reduce the risk of remaining tumoural tissues. After a positive screening for BRCA1 
and BRCA2, the patient might even decide to have a preventive mastectomy (breast 
removal) such has been the case for the actress Angelina Jolie. Before surgery, if the 
tumour mass is too large, chemotherapy can be used to shrink the tumour for better 
results. Chemotherapy is also used when the tumour has already metastasised (spread 
through the body) or to treat recurrent breast cancer.
4
 
After surgery, to prevent breast cancer recurrence, endocrine therapy or biological 
therapy can be used. The use of these therapies depends on the status of three receptors 
in breast cancer cells, i.e. estrogen receptor (ER), progesterone receptor (PR), and 
human epidermal growth factor receptor 2 (HER2). Breast cancer cells that do not 
express any of the three receptors are classified as triple-negative and in this case 
chemotherapy is the only treatment option in addition to surgery and radiotherapy. 
Triple-negative breast cancer (TNBC) accounts for 15-25% of all breast cancers and is 




1.3. Endocrine therapy 
The lifecycle of breast cells is normally regulated by the female sex hormones 
(estrogens) and, as might be expected, the proliferation of neoplastic cells in these 
tissues is often stimulated by these same hormones. Tumours which develop from these 
cells and whose growth is stimulated by these hormones are thus termed hormone 
dependent. To be stimulated by estrogens, cells must express functional ERs. For this 
reason, hormone dependent breast cancer is also referred to as estrogen receptor positive 
(ER+) breast cancer. Therefore, hormone independent breast cancer is often referred to 
as estrogen receptor negative (ER-). From recent studies, it seems that the transition 
from ER+ to ER- may occur as a step-wise process involving first the acquisition of 
estrogen insensitivity, even if ER expression remains, and subsequently the down-
regulation of ER expression.
6,7
 The endocrine therapy aims to disrupt the stimulation 
activity of estrogens on ER+ breast cancer by either preventing their binding to the ER 




1.3.1.  Selective Estrogen Receptor Modulators (SERMs) 
The estrogen receptor was the first target to be addressed for treatment of hormone 
dependent breast cancer. This approach relies on the inhibition of ER binding by 
estradiol (E2), thus preventing the E2 initiated signalling cascade. The first compounds 
showing tissue selective anti-estrogen effects were named selective estrogen receptor 
modulators (SERMs) and tamoxifen (Figure 1) is the most commonly used in therapy. 
There are two known isoforms of the estrogen receptor, namely ER and ER, 
which are diversely expressed in different tissues. Of the two receptors, ER has been 
reported to have greater influence on hormone dependent tumours while ER has a 
major role in controlling bone formation and calcium and phosphate homeostasis.
8
 
Unfortunately, SERMs have proved not to be pure antagonists and the agonist vs. 
antagonist activity has revealed to be tissue dependent. Due to this issue, the use of 
SERMs in therapy is associated, for instance, with an increased incidence in uterine 
cancer, a risk that is, however, usually outweighed by their positive effects. More 
recently, a new generation of compounds named Selective Estrogen Receptor Down-
regulators (SERDs) have shown reduced risks.
9
 SERDs act as potent antagonists by 
increasing ER turnover and display no agonist activity thus differing markedly from 
SERMs, which always possess a partial agonist character. Fulvestrant (Figure 1) is an 
example of a SERD but its use in therapy is limited by its costs. 
Recently, N-substituted tetrahydroisoquinolines (THIQs) have been demonstrated as 
effective ER selective or ER selective estrogen mimetics presenting a good 




Figure 1. Chemical structure of the SERM Tamoxifen and the SERD Fulvestrant. 
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1.3.2. Estrogens biosynthesis 
Every steroid hormone (glucocorticoids, mineralcorticoids, androgens and estrogens) 
is synthesised from cholesterol and each shares the same basic cyclopentaphenantrenic 
structure (three six-membered rings and one five-membered ring, respectively A, B, C 
and D) (Scheme 1). 
The conversion of dehydroepiandrosterone (DHEA) to androstenedione and the 
conversion of androstenediol to testosterone (T) are catalysed by a family of enzymes 
named 3-beta hydroxysteroid dehydrogenases (3β-HSDs) (Scheme 1). The most 
common isoform is 3β-HSD1, which catalyses the conversion of pregnenolone to 
progesterone and the conversion of 17β-hydroxypregnenolone to 17β-
hydroxyprogesterone (not shown in Scheme 1). Progesterone and 17β-
hydroxyprogesterone are the precursors of aldosterone and cortisol, respectively.
11
 
The interconversion of androgens is catalysed by another family of enzymes, namely 
17-beta hydroxysteroid dehydrogenases (17β-HSDs). 17β-HSD1 catalyses the 
conversion of DHEA to androstenediol and 17β-HSD3 catalyses the conversion of 
androstenedione to T. The conversion of T and androstenediol to their respective 
precursors is catalysed instead by the same isoform, 17β-HSD2 (Scheme 1). T can also 
be converted to the more active dihydrotestosterone (DHT) by the enzyme 5α-reductase 
(not shown in Scheme 1). 
The androgens androstenedione and T are converted by the enzyme aromatase to the 
estrogens estrone (E1) and estradiol (E2), respectively. E1 can also be converted to E2 
by 17β-HSD1 while the reverse reaction is catalysed by 17β-HSD2. In addition, E1 can 
also be converted to the inactive estrone sulphate (E1-S) and stored intracellularly. 
Moreover, in placental tissues, the E1 and E2 can be converted into the estriol (E3) 
(Scheme 1). 
Among the three estrogens (E1, E2 and E3), E2 is the most potent and binds to the 




Scheme 1. Steroidogenesis. Cholesterol is the starting point for the synthesis of glucocorticoids (red), mineral 
corticoids (yellow), androgens (blue) and estrogens (pink). 
 
1.3.3. Aromatase inhibitors 
Aromatase is one of the last enzymes involved in the synthesis of E2 (Scheme 1) and 
as such has been exploited for the treatment of hormone dependent breast cancer. 
Anastrozole (Arimidex, AstraZeneca, Figure 2) is the most common aromatase inhibitor 
used in therapy and is generally administered after an initial treatment with Tamoxifen. 
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial was a randomised 
controlled trial that studied a group of 9366 women who received breast cancer 
treatment with either Anastrozole, Tamoxifen or both for five years. The study 
continued until further five years from the end of the treatment and concluded that the 
group that received Anastrozole has significant better clinical results than the group 
6 
 
which received Tamoxifen only. The same study suggested that Anastrozole should be 
the preferred clinical approach for the treatment of post-menopausal women with 
localised ER+ breast cancer.
12
 
Another study associated Anastrozole with a 40% decrease in recurrence of cancer 
but also with an increased grade of bone frailty. The same study suggest that the 





Figure 2. Structure of Anastrozole, the aromatase inhibitor most commonly used in therapy. 
 
1.3.4. Steroid sulphatase inhibitors 
Steroid sulphatase (STS) is also another important enzyme involved in the 
biosynthesis of E2 especially in post-menopausal women. In fact, when a woman 
reaches menopause, the synthesis of estrogens in the ovaries stops and most estrogens 
are instead synthesised in peripheral tissues by the conversion of androstenedione to E1. 
E1 is then converted to E1 sulphate (E1-S) which is the main form of circulating 
estrogens. In the target tissues (e.g. ovaries), E1-S is converted back to E1 and then 
reduced to E2 by 17β-HSD1 (Scheme 1).14, 15 
Some inhibitors of STS, both steroidal (e.g. EMATE, Figure 3) and non-steroidal 
(e.g. STX64, Figure 3), are reported in the literature and inhibitors recently developed at 




Figure 3. Structure of the steroidal STS inhibitor EMATE and non-steroidal inhibitor STX64. 
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1.4. 17-Beta hydroxysteroid dehydrogenases (17β-HSDs) 
At present, fifteen types of 17β-HSDs have been reported in the literature.17-29 
17β-HSDs are responsible for the reduction or oxidation of hormones, fatty acids and 
bile acids and they all require nicotinamide adenine dinucleotide (phosphate or not, in 
its reduced or oxidised state (NAD(P)(H)), for their activity. Of the fifteen isoforms 
identified, 17β-HSD5 is the only aldo-keto reductase (AKR) while the other isoforms 
are all short-chain dehydrogenases/reductases.
30, 31
 
Even though they are named 17β-HSDs, the redox activity in position 17β is only the 
major one with most of the 17β-HSDs being capable of converting different substrates 
at different sites (e.g. position 3 on the steroid ring). In addition, most of 17β-HSDs 
have bidirectional capabilities in vitro but they appear to work unidirectionally in vivo. 
Although they have similar dimensions (250-350 amino acids) and they have highly 
conserved portions, the overall homology among the different 17β-HSDs is rather low. 
Moreover, they have been found to have different cellular localisations in the cytosol 
(17β-HSD1), microsomes (17β-HSD3), mitochondria (17β-HSD10) and peroxisomes 
(17β-HSD4) and to differ in tissue distribution.30, 31 
The two highly conserved regions are the catalytic domain which contains the 
sequence Tyr-X-X-X-Lys (where X is any amino acid) and the Rossmann fold.
32
 The 
Rossmann fold is a sequence of alternating α-helics and β-strands that constitutes the 
co-factor (NAD(P)(H)) binding domain.
32
  
Of the fifteen types, only 17β-HSD1, 17β-HSD2, 17β-HSD3 and 17β-HSD5 are 
strictly related to hormone dependent cancer. Of these, 17β-HSD1 and 17β-HSD2 are of 





17β-HSD1 is the primary enzyme that catalyses the conversion of E1 to E2 by 
reducing the carbonyl at position 17. To do so, 17β-HSD1 requires NADPH as 




The core of the structure is the seven-stranded parallel β-sheet (βA to βG), 
surrounded by six parallel α-helices (αB to αG), three on each side of the β-sheet.36 The 
steroid binding site is a hydrophobic pocket that shows a high degree of 
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complementarity with the substrate and these hydrophobic interactions are thought to 
provide a significant contribution to the thermodynamic force of binding.
36
 
The proposed mechanism involves the residues Ser142, Tyr155, Lys159 and Asn114, 
which stabilise the carbonyl of E1 through a net of hydrogen bonds and the same 
hydrogen bonds facilitate the second proton transfer from water. The hydride is instead 
transferred directly from the co-factor, which is in close proximity to the substrate. The 
pro-S hydrogen of the nicotinamide ring is transferred to the carbonyl to form the 17β-




Figure 4. Postulated catalytic mechanism for the reduction of E1 by 17β-HSD1. The substrate E1 is depicted in blue 
while the co-factor NADPH is in red.37 
The ratio between the expression of 17β-HSD1 and 17β-HSD2 has been directly 
correlated with the intracellular ratio between the concentrations of E1 and E2. This 
ratio, in addition to the ratio between the two enzymes, depends also on the 
concentration of the co-factor. It has been demonstrated in more than one cell line that 
breast cancer cells highly expressing 17β-HSD1 have an [E2]/[E1] of 9/1.38 When the 
gene expressing 17β-HSD1 is silenced or when the overexpression of 17β-HSD2 is 
induced, the ratio is reduced. A further decrease in the ratio is obtained by increasing 
NAD
+
 concentrations when 17β-HSD2 is expressed.38 In fact, 17β-HSD2 uses E2 and 
NAD
+
 as a substrate and low concentration of the co-factor inhibits the reaction (Figure 
5). In living cells, the NADH/NAD
+




Figure 5. Catalytic conversion of E1 to E2 by 17β-HSD1 and of E2 to E1 by 17β-HSD2. Though 17β-HSD1 can use 
both NADH and NADPH (with a greater affinity for NADPH), 17β-HSD2 is more NAD+ specific. 
The ratio 17β-HSD1/17β-HSD2 is increased in post-menopausal women with 
hormone dependent breast cancer.
39
 This is reflected in an increased concentration of 
E2, which stimulates cell growth via ER activation. Hence, inhibiting 17β-HSD1 would 
potentially lower the intracellular E2 concentration and consequently reduce tumour 
growth. Studies reveal that high levels of expression of 17β-HSD1 mRNA are 
associated with bad prognoses and lower survival rates.
40
 
Many examples of 17β-HSD1 inhibitors are reported in the literature, showing a 
great interest for this novel target.
41-45
 The drug candidate STX1040 (1, Figure 6) 
developed at the University of Bath has inhibited in vitro the proliferation of T-47D 





Figure 6. Structure of the steroidal inhibitor of 17β-HSD1 STX1040, developed at the University of Bath. 
 
1.5. Known inhibitors of 17β-HSD1 
The inhibitors of 17β-HSD1 are of two types: steroidal and non-steroidal. The 
steroidal inhibitors tend to have somewhat a worse drug-like profile, thus growing 
interest is cast on the development of new non-steroidal inhibitors. Even though the 
number of patents related to the inhibition of 17β-HSD1 has significantly increased in 
recent years, no inhibitor has yet reached the market to date. This highlights the 





1.5.1. Steroidal inhibitors of 17β-HSD1 
The majority of 17β-HSD1 inhibitors are based on the steroid structure. These 
compounds are based on modification of the substrate E1 or the product E2. The core 
steroidal structure can be substituted at different positions (C2, C6, C15, and C16) and 
small modifications of the core are possible. These allow the development of a structure 
activity relationship around the core structure of E1 or E2.  
 
1.5.1.1. Derivatives of E1 substituted at C2 
The works of Hillish et al.
46
 and Gege et al.
47
 describe the synthesis and evaluation 
of 2-substituted E1 derivatives. Introduction of large groups in this position leads to 
rather active compounds with IC50 values of 56 nM (2, Figure 7) and 47 nM (3, Figure 
7). This indicates that the binding pocket is large enough to accommodate such bulky 
groups. Compound 4 (Figure 7), bearing a chlorine in position 2, has an IC50 value of 
140 nM but the activity is drastically increased when a fluorine is introduce in position 
16. The stereochemistry of this group plays a pivotal role in the activity of the 
compound and while compound 5 (Figure 7) shows only marginal increase in activity, 
compound 6 (Figure 7) has an IC50 of 35 nM. Interestingly, when the same substitution 
is attempted in compound with a D ring expanded to a six-membered ring, the effect is 
reversed and derivative 8 (Figure 7) shows lower activity than 7 (Figure 7). 
 
Figure 7. Structure of some inhibitors of 17β-HSD1 based on 2-substituted E1. 
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The advantage of substitutions in position 2 is the enhanced stability. In fact, C2 is 
the prevalent position for metabolic oxidation by cytochrome P450 (CYP). Blocking the 





1.5.1.2. Derivatives of E1 and E2 substituted at C6 
A few examples of modification at C6 of the E1 structure are reported by Allan et 
al.
49
 The idea of this group was led by the observation of the presence in computational 
analysis of the residue of Ser222 in proximity with the C6 position. Thus, they expected 
substitution in this position to positively contribute to the activity of the compounds. 
Nevertheless, introduction of a ketone at C6 in compounds 9-11 (Figure 8) did not 
increase the activity compared to the non-oxo counterpart.
49
 It was concluded that, even 
though the position was tolerated, the carbonyl was not interacting with Ser222. The 





Figure 8. Structure of some 6-oxo and 6-oxime derivatives of E1 and modified E1 as 17β-HSD1 inhibitors. 
Other examples of longer chains in position 6 are reported by Poirer et al. based on 
the anti-estrogen 13 (Figure 9) which is modified at position 7. Compound 14 (Figure 9) 
was then synthesised by transposition and optimisation of the substituent from position 
7 to position 6 and showed an IC50 value of 0.17 µM (IC50 value of E1 is approximately 
300 nM).
50
 Similarly to what observed for the 16-fluoro derivatives 5-8 (Figure 7) the 
stereochemistry of the group introduced is important and compound 15 is 70 fold more 





Figure 9. Structure of some 6-substituted E2 derivatives50,51 
 
1.5.1.3.  Derivatives of E1 substituted at C15 
Examples of E1 derivatives substituted at position 15 can be found in two patents 
from Solvay Pharmaceuticals.
52, 53
 The range of chain length and type of substitutions 
suggests that groups in position 15 are well tolerated (17-24, Figure 10). Analysis of the 
crystal structure of 17β-HSD1 performed by Messinger et al. pointed out the presence 




Figure 10. Structure of some 15-substituted E1 derivatives.52, 53 
Compound 23 showed 87% inhibition at 100 nM in a recombinant 17β-HSD1 assay 
and an IC50 value of 4 nM. Compound 17, instead, proved effective at a dose of 
13 
 
5 µM/kg/day in vivo, causing a 60% reduction of tumour size in mice inoculated with 
MCF-7 breast cancer cells. 
 
1.5.1.4. Derivatives of E1 substituted at C16 
From docking studies, it has been postulated that a side chain substitution at position 
16 may possibly interact with the co-factor binding region, thereby generating dual site 
inhibitors. Poirier et al. showed that substituents at position 16 are well tolerated.
55
 The 
dual site inhibitors are very interesting because they take advantage of the interactions 
in both the E1 and NADPH binding pockets to obtain greater thermodynamic stability. 
Qui et al. were the first group to publish a hybrid dual inhibitor containing E1 and 




Figure 11. The first E2-adenosine hybrid inhibitor reported, EM-1745 (25).56  
Poirier et al. studied further modification of the linker to identify the optimal chain 
length. It was found that a spacer of 7-8 carbons (26-31, Figure 12, Table 1) between 
the ester and C16 was the optimal one giving compound 25 that has an IC50 value of 
52 nM. 
 
Figure 12. Structure of the C16 modified E2 dual site inhibitors with different linker lengths. 
14 
 
Table 1. Activity and relative substitution pattern of the C16 modified E2 dual site inhibitors measured in a 
recombinant 17β-HSD1 assay. 
Compound C16 orientation Spacer length IC50 (nM) 
26 α 10 310 
27 β 10 120 
28 β 11 1000 
25 β 8 52 
30 β 7 93 
31 β 6 430 
 
Investigations by Fournier et al.
57
 highlighted two major flaws in the use of 
compound 25 as an inhibitor. Despite its high activity in a purified 17β-HSD1 assay and 
in a cell lysate assay, the compound was inactive in a whole cell assay. It is possible that 
25 is not capable of passing through the cell membrane or that it is being metabolised 
before encountering the target.
57
 
This stability issue has challenged the synthesis of new derivatives with simplified 
structures and lead ultimately to the synthesis of STX1040 (1, Figure 6, page 9). 
STX1040 1 is the most potent inhibitor of 17β-HSD1 reported to date with the lowest 




1.5.2. Non-steroidal inhibitors of 17β-HSD1 
Of growing interest is the development of non-steroidal inhibitors of 17β-HSD1. 
These have several advantages over to the steroidal inhibitors, such as ease of synthesis, 
drug-likeness and may give easier access to selectivity and non-estrogenicity features. 
Moreover, it is difficult to introduce substituents in every position of the steroidal core. 
The selection of an opportune steroidal core structure can instead enable a more in depth 
SAR study of the binding region. 
Some basic features are retained by most of the compounds synthesised and include a 
phenol moiety and a hydrophobic scaffold that mimic the steroid core. The scaffolds 








 used biphenylketones to mimic the core features of E1, i.e. the phenol 
moiety and ketone. Compounds were easily synthesised from the respective boronic 
acid and arylbromide via Suzuki coupling. 
Compounds were assessed for their inhibitory activity against 17β-HSD1 using 
T-47D human breast cancer cells. The initial compound 32 (Table 2) showed promising 
results with 97% of inhibition at 10 µM and an IC50 value of 3.7 µM. Introduction of an 
ethyl group in the ortho position to the phenol moiety (34, 37, 42, Table 2) was 
tolerated but somewhat lower activities were registered. In addition, the ethyl group was 
also reducing the selectivity of the compounds against 17β-HSD1 as shown by the 
couple of compounds 35 and 37 (Table 2). Changing the phenol group into a methoxy 
group (33, 36, 38, 41 and 43, Table 2) or removing it (39, Table 2) led generally to 
inactive compounds. Compared to 32 (Table 2), the indanone 35 (Table 2) showed 
improved efficacy with an IC50 value of 1.7 µM whereas the compound 40 (Table 2) 
containing the tetralone ring had significantly lower activity. As a further modification, 
the same pyridyl moiety that characterises STX1040 1, was introduced (44-47, Table 2) 
but with no improvement in the activity. The position of the nitrogen in the pyridyl ring 
proved very important and, even if the 3-pyridyl derivatives 44 and 46 (Table 2) 
retained the activity of the parent compounds, the 2-pyridyl derivatives 45 and 47 
(Table 2) were completely inactive.
58
 
The preliminary data on this series of compounds is very encouraging but further 
optimisation is necessary to increase the activity of the compounds.  
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Inactive Nt Nt 
34 
 
73 51 5.4 
35 
 
81 17 1.7 
36 
 
Inactive Nt Nt 
37 
 
86 48 2.0 
38 
 
Inactive Nt Nt 
39 
 
Inactive Nt Nt 
40 
 





Inactive Nt Nt 
42 
 
51 Nt Nt 
43 
 
71 Nt 8.3 
44 
 
24 12 3.7 
45 
 
Inactive Nt Nt 
46 
 
39 Nt 4.7 
47 
 
Inactive Nt Nt 




1.5.2.2. Phenylnaphthalene and phenylquinoline derivatives 
Hartmann et al.
41, 59, 60
 reported the use of phenylnaphthalene based non-steroidal 
structures as inhibitors of 17β-HSD1. When the phenol group was in position 1 of the 
naphthalene ring (49, Table 3) the compound was moderately active with only 55% 
inhibition at 1 µM but when two hydroxyls were present in position 2 and 2' (48, Table 
3) the compound showed high percentage of inhibition. The calculated IC50 value for 
compound 48 was of 116 nM in a recombinant placental 17β-HSD1 assay. Both 
hydroxyl groups of compound 48 appeared to be very important as the removal of one 
or the other (87, 88, Table 3) lead to complete loss of activity. The introduction of 
substituents in position 1 turned out to be a more interesting approach. Aromatic rings 
separated by a spacer (55-57, Table 3) reduced the activity but a bromine (58, Table 3) 
or a phenyl ring (59, Table 3) with no linker showed good inhibition. Compounds 58 
and 59, with IC50 values of 40 nM and 20 nM, respectively, have improved activities 
compared to 48. It is not clear how the bromine in compound 58 may have such a 
positive effect, but electronic effects might be an explanation. In fact, the hydrogen 
bond from the hydroxyl in position 2 is very important and a hydrogen bond is stronger 
when the two groups involved have a similar pKa. Hence, modulation of the acidity of 
the hydroxyl group adjacent to the bromine might be a possible explanation. 
Table 3. Series of non-steroidal inhibitors of 17β-HSD1 based on the phenylnaphthalene core. 
Compound Structure 
% of inhibition 









































Ni = No inhibition; Nt = Not tested. 
It was hypothesised that the introduction of a heteroatom into the naphthalene could 
enhance activity by establishing a favourable interaction with a Tyr or a Ser residue, 
which appear to be in proximity to the C6 position of E1. To investigate this possibility, 
the quinoline derivatives 60 and 61 (Table 4) where synthesised but their activity was 
much lower than that of compound 48 (Table 3).
61
 
Table 4. Series of non-steroidal inhibitors of 17β-HSD1 based on the phenylquinoline core.61 
Compound Structure 
% of inhibition 










1.5.2.3.  Bis(hydroxyphenyl) substituted thiophenes, azoles, benzenes and 
pyridines 
Persisting in the research of new polar interactions with Tyr218 and Ser222, 
Hartmann et al. discovered a new pharmacophore for the inhibition of 17β-HSD1. This 
new scaffold was based on biphenyl substituted heterocyclic rings such as azoles, 
oxazoles , thiazoles and thiophenes.
62
 
To investigate the potential of these compounds, different substitution patterns in the 
central heterocyclic ring and on the biphenyl groups were synthesised and evaluated. 
The different heterocycles, 1,2,3-triazole, the oxazole or the isoxazole (62, 63 and 64, 
respectively, Table 5) were active with IC50 values of 0.84 µM, 1.61 µM and 0.31 µM, 
respectively. Introduction of a third substituent, such as a methyl or phenyl group (65 
and 66, respectively, Table 5), lead to complete inactivity. The thiazole and thiophene 
(67 and 68, Table 5) series proved to be more active with no significant difference in 
IC50 values, i.e. 0.05 µM and 0.069 µM, respectively. This means that the nitrogen in 
the ring is not involved in any significant polar interaction. 
Investigation of the influence of the relative position of the hydroxyl group 
demonstrated that the substitution in position 3 and 4' was the best pattern. In fact, the 
symmetric substitution in positions 3 and 3' of the two phenyl rings (70, Table 5) 
reduced the activity and substitution in positions 4 and 4' (69, Table 5) made the 
compound completely inactive. 
The introduction of a methyl in position 5 of the meta-hydroxyphenyl group (71, 
Table 5) decreased the activity but substitution in the same position with a fluorine (72, 
Table 5) led to an slight increase in activity compared to the unsubstituted compound 68 
(Table 5). 
When a small electron-withdrawing group, such as a fluorine, was introduced in 
position 3 of the para-hydroxyphenyl ring (73, Table 5), the activity was significantly 
increased. However, slightly larger groups as methyl or trifluoromethyl (74, 75, Table 
5) led only to a slight improvement compared to the parent compound 68 (Table 5). 
Instead, introduction of a larger group (76, 77, Table 5) was not very well tolerated and 
the activity of the compounds was lower than that of the parent compound 68 (Table 5). 
22 
 
Ortho- substitution was not investigated because it would disrupt the planarity of the 
molecule forcing the adjacent rings to twist. Planarity was found to be important for the 
activity of these compounds.
62
 























































Ni = No inhibition 
All of the compounds showed very low affinity for ER-α and ER-β. Inhibition of 
17β-HSD1 for compounds 73 and 74 (Table 5) was also evaluated in a whole-cell assay 
using T-47D cells. The respective IC50 values were 426 nM and 282 nM and proved that 
the two compounds were able to penetrate cells and inhibit the 17β-HSD1 dependent 
conversion of E1 to E2. Further biological studies demonstrated some inhibitory activity 
against CYP3A4 with IC50 values of 0.50 µM and 0.82 µM for 73 and 74, respectively. 
24 
 
Inhibition of CYP is usually undesired because brings cross interactions in multi-drug 




To address the metabolic problems encountered, substitution of the hydroxyl group 
with different substituents was attempted. The meta-hydroxyphenyl group was left 
unvaried and the other hydroxyl group was substituted with other hydrogen bond donor 
(e.g. NH2, SH) or lipophilic (e.g. F) groups. 
Substitution of the 4-hydroxyl group with an amine or a thiol (79 and 80, 
respectively, Table 6) led to a complete loss of activity. The activity of the compounds 
bearing a fluorine in position 4 or 3 (78 and 81, Table 6) did not differ much from the 
unsubstituted compound 84 (Table 6). Substitution in position 3 with the more polar 
sulphonamides (82 and 83, Table 6) led to a small loss of activity compared to 84. 
Nevertheless, these compounds stressed even more the importance of the two hydroxyl 
groups and all the modifications shown in Table 6 led to a substantial drop in activity. 
 
Figure 13. Structure of the compounds synthesised as modification of the hydroxyl moiety.  
Table 6. Substituents and biological activity of compounds without a 4-hydroxyl group. IC50 values were determined 
in a recombinant 17β-HSD1 assay.63 
Compound R IC50 (nM) 
78 4-F 717 
79 4-NH2 >5000 
80 4-SH >5000 
81 3-F 535 
82 3-NHSO2CH3 523 
83 Tosylamide 350 
84 H 342 
In the search for molecular diversity, a series of phenyl and pyridine derivatives was 
synthesised. These compounds were lacking a second hydroxyl group but the sulphur of 
25 
 
the thiophene ring was expected to be able to participate in the hydrogen bond in place 
of the oxygen. 
The series was generally less active than the previous one (62-77, Table 5, page 22), 
however, compounds possessed IC50 values in the nM range. Between the phenyl 
derivatives 85 and 86 (Table 7), the compound bearing an additional phenyl ring (86, 
Table 7) showed better activity with an IC50 value of 137 nM.  
 
Figure 14. Structure of the phenyl and pyridyl derivatives. 
Table 7. Substitution and biological evaluation of the series of phenyl and pyridyl derivatives.64 
Compound R X Y Z IC50 (nM) 
85 Cl C C C 560 
86 Ph C C C 137 
87 Cl N C C 139 
88 Cl C N C 850 
89 Cl C C N 238 
In the pyridyl series, instead, the position of the nitrogen was found to be important 
for the activity and when the N was far from the thiophene point of substitution (88, 
Table 7), the activity was significantly lower than in the other cases (87 and 89, Table 
7). Despite the somewhat lower activity compared to other series of compounds, the 
phenyl and pyridyl derivatives showed very low affinity for ER-α and ER-β and a good 
selectivity between 17β-HSD1 and 17β-HSD2.64 
 
1.5.2.4. Benzothienopyrimidones 
In their research for new non-steroidal therapeutics for breast cancer, Lilienkampf et 
al. screened a small commercial library of compounds. Based on molecular modelling 
experiments,
65
 compounds that met the structural hydrophobic requirement to fit in the 
26 
 
active site were selected. Compound 90 (Figure 15) was identified as a lead compound 
showing a percentage inhibition against 17β-HSD1 of 41% at 1 µM.66 
 
Figure 15. Lead compound of the benzothienopyrimidones series 
In an attempt to improve the activity of compound 90, some modifications were 
introduced at the sulphur position. Homologation of the D ring was also evaluated. 
Most of the compounds showed very good activity in both cell-free and cell based 
assay demonstrating their ability to penetrate inside the cells. Compounds substituted 
with different aliphatic chains did not show significantly different activity (91a-d, Table 
8). The carboxylic acid group was not tolerated and the activity of compounds 91e and 
91h (Table 8) was almost completely lost compared to the rest of the series. Both 
hydrophilic and lipophilic moieties were well accepted but compounds bearing a 
substituted phenyl group (91f-l, Table 8) showed a lack of selectivity between 17β-
HSD1 and 17β-HSD2, with the less selective compounds being 91j-l (Table 8).67 Even 
though by expanding the D ring (91n, Table 8) the biological activity was mostly 
retained, when the ring was reduced to a five-membered ring (91m, Table 8) the activity 
was almost lost. This indicates that the D ring is involved in some hydrophobic 




Figure 16. Structure of the series of benzothienopyrimidones and relative activities against 17β-HSD1 in both 





Table 8. Substitution pattern and biological activity of a series of benzothiopyrimidones.67 
Compound R n 
% of inhibition of 
17β-HSD1          
(cell-free assay) 
% of inhibition of 
17β-HSD1            
(cell based assay) 
0.1 µM 1 µM 0.1 µM 1 µM 
91a  3 72 95 66 100 
91b  3 73 92 74 100 
91c  3 68 93 54 100 
91d 
 
3 65 93 72 100 
91e 
 
3 0.3 3 Nt Nt 
91f 
 
3 63 85 41 99 
91g 
 
3 87 92 37 77 
91h 
 
3 4 22 Nt Nt 
91i 
 
3 89 90 25 72 
91j 
 
3 59 92 37 77 
91k 
 
3 94 97 53 84 
91l 
 
3 86 91 18 90 
91m  1 17 67 Nt Nt 
91n  4 63 75 Nt Nt 




1.5.2.5. Coumarin derivatives. 
Starčević et al. recently reported a number of inhibitors of 17β-HSD1 based on the 
coumarin structure.
68-70
 The group initially screened a series of flavonoid compounds 
and found that many showed good percentage of inhibition at 6 µM. Among the tested 
flavones compound 92 (Figure 17) showed the highest activity with more than 90% of 
inhibition at 6 µM and 41% of inhibition at 0.6 µM. 
 
Figure 17. 7,4'-Dihydroflavone 92. The best flavone inhibitor resulted from the evaluation of Starčević et al.68 
Among the simple flavones tested, 93a (Table 9) showed good inhibition even at 0.6 
µM with an IC50 value of 360 nM. When the triflate was replaced by a methoxy group 
the activity dropped drastically and compound 93b (Table 9) showed only 23% 
inhibition at 0.6 µM. Similarly, substituting the ketone (93c, Table 9) with an ester was 




Figure 18. Structure of simple coumarin derivatives as inhibitor of 17β-HSD1. 
 
 
Table 9. Substituents and biological evaluations of the coumarins 93a-c against 17β-HSD1.68 
Compound R1 R2 
% of inhibition of 17β-HSD1 










Ni = No inhibition 
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When the triflate group was replaced with a phenyl ring, the activity dropped 
significantly (94a, Table 10). The introduction of a methyl group on the phenyl ring 
(94b, Table 10) did not increase the activity. However, the introduction of a hydroxyl 
group restored the activity and compound 94c (Table 10) was even slightly more active 
than 93a (Table 9) with an IC50 value of 270 nM. In addition, similarly to the previous 
example, substitution of the ketone with an ester (94d, Table 10) was not tolerated and 




Figure 19. Series of 7-phenyl substituted coumarin as inhibitors of 17β-HSD1. 
Table 10. Substituents and biological evaluations of the 7-phenyl substituted coumarins 94a-d against 17β-HSD1.68 
Compound R1 R2 
% of inhibition of 17β-HSD1 
0.6 µM 6 µM 
94a 
 
H 57 63 
94b 
 
Me 40 72 
94c 
 
OH 76 100 
94d 
 
H Ni 7 
Ni = No inhibition 
None of the coumarin derivatives showed any inhibitory activity against 17β-HSD2 
and none of them showed affinity for either ERα or ERβ. These results were promising, 
even though further development was still necessary. 
 
1.6. Estrogen receptor-related receptor alpha 
The nuclear receptor (NR) superfamily was originally defined as a group of ligand 
activated transcription factors that had structural similarity. However, it was soon clear 
that the number of NR exceeded the number of ligands (e.g. steroid hormones, thyroid 
hormones, etc.).
71





 The first orphan NRs identified were the estrogen 
receptor-related receptors (ERRs) known also as NR3B. 
The NR3B subgroup of nuclear receptors consist of ERRα (NR3B1), ERRβ 
(NR3B2) and ERRγ (NR3B3). The NR3B members belong to the a larger class of 
nuclear receptor which include also the two estrogen receptors, ERα and ERβ.73 In 





 and also in simpler animal that lack ERs.
76
 This has led to 
the hypothesis that ERRs might be ancestral evolutionary precursors of the ERs.
76
 Of 
the three ERRs, ERRα is more abundant than ERRγ which in turn is more abundant 
than ERRβ. 
ERRα was the first to be discovered and is formed by a single peptide of 423 amino 
acids. They are composed by three main sections: the regulatory amino-terminal 
domain, the DNA binding domain (DBD) and the ligand binding domain (LBD). All the 
three ERRs show a high sequence identity with the ERs with ca. 70% homology at the 





Figure 20. Level of homology among the ERs and ERRs at the DBD (DNA binding domain) and LBD (ligand 
binding domain). 
ERRα is ubiquitously present in every tissue but its activity is tissue specific. Despite 
its main functions seems related to energy metabolism, ERRα orchestrate myriad of 




Figure 21. Principal regulatory roles played by ERRα in the different tissues of the body. 
ERRα is involved in osteoblast cell differentiation and bone homeostasis and ERRα 
deficient mice have a higher bone mass and bone density.
78-81
 Whereas in brown 
adipose tissue (BAT) ERRα stimulates the metabolism of fats, in white adipose tissue 
(WAT) it induces adipogenesis. BAT is abundant in hibernating mammals and human 
infants and its function is to produce heat. BAT produces heat through a “short-circuit” 
in oxidative phosphorylation (OXPHOS) in the inner membrane of the mitochondria. 
ERRα enhances BAT activity by inducing expression of OXPHOS related genes. In 
WAT, ERRα stimulates accumulation of fats and for this it has been proposed as a 
possible target for metabolic diseases.
82, 83
 ERRα deprived mice are generally healthy 
and show lower fat accumulation, lower body weight and leaner muscles.
84
 
ERRα helps regulating OXPHOS activity in other tissues such as heart, skeletal 
muscles and liver. ERRα is involved in the circadian adaptation of metabolism showing 
regular fluctuation of mRNA levels during the day-night cycle.
85
 
Controversially, ERRα has been demonstrated to be important in the tumour 
adaptation to hypoxic conditions.
86
 Tumour masses often grow independent of 
OXPHOS because of their high metabolic rate in association with a surrounding 
environment incapable of properly distributing oxygen. ERRα is important for the 
adaptation during the transition from normoxic to hypoxic condition and ERRα 
silencing or inhibition affects hypoxic tissues. In contrast, ERRα inhibits the 
transcription of lactate dehydrogenase A (LDA) which is an essential enzyme for 
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hypoxic metabolism. It appears that the beneficial effects of ERRα in hypoxic 
conditions are related to the increased transcription of proteins related to the 
tricarboxylic acid (TCA) cycle that take place in the mitochondria.
87
 In fact, the 
intermediates of this cycle play important roles in the catabolic activity that in tumour 
cells is enhanced in order to sustain their multiplication.
80
 In addition, ERRα 
transcription is directly increased by the hypoxia-inducible factor (HIF) and the 
association of the two elements has been proven to be a key step in phenotypic 
differentiation and hypoxic adaptation.
88
 
ERRα has also been associated with high expression of the vascular endothelial 
growth factor (VEGF) which is necessary for the angiogenesis, the formation of blood 
vessels, necessary to sustain tumour growth.
89, 90
 Probably due to the effects on VEGF 
expression, ERRα is implicated in tumour progression and also in metastasis formation. 
In fact, using a trans-well migration assay Stein et al.
91
 demonstrated how ERRα 
knockdown resulted in a 65% reduction of cell migration. 
 
1.6.1. ERRα and breast cancer 
In addition to the other physiological functions, ERRα has been linked to breast 
cancer. ERRα has been reported to have a prognostic value in cancer treatment 
outcomes and elevated ERRα expression is associated with bad prognosis, more 
malignant phenotypes and a higher risk of recurrence.
77, 83
 Some studies have also 
correlated ERRα to the expression of ErbB2 which in turn is associated to an increase 
risk of tamoxifen resistance.
92
 ERRα is capable of both inhibiting and enhancing the 
expression of ErbB2 depending on the concentration of the co-activator glucocorticoid 
receptor interacting protein 1 (GRIP1). At a high concentration of GRIP1, ERRα is 
capable of overexpressing ErbB2 even in the absence of any ligand mediated response 
by ERα.93 
Another important correlation between ERRα and breast cancer lies in the cross-talk 
between the latter and ERα. In fact, ERRα and ERα not only share a great homology at 
the LDB but also in their target genes. 
As with many NRs, ERRα requires the binding of certain co-activators and has to 
dimerise to initiate transcription. Whereas ERRα is constitutively active, ERα is able to 
initiate transcription only in response to a ligand (E2) activation. Even though the type 
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of protein expressed by both transcription factors are mostly similar, they do so 
activating their own separated genes. Deblois et al.
94
 found that only 18% of the total 
pool of genes was common to the two receptors. 
ERRα and ERα bind DNA recognising different promoters, namely estrogen 
receptor-related receptor response element (ERRE) and estrogen receptor response 
element (ERE), respectively. The common genes possess a modified promoter termed 
ERRE/ERE, in which an ERRE (underlined) merges with a classical ERE (bold) 
(TNAAGGTCANNNTGACCT). These ERRE/ERE sites can be occupied by only a 
single receptor at a time (ERRα or ERα).95 
Among ERRα target genes, there are genes taking part in the estrogen mediated 
signalling pathways. In fact, ERRα induces expression of aromatase and 




Most importantly, even if there is disagreement in the literature concerning the 
effects of ERRα inhibition in ER+ breast cancer,80, 83, 97, 98 ERRα is well accepted as a 
potential therapeutic target in breast cancer, especially ER- breast cancer.
80, 83, 85, 99, 100
 
 
1.6.2. Known inhibitors of ERRα 
The most interesting piece of literature concerning ERRα inhibitors probably comes 
from Novartis laboratories.
101
 The group published the crystal structure of the receptor 
binding a small molecule inverse agonist (96, Figure 22).  
 
Figure 22. Two compounds reported by Novartis as ERRα inhibitors. 
The crystal structure, compared to the unbound receptor (A, Figure 23), shows how a 
key interaction lies between the inhibitor and Phe328. The secondary amine place the 
compound near the residue of Glu331 in a region normally occupied by Phe328. Hence, 
the inhibitor forces the residue of Phe328 away, which in turn clashes with the Phe510. 
The displacement of Phe510 ultimately generates a distortion in the alpha helix named 
H12. The displaced H12 then occupies the co-regulator peroxisome proliferator-
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activated receptor gamma co-activator 1-alpha (PGC-1α) binding region (B, Figure 23). 
Hence, PGC-1α cannot bind anymore to ERRα.  
 
Figure 23. Crystal structure of ERRα reported from Novartis of the unbound receptor (A) in complex with PGC-1α 
and of the receptor in complex with the inhibitor (B)101. Cpd1a correspond to compound 96. The presence of the 
inhibitor displaces the alpha helix H12 which in turn occupies the co-regulator binding site. 
The EC50 values reported for the two compounds are 700 nM and 190 nM for 95 and 
96, respectively. It is rather interesting to notice the effect that the small methyl group 
have on the activity, considering that the group lies in the edge of the enzyme.
101
 
Noteworthy is also the enormous difference in the binding site of the unbound and 
bound receptor. In fact, the ligand binding domain does not naturally have enough space 
to accommodate the compound. Nevertheless, the flexibility of the chains allows the 
compound to penetrate and a new thermodynamic equilibrium is generated which leads 
to the displacement of the helix H12. 
Diethylstilbestrol (DES, 97, Figure 24) and the similar hexoestrol (98, Figure 24) and 
dienestrol (99, Figure 24) show significant activity against ERRα. DES has been 






Figure 24. Structure of the three inhibitors of ERRα: DES, hexoestrol and dienestrol. 
4-Hydroxytamoxifen (4-OHT, 100, Figure 25) is an ERRγ inverse agonist with no 
affinity for ERRα. This was found to be due to a clash with Phe328 in ERRα.103 
 
Figure 25. Structure of the ERRγ inverse agonist 4-OHT 100.  
Wang et al.
104
 demonstrated the activity against ERRα of the flavonoid kaempferol 
(101, Figure 26) with a luciferase assay. In this whole cell system, 101 had the same 
effect at 20 µM as XCT790 (103, Figure 27) at 10 µM. Kaempferol has a much stronger 
affinity for ERβ (for which is an activator) and at the concentration at which it shows 
effects against ERRα, it also activates ERα. 
 
Figure 26. Structure of the flavonoid kaempferol as a week inverse agonist of ERRα. 
In 2004, Busch et al.
105
 reported the synthesis of XCT790 (103, Figure 27) as 
optimisation of the lead compound 102 (Figure 27) identified with a high throughput 
screen (HTS). 102 (Figure 27) showed an EC50 value of 2.0 µM in a fluorescence 
polarisation assay. The ether linker and the thiadiazole moiety of compound 102 (Figure 
27) were optimised to ultimately obtain XCT790 (103, Figure 27), which showed an 




Figure 27. Structure of the potent ERRα inhibitor XCT790 and the lead compound from which it originated. 
None of the few examples of ERRα inhibitors reported in the literature has reached 
clinical trials. This leaves the field open for the development of new potent and 
selective inhibitors of ERRα for the treatment of cancer. 
 
1.7.  The importance of drug-like properties in drug discovery 
 When developing new drugs, potency is not the only feature a molecule needs to 
possess. It is too often forgotten that it does not matter how active a molecule is against 
a target if, when administered to the patient, it cannot reach the target itself. 
In 1988 an important piece of literature was published by Prentis et al.
106
 concerning 
the reasons for failure of drug development. The article revealed that ca. 39% of drugs 
were failing in development because of poor biopharmaceutical properties. In fact, 
compounds were developed only for their potency and concerns about the 
administration, distribution, metabolism, excretion and toxicity (ADMET) properties 
were left to a later stage. 
 In subsequent years, the discovery process was enhanced by including the 
physiochemical properties in the criteria for the selection of the lead compounds. As a 
result, the failure rate because of biopharmaceutical problems dropped from 39% in 
1988 to 10% in 2000.
107
 
During the optimisation period, a new concept was introduced to describe how 
probable would be the transformation of a lead compound into a marketed drug. This 
concept is drug-likeness. As a definition by Christopher A. Lipinski: “Drug-like is 
defined as those compounds that have sufficiently acceptable ADME properties and 
sufficiently acceptable toxicity properties to survive through the completion of human 
Phase I clinical trials.”108 
Rules were then introduced to define the drug-likeness compounds during their 
development. These rules are not absolute but a guide for choosing better candidates 
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and a way to keep the physicochemical parameters under control during drug 
development. Very well-known is the Lipinski “rule of five”, also referred as “Lipinski 
rules”. 
In his article, Lipinski states that “poor absorption or permeation are more likely 
when”: 
- The molecule has five or more hydrogen bond donors. 
- The molecular weight is higher than 500 Daltons. 
- The logP is higher than five 
- The molecule has more than ten hydrogen bond acceptors108 
These rules were set for the development of orally active compounds. In fact, the 
rules need to be set keeping in mind the target of the molecule. For instance, for the 
development of drugs that act on the brain, the molecules need to be lipophilic to pass 
the blood-brain barrier (BBB). Alternatively, compounds that need to be administered 
by infusion may require less strict parameters than the ones for oral administration. 
Other rules have been fixed, such as Veber rules, Ghose rules, lead-likeness, and the 
choice is at the developer discretion. 
 
1.8.  Aims of the project 
This project is focused on the development and subsequent optimisation of lead 
compounds for the treatment of breast cancer targeting the estrogen biosynthesis or the 
estrogen signalling pathways. The main targets are 17β-HSD1 and ERRα, which have 
been shown to play pivotal roles in ER+ and ER- breast cancer, respectively, as 
described in the previous sections. 
The 1,2,3,4-tetrahydroisoquinoline is chosen as the core scaffold based on its 
structural similarities to E1, E2 and DES, respectively the substrate and product of 17β-
HSD1 and a known inhibitor of ERRα (Figure 28). There are good precedents in the 
literature and from our own work to support this choice.
10, 109
 Furthermore, in addition 
to low molecular weight, good hydrophilic-lipophilic balance and other drug-like 
properties, the THIQ scaffold possesses potential for broad functionalisation, thus 




Figure 28. Rationale behind the choice of THIQ as the scaffold for development as an inhibitor of 17β-HSD1 and 
inverse agonist of ERRα. Structure of the core THIQ compared with compound 48 (Table 3, page 18), E2, DES (97, 
Figure 24, page 35) and hexoestrol (98, Figure 24, page 35) 
The chemical aspect of the project involves the planning and, when necessary, the 
development of short, robust and cost effective synthetic routes that would give access 
to the whole range of differently substituted THIQs. High yielding reactions are 
desirable but this is considered a secondary matter in order to achieve the main 
objectives. A set of substituted THIQs is to be obtained through the chosen routes using 
the Topliss
110
 approach and similar logic-driven processes. 
The synthesised compounds are to be subsequently evaluated against the two primary 
targets. In order to have a prompt access to their biological activity, an assay for the 
17β-HSD1 inhibition was to be developed carrying on previous work from our group. 
Alternatively, the compounds were going to be evaluated through a collaboration with 
the external sponsor Ipsen or other external groups. 
Development of a cellular assay is to be considered to obtain information not only 
regarding the enzyme inhibition but also the estrogenicity or anti-estrogenicity that the 
test compounds might possess. Crystallisation of a few selected compounds with the 
enzyme was also attempted in order to obtain a better insight into the binding 
conformation and possible interactions. 
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 The target compounds wereevaluated against ERRα using a commercially available 
assay. The biological data thus obtained are used to optimise the test structure of the 
compounds in an iterative process. 
In addition, general cytotoxicity was evaluated with the help of the NCI through their 
screening panel of 60 cell lines. At the same time, off-target activity against other 

















CHAPTER 2  
Results and discussion 
Chemistry 
1,2,3,4-Tetrahydroisoquinolines (THIQ) are common compounds present in a large 





norcoclaurine (105, 104 and 106, respectively, Figure 29) or the more complex pavine, 
tubocurarine and tetrandrine (107, 108 and 109, respectively, Figure 29).
113
 Due to the 
importance of THIQs in drug discovery, a wide range of synthetic methods have been 




Figure 29. Structure of some natural alkaloids that contain a THIQ moiety, namely carnegine, salsolinol, 
norcoclaurine, pavine, tubocurarine and tetrandrine. 
It was envisaged that the construction of the reduced ring offered the best approach 
to access substitutions in every position available. This could be achieved through 
already established reactions namely Pomeranz-Fritsch (PF), Pictet-Spengler (PS) and 
Bischler-Napieralski (BN) (Scheme 2). 
 
Scheme 2. Synthetic approaches considered for the synthesis of the THIQ core. 
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2.1. Pomeranz-Fritsch approach 
The Pomeranz-Fritsch approach was the first to be investigated because it was 
expected to give flexibility for the introduction of substitutions and because the reaction 
was to some extent less represented in the literature, making it more appealing for future 
patent purposes. The proposed synthesis of the THIQs was to be achieved starting from 
the appropriately substituted and commercially available benzaldehydes (116, Scheme 
3), anilines (113, Scheme 3) and dialkyl acetals (114, Scheme 3). It involved an initial 
alkylation of the starting aniline 113 with the haloacetaldehyde diethylacetal 114 to 
obtain the secondary aniline 115, which could then be reductively alkylated with a 
substituted benzaldehyde 116 to give intermediate 117. The resultant acetal 117 could 
then be cyclised to the 4-hydroxy-THIQ 118 and reduced to yield the target THIQ 119.  
 
Scheme 3. Proposed synthesis for the substituted THIQ through the PF ring closure. 
 
2.1.1. Synthesis of N-(2,2-dialkoxy)aniline 
For the aniline (113a,b, Scheme 4) alkylation many reaction conditions were 
explored. Interestingly, the alkylchloride 114a (Scheme 4) was not effective as an 
electrophile and no product was obtained under any of the conditions tested (Table 11, 
entries 1-16).  
 
Scheme 4. Aniline alkylation. Refer to Table 11 for reagents and conditions. 
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Table 11. Aniline alkylation conditionsa 






1 4-Cl Cl NaH Et2O none rt 4 0% 
2 4-Cl Cl NaH Et2O NaI reflux 2 0% 
3 4-Cl Cl K2CO3 MeCN TBAI reflux 24 0% 
4 4-Cl Cl NaH DMSO none 80 24 0% 
5
b 
4-Cl Cl none MeCN KI 150 15 min 0% 
6
b 
4-Cl Cl none MeCN KI 170 10 min 0% 
7
b 
H Cl none MeCN KI 100 10 min 0% 
8
b 
H Cl none MeCN KI
c 
100 10 min 0% 
9 H Cl NaHCO3 EtOH none reflux 72 0% 
10 H Cl NaH DMSO none rt 5 0% 
11 H Cl NaH DMSO none 80 8 0% 
12
b 
H Cl NaH DMSO none 100 15 min 0% 
13
b 
H Cl NaH DMSO none 150 15 min 0% 
14 H Cl KHMDS DMSO none rt 24 0% 
15 H Cl NaH DMF none 60 24 0% 
16 H Cl Et3N none none 60 24 0% 
17
 









H Br NaH DMF none rt 24 30% ca.
 
20 H Br K2CO3 EtOH none 80 18 75%
d 
21 H Br KOH EtOH none 80 18 50%
d 
22 H Br Et3N EtOH none 80 18 75%
d 
aReactions were conducted at 1.0 M concentration. bReactions were performed in a microwave. c6.0 eq. of KI were 
used. dYield based on NMR of crude. e5-15% of double alkylated aniline formed. fReaction was conducted at 0.1 M 
concentration. 
In contrast, the alkylbromide (114b, Scheme 4) proved to be reactive at rt and, 
indeed, double alkylation became an issue (Table 11, entries 17-18), which could be 
partly overcome by changing the procedures (e.g. the dilution), albeit at the cost of a 
reduced yield (Table 11, entry 19). Best results were obtained with the use of weaker 
bases such as K2CO3 and Et3N (Table 11, entries 20, 22).  
An alternative approach for the synthesis involving a direct reductive amination was 
evaluated (Scheme 5). The reaction parameters (e.g. solvent and reducing agent) were 
chosen upon literature examples.
120
 The reaction reached completion within 1 h at rt and 
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the amine 121 (Scheme 5) was obtained with a yield higher than 95%. An excess of 
sodium triacetoxyborohydride (NaBH(OAc)3) was necessary to drive the reaction to 
completion but the reagents were used in stoichiometric ratio and no double alkylation 
was observed. 
 
Scheme 5. 2,2-dimethoxyacetaldehyde reductive amination. Reagents and conditions: a) NaBH(OAc)3, CHCl3, rt. 
With these results in hand, the synthesis of THIQ could be accelerate by carrying out 
two sequential reductive aminations in one pot and thus moved to explore this 
possibility. 
 
2.1.2. Synthesis of N-benzyl-N-(2,2-dimethoxyethyl)anilines 
The synthesis of compounds 123a-z using two sequential reductive aminations in one 
pot is shown in Scheme 6 and the results obtained are presented in Table 12. The yields 
range from good to very good with a range of substituents on both the aromatic rings. 
Unsurprisingly, the reaction was unsuccessful when using 3-chloroaniline and 2-
chloroaniline as starting materials (products 123t and 123v, Table 12) and only the 
intermediates 122t,v (Table 12) were recovered. In these cases, the reaction stopped 
after the first alkylation. 
 
Scheme 6. Double reductive amination approach. Reagents and conditions: a) NaBH(OAc)3, CHCl3, rt. b) 2,2-










Table 12. Double reductive amination. 
Benzaldehyde R1 Aniline R2 Product 
Yields 
(%) 
116a H 113a H 123a 99 
116a H 113c 3-OMe 123b 73 
116a H 113d 3,5-(OMe)2 123c Nf
a 
116a H 113e 3,4,5-(OMe)3 123d 85 
116b 4-OMe 113a H 123e 85 
116c 3-OMe 113a H 123f 66 
116d 4-Cl 113a H 123g 89 
116e 3-Br 113a H 123h 54 
116b 4-OMe 113b 4-Cl 123i 91 
116c 3-OMe 113b 4-Cl 123j 90 
116f 2-OMe 113b 4-Cl 123k 96 
116g 4-OH 113a H 123l 90 
116g 4-OH 113c 4-Me 123m 94 
116g 4-OH 113b 4-Cl 123n 66 
116g 4-OH 113d 4-OMe 123o 90 
116g 4-OH 113e 4-OH 123p Nf
a
 
116b 4-OMe 113f 4-Me 123q 91 
116b 4-OMe 113g 4-Et 123r 86 
116b 4-OMe 113d 4-OMe 123s 97 
116b 4-OMe 113h 3-Cl 123t Nf
a
 
116b 4-OMe 113i 3-OMe 123u 89
b 
116b 4-OMe 113l 2-Cl 123v Nf
a 
116b 4-OMe 113m 2-OMe 123w 81
b 
116h 3,4-(OMe)2 113d 4-OMe 123x 91 
116i 3,4,5-(OMe)3 113d 4-OMe 123y 98 
116l H 113b 4-Cl 123z 82 
aNf = product did not form. bReaction was concentrated during the second step. 
Difficulties occurred also when 3- and 2-methoxyaniline were used (products 123u 
and 123w, Table 12) but in this case it was possible to force product formation by 
concentrating the reaction mixture under reduced pressure and increasing the reaction 
time. These behaviours could easily be explained taking into consideration the 
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electronic and steric effect of the substituents on the nucleophilicity of the nitrogen. 
Substituents ortho to the nitrogen created steric hindrance that made the nucleophilic 
attacks more difficult (entries 123v, 123w, Table 12). Additionally, the 
electron-withdrawing effect of the chlorine reduced the electron-density on the nitrogen 
consequently reducing its nucleophilicity. An opposite effect was exerted by 
electron-donating groups. The sum of these steric and electronic effects could thus 
explain the reactivity issues of compounds 123t-w (Table 12) as shown in Figure 30. 
 
Figure 30. Steric and electronic effects of the substituent on the nucleophilicity of the aniline. *Yields refer to the 
product having the respective aniline as starting material. 
The 4-hydroxyaniline gave initial solubility problems in chloroform that could be 
overcome using THF as the solvent. However, solving the solubility issue did not lead 
to the desired product 123p (Scheme 6, Table 12) and again only the intermediate 
N-benzylaniline 122p (Scheme 6, Table 12) was recovered. 
An interesting side reaction was observed when the synthesis of compound 123c 
(Scheme 6, Table 12) was attempted. In this case the desired product 123c was not 
obtained and 124 (Scheme 7) was obtained instead with a 62% yield. 
 
Scheme 7. Double reductive amination did not yield the desired product 123c (Table 12) but the C-alkylated product 
124. Reagents and conditions: a) NaBH(OAc)3, CHCl3, rt. b) 2,2-dimethoxyacetaldehyde, NaBH(OAc)3, rt. 
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It appeared that the intermediate iminium ion, in place of the expected reduction, 
underwent an intramolecular rearrangement through a Vilsmeier like mechanism to 
yield 124 (Scheme 8). The same product 124 was formed when a solution of the 
secondary aniline (122c, Scheme 8) and 2,2-dimethoxyacetaldehyde (120, Scheme 8) 
were stirred in chloroform in the absence of NaBH(OAc)3, proving that the reducing 
agent was not involved in the rearrangement. 
 
Scheme 8. Possible mechanism of the intramolecular rearrangement leading to the formation of 124. 
A kinetic 
1
H-NMR experiment was performed in an attempt to gain insight into the 
mechanism. Unfortunately, even though the starting material and the product had quite 
different NMR spectra, the reaction mixture proved too convoluted for clear 
interpretation. Some signals, not belonging to the starting material or the product, were 
visible but the identity of the intermediate could not be determined. This side reaction 
was, however, clearly faster than the reduction and this suggested that it was an 
intramolecular rearrangement process. Even when the reaction was performed with a 
deprotonated hydroxyl (a good nucleophile) near the carbon of the iminium ion 
(compound 125, Scheme 9) the alkylation occurred mainly on the aromatic ring 
(compound 127, Scheme 9) and the benzoxazine 126 (Scheme 9) was recovered only 




Scheme 9. Competition between the formation of benzoxazine 126 vs. Vilsmeier-like product 127. 
This Vilsmeier-like process intriguingly only occurred when the aniline was 
3,5-dimethoxy substituted, as none of the other anilines assayed gave this product 
(Table 12, page 45). It had to be considered, that the benzoxazine formation was a 
reversible reaction and that the stability of 126 (Scheme 9) influenced the irreversible 
formation of 127 (Scheme 9). The stability of the benzoxazine ring was then briefly 
evaluated to understand if that might have influenced the formation of compound 127 
(Scheme 9). Moreover, the benzoxazine structure was similar to THIQ giving rise to an 
interest in its potential use as alternative core structure. The benzylamine 128 (Scheme 
10) was chosen as the candidate for the synthesis of the respective benzoxazines 130a-j 
(Scheme 10). The choice of 128 was motivated by the lack of a methoxy group on the 
aniline ring, which allowed control of the reactivity towards formation of compounds 
like 124 (Scheme 6, page 44) and 127 (Scheme 9). The benzylamine 128 was duly 
subjected to reaction with a range of different aldehydes (compounds 129a-h, Figure 
31) and ketones (compounds 129i,j, Figure 31).  
 
Scheme 10. Synthesis of benzoxazines. Reactions and conditions: 129a-j (Figure 31); CHCl3, rt. 
 
Figure 31. List of substitutions of aldehydes (129a-h) and ketones (129i,j) tested for the benzoxazine ring formation. 
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Table 13. Results and conditions for the benzoxazines formationa 





K2CO3 CHCl3 Quant  11 129e MS CHCl3 0% 
2 129b K2CO3 CHCl3 0%  12 129f K2CO3 CHCl3 0% 
3 129b
 K2CO3 H2O/CHCl3 0%  13 129g K2CO3 CHCl3 0% 
4 129c K2CO3 CHCl3 50%  14 129h
b 
 CHCl3 26% 
5 129c K2CO3 H2O/CHCl3 90%  15 129h
b 
K2CO3 CHCl3 0% 
6 129d K2CO3 CHCl3 15%  16 129h
b 
MS CHCl3 11% 
7 129d MS CHCl3 30%  17 129i  CHCl3 0% 
8 129d  H2O/CHCl3 58%  18 129i K2CO3 CHCl3 0% 
9 129e K2CO3 CHCl3 0%  19 129j  CHCl3 0% 
10 129e PTSA CHCl3 0%  20 129j MS CHCl3 0% 
SM = Starting Material (referring to the compound reacted with 128); MS = 4Å molecular sieves; 
Cond. = Conditions; Quant = Quantitative; aReaction was followed by LC-MS. bCompound is commercially available 
as aqueous solution. 
It was possible to form the desired benzoxazine only with compounds 129a,c,d,h 
(Table 13) and, of these, only 129a (Table 13) led to quantitative conversions. An 
aromatic ring α to the carbonyl group had a drastic effect on reactivity and resulted in 
no product formation. It was not possible to precisely determine the contribution of the 
substituents but it appears that an inductively electron withdrawing group α to the 
carbonyl had a positive effect in formation of the benzoxazine ring. The reaction itself is 
a condensation with the elimination of a molecule of water (dehydration) and for this 
reason water itself might be expected to have a negative influence on the course of the 
reaction but this was not found to be the case. In practice, the addition of water 
delivered enhanced conversions for compounds 129c, 129d and 129h (entries 4-8 and 
14-16, Table 13). 
The stability of compound 130a (Scheme 10, page 48) was tested in neutral water, 
1N NaOH and 1N HCl. Intriguingly, the compound was revealed to be rather unstable 
and after 4 h the amount of the starting material 128 (Scheme 10, page 48) was 
respectively 77%, 87% and 100% by LC-MS. Thus, the instability of compounds 130a-j 
in aqueous media prevents their use for biological testing, which are commonly 
performed in aqueous buffers. In addition, the same instability might be the reason why 
the formation of 126 (Scheme 9, page 48) could not compete with the formation of 127 
(Scheme 9, page 48). 
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Analogues of compounds 123t and 123v (Table 12, page 45), that were not 
accessible via the double reductive amination approach, were made according to the 
synthesis initially planned (131t,v, Scheme 11) with yields of 21% and 34%, 
respectively. 
 
Scheme 11. Synthesis of the analogues of 123t and 123v, namely 131t, 131v. a) NaBH(OAc)3, CHCl3, rt; b) NaH, 
DMF, 60 °C. 
According to the planned synthesis, 1- and 3-substituted THIQ could be achieved 
starting from the opportunely substituted benzaldehyde and dimethylacetal, respectively 
(Scheme 12).  
 
Scheme 12. Proposed strategy for the synthesis of 1 and 3-substituted THIQ. 
Interestingly, when the synthesis of acetals 138i and 138s (Scheme 13) was 
attempted, the compounds could not be obtained through the standard double reductive 
amination and the synthesis was then modified accordingly (Scheme 13) similarly to 
what described for the analogues of compounds 123t and 123v (Scheme 11). 
 
Scheme 13. Synthesis of compounds 138i and 138s. a) NaBH(OAc)3, CHCl3, rt; b) NaH, THF, reflux. 
The acetal 138s (Scheme 13) was obtained with a 24% yield while compound 138i 
(Scheme 13) proved problematic to be fully purified by flash chromatography and was 
then used for the next step without being isolated. Due to the low yields and the 
somewhat difficult purification, the investigation of this pathway for the synthesis of 1-
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substituted THIQs was postponed (see chapter 2.2 for the synthesis of 1-substituted 
THIQs).  
With the same reductive amination, compounds 122n,p, 139n, and 140n (Scheme 
14) were also synthesised as open ring analogues of the parent THIQs. 
 
Scheme 14. Synthesis of compounds 122n,p, 139n, and 140n via reductive amination. a) NaBH(OAc)3, CHCl3, rt; b) 
NaBH(OAc)3, propanal, CHCl3, rt; c) NaBH(OAc)3, isobutyraldehyde, CHCl3, rt; 
In conclusion, the double reductive amination step was generally successful with 
good yields on simply substituted compounds. In addition, the reaction was performed 
at room temperature and, considering the mild nature of the reducing agent, it was not 
necessary to perform the reaction under inert atmosphere conditions. The reductive 
amination was also used to readily access the benzylanilines necessary for the synthesis 
of the acetals 131t,v and 138i,s, which were not accessible through the standard double 
reductive amination (Scheme 11 and Scheme 13). Further investigation of the formation 
of compound 124 (Scheme 8, page 47) and on the stability of the benzoxazines 130a-j 
(Scheme 10, page 48), even though interesting, would have also been time consuming 
and would have lain outside the main objectives of this project. 
 
2.1.3. The Pomeranz-Fritsch cyclisation. 
The acid catalysed ring closure reaction of a dialkyl acetal is an established reaction 
named Pomeranz-Fritsch (PF). The reaction is an intramolecular aromatic electrophilic 
substitution and is controlled by the same electronic factors that control this family of 
reactions. The presence of electron donating groups on the aromatic ring facilitates the 
reaction and they exert, to some extent, a directing effect, thus delivering a level of 
regioselectivity. The PF was firstly reported for the synthesis of isoquinoline (142, 
52 
 
Scheme 15) involving a one-pot condensation of a benzaldehyde (116a, Scheme 15) 




Scheme 15. Original Pomeranz reaction. 
Since it was originally reported in 1893 there have been only a few reports on the 
applicability of this reaction to diversely substituted systems. The PF reaction is mainly 
reported in the literature for ring closure for compounds bearing more than one 
activating group to facilitate the reaction.
117, 123-125
 However, most of the acids used 
have proved to be ineffective catalysts when the position for ring closure was not 
electronically activated. The present studies contribute in part to better understand how 
diversely substituted systems undergo PF reaction and the regioselectivity observed in 
these cases. 
In the present work and according to the results of Suzuki et al.,
126
 when a 
mesomeric electron donating group, such as a methoxy group, is present para- to the 
position for the ring closure 6 N HCl (entry 1, Table 14) is strong enough to bring the 
reaction to completion. On the contrary, when the same methoxy group was in the meta 
position the only acid that was capable of catalysing the reaction was 70% HClO4 (entry 
11, Table 14). To some extent understandable, was the effect of the latter acid on the 
more active system (entry 5, Table 14) which led to a complete degradation of the 
starting material. 
 
Scheme 16. Para-activating effect of the methoxy group. Reagents and conditions: Acid used are shown in Table 14 
and reactions are performed rt. 
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Table 14. Acids screened for the PF cyclisation with or without para-activating group. 





1 123f 6 N HCl -0.4
e
 0% Quant. 
2 123f Conc. HCl (36%) -0.4
e
  0% Quant. 
3 123f Conc. H2SO4 (97%) -2.5
e
 0% 0% 
b 
4 123f TFA  100% 0% 
5 123f Conc. HClO4 (70%) -13.0
e
 0% 0% 
b 
6 123e 6 N HCl -0.4
e




123e 6 N HCl -0.4
e
 0% 0% 
d 
8 123e Conc. HCl (36%) -0.4
e
 0% 0% 
d 
9 123e Conc. H2SO4 (97%) -2.5
e
 0% 0% 
b 
10 123e TFA  100% 0% 
11 123e Conc. HClO4 (70%) -13.0
e
 0% Quant. 
*pKa referred to the acid catalyst used in the reaction; **SM = Starting Material; aReaction was performed in a 
microwave at 100 °C for 30 min; bDegraded to unknown compound; cThe hemiacetal was formed; dThe aldehyde was 
formed; epKa measured in DCE127 
The PF reaction was unsuccessful when the cyclisation of compound 123g, bearing a 
rather electron withdrawing chlorine group, was attempted but the cyclisation of 123h, 
bearing the less deactivating bromine, proceeded smoothly towards the desired product 
(Scheme 17). 
 
Scheme 17. Electron-withdrawing effects on the PF ring closure. 
At this stage of the study, the size of the reactions was scaled up to a few grams. A 
minor product, the amount of which was negligible at smaller scales, became clearly 
identifiable and was successfully isolated. It could be expected that the regiochemistry 
of the reaction would have greatly favoured para- substitution giving the 7-substituted 
THIQs 144h and 144j (Scheme 18). Nevertheless, it was possible to isolate a significant 
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amount of the 5-substituted THIQs 145h and 145j (Scheme 18). The ratio between the 
two regioisomers was found to be constant, with a ratio of 5:1 in favour of the para- 
substituted compounds 144j and 144h (Scheme 18). 
 
Scheme 18. Ortho vs. para competition for ring closure. 
It was predictable that the electron donating mesomeric effect of the methoxy group 
was virtually identical in both para and ortho positions and that the regio-selectivity 
would be controlled by merely steric factors. Inexplicably the ratio remained constant 
even with the bromine as substituent. Bromine is mainly inductively electron 
withdrawing and this effect, differently from the mesomeric effect, is much stronger in 
the ortho position. Thus, the formation of 145h (Scheme 18) was expected to be 
disfavoured not only by steric factors but also by electronic effects. Nevertheless, access 
to compounds like 145j and 145h (Scheme 18) was much easier than originally 
envisaged and a more elaborate route to access them was not necessary.  
Contrary to 144j (Scheme 18), the presence of an extra methoxy group, i.e. 123x 
(Scheme 19), led to no ortho substitution and only compound 146x (Scheme 19) was 
recovered. This result was in line with the tendency observed in the literature to obtain 
only the para substitution considering that, as stated before, the majority of the systems 
investigated were highly activated like 123x (Scheme 19). 
 
Scheme 19. Cyclisation of compound 123x occurred only in the para position (146x). No ortho cyclised product 
(147x) was observed. 
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The reaction proceeded without problems even when only the ortho position was 
available for ring closure as for 123y (Scheme 20). More difficult to explain was the 
behaviour of 123k (Scheme 20), which did not generate any product when subjected to 
the PF reaction with 70% HClO4. This lack of reactivity might be explained by the 
steric hindrance provided by the methoxy group, which might reduce the rotational 
freedom of the benzyl group necessary for proper conformation for the ring closure. In 
addition, this effect might be enhanced by intramolecular charge stabilisation of the 




Scheme 20. Ring closure of compounds 123y and 123k. 
 
Figure 32. Possible intramolecular charge stabilisation of the protonated 123k. 
The PF reaction itself can proceed through different pathways to give the same 
product (143a, Scheme 21). Even though all of the pathways can happen at the same 
time and all of them are favoured according to Baldwin rules, the 6-exo-trig cyclisation 
should be energetically favoured because it involves only rearrangement of electrons 




Scheme 21. Possible pathways for the PF reaction. 
A kinetic experiment aiming to explore the cyclisation of compound 123i and thus 
identify any long lifetime intermediates was performed directly in an NMR tube. 
However, the strongly ionic environment led to very convoluted 
1
H NMR spectra, 
which were very difficult to interpret. The kinetic experiment was then repeated by 
performing the reaction normally and taking aliquots at regular intervals to give samples 
for 
1
H NMR analysis. 
Acetal 123i (Scheme 22, Figure 33) was clearly converted immediately to the 
aldehyde which subsequently ring closed. It is possible to see how the two protons of 
the aldehyde (Ha and Hb, Scheme 22, Figure 33) disappeared quickly together with the 
emergence of two protons of the product (Hc and Hd, Scheme 22, Figure 33). 
 




Figure 33. The stacked spectra refer, from the bottom to the top, to the starting material 123i (SM), the samples at 0, 
10, 20, 40 min and the last one is the worked up reaction after 60 min. Spectra have been elaborated for a better 
visualisation. 
Though the kinetic experiment seemed to demonstrate that the preferred pathway 
would proceed through aldehyde formation, contrasting results were found. As a matter 
of fact, the formation of the methyl ether (151l-o, 153f, Scheme 23) was noticed to 
occur in parallel with the free alcohol formation (143l-o, 144f, Scheme 23) and this 
implied that the other pathways had to be involved in a certain proportion. In some 
following experiments it was noticed that the ratio between the two products could be 
controlled by varying the reaction concentration (Scheme 23).  
 
Scheme 23. Methyl ethers 153f, 151l-o vs. alcohols 144f, 143l-o formation in the PF reaction. 123f,l-o (Table 12, 
Scheme 6, page 44). 
Formation of the methyl ether 151l-o was minimised by reducing the reaction 
concentration to 0.3 M (entry 2, Table 15), which was then considered the optimal 
concentration for the reaction. A rather different ratio was observed when the reaction 
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was performed with 6 N HCl, where only ca. 15% of the ether 153f formed in the 
reaction at 1.0 M concentration. Notably, 6 N HCl (6 N ≈ 18%) has a higher water 
content than 70% HClO4 and that water was necessary for the hydrolysis of the acetal to 
the hemiacetal and from the latter to the aldehyde. Hence, it was possible to postulate 
that the amount of water in the reaction, more than the acid strength, was the factor that 
controls the ratio among the three different reaction processes and consequently the 
ratio between the two products 143l-o, 144f and 151l-o, 153f. 
Table 15. Ratio between the formation of 143l-o, 144f and 151l-o, 153f at different reaction concentrations. 




 1.0 144f + 153f 7-OMe H 5:1 
2 123l 0.9 143l + 151l 6-OH H 2:1 
3 123l 0.3 143l + 151l 6-OH H 1:0 
4 123m 0.7 143m + 151m 6-OH CH3 1:1 
5 123n 0.9 143n + 151n 6-OH Cl 1:1 
6 123o 0.8 143o + 151o 6-OH OMe 1:1 
aRatios alcohol vs. ether were calculated by 1H NMR of the crude reaction mixture; bReaction was performed with 6N 
HCl. 
It is reported in the literature that the PF reaction can be used in some cases for the 
synthesis of indoles.
129, 130
 The indole formation would compete with the THIQ 
formation possibly leading to lower yields of THIQs up to the complete inability to 
obtain the desired THIQs. For this reason, the possible competition between the 
formation of 5- (154a,b,d, Scheme 24) and 6-membered (143a,b,d, Scheme 24) ring 
was investigated, as that could have become an issue for some future substitution on the 
aniline ring. When compound 123a (Scheme 24) was treated with 70% HClO4, the 
reaction proceeded towards the formation of the THIQ 143a (Scheme 24). Even when 
the position for the indole formation was activated by one single methoxy group (123b, 
Scheme 24), the 6-membered ring formation was more competitive and only the THIQ 
143b (Scheme 24) was recovered while no indole 154b (Scheme 24) formation was 
observed. Nevertheless, when the system was highly activated (123d, Scheme 24), the 





Scheme 24. 5- vs. 6-membered ring formation. 
The indole 154d (Figure 34) was not isolated but the 
1
H NMR of the reaction 
mixture was clear enough to leave no doubts. The only side product that was visible on 
the spectrum was the debenzylated analogue of the indole 154d (Figure 34). 
 
Figure 34. 1H NMR of the crude reaction mixture of compound 154d. The sections of spectrum 4.1-5.2 ppm and 5.3-
6.4 ppm has been digitally removed for a clearer view. No signal was visible in the removed sections.  
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The possible competition between the formation of 6- and 7-membered ring was also 
investigated. The appropriate precursor 155 (Scheme 25) was synthesised from 
benzaldehyde and 2,2-dimethoxyethylamine (respectively 116a and 141, Scheme 25) 
via a double reductive amination and duly cyclised with 70% HClO4. However, it was 
not possible to stop the reaction after the initial PF ring closure (156 and 157, Scheme 
25). Instead, only the double ring closed compound 158 (Scheme 25) was recovered. 
Hence, in the reaction conditions tested, unlike in the previous example (Scheme 24, 
page 59), it was not possible to determine if there was a significant competition between 
the 6- and 7-membered ring closure. 
 
Scheme 25. 6- vs. 7-membered ring formation from the cyclisation of compound 155. Reagents and conditions: 
a) NaBH(OAc)3, CHCl3, rt. b) 2-Phenylacetaldehyde, NaBH(OAc)3, rt. c) 70% HClO4, rt. 
Since HClO4 was able to cyclise compounds even when no methoxy group was 
present para- to the site of ring closure while 6 N HCl was not, a possible selectivity 
between meta- and para- cyclisation was investigated. The acetal 159 was synthesised 
from 4-methoxybenzaldehyde (116b, Scheme 26) and 2,2-dimethoxyethylamine (141, 
Scheme 26) via a double reductive amination approach and then cyclised with 70% 
HClO4. The only product recovered was the double alkylated compound 161 (Scheme 
26). Instead, the cyclisation using 6 N HCl led to a single cyclisation giving only 
compound 160 (Scheme 26). HCl was able to catalyse the ring closure only para- to the 





Scheme 26. Regioselectivity of the PF reaction under electronic control. In presence of 70% HClO4, compound 159 
cyclise to compound 161 while in presence of 6 N HCl only compound 160 is recovered. Reagents and conditions: a) 
NaBH(OAc)3, CHCl3, rt. b) 3-Methoxybenzaldehyde, NaBH(OAc)3, rt. c) 70% HClO4, rt. d) 6 N HCl, rt. 
In many cases, when all of the acetals 123a-y (Scheme 6, Table 12, pages 44-45) and 
131t,v (Scheme 11, page 50) where subjected to the PF cyclisation, the reaction 
proceeded so cleanly that the degree of purity was sufficient to proceed to the following 
step without any further purification. An example of the purity of the crude compound 
143a is given in Figure 35. 
 
Figure 35. 1H NMR of the non-purified compound 143a. 
The results of the successful ring closure via the PF reaction (Scheme 27) are 
summarised in Table 16. With the exception of 123g (Scheme 17, page 53) and 123k 
(Scheme 20, page 55), which have been previously discussed, and 131v (Scheme 11, 
page 50), all the compounds were successfully ring closed in the experimental 
conditions used. Moreover, when it was judged unnecessary, the compound was not 
purified after the work up. The two diastereoisomers 144h and 145h were separated, 
while the mixtures of diastereoisomers 144f-145f and 144j-145j were not separated and 
the ratios were determined by 
1




Scheme 27. Scheme of the of the PF ring closure. 
Table 16. Summary of PF results. 
SM R1 R2 Acid Product Yield (%) 
123a H H 70% HClO4 143a 67 
123b H 3-OMe 70% HClO4 143b Np 
123e OMe H 70% HClO4 143e 45 
123f OMe H 6N HCl 144f + 145f 71
b
 
123g Cl H 70% HClO4 143g Nf 
123h Br H 70% HClO4 144h  48
c
 
    145h 10
 c
 
123i OMe 4-Cl 70% HClO4 143i Np 
123j OMe 4-Cl 6N HCl 144j + 145j 31
d
 
123k OMe 4-Cl 70% HClO4 162k Nf 
123l OH H 70% HClO4 143l Np 
123m OH 4-Me 70% HClO4 143m Np 
123n OH 4-Cl 70% HClO4 143n Np 
123o OH 4-OMe 70% HClO4 143o Np 
123q OMe 4-Me 70% HClO4 143q Np 
123r OMe 4-Et 70% HClO4 143r 31 





 OMe 3-Cl 70% HClO4 143t 41 
123u OMe 3-OMe 70% HClO4 143u 36 
131v
a
 OMe 2-Cl 70% HClO4 143v Nf 
123w OMe 2-OMe 70% HClO4 143w 26 
123x OMe 4-OMe 6N HCl 146x 62 
123y OMe 4-OMe 6N HCl 148y 82 
123z H 4-Cl 70% HClO4 143z 61 
aCompounds 131t and 131v are diethyl acetal instead of dimethyl acetal. bRefers to the sum of 144f and 145f that 
were not separated (ratio 144f/145f 5:1). c144h and 145h were isolated from the same reaction. dRefers to the sum of 
144j and 145j that were not separated (ratio 144j/145j 4:1). SM = Starting Material. Nf = Not formed. Np = Not 
purified. 
Compounds 138i and 138s were also successfully ring closed using 70% HClO4 as 
catalyst (Scheme 28). Again, the two diastereoisomers formed were not isolated and 
were carried through to the next reaction as a mixture. 
 
Scheme 28. PF ring closure of compounds 162i and 162s. 
In conclusion, the PF reaction was versatile and robust, allowing us to obtain a wide 
range of 4-hydroxytetrahydroisoquinolines. The alcohol that was formed as a product of 
the PF reaction might represent an advantageous point for further strategic modification. 
The site of ring closure might be predicted based on the starting material structure and 
the reaction conditions chosen and also be controlled by carefully selecting the 
conditions or strategically placing activating groups. In addition, the reaction gave 
products with moderate to good yields and proved to be clean to the extent that in some 
cases purification was not essential. Moreover, in some cases (ring closure of 123f, 
123h, 123j) it was possible to obtain two different regioisomers with one single 
reaction. 
 
2.1.4. Dehydroxylation of 4-Hydroxytetrahydroisoquinolines.  
The last step of the synthesis was the dehydroxylation of compounds 143a-e,g,i,l-
w,z, 144f,j, 145f,j and 162i,s to give the respectively final THIQ. The dehydroxylation 
of compounds similar to 144f is reported in the literature using NaBH4 as reducing 
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agent and TFA as catalyst.
131
 The aforementioned conditions were not appropriate for 
all the compounds synthesised. In fact, only compounds 144f,j and 145f,j bearing a 
methoxy substituent in position 7 or 5 of the THIQ ring underwent a successful 
dehydroxylation. Compounds 144f and 145f, as well as compounds 144j and 145j, were 
reduced as a mixture and the two isomers 164f,j and 165f,j could be successfully 
separated via standard flash chromatography (Scheme 29). 
 
Scheme 29. Dehydroxylation of compounds 144f,j and 145f,j. 
Similarly compounds 146x and 148y underwent a reduction using the same reaction 
conditions to give compounds 167x and 168y, respectively (Scheme 30). 
 
Scheme 30. Dehydroxylation of compounds 146x and 148y. 
As stated above, any attempt to reduce compounds like 143e (method a, Scheme 31) 
using NaBH4/TFA failed and the use of a stronger Brønsted acid such as TfOH (method 
b, Scheme 31) did not improve the results. The catalytic hydrogenation of compound 
143e with a Pd/C catalyst (method c, Scheme 31) as a means to remove the 4-hydroxyl 
group was also evaluated. A range of common hydrogenation solvents was tested, but 
none of them could yield the desired product 163e (Scheme 31). The reaction was also 
attempted in a flow reactor at 100 °C (in THF/MeOH with a 0.5 mL/min flow and 70 
bar of H2) but, as with the previous attempts, no product 163e (Scheme 31) was formed. 
The free hydroxyl 143l (Scheme 31) was then converted to the corresponding acetyl 
ester 169 (Scheme 31) as literature reports suggested that the acyloxy derivative would 
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be more labile than the corresponding hydroxyl group,
131
 but this proved not to be the 
case for compounds that did not bear a methoxy group in position 7 (e.g. 143e,l, 
Scheme 31). 
 
Scheme 31. Attempts to dehydroxylate compounds 143e and 143l. Reagents and conditions: a) NaBH4, TFA, DCM, 
rt; b) NaBH4, TfOH, DCM, rt; c) Pd/C, H2 1 atm; d) AcCl, AcOH; e) Pd/C, H2 1 atm. 
Other reducing agents such as triethylsilane were then evaluated. Reduction with 
triethylsilane is known in the literature with a wide range of substrates.
132-136
 
Triethylsilane proved to be capable of giving the desired product in the presence of 
boron trifluoride etherate as a Lewis acid and DCM as a solvent. Even though the 
reaction was slow at rt, at reflux it was possible to obtain full conversion in 12-18 h. It 
is reported in the literature that the reduction with silanes might undertake two principal 
pathways depending on the nature of the reactant and more importantly on the polarity 
of the solvent. A concerted mechanism is favoured in apolar or moderately polar 
solvents
137
 (example A, Scheme 32) while with highly polar solvents a pathway that 
involves charged intermediates might take place
138
 (example B, Scheme 32). In the 
experimental conditions attempted, the concerted mechanism is believed to be 
predominant and this could explain why it was possible to reduce compounds that do 
not have the ability to stabilise the benzylic cation. These conditions successfully led to 
product formation even with unsubstituted THIQs. Notably, the same compounds that 
underwent facile cyclisation with the less strong hydrochloric acid were also 
successfully reduced by the TFA/NaBH4 system and compounds that needed harsher 




Scheme 32. Possible mechanism for dehydroxylation with triethylsilane. A) Concerted mechanism involving 
non-ionic species; B) Mechanism involving charged species. 
After initial optimisation of the reaction conditions, the whole range of THIQs 
synthesised were subjected to dehydroxylation with Et3SiH. When the dehydroxylation 
of compounds 143l-o (Table 17), which bear a free phenolic group, was attempted, the 
expected product was visible by 
1
H NMR of the crude reaction mixture but it was not 
possible to isolate it by standard purification methods. It was never possible to recover 
the products by normal phase flash chromatography and crystallisation attempts were 
unsuccessful probably due to the low purity of the compound in the crude reaction 
mixture. Reverse phase column chromatography was found to be the only method that 
could deliver the desired product with a high grade of purity and in reasonable amounts. 
Driven by this unfortunate discovery it was decided to use only THIQs with a protected 
phenol. THIQs bearing a methoxy group (e.g. 143b, Table 16, page 62) synthesised 
were chosen as a protected THIQs, which could be subsequently easily deprotected with 
high yields and low purification requirements. The results of the dehydroxylation 




Figure 36. Structure of substitutions for the final THIQs. 
Table 17. Summary of the results for the dehydroxylation reaction. 
SM Product R1 R2 Conditions Yields (%) 
143a 163a H H B 67 
143b 163b H 3-OMe B 11 
143e 163e OMe H B 35 
144f + 145f
a 
164f + 165f OMe H A 85
c 









165j OMe 4-Cl A 11
d
 
143l 163l OH H B 35
e
 
143m 163m OH 4-Me B 45
e
 
143n 163n OH 4-Cl B 50
e
 
143o 163o OH 4-OMe B 20
d
 
143q 163q OMe 4-Me B 25
d
 
143r 163r OMe 4-Et B 51 
143s 163s OMe 4-OMe B 21
d
 
143t 163t OMe 3-Cl B 52 
143u 163u OMe 3-OMe B 44 
143w 163w OMe 2-OMe B 38 
146x 167x 6,7-(OMe)2 4-OMe A 29 
148y 168y 5,6,7-(OMe)3 4-OMe A 49 
143z 163z H 4-Cl B 76 
162i 166i OMe 4-Cl B 4
d 
162s 166s OMe 4-OMe B 6
d 
aCompounds were reacted as a mixture and not separated afterwards. bCompounds were reacted as a mixture and 
separated afterwards. cReaction was performed on a 10 mg scale and the yield refers to the conversion as measured 
by LC-MS. dYield of the last three steps. eConversion measured by LC-MS; compound was not purified successfully. 




The dehydroxylation of the 4-hydroxytetrahydroisoquinoline derivatives could be 
successfully accomplished by selecting the appropriate conditions. The same electronic 
factors that controlled the PF ring closure, control to a similar extent also the 
dehydroxylation itself. Even though the NaBH4/TFA system was effective only in a few 
cases, it was possible to dehydroxylate the remaining compounds using Et3SiH and 
BF3·Et2O. The latter conditions gave apparently lower yields, they referred mostly to 
the sum of the two last steps and did not differ significantly from the overall two-step 
yield when NaBH4/TFA was used for the reduction. The main concern of the project 
was to secure as large a number of compounds as possible, therefore the results obtained 
were accepted and no further optimisation of the reaction was attempted. 
 
2.1.5.  Methoxy deprotection of final THIQs 
As previously stated, after the difficulties encountered during the purification of 
compounds bearing a phenolic group (Compounds 163l-o, Table 17) it was decided to 
access these type of compounds from the methoxy compounds like 143b (Table 16, 
page 62).  
One last step for the deprotection of the methoxy derivatives was introduced to 
obtain the free phenol derivatives. It was very important to obtain the phenolic 
derivatives because they are more closely related to the structure of E2 and it was 
envisaged they could possess higher potency. Further detail concerning the structure 
activity relationship of these compounds will be discussed in detail in CHAPTER 3 
(from page 101). 
Many procedures are reported in the literature for the demethylation of an 
arylmethoxy group to give the free phenol.
139, 140
 The problem was initially addressed 
using 48% aqueous HBr at 100 °C and the clean product could be obtained as the 




Figure 37. Structure of substitutions for the hydroxytetrahydroisoquinolines. 
Table 18. Summary of the results for the deprotection of the arylmethoxy THIQs. 
SM R Product Conditions Yield (%) 
163e H 170e A 90 
163i 4-Cl 170i A 79 
164j 4-Cl 171 A 74 
165j 4-Cl 172 A 75 
163q 4-Me 170q A 95 
163s 4-OH 170s A 91 
163t 3-Cl 170t A 64 
163u 3-OH 170u A 67 
163w 2-OH 170w A Nr 
167 4-OH 173 B 74 
168 4-OH 174 B 99 
Conditions: A) 48% aq. HBr, 100 °C, 1-2 h, inert atmosphere; B) BBr3, DCM, -78 °C to rt, 2 h, inert atmosphere. 
SM = Starting material. Nr = Not recovered. 
Under these conditions it was not possible to easily recover every compound and 
BBr3 in DCM was later found to be a better demethylating agent. Even when using 
BBr3 in DCM, the clean product could be obtained as the hydrobromide by filtration 
after quenching the reaction with water. These conditions gave better results and were 
used as the standard procedure for the deprotection of the phenols 170e,i,q,s-w, 171-174 
(Figure 37, Table 18). 
 
2.1.6. Further functionalisation of the 4-hydroxy THIQs. 
To simply prove the possibilities of functionalisation and to introduce bigger groups, 
the 4-hydroxy THIQs 143n and 146x were benzylated following their deprotonation 
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with NaH (Scheme 33). Initially, the reactions did not proceed well but the addition of 
crown ether 15-crown-5 gave moderate yields of the product. 
 
Scheme 33. Benzylation of the 4-hydroxy THIQs 143n and 143x. a) NaH, 12-crown-5, THF, 1 h, rt; b) BnBr, THF, 
4-6 h, rt. 
 
2.2. The Pictet-Spengler (PS) and Bischler-Napieralski (BN) approach 
As a means to expand the synthetic possibilities and flexibility offered by the PF 
approach, as stated at the beginning of CHAPTER 2, an alternative synthetic approach 
was investigated (Scheme 34). Both the PS and BN reactions are exploited in the 





Scheme 34. Proposed synthesis for the substituted THIQs through the PS and BN ring closure. 
Both pathways share the key intermediates 178 and 179 and differ only during the 
cyclisation process. Commercially available 3-methoxyphenylacetic acid 177 and an 
appropriately substituted aniline could be combined to give amide 178 that could be 
subsequently reduced to amine 179. The latter intermediate 179 was cyclised in the PS 
conditions to give the final THIQ 143. Alternatively, amide 180 could be obtained by 
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condensation of amine 179 with the appropriately substituted acid. The same amide 180 
could then be cyclised under the BN conditions to give the final THIQ 181. 
 
2.2.1.  Synthesis of the amides 178 
The synthesis of the amides 178a-h was carried out by converting commercially 
available 3-methoxyphenylacetic acid into the corresponding acid chloride using SOCl2 
as shown in Scheme 35. The acid chloride obtained was then reacted with the 
appropriately substituted aniline in refluxing toluene to give the desired amides 178a-h 
(Scheme 35, Table 19). The unreacted starting materials could be easily removed by 
washing the reaction mixture sequentially with aqueous 1 M HCl and 1M NaOH and 
the products were subsequently purified by recrystallisation from EtOAc/pet. ether 
when necessary. If the product had a purity higher than 95% by 
1
H NMR then no 
recrystallisation was performed (Table 19). 
 
Scheme 35. Synthesis of intermediates 178a-h. Conditions: a) SOCl2, DCM, rt, 1 h, inert atmosphere; b) Na2CO3, 
Toluene, reflux, 12-16 h, inert atmosphere. 
Table 19. Summary of the results for the synthesis of amides 178a-h. 
Compound R Yield (%) 
178a H 46 
178b 4-Cl 85 
178c 4-OMe 51 
178d 3-Cl 80 
178e 3-OMe 87 
178f 2-Cl 66 
178g 2-OMe 93 
178h 3,4-Cl2 76 
 
2.2.2. Reduction of the amides 178a-h. 
Amides 178a-h were reduced using LiAlH4 as the reducing agent and the reactions 
were performed in refluxing anhydrous THF under inert atmosphere to yield amines 
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179a-h as shown in Scheme 36. The products 179a-h could generally be obtained by 
precipitating it as hydrochloride salt from the crude reaction mixture (Table 20). 
 
Scheme 36. Reduction of amides 178a-h. a) LiAlH4, THF, 80 °C, 4-6 h. 
Table 20 Summary of the results for the reduction of amides 179a-h. 
Compound R Yield (%) 
179a H 64 
179b 4-Cl 64 
179c 4-OMe 59 
179d 3-Cl 74 
179e 3-OMe 68 
179f 2-Cl 97 
179g 2-OMe 45 
179h 3,4-Cl2 75 
 
2.2.3. The Pictet-Spengler cyclisation. 
The Pictet-Spengler (PS) reaction originally involved the condensation of β-
phenylalanine 183 and formaldehyde dimethylacetal to yield THIQ (Scheme 37). 
 
Scheme 37. Scheme of the original PS condensation.142 
The reaction has recently celebrated 100 years of success in the laboratory following 
its first discovery and the reaction has been implemented in the synthesis of many 
alkaloids.
113, 143
 Further investigations of the reaction have led to conditions that 
allowed not only the introduction of substituents, but also a certain degree of diastereo- 
and enantio-selectivity at the newly formed stereogenic centre.
113
 The reaction was also 
studied under enzymatic catalytic conditions and the enzyme was named 
Pictet-Spenglerase from the homonymous reaction.
113
 
Due to previous work undertaken by our group, the conditions used were different 
from the ones originally reported by Pictet and Spengler.
142
 These conditions required 
the use of paraformaldehyde as the formaldehyde source and p-toluenesulphonic acid 
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(PTSA) as the acid catalyst (Scheme 38). Under these conditions and in refluxing 
toluene, amines 179d-h cyclised to THIQs 163t-w,aa with acceptable yields (Scheme 
38, Table 21). Similarly to what was observed with the PF reaction, cyclisation occurred 
with an incomplete regioselectivity, affording the regioisomers 185v,aa alongside the 
major products 143v,aa (Scheme 38, Table 21). The two isomers were easily separated 
by flash column chromatography. 
 
Scheme 38. Cyclisation of compounds 179d-g,aa. Reagents and conditions: a) paraformaldehyde, PTSA, toluene, 
reflux, 12-18 h. 
Table 21. Yields of the PS cyclisation. 
SM R Product Yield (%) Product Yield (%) 
179d 3-Cl 163t
a 
23   
179e 3-OMe 163u Nf   
179f 2-Cl 163v 57 185v 4 
179g 2-OMe 163w Nf   
179h 3,4-Cl2 163aa 55 185aa 4 
a Formation of isomer 185t was not observed. SM = Starting Material; Nf = Not formed 
Through the PS cyclisation it was possible to obtain compounds like 163t, 163v and 
163aa (Scheme 38, Table 21) that proved difficult to be obtained by the PF pathway 
(Table 16, page 62). In fact, compounds with highly electron-withdrawing groups on the 
aniline ring as for 163aa (Scheme 38, Table 21) showed synthetic difficulties during the 
initial alkylation step (131t,v, Scheme 11, page 50) and compounds bearing a chlorine 
in the ortho position to the nitrogen did not cyclise under the PF conditions (131v, 
Table 16, page 62). Moreover, THIQs such as 185v and 185aa (Scheme 38, Table 21) 
have proven inaccessible through the PF cyclisation (cyclisation of 123k, Table 16, 
page 62). 
Conversely, the THIQs 163u and 163w (Scheme 38, Table 21) did not form under 
the experimental conditions used but the causes were not investigated as the same 




2.2.4.  The Bischler-Napieralski cyclisation. 
 The BN reaction was first discovered in 1893
144
 and allowed the cyclisation of 
β-arylethylamides to form 3,4-dihydroisoquinolines. The application of this reaction for 
the synthesis of THIQs involves de facto two steps, cyclisation to form a 
3,4-dihydroisoquinoline (DHIQ) followed by a reduction to obtain the THIQ (Scheme 
39). 
 
Scheme 39. Application of the BN reaction to the synthesis of THIQs. 
The advantage of the BN reaction was that it allowed the facile introduction of 
substituents in position 1 of the THIQ ring. On the other hand, it was not possible to 
obtain THIQs with no substituents in the same position 1 by this method. The reaction 
is carried out under dehydrating conditions and phosphorous oxychloride (POCl3) is 
often used as the dehydrating agent even though other reagents such as phosphorous 




Scheme 40. Synthesis of amides 180a-i (refer to Table 22 for compound substitution). a) The appropriate 
commercially available acid chloride, pyridine, DCM, rt, 12–18 h. 
Table 22. Summary of the synthesis of amides 180a-i. 
SM Product R1 R2 Yield (%) 
179b 180a Cl Me 91 
179b 180b Cl Et 96 
179b 180c Cl i-Pr 93 
179b 180d Cl t-Bu 70 
179b 180e Cl Ph 89 
179b 180f Cl Bn 98 
179b 180g Cl (CH2)2Ph 76 
179a 180h H Bn 73 
179c 180i OMe Bn 84 
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In order to proceed with the synthesis it was necessary to obtain first the amides 
180a-i (Scheme 40, Table 22) which could be subsequently cyclised under BN reaction 
conditions. 
The amides thus synthesised were subjected to the BN reaction conditions with 
POCl3 in refluxing toluene. After initial addition of the amide to the POCl3, the iminium 
ion generated cyclises and after aromatisation is restored, phosphenic chloride is 
expelled and the 3,4-dihydroisoquinolinium ion 189 is formed (Scheme 41). 
 
Scheme 41. Mechanism of cyclisation during the BN reaction. 
When no substituent was present on the nitrogen of the starting phenylethylamide the 
obtained product was neutral and could be easily isolated. Conversely, intermediate 189 
(Scheme 41) was charged and work up of the reaction in aqueous media to remove 
excess reagents would have led to reduced yield. Therefore, product formation was 
confirmed by thin layer chromatography (TLC) and when all the starting material had 
reacted only a spot on the base line remained visible. This spot was easily visualised 
under a UV lamp at 254 nm and had a typical blue fluorescence at 365 nm. The reaction 
was then quenched with methanol and the excess of POCl3 was converted to 
trimethylphosphate, which did not interfere with the reduction step. The solvents were 
evaporated and the crude residue reduced with NaBH4 using methanol as the solvent to 
yield the final THIQ 181a-i (Scheme 42, Table 23). Similarly to what was observed 
with the PS reaction, the other isomers 190a-i could be isolated, albeit in very poor 




Scheme 42. BN cyclisation of amides 180a-i. a) POCl3, anhydrous toluene, reflux, 12-18 h, quenched with MeOH. b) 
NaBH4, MeOH, rt, 6 h. 
Table 23. Results of the BN cyclisation of amides 180a-i. 
SM R1 R2 Product Yield (%) Product Yield (%) 
180a Cl Me 181a 69 190a 3 
180b Cl Et 181b 71 190b 5 
180c Cl i-Pr 181c 56 190c 12 
180d Cl t-Bu 181d Nf 190d Nf 
180e Cl Ph 181e 68 190e 2 
180f Cl Bn 181f 78 190f 4 
180g Cl Phenylethyl 181g 67 190g 3 
180h H Bn 181h 58 190h 6 
180i OMe Bn 181i 61 190i 8 
SM = Starting material; Nf = Not formed. 
Only amide 180d did not cyclise under the experimental conditions used and this was 
probably due to steric hindrance of the substituent. In fact, the t-butyl group could 
possibly clash with the proton ortho to the cyclisation position not allowing a proper 
conformation for the ring closure. 
Some of the THIQs thus synthesised possessed CLogP values that were marginally 
outside the Lipinski rules (Chapter 1.7, page 36) and, in order to try to address the 
problem at an early stage, the introduction of a more polar group was attempted. 
Therefore, amides 180j-l (Scheme 43, Table 24) were synthesised but it was necessary 
to use a coupling agent such as EDCI to generate amides 180j-l (Scheme 43, Table 24) 




Scheme 43. Synthesis of amides 180j-l. a) The opportune pyridylacetic acid hydrochloride, EDCI, Et3N, DCM, rt, 
12-18 h. 
Table 24. Results for the synthesis of amide 180j-l. 
Product Ar Yield (%) 
180j 4-Pyridyl 64 
180k 3-Pyridyl 60 
180l 2-Pyridyl 67 
 
Interestingly, every attempt to cyclise amides 180j-l failed, giving back the starting 
material with no clear explanation. 
During the BN cyclisation, a new stereogenic centre was generated thus leading to 
the formation of two different enantiomers. Considering that the two enantiomers were 
likely to possess different biological activity, a method to obtain one single enantiomer 
was investigated. There are examples in the literature of asymmetric BN reaction
141
 but 
they generally involve the use of expensive catalysts. Alternatively, the two enantiomers 
could be separated from the racemic mixture by chiral chromatography. Instead, the 
synthesis from a chirally pure acid was planned using an appropriately O-protected 
mandelic acid (Scheme 44). The amides 180m-n (Scheme 44) were synthesised and 
then subjected to the BN conditions, however, both the amides failed to cyclise and for 
181n (Scheme 44) the starting material was recovered. 
 
Scheme 44. Attempted synthesis of THIQs 181m-n. a) The opportunely protected mandelic acid, EDCI, Et3N, DCM, 
rt, 12-18 h. b) POCl3, anhydrous toluene, reflux, 12-18 h, quenched with MeOH. c) NaBH4, MeOH, rt, 6 h. 180m: R 
= Me; 180n: R = Ac. 
In conclusion, the BN cyclisation was generally very efficient for the introduction of 
simple substituents to position 1, while the pyridyl ring was not tolerated in the same 
experimental conditions. Moreover, though compounds 180f, 180h and 180i (Scheme 
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43, Table 24), bearing a benzyl group, cyclised with no problems, the addition of an 
electron-withdrawing substituted oxygen on the benzylic position, as for the amides 
180m and 180n (Scheme 44), prevented the cyclisation from happening. 
 
2.2.5. Methoxy deprotection of final THIQs 
As previously seen in chapter 2.1.5 (page 68), one last step for the deprotection of 
the methoxy-substituted THIQs was introduced in order to obtain the free phenol 
derivatives 191a-i (Scheme 45, Table 25). 
 
Scheme 45. Deprotection of THIQs 181a-i. a) BBr3, DCM, -78 °C to rt, 2 h, inert atmosphere. 
Table 25. Summary of the results for the deprotection of THIQs 181a-i. 
Product R1 R2 Yield (%) 
191a Cl Me 41 
191b Cl Et 61 
191c Cl i-Pr 58 
191e Cl Ph 79 
191f Cl Bn 44 
191g Cl Phenethyl 61 
191h H Bn 87 
191i OH Bn 96 
 
2.2.6. The Pictet-Spengler approach modification: towards 3-substituted THIQs. 
Due to the difficulties encountered during the synthesis of 3-substituted THIQs with 
the PF approach (see synthesis of precursors to the THIQs 165i,s in chapters 2.1.2 to 
2.1.4, pages 50 to 67) an alternative method was investigated. It was decided to attempt 
to introduce an alkylation step during the synthesis by using a PS approach. Analysing 
the synthetic steps, amide 178 (Scheme 46) was chosen as the substrate for the 
alkylation reaction. In fact, when amide 178 (Scheme 46) was reduced to amine 179 
(Scheme 46) prior to its PS cyclisation, it would become rather difficult to introduce a 




Scheme 46. Synthesis of THIQ 143 through the PS approach. In red are highlighted the positions that are 
strategically difficult to exploit for an alkylation reaction. In green is highlighted the position with higher 
functionalisation capabilities. 
A carbonyl can be easily alkylated with a wide range of nucleophiles but amides are 
much less reactive due to the O-C-N electron delocalisation. Moreover, a carbanionic 
nucleophile is also a strong base and under these conditions, deprotonation of the amide 
would happen first nullifying any chance of C-alkylation (Scheme 47). 
 
Scheme 47. Deprotonation of amide 178 by a simple carbanion. 
It was hoped that converting the oxygen into a good leaving group would lead to a 
successful C-alkylation that would not require any additional steps. Revising the 
mechanism of the BN reaction (Scheme 41, page 75), POCl3 was expected to be a good 
starting point for such investigations. 
 
Scheme 48. Envisaged mechanism for the alkylation of amide 178. a) Toluene, 100 °C, 18 h; b) MeMgBr, toluene, rt 
for 1 day then reflux for 1 day. 
The amide 178 (Scheme 48) did not react at all with POCl3 at rt but full conversion 
occurred at 100 °C as judged by TLC. Excess solvents and reagents were evaporated 
and the residue was dissolved in toluene and reacted with MeMgBr at rt for one day. No 
conversion occurred so the mixture was heated to refluxing conditions. Surprisingly, the 
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isolated compounds did not correspond to imine 195 but to amides 196 and 197 (Figure 
38). 
 
Figure 38. Compounds isolated after attempted alkylation of amide 178. 
Amides 196 and 197 (Figure 38) were recovered in 20% and 27% yields, 
respectively and the starting material 178 in 18% yield. Due to their structural 
similarities, it was believed that the formation of the products 196 and 197 (Figure 38) 
occurred from the same common intermediate. Chlorination of amides like 198 with 





Scheme 49. Possible explanation for the formation of the amides 196 and 197. a) PCl5, CCl4, 95 °C; b) POCl3, 
Toluene, reflux; c) MeMgBr; d) Aqueous workup. 
In the hypothesis that POCl3 would react in a very similar way, the amide 178 
(Scheme 49) could then be converted into the intermediate 202 (Scheme 49), which 
could then undergo a nucleophilic substitution by MeMgBr to give, after quenching, the 
amide 196 (Scheme 49). Instead, the unreacted amount of 202 (Scheme 49) would be 
81 
 
converted to the amide 197 (Scheme 49) during the quenching itself. This hypothesis, 
though, is yet to be proved and further in depth mechanistic investigations would be 
required. Nevertheless, the formation of the intermediate 202 (Scheme 49) seemed both 
plausible and a good explanation for the formation of the unexpected products 196 and 
197 (Scheme 49). 
An alternative procedure to obtain the desired 3-substituted THIQs was then 
evaluated. The direct alkylation of a carboxylic acid is possible with an organolithium
146
 
but only few of this type of compounds are commercially available. Conversely, a wide 
range of Grignard reagents are readily commercially available and, in addition, they can 
be handled and stored more easily. However, Grignard reagents are not able to directly 
alkylate carboxylic acids unlike the organolithium reagents and their addition to esters 
usually give significant problems of dialkylation. The Weinreb reaction was used to 
overcome this limitation and to access a wide range of substitutions. The Weinreb 
reaction was firstly reported by Weinreb and Nahm in 1981
147
 and is a useful tool to 
access mono-alkylation of acids to give ketones. The reaction uses 
N,O-dimethylhydroxylamides as the substrate, which are named Weinreb amides from 
the same reaction and the alkylation can be performed with a variety of nucleophiles 
even though Grignard and organolithium reagents are most extensively used. The 
peculiarity of this reaction lays in the stabilisation of the intermediate anion by metal 
chelation, which prevents the compound from undergoing a second alkylation (204, 
Scheme 50). Only when the reaction is quenched, and the alkylating agent (usually in 
excess) destroyed, is the anion protonated generating the intermediate species (205, 
Scheme 50), which collapses to give the final ketone and N,O-dimethylhydroxylamine 
(respectively 206 and 207, Scheme 50). The Weinreb amide and the chelated 
intermediate are so stable under the reaction conditions that is possible to perform an in 
situ metalation of alkyl- or arylhalides
147
 to give the respective Grignard reagents that 
then react immediately to give the final ketone. 
 
Scheme 50. Weinreb reaction mechanism. 
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Based on this reaction a modified synthetic scheme towards 3-substituted THIQs was 
planned (Scheme 51) and the Weinreb amide 208 (Scheme 51) was synthesised from 
commercially available 3-methoxyphenylacetic acid (177, Scheme 51) and 
N,O-dimethylhydroxylamine hydrochloride. 
 
Scheme 51. Planned synthetic strategy towards the 3-substituted THIQs 211. 
When amide 208 (Scheme 51) was synthesised by converting the acid into the acid 
chloride and then reacting the latter with N,O-dimethylhydroxylamine 207, the yield 
was 48%. This was due to the low nucleophilicity of the amine and it was possible to 
increase the yield to 64% by converting the amine into a more reactive species 
according to the literature procedure (Scheme 52).
148
 The amine was initially reacted 
with PCl3 to give adduct 212, which was then reacted with the acid to give 208. 
 
Scheme 52. Synthesis of the Weinreb amide 208. a) DIPEA, Et2O, 1 h at 0 °C then 12 h at rt; b) Toluene, 60 °C. 
 
2.2.7. Weinreb reaction: alkylation of amide 208. 
The Weinreb reaction was conducted under the original experimental conditions
147
 
and the Grignard's 213a-e were used as nucleophiles (Scheme 53, Table 26). 
 
Scheme 53. Weinreb reaction of amide 208 with the nucleophiles 213a-e. a) THF, rt. 
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Table 26. Summary of results for the Weinreb reaction. 
Product R X Yield (%) 
209a Me Br 93 
209b Et Br 86 
209c i-Pr Br Nf
* 
209d Ph Br 66 
209e Bn Cl 28 
* N-demethoxylation occurred and amide 218 formed instead with a 62% yield. Nf = Not formed. 
Ketones 209a, 209b and 209d formed in good yield, while the yield for ketone 209e 
was poor. Conversely, ketone 209c did not form and amide 218 formed instead. In fact, 
it is reported in the literature that the reaction of Weinreb amides like 208 with poorly 
nucleophilic Grignard's such as i-PrMgBr would proceed towards N-demethoxylation 
(Scheme 54).
149
 The reaction is initiated by deprotonation of the N-methoxy group and 
proceeds by elimination of formaldehyde to give the stabilised anion, which is then 
protonated to deliver the final amide 218. 
 
Scheme 54. Degradation of the Weinreb amide 208 in the presence of poorly nucleophilic strong bases such as a 
non-nucleophilic Grignard. 
 
2.2.8.  Reductive amination of ketones 209a,b,d,e. 
The ketones 209a,b,d,e obtained through the Weinreb reaction were reductively 
aminated to give the amines 210a,b,d,e using the conditions described in chapter 2.1.2 
modified according to the literature procedures
120
 for ketones (Scheme 55, Table 27). 
When synthesis of amine 210a (Scheme 55, Table 27) was first attempted in 
chloroform the yield was only 14%. Similarly to what observed during the synthesis of 
amines 138i,s (Scheme 13, page 50) the ketones were sterically more hindered than 
aldehydes and the direct reductive amination was more difficult but the reactivity of the 




Scheme 55. Reductive amination of ketones 209a,b,d,e. a) 4-Chloroaniline, NaBH(OAc)3, DCE, AcOH, rt, 6-12 h. 
Table 27. Reductive amination of ketones 209a,b,d,e. 
Product R Yield (%) 
210a Me 48 
210b Et 49 
210d Ph Nf 
210e Bn 28 
Nf = Not formed. 
It was not possible to obtain amine 210d (Scheme 55, Table 27) even with an acid 
catalyst and this was probably due to the lower reactivity of the compound. In fact, the 
ketone 209d (Scheme 55) was the only compound of the series in which the carbonyl 
was conjugated to an aromatic ring. The other three compounds could be obtained in 
low to moderate yields and no further optimisation was attempted. 
 
2.2.9. The Pictet-Spengler cyclisation: towards 3-substituted THIQs. 
Amines 210a,b,e (Scheme 56, Table 28) were cyclised under PS conditions to give 
3-substituted THIQs 211b,e and 166i (Scheme 56, Table 28). Under these conditions 
amine 210e (Scheme 56, Table 28) failed to cyclise and the only product obtained were 
166i and 211b (Scheme 56, Table 28). Again, as observed before (chapter 2.2.3, page 
72) when the amine did cyclise, a small amount of the regioisomer 219 was observed 
and isolated if possible. 
 
Scheme 56. PS cyclisation of amines 210a,b,e. Reagents and conditions: a) paraformaldehyde, PTSA, toluene, 





Table 28. Results of the PS cyclisation of amines 210a,b,e. 
SM R Product Yield (%) Product Yield (%) 
210a Me 166i 79 219a No 
210b Et 211b 44 219b 4 
210e Bn 211e Nf 219e Nf 
SM = Starting material; Nf = Not formed; No = Not observed. 
Compound 166i (Scheme 56) was resynthesised in order to have a direct comparison 
between the PF and PS approaches to obtain 3-substituted THIQs. The overall yield for 
compound 166i (Scheme 56) was 4% when synthesised using the PF approach, while 
the yield increased to ca. 23% when the modified PS approach was used. In addition, 
even though the pathway was unsuccessful at different stages, it has to be stated that 
reactions were not optimised. 
 
2.2.10.  The Pictet-Spengler approach modification: towards 4-substituted THIQs. 
Analogously to the synthesis of the 3-substituted THIQs, the first approach 
investigated for the synthesis of 4-substituted THIQ was alkylation of amide 178b 
(Scheme 57). In order for alkylation to occur α to the carbonyl the amide needed to be 
protected or deprotonation would occur on the nitrogen, generating the stabilised anion 
220 (Scheme 57) which would lead to the N-alkylated amide 221 (Scheme 57). Instead, 
the protected amide 222 (Scheme 57) could only be deprotonated α to the carbonyl to 
give anion 223 (Scheme 57), alkylation of which would lead to amide 224 (Scheme 57). 
Subsequent deprotection of amide 224 (Scheme 57) would yield the desired product 225 
(Scheme 57). The negative aspect of this approach would have been the introduction of 
two additional steps, both lengthening the time for the synthesis and reducing the 
overall yield of the process. Even if the yield was of secondary importance, the need to 




Scheme 57. Deprotonation-alkylation of unprotected and protected amide 178b. 
In order to limit the number of additional steps, a protecting group that could be 
introduced and removed during different steps of the current synthesis was evaluated. 
The carboxybenzyl (CBZ) group was chosen, following a literature analysis of its 
introduction and cleavage conditions. In fact, there are examples of CBZ protection in 
the literature under conditions that deprotonate the amine
140
 and cleavage of the same 
CBZ group by metal hydrides.
150
 The possibility of a synthesis such as the one shown in 
Scheme 58 was then explored. 
 
Scheme 58. Planned synthetic scheme for the introduction and cleavage of the CBZ protecting group within the 
existing synthetic steps. 
To evaluate this hypothesis, protected amide 222 (Scheme 58) was synthesised and 
isolated, and subjected to cleavage with LiAlH4 to give the starting amide 178b 
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(Scheme 58). The synthesis of 222 (Scheme 58) proceeded smoothly but when the 
obtained protected amide was reacted with LiAlH4, a convoluted mixture of products 
was obtained. The same amide 222 (Scheme 58) could not be deprotected by catalytic 
hydrogenation with Pd/C and H2, a procedure considered standard for the removal of 
the CBZ protecting group. The very optimistic plan depicted in Scheme 58 was then 
abandoned in favour of a more robust approach. 
Due to the above-mentioned difficulties with direct alkylation of amide 178b 
(Scheme 58) and the greater difficulties for direct alkylation of the starting 
3-methoxyphenylacetic acid (177, Scheme 59), the methyl ester 226 (Scheme 59) was 
chosen as the substrate for the alkylation reaction. Though the methyl ester 226 
(Scheme 59) was commercially available, for the present work it was obtained by 
Fischer esterification. When 3-methoxyphenylacetic acid 177 was refluxed in methanol 
in the presence of catalytic amounts of conc. H2SO4 the reaction did not proceed. The 
Fischer esterification is a condensation reaction with elimination of water, thus 
anhydrous conditions were required to drive the equilibrium of the reaction towards 
formation of the product. These conditions were obtained by the introduction of CaH2 
as dehydrating agent and the use of a Soxhlet extractor to keep it separated from the 
reaction environment. In fact, the CaH2 would react with the 3-methoxyphenylacitic 
acid (177, Scheme 59) deprotonating it and preventing it from esterification and the 
same hydride would also neutralise the H2SO4 in solution. Using the Soxhlet extractor 
the refluxing solvent evaporated and condensed into the apparatus where it was 




Figure 39. Representation of a Soxhlet extractor used during the Fisher esterification. The solvent is heated to reflux 
and the vapours (in red) are condensed (in blue) and dried by CaH2. CaH2 is retained by a paper filter and the 
anhydrous solvent (in green) is returned in the reaction flask. 
After refluxing for 3 h under these conditions, the solvent was evaporated and the 
residue was dissolved in EtOAc and washed with 1 N NaOH to neutralise the H2SO4 
and to remove any unreacted starting material. In this way, the product 226 (Scheme 59) 
was obtained in 88% yield and did not require any further purification. 
 
Scheme 59. Fischer esterification of the 3-methoxyphenylacetic acid 177. 
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Ester 226 (Scheme 60) was then considered the starting point for the synthesis of 
4-substituted THIQs (Scheme 60). The planned synthesis was only one step longer than 
the previous method involving the PS approach (Scheme 34, page 70) 
 
Scheme 60. Planned strategy for the synthesis of 4-substituted THIQs 228. 
 
2.2.11. Alkylation of ester 226. 
To alkylate ester 226 (Scheme 61, Table 29), it was first deprotonated with LDA 
at -78 °C and then treated with an alkylhalide. The reaction proceeded generally with 
good yield and in some cases, the product was significantly clean as judged by 
1
H NMR 
and no purification was performed. The iodo derivatives were more reactive and gave 
superior yields. In addition, the geminal dimethylated compound 227f could be obtained 
simply using two equivalents of iodomethane and LDA. 
 
Scheme 61. Alkylation of ester 226. a) LDA, THF, -78 °C, 1 h; b) RX, THF, -78 °C to rt, 4-6 h. 
Table 29. Summary of the results for the alkylation of ester 226. 
Product R X Yield (%) 
227a Me I Np 
227b Et I Np 
227c i-Pr Br 20 
227d Bn Br 86 








2.2.12. Ester to amide conversion. 
The conversion of esters 226 (Scheme 62) into amides is an equilibrium reaction and 
the driving force is the pKaAH (pKa of the conjugated acid) of the leaving species 
(Scheme 62). The pKa of MeOH is 29 (in DMSO)
151
 while the pKa of 4-chloroaniline 
(113b) is 29.4 (in DMSO).
152
 The difference between the two pKas was too narrow and 
it would not be enough to drive the equilibrium towards the amide 178b (Scheme 62) 
formation but another factor played an important role and this was the stability of the 
compound formed. In fact, the amide 178b (Scheme 62) that formed was much less 
electrophilic and it could not be converted to the ester 226 (Scheme 62) anymore. 
 
Scheme 62. Direct conversion of the ester 226 into the amide 178b. 
The reaction was usually performed without solvent, at high temperature but no 
conversion to amide 178b (Scheme 62) occurred even when catalytic amounts of 
KOtBu or NaH were added. Driven by the need for a reliable method for conversion of 
ester 226 (Scheme 62) into amide 178b (Scheme 62), the investigation moved to the use 
of Al(CH3)3. Al(CH3)3 itself is extremely pyrophoric and very difficult to handle but in 
the recent years the use of bis(trimethylaluminum)-1,4-diazabicyclo[2.2.2]-octane 
(DABAL) as a source of Al(CH3)3 has been reported with very good results.
153, 154
 The 
conversion of esters to amides has been shown to proceed with very good yield for a 
range of substrates.
154
 DABAL is non-pyrophoric and, although moisture sensitive, it 
can be weighed on the bench and reactions open to the air have been reported.
153
 The 
reaction was very clean and excess aniline could easily be washed away during the 
workup (Scheme 63, Table 30). For these reasons, in most cases any further purification 
was considered unnecessary. As an example, the 
1
H NMR spectrum of crude amide 




Figure 40. 1H NMR of crude amide 224a. 
 
Scheme 63. Synthesis of amides 224a-f. a) DABAL, THF, 40 °C; b) 227a-f. 
Table 30. Summary of the results for the synthesis of amides 224a-f. 















 Np = Not purified. *224f is geminal dimethylated. 1A small amount of the compound was isolated from one previous 
attempt for characterisation. 
 
2.2.13. Reduction of amides 224a-f. 
Reduction of amides 224a-f (Scheme 64) was carried out as previously described 
(chapter 2.2.2, page 71). Again, for none of the compounds was purification considered 
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necessary and as an example, the 
1
H NMR spectrum of amine 225a (Scheme 64) is 
reported in Figure 41. 
 
Scheme 64. Reduction of amides 224a-f. a) LiAlH4, THF, 80 °C, 6-12 h. 
 
Figure 41. 1H NMR of the crude amine 225a. 
 
2.2.14.  PS cyclisation of amines 225a-f. 
Amines 225a-f (Scheme 65) were cyclised under the PS conditions already described 
in chapter 2.2.3 (page 72) to give the THIQs 228a-f (Scheme 65). As stated in the same 
chapter, small amounts of the 8-substituted THIQs 230a-f (Scheme 65) were observed 
and if possible isolated (Scheme 65, Table 31). 
 
Scheme 65. PS cyclisation of the amines 225a-f. Conditions: a) paraformaldehyde, PTSA, toluene, reflux, 12-18 h. 
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Table 31. Summary of the results for the cyclisation of amines 225a-f. 
SM R Product Yield (%) Product Yield (%) 




225b Et 228b 53
1 
230b No 
225c i-Pr 228c 27
2 
230c No 












SM = Starting Material; No = Not observed; * 225f and 228f are geminal dimethylated; 1Yield of the last 4 steps; 
2Yield of the last 2 steps; 3Yield of the last 3 steps. 
The yields were generally good and it is noteworthy that compounds 228a, 228b, 
228f and 230a were obtained without thorough purification until the last step of the 
whole synthesis. 
 
2.2.15. The Bischler-Napieralski approach modification: towards 1,4-disubstituted 
THIQs. 
As previously mentioned in chapter 2.2.4 (page 74), the BN reaction can be used to 
introduce a substituent in position 1 of the THIQ ring. To test the versatility of the 
syntheses conducted in this work, the synthesis of 1,4-disubstituted THIQ was 
attempted. In order to proceed with the BN cyclisation, amines 225a, 225b and 225d 
(Scheme 66, Table 32) were converted to the corresponding phenacetamides 231a, 231b 
and 231d (Scheme 66, Table 32). 
 
Scheme 66. Acylation of amines 225a-d. a) Phenacetyl chloride, Et3N, DCM, rt. 
Table 32. Results of the acylation of the amines 225a,b,d. 







1Yield of the last 4 steps. 2Yield of the last 3 steps. 
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Amides 231a,b,d (Scheme 67) were duly subjected to cyclisation under BN 
conditions to give the corresponding THIQs. The introduction of a second substituent 
increases the molecule complexity and during the BN reaction a second stereocentre is 
generated. Therefore, a mixture of four diastereoisomers was anticipated. Very 
interestingly, only two diastereoisomers formed, the THIQs trans-232a,b,d and 
trans-233b,d (Scheme 67, Table 33) which were successfully separated by flash column 
chromatography. 
 
Scheme 67. BN cyclisation of amides 231a,b,d. a) POCl3, anhydrous toluene, reflux, 12-18 h. b) NaBH4, MeOH, rt, 
6 h. 
Table 33. Results of the BN cyclisation of amides 231a,b,d. 
SM R Product Yield (%) Product Yield (%) 
231a Me trans-232a 36 trans-233a 0 
231b Et trans-232b 46 trans -233b 12 
231d Bn trans-232d 46 trans -233d 8 
 
It was not possible to determine the composition of the mixture at this stage and 
compounds trans-232a,b,d were deprotected to give the free phenolic derivatives 





Scheme 68. Demethylation of the disubstituted THIQs trans-232a-d. a) BBr3, DCM, -78 °C to rt. 
In an attempt to disclose the real composition of the mixture, X-ray diffraction 
analysis was performed on a small crystal obtained but the signal quality was too low 
and the structure was not determined. In addition, the small amount of compound 
available limited the number of recrystallisation attempts. For this reason, other 
analytical methods to identify the composition of the mixture were considered. 
Chiral HPLC analysis of trans-234j yielded a chromatogram which showed only two 
peaks (Figure 42). From the chromatogram it was deduced that only two enantiomers 
are present or otherwise four peaks should have been visible on the chromatogram itself. 
 
Figure 42. Chiral HPLC chromatogram of compound trans-234j. 




C NMR analysis. The spectra showed only one peak per nucleus, while the presence 
of a second diastereoisomer should have shown two peaks for each nucleus or at least 
for the ones near the stereocentres. This data suggested that only one diastereoisomer 
was present but did not give any information regarding the relative stereochemistry of 




H NOESY NMR analysis which is 




Figure 43. Three dimensional conformation of compound trans-234j seen from the “top” (on the left) and from the 
“side” (on the right). NOESY interactions are represented by double headed arrows. 
 
Figure 44. NOESY spectrum of compound trans-234j. Spatial interactions appear as cross-peaks outside the 
diagonal and the signals corresponding to the interactions highlighted in Figure 43 are traced by black lines. 
From the spectrum, H3a interacted with both H4 and H6 and this was possible only if 
the spatial relationship between the substituents in position 1 and 4 was trans. 
Interestingly, only H6 was able to sense H3a, while on the contrary H5 could sense H10 
suggesting a possible locked conformation for the benzyl group in position 1. This 
hypothesis was also reinforced by the strong interaction between the aromatics of the N-
phenyl ring and the 1-benzyl substituent, which might be due to intramolecular π-π 
stacking between the two rings. This interaction might prevent the free rotation of the 1-
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benzyl substituent. It is also important to note that the NOESY signals were only visible 
on the salt of compound trans-234j and when the same experiment was attempted on 
the free base the signals disappeared. This was due to the fact that the protonated 
nitrogen was no longer capable of undergoing a fast pyramidal inversion preventing the 
saturated ring from flipping between the two possible twisted chair conformations. 
Consequently, the chance of strong spatial interactions was increased from the 
generated rigidity. 
In order to emphasise the enantiomeric content of the sample, a NMR chiral shift 
reagent (CSR) analysis was performed to yield the spectra reported in Figure 45. The 
experiment was executed through a portion-wise addition of chiral shift agent, namely 
Europium(III) tris[3-(heptafluoropropylhydroxymethylene)-d-camphorate] (Eu(hfc)3), 
to the solution of compound trans-234j in deuterated DMSO. 
 
Figure 45. Stacked 1H NMR spectra of trans-234j during the CSR experiment. Compound amount was 1.5 mg, and 
the spectra refer from top to bottom to the sequential addition of Eu(hfc)3. On the right of the spectrum is expressed 
the total amount of Eu(hfc)3 present in the tube at the moment of the analysis. Signal splitting is highlighted by black 
arrows. 
 The peaks started to separate when the mass ratio between the compound and the 
CSR was 3:1 and maximise at a ratio of 1:2, and no peak deterioration was observed 
even at a mass ratio of 1:6. The final solution obtained was subjected to a full NMR 




C HSQC reported in Figure 46). The signals corresponding 
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to H7 and H8 split into two new peaks each, while for H4 only one new peak was visible 
and maybe the other peak was covered by the water peak in the spectrum. Interestingly, 
no change was visible for any other proton and in addition, when the same analysis was 
performed on the corresponding free base of trans-234j, the peaks appeared broader 
and, for similar reasons to the NOESY experiment, no signal splitting was observed. 
In a similar way, the 
13
C attached to H7 and H8 and the one attached to H4 had new 
signals that could be related to the corresponding protons by HSQC as shown in Figure 
46. 
 
Figure 46. 1H-13C HSQC analysis of trans-234j + 6.0 mg of Eu(hfc)3. 
1H-13C correlation is highlighted by black 
lines. 
Having proved that only the trans- isomers were formed, it was still unclear how this 
was possible considering that each step involved in the synthesis was completely 
achiral. It is necessary to consider that the first chiral centre was introduced in the first 
step of the synthesis, while the second centre was formed only at a later stage. In this 
way, the first chiral group could possibly induce the chirality of the second one during a 
later step of the reaction. Examples of stereo-induction from substituents in position 3 is 
well noted and exploited in the literature,
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 therefore induction from a group in position 




2.2.16. Deprotection of the final THIQs synthesised through the modified PS and 
BN approaches. 
One last time, the protected THIQs synthesised were demethylated to yield the 
corresponding phenolic derivatives. The reaction was carried out under the same 
conditions described in chapter 2.1.5 (page 68) using BBr3 as demethylating agent and 
DCM as reaction solvent. The results of the reaction represented in Scheme 69 are 
reported in Table 34 below. 
 
Scheme 69. Deprotection of 3- and 4-substituted (166i, 211b and 228a-f, respectively) and 1,4-disubstituted THIQs 
(232a-e). Reagents and conditions: a) BBr3, DCM, -78 °C to rt, 2 h, inert atmosphere. 
Table 34. Results of the deprotection of the THIQs obtained through the modified PS and BN approaches. 
SM X Y Z Product Yield (%) 
166i H Me H 234a 87 
211b H Et H 234b 24 
228a H H Me 234c 58 
228b H H Et 234d 47 
228c H H i-Pr 234e 31 
228d H H Bn 234f 66 
228e H H 2-methoxyethyl 234g Ni
 
228f H H (Me)2
* 
234h 85 
232a Bn H Me 234i 63 
232b Bn H Et 234j 86 
232d Bn H Bn 234k 45 
SM = Starting material; Ni = Not isolated; * Compounds 228f and 234h are geminal dimethylated. 
The reaction proceeded with variable yields but with no significant deviation from 
the standard course for the reaction itself apart from compound 228e, which did not 
yield the desired product.  
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2.3. General conclusions. 
The chemistry reported in this work demonstrates that it is possible to obtain simple 
substitutions in every position of the THIQ scaffold. The short synthetic strategies 
applied have led to a reasonable number of compounds in short time. Also noteworthy 
is the overall use of cost effective procedures and inexpensive starting materials. In 
addition, it was possible to carry out many intermediate steps without purification. This 
not only contributed to rapidly accessing the desired compounds but also had a positive 
impact on the average synthetic costs. In addition, the majority of the reactions were 
carried out at temperatures near rt, which will be useful in future when an industrial 
adaptation process is evaluated.  
The three cyclisation methods used compensate for the limitations of each other and 
together formed a reliable synthetic approach though increasing the complexity of the 
molecules required small adjustments to the synthesis itself. Future optimisation of the 
reactions applied might lead to increased yields. The problem of the stereochemistry 
still remains to be fully addressed but particularly appealing is the stereo-induction 
obtained in the 1,4-disubstituted compounds. 
Interesting would be to establish if the ratio between the two regioisomers that were 
obtained during the cyclisation reactions could be influenced by temperature and 
concentration. 
In conclusion, though improvements might be necessary, the synthetic approaches 





CHAPTER 3  
Results and discussion 
Biological evaluation and computational chemistry 
The synthesised THIQs and some basic intermediates were evaluated against the two 
main targets: 17βHSD1 and ERRα. The activity of the compounds was also evaluated 
against non-primary targets in order to obtain information on their selectivity and their 
possible applications outside the aim of the project was also considered. Moreover, to 
have prompt access to the biological results against 17βHSD1, attempts to develop a 
colourimetric assay were made. In addition, to obtain information on the binding mode 
of the synthesised compounds, co-crystallisation with the enzyme was evaluated. 
Molecular modelling was used to evaluate possible binding modes. 
 
3.1. 17β-hydroxysteroid dehydrogenase type 1 (17βHSD1) 
To investigate the inhibitory capabilities of the synthesised THIQs against 17βHSD1, 
the development of an in-house assay was considered. Commonly, activity of 17βHSD1 
is evaluated using a radiochemical assay which involves the use of HPLC combined 
with radioflow detectors in order to separate and quantify the amount of E1 and E2, 
respectively the substrate and the product of the enzymatic reaction.
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 Alternatively, the 
separation of the two components is performed by TLC and each sample is then 
analysed by a radiodetector.
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 To simplify the assay procedure and avoid the use of 
radiochemicals, previous work from our group developed a colourimetric assay (see 
chapter 3.1.3, page 107). For this assay the enzyme needed to be expressed and purified, 
and the conditions for the assay optimised. Moreover, to obtain as much information as 
possible on the binding of the synthesised compounds, co-crystallisation of the enzyme 
with a selected THIQ was performed, so milligram quantities of enzyme were required. 
 
3.1.1.  Protein expression and purification. 
17βHSD1 is naturally expressed in certain human cell lines or can be overexpressed 
using transfected expression vectors. However, the amount of enzyme produced in these 
cells is not enough to obtain the quantity of protein necessary for the assay and 
crystallisation experiments. The large scale cultivation of human tissue is also more 
difficult and expensive. Our group had successfully expressed 17βHSD1 in 293-EBNA 
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mammalian cells but subsequently moved to bacterial systems to more easily produce 
larger amounts of the protein. The mammalian expression used the gene for 17βHSD1 
cloned into the pCEP4 vector. For the bacterial expression, the gene for 17βHSD1 was 
extracted from the pCEP4 vector and cloned into the pET-24a(+) bacterial expression 
vector. To do this, two restriction enzymes, NheI and Xho1, were used to remove the 
gene from pCEP4 and to digest the bacterial vector pET-24a(+). The gene and digested 
pET-24a(+) vector were purified and ligated to form the full vector (Figure 47).  
 
Figure 47. Schematic representation of the insertion of the 17βHSD1 gene into the pET-24a(+) from the pCEP4 
mammalian vector. 
The new vector generated was used to transform the Escherichia coli (E. coli) 
expression strain Rosetta 2, which is designed for expression of human proteins in 
bacterial cells. Rosetta 2 is the traditional BL21(DE3)pLysS expression strain but they 
also contain a vector for the production of rare t-RNAs (codons AGA, AGG, AUA, 
CUA, GGA, CCC and CGG). These t-RNAs recognise codons that are typical of 
eukaryotic cells but are rare in bacterial genetic material and for this reason they might 
become necessary when producing recombinant proteins. 
The pET-24a(+) vector is not a mere vehicle and, in addition to the gene for 
17βHSD1 ligated to it, contains other key sections. One is the kanamycin resistance 
factor, which allows the selection of the cells that are transformed by growing them in 
kanamycin supplemented media. Another important one is the lac operator which is the 




Figure 48. Map of the protein cloning expression region of pET-24a showing the promoter, lac operator, NheI and 
XhoI restriction enzyme binding sites, His-tag coding region and the terminator sequence. 
In E. coli, the lac operon normally encodes for a series of protein involved in the 
transport and metabolism of lactose. An operon is a genetic structure containing a 
promoter, an operator, a series of genes and a terminator sequence. The operator is 
usually occupied by the lac suppressor which prevents transcription in normal 
conditions. The lac suppressor has high affinity for allolactose (Figure 49) and when the 
repressor binds allolactose, a conformational change displaces the repressor from the 
operon and the transcription is initiated. This system enable control of the expression of 
the protein involved in the metabolism of lactose depending on the presence or absence 
of lactose in the surrounding environment. 
The pET-24a(+) vector contains the lac operator, which binds the lac repressor and 
consequently the genes on the vector cannot be transcribed. In the experimental 
conditions, isopropyl β-D-1-thiogalactopyranoside (IPTG), a structural analogue of 
allolactose, is used to initiate the protein expression. IPTG binds the lac repressor 
displacing it from the operator and thus allows the transcription to start. 
 
Figure 49. Structure of allolactose and its mimic IPTG. 
Two important factors that influence the quality of the protein produced are the speed 
of production and the total amount produced. If the protein is produced too quickly then 
it might misfold becoming inactive. Instead, if the amount of protein synthesised is 
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excessive, the protein might aggregate or precipitate out of the cytosol and become 
unusable. To control the speed of expression, different concentrations of IPTG where 
initially screened and 12.5 µM was found to be the optimal concentration for protein 
expression. In fact, the speed of expression is proportional to the gene activation 
induced by IPTG. At the same time, just before the addition of IPTG the cell cultures 
were cooled to 16 °C to reduce the metabolism of the cells and consequently further 
reduce the speed of production of the protein. 
After the addition of IPTG, the culture was left overnight at 16 °C and then 
centrifuged to harvest the cells. The pellet was frozen to make the cells more fragile and 
then mechanically lysed. The lysate was centrifuged and the supernatant collected to 
give the crude protein which needed to be purified. Thanks to the previous work 
undertaken by our group, both untagged and His-tagged versions of 17βHSD1 were 
available. The tagged 17βHSD1 (H6-17βHSD1) possesses 6 extra histidine residues on 
the N-terminal that do not interfere with the catalytic capabilities of the enzyme but 
allow affinity purification. Histidine has high affinity for nickel ions and this affinity 
can be exploited for column purification. A column loaded with Ni
2+
 binds the histidine 
tag on the protein and the majority of impurities are washed away. The protein is then 
eluted with an imidazole gradient. Imidazole shares structural similarities with histidine 
(Figure 50) and at higher concentrations displaces the tagged protein from the column. 
 
Figure 50. Structure of histidine and imidazole. 
Among the fractions obtained, the ones containing the enzyme were identified by 
SDS PAGE gel, collected and then subjected to dialysis overnight to reduce the high 
concentration of imidazole and NaCl. Because this technique relies on the specific 
affinity between the protein tag and the Ni
2+
 ions it usually yields high purity levels. 
Nevertheless, higher levels of purity are often required especially for protein 
crystallisation. Hence, the dialysed protein solution was subjected to a second 
purification step with a Q-sepharose column, which is an ion exchange column. The 
protein is thus eluted with a gradient of NaCl and again the fractions containing the 
enzyme are identified by SDS PAGE gel, collected and then subjected to dialysis to 
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reduce the concentration of NaCl. The dialysed protein solution was concentrated to the 
desired concentration for use in either biological assays or crystallisation trials. 
 
3.1.2. Protein crystallisation. 
Several structures of 17βHSD1 with different ligands are available in the Protein 
Data Bank repository and the data obtained from previous work in our group in addition 
to the already established crystallisation conditions reported in the literature
36
 were used 
as the starting point for a new set of crystallisation attempts. 
Using the vapour diffusion technique different conditions were selected for 
crystallisation attempts. The crystallisation buffer containing 0.15 M MgCl2, 0.1 M 
Hepes pH 7.5 and 20% glycerol was selected from the literature and a range of 
PEG4000 concentrations (from 5% to 25%) were screened. 
The following conditions were selected, instead, from an automated screening 
previously undertaken by our group: 
- 0.3 mM MgAc2 and 0.1 M sodium cacodylate with a range of PEG8000 
concentrations from 10% to 35%. 
- 100 mM Hepes buffer (pH 7.5), 0.16 mM MgCl2 and 20 % glycerol with a range 
of PEG6000 concentrations from 10% to 35%. 
- Sodium citrate pH 6.5 in a range of concentrations from 1.3 M to 1.8 M. 
Four repetitions were set for each condition and the protein was left to crystallise 
over one to two weeks. Among the conditions tried, 25% PEG4000 was the one that 
gave the best results and was selected for the investigation of some additives. Two 
repetitions for each additive were set up but none of the additives gave better results 
than the original 25% PEG4000 solution. 
The composition of the solution that gave the best results was identified as 25% 
PEG4000, 0.15M MgCl2, 0.1 M Hepes pH 7.5 and 20% glycerol. Several repetitions 
were set and to some was added a solution of 170i (Figure 51) alone or a mixture of 
170i and NADP
+




Figure 51. Structure of compound 170i used for the crystallisation trials. 
To estimate if the crystals forming are protein or simply salts from the buffer, the 
drop is usually watched with a stereoscope and the incident light is polarised in different 
axis. Proteins usually glow in colours that change with the change of polarisation 
(Figure 52). 
 
Figure 52. Pictures of a hanging drop of buffer with crystals of apo-17βHSD1. On the left the drop is seen under 
normal light. On the right the drop is seen under polarised light and the crystals becomes shiny. 
Even if the addition of 170i did not have any significant effect on the shape of the 
crystals, when NADP
+
 was added the crystals become clustered needles. Despite the 
large dimensions of the cluster, the needles were too thin to be suitable for an X-ray 




Figure 53. Pictures of a hanging drop of buffer with crystals of 17βHSD1 after the addition of NADP+. On the left 
the drop is seen under normal light. On the right the drop is seen under polarised light. 
Disappointingly, only the apo-enzyme (no inhibitor and no cofactor) gave one single 
crystal big enough to attempt an X-ray diffraction (Figure 54). In addition, when the 
crystal was analysed it degraded under the X-ray beam and only part of the data was 
successfully acquired. A reconstruction from the partial data obtained was attempted but 
the amount and the quality of the data were too low to afford any tangible structure. 
 
Figure 54. Pictures of a crystal of 17βHSD1 obtained with a SEM. The black bar denotes the scale of the picture and 
the dimensions of the crystal can be estimated to ca. 75 µm of length. 
 
3.1.3.  Colourimetric enzymatic assay. 
As already described, 17βHSD1 catalyses the conversion of E1 into E2 and uses 
NADPH as the hydride donor (Figure 55) and though in vivo this process proceeds only 
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towards the formation of E2, the reaction is reversible in vitro. In fact, the content of 





Figure 55. Schematic representation of the conversion of E1 to E2 by 17βHSD1. 
Ideally, the assay would either measure the consumption of NADPH or the formation 
of NADP
+
. NADPH has its maximum point of absorption at 260 nm with a molar 
extinction coefficient (ε) of 1.69·104 M-1 cm-1 but at the same wavelength NADP+ 
absorbs with a similar ε making it impossible to measure either the formation of NADP+ 
or the consumption of NADPH at 260 nm. In addition, at this wavelength other organic 
compounds might absorb interfering with the readings. Nevertheless, it is possible to 









 does not. 
The enzyme inhibition is measured calculating the V0 (initial rate of reaction) of the 
enzyme with or without inhibitor and the ratio between the two represent the level of 
inhibition. To be able to measure V0 it is necessary to be in steady-state conditions 
which means that the concentration of the substrate is effectively constant and the rate 
of product formation is negligible. In fact, when the product concentration becomes 
significant, the reverse reaction becomes competitive and this is reflected in a variation 
of the apparent V0. This also means that the concentration of NADPH, which is a 
substrate of the enzyme together with E1, would not change significantly over time thus 
making it impossible to measure its consumption. It is possible to overcome this 
problem by analysing the reverse reaction and measuring the NADPH formation (Figure 
55). Nevertheless, the conditions impose that the amount of product formed must be low 
in comparison to the substrate and, as stated above, the ε of NADPH at 340 nm is low. 
These two conditions imply the measurement of signals over a relatively small 
absorbance range, therefore accurate procedures were needed to prevent large errors. 
The work previously carried out by our group highlighted that the equipment available 
was not able to give consistently accurate data using this approach. 
A recent piece of literature shows how it is possible to enhance the detection of 




internal salt (MTS) and phenazine ethosulfate (PES).
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 The MTS-PES system is 
usually used for cell viability assays because it is reduced to the formazan form in 
presence of NADH and NADPH (Scheme 70), which are commonly accepted as general 
cell viability indicators. 
 
Scheme 70. Conversion of the tetrazolium salt form of MTS into the formazan form. 
The reduction of MTS is usually slow and for this reason an electron carrier (PES) is 
introduced to facilitate the reaction. Using this approach, the NADPH formed by the 
oxidation of E2 to E1 transfers its electron to PES which then reduces MTS to formazan 
(Scheme 71, page 110). The latter has a strong absorption at 490 nm where not many 
common compounds absorb thus both reducing interferences and enhancing the signal 
of the NADPH formed.  
The assay was then set to measure the conversion of E2 to E1 which is the reverse 
reaction compared to what occurs in living cells. Previous work has shown a reasonable 
correlation of the steroidal inhibitors between the MTS assay and the radio-assays albeit 
with ten to fifty fold loss of sensitivity. 
The assay was performed incubating enzyme, inhibitor and NADP
+
 for 10 minutes at 
37 °C in a 96-well plate and the reaction was started by the addition of a mixture of E2 
and MTS/PES. The reaction was monitored reading the plate at 490 nm every 10 
seconds for two minutes. The data was plotted using GraphPad to calculate the slope 
which is a reflection of Vmax. The percentage of inhibition was calculated as a ratio 





Scheme 71. Redox cascade that leads to the reduction of the tetrazolium salt MTS to the formazan. 
When an initial set of simple THIQs was tested (compounds 163a,e,i,q,s and 
170e,i,o,q,s, Figure 56, Table 35) it was actually found that there was no correlation 
between the inhibitory activity of these non-steroidal compounds in the MTS assay and 
in the whole cell radio-assay. Compounds were initially tested at 10 µM concentration 
but they were found inactive at this concentration (Figure 56, Table 35). Notably, the 
standard deviation (STD) values in the measurements were very high for the THIQ 
compounds but significantly smaller for the steroidal compound STX1040 (Figure 56, 
Table 35). 
 
Figure 56. Structure of the initial set of compounds tested against 17βHSD1 on the colourimetric assay and the 
control steroidal inhibitor STX1040. 
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Table 35. Results for the compounds tested against 17βHSD1 at 10 µM in the colourimetric assay. 
Compound R1 R2 % inhib. (10 µM) 
STX1040 1   88.2 ± 0.5 
163a H H -27.5 ± 3.5 
163e OMe H 10.2 ± 19.6 
163q OMe Me 8.2 ± 14.7 
163i OMe Cl 16.8 ± 13.8 
163s OMe OMe 2.3 ± 17.2 
170e OH H 11.2 ± 20.5 
170q OH Me 9.3 ± 15.9 
170i OH Cl 6.9 ± 15.9 
163o OH OMe 4.3 ± 18.0 
170s OH OH 0.4 ± 16.9 
The percentage of inhibition reported were the result of a single experiment in triplicate. 
Compounds did not show activity even when the concentration was raised to 200 µM 
and this was not in line with the controls used. STX1040 (Figure 56, Table 36) and 
STX3562 were used as range control, the first is a potent steroidal inhibitor with an IC50 
of 27nM (from whole cell radiochemical assay) and the second showed only 28% 
inhibition at 10 µM in the same assay. In the same assay the THIQ 170i (Figure 56, 
Table 36) showed 78% inhibition at 750 nM and even if the results were not directly 
comparable it was clear that the activity of 170i should place itself between the ones of 
STX1040 and STX3562. Interestingly, when tested in the colourimetric assay the results 
were different with STX1040 1 showing 92.4% inhibition, STX3562 showing 46.7% 
inhibition and 170i being inactive. It was not clear why the steroidal compounds seemed 
to follow a similar trend in the two different assays while the THIQ derivative did not. 
Table 36. Comparison between the colourimetric assay and the results from Ipsen. 
Compound % inhib. (200 µM) Ipsen results 
STX1040 1 92.4 ± 1.0 IC50 = 27 nM 
STX3562 46.7 ± 1.9 28% @ 10 mM 
170i 3.9 ± 4.7 78% @ 0.75 mM 
The percentage of inhibition reported were the result of a single experiment in triplicate. 
Being 170i in theory amphiprotic, it was evaluated if the pH of the buffer would have 
had any influence on the activity of the compounds. The assay, which was normally 
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performed at pH 7.5, was repeated at pH 6.5 and 9.2 and the inhibition of 170i and 
STX1040 was recorded (Table 37) but no major differences were found. 
Table 37. Comparison of the activity of STX1040 and 170i at three different pHs: 6.5, 7.5, 9.2. 
Inhibitor 
% inhibition (@ 200 µM) 
pH 6.5 pH 7.5 pH 9.2 
STX1040 91 ± 1 92 ± 1 92 ± 2 
170i 6 ± 1 4 ± 5 -3 ± 5 
The percentage of inhibition reported were the result of a single experiment in triplicate. 
It was possible for compound 170i to interfere with some component of the assay 
even if it should not be able to act as a substrate it could always interfere directly with 
any redox reaction. For this reason it was evaluated if 170i had any effect when no E2 
was present. The activity of the enzyme was set to 100% when no inhibitor was present 
and to 0% when no E2 and no inhibitor were present. The addition of 170i (1 mM in 
assay) in the presence of E2 reduced the activity of the enzyme to 77% (23% inhibition) 
while when 170i was added in the absence of E2 no significant activity was registered 
(Figure 57). Hence compound 170i did not react with the dye or NADP
+
 but 



















Figure 57. Graph of the measured V0 of 17βHSD1 without E2 or 170i, with E2 but no 170i, with E2 and 170i and 
with 170i but no E2. The concentration of 170i was set to 1 mM. Values were normalised for a better reading. The 
percentage of inhibition reported were the result of a single experiment in triplicate. 
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It was not clear why compound 170i which shows a reasonable activity in the whole 
cell radiochemical assay showed very weak activity on the MTS assay. The reason 
might lay in the fact the enzyme was tested in opposite directions in the two assays or 
some biochemical activation might occur in vivo.  
Another factor that complicated the analysis of the problem was that the enzyme has 
two substrates and the binding of one or the other might lead to different affinity for the 
inhibitor. In particular, some docking studies performed by Dr. Mark Thomas have 
highlighted the possibility of a positive π-π stacking interaction between the N-aryl ring 
of 170i and the nicotinamide ring of NADPH (Figure 58). However, docking of the 
synthesised THIQ into the substrate pocket have proven doubtful. In fact, hydrogen 
bond donors and acceptors did not point towards any polar residue. In addition, multiple 
binding modes were found by the software but the scoring was never related to the 
efficacy of the compound itself. To be able to obtain more information from the docking 
studies, a crystal structure of the enzyme with a THIQ inhibitor would be necessary. 
 
Figure 58. Docking of compound 170i. Highlighted is the possible interaction between the inhibitor and the cofactor 




3.1.4. Qualitative whole cell assay. 
As the results for the assay using purified enzyme showed lower than expected 
inhibitions by THIQs, a different approach was planned following the literature. 
17βHSD1 is expressed in T47-D breast cancer cells more than in other cell lines.157 
T47-D cells are estrogen dependent breast cancer cells and thus have a direct growth 
response to E2 levels. Examples are reported in the literature where this cell line has 
been used to obtain qualitative in vivo information about 17βHSD1 inhibition. The 
strategic approach consists of measuring the cell growth after treating the cell with the 
inhibitor alone or with a mixture of inhibitor and E1 or E2. E1 is readily converted to 
E2 by 17βHSD1 and inhibition of the enzyme would reduce the stimulating effect of 
E1. Moreover, by treating the cells with only the inhibitor it is possible to evaluate their 
estrogenicity. Furthermore, by analysing the effect of the inhibitor against the E2 
stimulated growth of cells, it is possible to evaluate the anti-estrogenic properties of the 
inhibitor. The combination of these data can afford important qualitative information on 
the properties of the synthesised compounds. 
 
Figure 59. Flow chart depicting the information obtainable by treating T47-D cells with an inhibitor and with or 
without E1 or E2. GI = growth inhibition; GS = growth stimulation. 
T47-D cells, kindly donated by Dr. A. Purohit (Imperial College of London), were 
grown in the standard conditions reported in the literature
69
 and for the experiments the 
medium was slightly modified. For the experiment, the medium was supplemented with 
charcoal stripped serum instead of normal fetal calf serum in order to eliminate the 
interference from the hormones present in the normal serum. However, to have a better 
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understanding of the behaviour of the cells, the experiments were repeated in both 
charcoal stripped serum supplemented medium (CSM) and normal serum supplemented 
medium (NM). A first experiment was set up and 170e, 170i, 170q, 170s and 163o were 
selected as an initial set of inhibitors (Figure 60). For the experiment the concentration 
of E1 and E2 were set to 0.1 nM because it is reported in the literature to be the 




Figure 60. Initial set of compounds used for the screening. Compounds were used as hydrobromide salts except for 
163o which was used as hydrochloride salt.  
When the cells were treated with the chosen set of compounds 170s showed high 
estrogenicity properties at all concentrations while 163o was estrogenic only at higher 
concentrations and the others did not show a significant estrogenic degree (Figure 61). 
 
Figure 61. Growth percentage of T47-D cells treated only with the set of THIQs. Growth of cells with the carrier only 
was arbitrarily set to 100%. On the left graph compounds are grouped by concentration while on the right graph the 
data are grouped by dose response of each compound. The percentage of inhibition reported were the result of a 
single experiment in triplicate. 
When cells were treated with E2 and the set of compounds, no significant effects 
were visible. Compounds did not show anti-estrogenic activity and rather show mild 
estrogenicity at 100 µM concentration (Figure 62).  
 
Figure 62. Growth percentage of T47-D cells treated with E2 the set of THIQs. Growth of cells with E2 only was 
arbitrarily set to 100%. On the left graph compounds are grouped by concentration while on the right graph the data 
are grouped by dose response of each compound. The percentage of inhibition reported were the result of a single 
experiment in triplicate. 
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Similarly, when cells were treated with E1 and the set of compounds no relevant 
inhibition was observed and only a certain degree of estrogenicity was observed at 100 
µM. These results contrasted with the results from the whole cell radiochemical assay 
which showed for each of them a reasonable percentage of inhibition at 1.0 µM. 
 
Figure 63. Growth percentage of T47-D cells treated with E1 the set of THIQs. Growth of cells with E1 only was 
arbitrarily set to 100%. On the left graph compounds are grouped by concentration while on the right graph the data 
are grouped by dose response of each compound. The percentage of inhibition reported were the result of a single 
experiment in triplicate. 
When the growth of the cells treated with the vehicle only or with E1 or E2 was 
compared with the growth of untreated cells, a significant discrepancy became visible. 
In fact, in all the three cases the treated cells had significantly lower growth than the 
untreated ones albeit the ones treated with E1 or E2 showed higher relative growths 
than the ones treated with DMSO only (Figure 64). Moreover, comparing the growth of 
the untreated cells in the three experiment showed a great behavioural variability 
(Figure 64). 
 
Figure 64. Effect of the vehicle DMSO on the T47-D cell growth. Values are expressed in raw optical density units 
and are not normalised to emphasise the difference in growth among the three experiments. The percentage of 
inhibition reported were the result of a single experiment in triplicate. OD = Optical Density 
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Intrigued by these results the effect of DMSO and the use of ethanol as an alternative 
vehicle were evaluated. Growth curves of the cells alone or in presence of 1% ethanol 
with or without E1 or E2 were registered at 2 days intervals. Interestingly, not much 
difference was visible between the three conditions when NM (graphs C and D, Figure 
65) was used while a great stimulation was induced by ethanol when cells were grown 
in CSM (graphs A and B, Figure 65). It is noteworthy also that no significant 
stimulation from E1 (graphs A and C, Figure 65) or E2 (graphs B and D, Figure 65) was 
visible in either media making statistically insignificant the results obtained in the 
previous experiments about the compounds tested. 
 
Figure 65. Growth curves of T47-D cells with or without ethanol or either E1 or E2. Graphs A and B refer to cells 
grown in CSM while graphs C and D refer to cells grown in NM. The percentage of inhibition reported were the 
result of a single experiment in triplicate. OD = Optical Density 
It was not clear why ethanol had such stimulating effect but, after eliminating the 
possibility of cross contamination repeating the test, the theory that cells were using 
ethanol as a carbon source became more prominent (1% ethanol correspond to ca. 
0.17 M). From this point of view, the absence of effect when the NM was used might be 
explained by the fact that the latter might contain more nutrients than the CSM and then 
the effect of ethanol became negligible. One problem that could not be addressed was 
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the exact composition of the CSM. In fact, different batches of serum have different 
composition and their content is not quantified, but this factor was minimised using the 
same batch for every experiment. 
When the growth of untreated cells was reported in a graph in relation to the passage 
number it was possible to visualise the change in behaviour over the time (Figure 66). 
The cells were unsuitable for the purpose of the assay because they did not show any 
estrogen responsiveness which should be typical of this cell line. 
 
Figure 66. Growth of untreated cells at different passages. On the x axis is reported the number of passages while on 
the y axis is reported the optical density measured normalised to the reading at day 0. The number of cells seeded was 
always the same and confirmed by the reading at day 0. The percentage of inhibition reported were the result of a 
single experiment in triplicate. OD = Optical Density 
One last experiment was set up to compare the characteristics of the cells at passage 
10 with a new stock of cells at passages 5 and 11 that were taken from the frozen stock. 
To maximise the information obtained, cells were treated with 1% DMSO or 1% 
ethanol only or a combination of E1, E2 and 4-hydroxytamoxifen (HO-tam) (graphs A, 
B and C, Figure 67). HO-Tam is a well-known estrogen receptor (ER) inhibitor
159
 and 
was used in the assay to prove that the growth stimulation from either of the two 
estrogens, if there was any, was due to ER activation. 
 In the three cases DMSO had a cytostatic effect while ethanol was stimulating cell 
growth even though at different degrees among the three experiments. E1 and E2 were 
not substantially stimulating cell growth compared to the vehicle only. In the late 
passage of the new stock (graph C, Figure 67) cells were actually showing some 
inhibitory activities. Similarly, no significant differences were visible between the cells 
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treated with E1 or E2 only and E1 or E2 with HO-tam, strengthening the hypothesis that 
cell growth was not stimulated by any ER mediated mechanism. 
 
Figure 67. Graph A: cell growth of the original stock of cells used for every experiment previously mentioned. Graph 
B: early passage of a new stock of cells. Graph C: late passage of the same stock of cells used in graph B. Cells were 
treated in the same conditions: CSM supplemented with 1% DMSO, 1% ethanol, E1, E2 or HO-tam with or without 
E1 or E2. The carrier for introducing E1, E2 and HO-tam was ethanol. The growth of untreated cells was arbitrarily 
set to 100%. The percentage of inhibition reported were the result of a single experiment in triplicate. 
A more thorough research in the literature highlighted the fact that T47-D cell line is 
rather unstable and different phenotypes, if not genotypes, are observed through the 
time.
158, 160-162
 A paper from Graham et al.
6
 even proposed the hypothesis that this cell 
line could be a good model for the transition from estrogen dependant to estrogen 
independent status of breast cancer. 
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It was not possible to carry out a full characterisation of the T47-D cells used but it 
was concluded that they were unsuitable for the assay proposed and that a fully 
characterised and guaranteed batch of cells should be used for further experiments. 
 
3.1.5. Structure activity relationship of the synthesised compounds against 
17βHSD1. 
Not having access to a reliable in-house screening processes the compounds 
synthesised were initially tested by our sponsor, Ipsen. When our sponsor could no 
longer test the compounds it was decided to establish an external collaboration with the 
group of Prof. Tea Linisnik Rizner. Only a limited selection of compounds (Figure 68, 
Table 38) could be tested by Prof. Rizner. Compounds were tested at 6.0 µM for 
percentage of inhibition against 17βHSD1 and for the ones showing more than 60% 
inhibition, the test was repeated at 0.6 µM. An IC50 value was obtained for the best 
inhibitor obtained from the tests. 
 
Figure 68. Structure and substitution pattern of the compounds selected and tested against 17βHSD1. Refer to Table 
38 for compound substitution. 
Table 38. List of compounds selected for screening against 17βHSD1. The table reports the substituents and the % 
inhibition at 6 µM and 0.6 µM.  





163a H H H H H H H H 9.3 Nt 
163e H MeO H H H H H H 27.0 Nt 
163q H MeO H H 4-Me H H H 27.0 Nt 
163i H MeO H H 4-Cl H H H 38.0 Nt 
163s H MeO H H 4-MeO H H H 13.0 Nt 
170e H OH H H H H H H 45.0 Nt 
170q H OH H H 4-Me H H H 38.0 Nt 
170i H OH H H 4-Cl H H H 64.0 Nt 
163o H OH H H 4-MeO H H H 12.7 Nt 
170s H OH H H 4-OH H H H 42.0 Nt 
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163t H MeO H H 3-Cl H H H 33.5 Nt 
163v H MeO H H 2-Cl H H H 25.3 Nt 
172 OH H H H 4-Cl H H H 45.4 Nt 
171 H H OH H 4-Cl H H H 47.1 Nt 
143z H H H H 4-Cl H H OH 15.7 Nt 
163z H H H H 4-Cl H H H 40.9 Nt 
170aa H OH H H 3,4-Cl2 H H H 79.8 17.2 
170t H OH H H 3-Cl H H H 65.5 Nt 
170u H OH H H 3-OH H H H 76.2 28.3 
167 H MeO MeO H 4-MeO H H H 25.4 Nt 
146x H MeO MeO H 4-MeO H H OH 12.6 Nt 
173 H OH OH H 4-OH H H H 0.0 Nt 
174 OH OH OH H 4-OH H H H 21.1 Nt 
191a H OH H H 4-Cl Me H H 44.1 Nt 
191b H OH H H 4-Cl Et H H 40.7 Nt 
191c H OH H H 4-Cl i-Pr H H 73.1 10.8 
191e H OH H H 4-Cl Ph H H 90.1 4.7 
191f H OH H H 4-Cl Bn H H 81.0 0.0 
143n H OH H H 4-Cl H H OH 22.3 Nt 
145h Br H H H H H H OH 47.1 Nt 
144h H H Br H H H H OH 12.9 Nt 
191g H OH H H 4-Cl (CH2)2Ph H H 74.8 11.0 
191h H OH H H H Bn H H 73.7 10.6 
191i H OH H H 4-OH Bn H H 68.8 24.1 
234a H OH H H 4-Cl H Me H 54.0 Nt 
234b H OH H H 4-Cl H Et H 54.3 Nt 
234c H OH H H 4-Cl H H Me 77.2 19.9 
234d H OH H H 4-Cl H H Et 91.5 45.9 
234e H OH H H 4-Cl H H i-Pr 100.0 60.3 
234f H OH H H 4-Cl H H Bn 84.3 0.0 
234h H OH H H 4-Cl H H Me2 80.9 39.6 
234i H OH H H 4-Cl Bn H Me 69.8 23.5 
234j H OH H H 4-Cl Bn H Et 95.1 52.7 
234k H OH H H 4-Cl Bn H Bn 58.6 Nt 




Four non-cyclic compounds were also tested to define the importance of the 
importance of the THIQ structure (Figure 69, Table 39). 
 
Figure 69. Structure of the non-cyclic compounds tested against 17βHSD1. 
Table 39. Non-cyclic intermediates tested against 17βHSD1. 
Compound R1 R2 
% Inhibition 
 (6 µM)  (0.6 µM) 
122n Cl H 50.2 Nt 
122p OH H 7.4 Nt 
139n Cl Pr 70.6 19.1 
140n Cl i-Bu 86.5 17.3 
Nt = not tested; The percentage of inhibition reported were the result of a single experiment in duplicate. 
 
3.1.5.1.  Comparison between the assays from Ipsen and Prof. Rizner's group 
While the Ipsen assay was a whole cell assay, the one used by Prof. Linisnik Rizner's 
group used crude cell lysates. In addition, although both were radiochemical assays, 
Prof. Linisnik Rizner's group used an HPLC combined with a flow radiodetector for the 
analysis of the samples, while in the assay from Ipsen the E1 and E2 in the assay point 
were separated by TLC and then quantified separately. Initially the results obtained 
from Prof. Linisnik Rizner's group were compared with the one previously obtained 
from Ipsen. The two assay showed to be mostly in line with one another and only 
compound 163a laid largely outside the trend (Table 40). Very encouragingly, 
compounds showed to be significantly active in both whole-cell and cell-lysate assay 
thus meaning that they could easily penetrate inside the cells. 
 
Figure 70. Structure of the compounds tested to evaluate the effect of the nature of groups R1 and R2. Refer to Table 
40 for R1 and R2 descriptions. 
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Table 40. Comparison of the results from the assays from Ipsen and the assay from Prof. Lanisnik's group. 
Compound R1 R2 
17βHSD1 (% of inhibition) 
Ipsen Lanisnik's group 
@ 1.0 µM @ 6.0 µM 
163a H H 71.0 9.3 
163e OMe H 65.5 27.0 
163i OMe Cl 68.0 38.0 
163q OMe Me 62.0 27.0 
163s OMe OMe 32.0 13.0 
   @ 750 nM @ 6.0 µM 
170e OH H 52.7 45.0 
170i OH Cl 77.6 64.0 
170q OH Me 54.0 38.0 
170s OH OH 26.7 42.0 
The percentage of inhibition reported were the result of a single experiment in duplicate. 
3.1.5.2.  Effects of the nature of substituents on the N-phenyl ring 
Considering the R2 substitution (Figure 70) of the 6-methoxy- series (163e,i,q,s), the 
polar methoxy group showed the least activity (13.0%, 163s, Table 40). Removing the 
group increased slightly the activity (27%, 163e, Table 40) and the introduction of a 
lipophilic group such as methyl does not vary significantly the activity (27%, 163q, 
Table 40) while the lipophilic and electron withdrawing group moderately increased the 
activity (38%, 163i, Table 40). Similarly within the 6-hydroxy series (170e,i,q,s) the 
chloro-substituted compound was the most active (64%, 170i, Table 40) while the other 
derivatives showed very similar activities (170e,q,s, 38%-45%, Table 40). Moreover, 
the 6-hydroxy (170e,i,q,s, Table 40) series was generally more active than the 6-
methoxy series (163e,i,q,s, Table 40) and as such was selected as standard functionality 
for further evaluations. This effect could be explained by looking at the structural 




Figure 71. Structures of E1 (on the left) and the tested series of THIQs (on the right). At the centre, the overlap of the 
two structures highlights the similar spatial disposition of the steroidal phenol and R1. 
 R1 very likely mimicked the steroidal phenolic group which was fundamental for the 
activity of estrogens. In fact, androgens and estrogens differ mainly in the structure of 
the A-ring and the phenolic group is characteristic of all the three estrogens (E1, E2, 
E3). For this reason, a phenolic group in compounds 170e,i,q,s might occupy the same 
region as the phenolic group of E1 and have better affinity for the enzyme. 
Other information that it was possible to obtain from the series is the effect of the R2 
substituents with the use of the Craig plot. This graph is obtained by plotting the group 
lipophilicity (π) against their electronic effects (σ). Hydrogen is considered the 
reference and sits at the origin of the axis while π and σ are reported along the x axis 
and y axis, respectively. Apolar groups occupy the right region of the graph while polar 
groups are on the left side. Groups that are more electron-withdrawing are found in the 
top region of the graph while groups that are electron donating occupy the bottom part. 
Looking at the differences among the H, Me and OH substituents one can see how they 
have rather different π values and σ but all the σ values are lower than or equal to zero. 
These groups correspond to compounds 170e,q,s that had very similar activity. 
Compound 170i was significantly more active than the other and differed by the 
presence of a chlorine group. Even though this group had a similar π value to the Me 




Figure 72. Craig plot with the R2 substituents (Figure 70) highlighted. In red are circled the groups with minor 
activity, while in green is circled the Cl which corresponds to the most active substitution. The green and red arrows 
represent respectively the positive and negative effects of σ on the activity. 
The use of the Craig plot made it easy to visualise how the lipophilicity did not 
influence the activity of the R2 substituents (Figure 70) while an electron-withdrawing 
effect enhanced it significantly. 
 
3.1.5.3.  Effect of hydroxyl group in position 4, 5, 6 and 7 
The effect of the chlorine could be seen by comparing the unsubstituted compound 
163a with 163z that beared a chlorine group. The latter was ca. four times more active 
and the activity was increased by another 50% by the presence of the hydroxyl group in 
position 6 (170i). If the hydroxyl group was inserted in position 4 (143n and 143z) 
some activity was lost while the insertion of the same group in position 5 (172) or 7 




Figure 73. Structure of compounds 143z, 163a,z, 170i, 171 and 172 and relative percentage of inhibition at 6 µM. 
Compounds are organised with the weakest inhibitor at the top and the strongest inhibitor at the bottom to better 
visualise the effect of the different substitution pattern. The percentage of inhibition reported were the result of a 
single experiment in duplicate. 
 
3.1.5.4.  Effect of the position of the substituent on the N-phenyl ring 
The influence of the position of R2 was then investigated through compounds 
170i,s,t,u,aa and 163i,t,v (Figure 74, page 127). Shifting the chlorine from 4' (170i, 
Table 41, page 127) to 3' (170t, Table 41, page 127) resulted in a retention of activity 
which meant that the chlorine in both position had very similar effect. If a chlorine was 
inserted in both positions (170aa, Table 41, page 127), an additive effect was registered 
even though the resultant effect was smaller than the sum of the two individual effects. 
Not having access to a 2'-chloro substituted compound in the 6-hydroxy series, the 
effect of the chlorine in position 2' was evaluated in the 6-methoxy series which had 
shown lower activities but similar trends. Again, moving the chlorine from 4' (163i, 
Table 41, page 127) to 3' (163t, Table 41, page 127) resulted in a retention of activity as 
seen for compounds 170i and 170t but when chlorine was moved to the position 2' 




Figure 74. Structure of the compounds tested to evaluate the influence of the position of the group R2 on the N-
phenyl ring. Refer to Table 41 for R1 and R2 substitutions. 
Table 41. Influence of the position of R2 on the inhibitory activity against 17βHSD1. 
Compound R1 R2 
17βHSD1 
(% of inhibition at 6 µM) 
170i OH 4-Cl 64.0 
170t OH 3-Cl 65.5 
170aa OH 3,4-Cl2 79.8 
170s OH 4-OH 42.0 
170u OH 3-OH 76.2 
163i OMe 4-Cl 38.0 
163t OMe 3-Cl 33.5 
163v OMe 2-Cl 25.3 
The percentage of inhibition reported were the result of a single experiment in duplicate. 
The loss of activity when a group was introduced in position 2' can be explained 
considering the effect of such substitution in the 3D structure of the molecule which 
was substantially flat (image B, Figure 75) but the steric effect introduced by groups in 
position 2' (image A, Figure 75) would lead to a twisting in the C1'-N bond which would 
consequently result in a loss of planarity. 
 
Figure 75. Crystal structure of compound 164j (Table 17, page 67) which show the planarity of the molecule; A) 
Top view; B) Side view; In red are marked the negative steric interactions that might arise when a bulky substituent is 
introduced in position 2' (or 6'). 
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When the effect of the hydroxyl group was considered, shifting it from position 4' to 
3' resulted in almost a two-fold increased activity. Superimposition of the minimised 3D 
model of E2 with the THIQ core showed how closely related the group in position 3' 
overlapped with the 17β-hydroxyl group of E2 (Figure 76). 
 
Figure 76. Superimposition of the minimised 3D structure of E2 and the core structure of THIQ. The key points are 
circled and explained in the picture. 
 
3.1.5.5.  Effect of multiple substituents in positions 4, 5, 6 and 7 of the THIQ ring 
The effect of multiple polar groups in positions 4, 5, 6, and 7 led to contrasting 
results. Compound 167 (Figure 77), bearing two methoxy groups in position 6 and 7, 
was slightly more active than compound 163s (Figure 77), which only had one methoxy 
group in position 6. However, the activity was lowered by an additional hydroxyl group 
in position 4, such as in 146x (Figure 77). 
 
Figure 77. Structure of compounds 163s, 167 and 146x with relative percentage of inhibition at 6 µM. The 
percentage of inhibition reported were the result of a single experiment in duplicate. 
Conversely, when a second hydroxyl group was introduced in position 7, such as in 
compound 173 (Figure 78), the activity was completely lost compared to compound 
170s (Figure 78) that bore one single hydroxyl group in position 6 and was partially 
restored by the introduction of a third hydroxyl group in position 5 (compound 174, 
Figure 78). It appeared that even if position 6 was the favoured for the hydroxyl group, 
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the same group in position 5 could still exert a positive effect while position 7 did not 
tolerate the group at all. 
 
Figure 78. Structure of compounds 170s, 173 and 174 with relative percentage of inhibition at 6 µM. The percentage 
of inhibition reported were the result of a single experiment in duplicate. 
This discrepancy might suggest that position 7 did not tolerate hydrogen bond donor 
but a hydrogen bond acceptor was beneficial. An alternative explanation might be that 
the hydroxyl derivative 170s (Figure 78) and the methoxy derivative 163s (Figure 77) 
had two different binding modes and thus two different structure activity relationships. 
Interesting results were also found when the polar hydroxyl group on the THIQ ring 
was substituted by the hydrophobic bromine as in compounds 144h and 145h (Figure 
79). Even if both compounds bore a hydroxyl group in position 4 which should lead to a 
loss of activity as observed for compounds 143n, 143z (Figure 73, page 126) and 146x 
(Figure 77, page 128), they were still more active than the parent unsubstituted 
compound 163a (Figure 79). Between the two positions, it appeared that position 5 
favoured the presence of the lipophilic group more than position 7. 
 
Figure 79. Structure of compounds 144h, 145h with relative percentage of inhibition at 6 µM compared with 
compound 163a. The percentage of inhibition reported were the result of a single experiment in duplicate. 
 
3.1.5.6.  Effect of substitution in position 1 
When a methyl or ethyl group was introduced in position 1 of compound 170i 
(Figure 80, Table 42), such as for compounds 181a and 181b (Figure 80, Table 42), the 
activity of the compound was lowered but an isopropyl group (181c, Figure 80, Table 
42) increased the activity above that for the parent compound 170i (Figure 80, Table 
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42). The activity was increased further by the introduction of a phenyl group, as for 
181e (Figure 80, Table 42), reaching 90.1% of inhibition at 6 µM. While introducing a 
one or two carbon long linker (181f and 181g, respectively, Figure 80, Table 42) 
decreased the activity sequentially. Unexpectedly, the trend was reversed when the most 
potent compounds were tested at 0.6 µM giving compounds 181g and 181c (Figure 80, 
Table 42) as the most potent with ca. 11% of inhibition each while compound 181e 
showed only ca. 5% inhibition and 181f was completely inactive. 
 
Figure 80. Structure of the compounds tested to evaluate the influence of the substituent R in position 1. Refer to 
Table 42 for R substitutions. 
Table 42. Influence of the substituent in position 1 on the inhibitory activity against 17βHSD1. 
Compound R 
17βHSD1 
(% of inhibition at 
6 µM) 
(% of inhibition at 0.6 
µM) 
170i H 64.0 Nt 
181a Me 44.1 Nt 
181b Et 40.7 Nt 
181c i-Pr 73.1 10.8 
181e Ph 90.1 4.7 
181f CH2Ph 81.0 Inactive 
181g (CH2)2Ph 74.8 11.0 
Nt = Not tested at this concentration; The percentage of inhibition reported were the result of a single experiment in 
duplicate. 
 
3.1.5.7. Effect of substitution on the N-phenyl ring for the 1-substituted THIQs 
To understand if the binding mode was changed due to the introduction of group 
with high steric requirement and to be sure that the substitution on the N-phenyl ring 
was still the appropriate one, the activity of compound 181f (Figure 81, Table 43) was 
compared to the one of compounds 181h and 181i (Figure 81, Table 43) which 




Figure 81. Structure of the 1-benzyl substituted compounds 181f,h-i. Refer to Table 43 for R substitutions. 
Table 43. Influence of the N-phenyl substituent on the activity of compounds 181f,h-i. 
Compound R 
17βHSD1 
(% of inhibition at 6 µM) (% of inhibition at 0.6 µM) 
181f Cl 81.0 Inactive 
181h H 73.7 10.6 
181i OH 68.9 24.1 
The percentage of inhibition reported were the result of a single experiment in duplicate. 
3.1.5.8.  Effect of substitution in position 3 
Substituents in position 3 slightly lowered the activity of the compounds 234a and 
234b (Figure 82) when compared with the unsubstituted 170i although this was 
independent of the size of the substituent. 
 
Figure 82. Structure of 3-substituted compounds 234a-b and their relative percentage of inhibition at 6 µM in 
comparison with the unsubstituted compound 170i. The percentage of inhibition reported were the result of a single 
experiment in duplicate. 
 
3.1.5.9.  Effect of substitution in position 4 
Very interesting results were obtained investigating the effect of substitution in 
position 4 with sequentially larger groups. In this position Me, Et and i-Pr (234c, 234d 
and 234e, respectively, Figure 83, Table 44) increased substantially the activity up to a 
complete inhibition at 6 µM for compound 234e (Figure 83, Table 44). Compound 234e 
was the most active among the tested compounds and showed an IC50 value of 336 nM. 
Compound 234f (Figure 83, Table 44) bearing a benzyl group was less active than 
compound 234e (Figure 83, Table 44) even though it was still more active than the 
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unsubstituted compound 170i. When the compounds were tested at 0.6 µM the 
difference in activity among the compounds was emphasised and moving from Me to 
i-Pr the activity had a three-fold increment and compound 234h (Figure 83, Table 44), 
which was only marginally more active than 234c (Figure 83, Table 44) at 6 µM, was 
twice as active than it at 0.6 µM. 
 
Figure 83. Structure of 4-substituted compounds 234c-f,h and the parent unsubstituted compound 170i. Refer to 
Table 44 for R substitution. 
Table 44. Influence or the substituent in position 4 on the activity of compounds 234c-f,h compared with the activity 
of the unsubstituted compound 170i. 
Compound R 
17βHSD1 
(% of inhibition at 6 
µM) 
(% of inhibition at 0.6 
µM) 
170i H 64.0 Nt 
234c Me 77.2 19.9 
234d Et 91.5 45.9 
234e i-Pr 100 60.3 
234f Bn 84.3 Inactive 
234h (Me)2 80.9 39.6 
Nt = not tested at this concentration; The percentage of inhibition reported were the result of a single experiment in 
duplicate. 
Another important consideration that has not been done yet is that all the chiral 
compounds were tested as racemic mixtures and the two enantiomers might have 
different inhibitory activities one to another. Comparing the activities of 234c and 234h 
(Figure 84) might not be unreasonable to think that one enantiomer of 234c (Figure 84) 
might be inactive or significantly less active than the other one. In fact, if that would be 
the case, the racemate that would obviously contain only 50% of one enantiomer and 
should be less active than the single enantiomer. Compound 234h contained the group 
of both enantiomers (Figure 84) at the same time and thus had 100% content of each 
enantiomer. However, this was a mere speculation and a chiral resolution of the 




Figure 84. Relationship between 234c and 234h. 234h possess the groups of both enantiomer of 234c at the same 
time. The percentage of inhibition reported were the result of a single experiment in duplicate. 
 
3.1.5.10. Effect of disubstitution in position 1 and 4 
The effect of the substituent in position 4 could be seen also in the series of 
1,4-disubstituted compounds 234i-k (Table 45). Even if compounds such as 181f (Table 
43, page 131), bearing a benzyl group in position 1 have proved inactive at 0.6 µM, and 
the N-aryl substitution has proved to be worse than others (181h-i, Table 43, page 131), 
nevertheless compounds 234i-j (Table 45) have shown good activity even at 0.6 µM. 
 
Figure 85. Structure of 1,4-disubstituted compounds 234i-k. Refer to Table 45 for R substitution. Only one of the 
two enantiomers has been drawn. 
Table 45. Effect of the substituent in position 4 on the activity of compounds 234i-k. 
Compound R 
17βHSD1 (% inhibition) 
@ 6 µM @ 0.6 µM 
181f H 81.0 Inactive 
234i Me 69.8 23.5 
234j Et 95.1 52.7 
234k Bn 58.6 Nt 
Nt = Not tested at this concentration; The percentage of inhibition reported were the result of a single experiment in 
duplicate. 
 
3.1.5.11. Comparison between THIQs and the open ring analogues 
When comparing the THIQs derivatives 170i,s (Figure 86) with the respective 
benzylanilines 122n,p (Figure 86) it was noteworthy how, when the substituent on the 
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aniline was a chlorine (122n, Figure 86), the THIQ ring was not essential for a good 
activity even if the rigidity introduced by that ring led to a slight increase in activity. 
When the aniline ring was substituted with a hydroxyl group (122p, Figure 86) the 
effect of the THIQ ring was even more marked. Furthermore, even though compounds 
234c and 139n (Figure 86) had the same potency also at 0.6 µM, the benzylaniline 140n 
(Figure 86) was significantly less active than the parent THIQ 234h (Figure 86). Thus, 
the presence of the THIQ ring was indeed beneficial and its effect became even more 
important for the 1-, 2- or 3-substituted derivatives. 
 
Figure 86. Structure and activity of the THIQs 170i,a and 234c,h compared with the open ring analogues 139n and 
140n. The percentage of inhibition reported were the result of a single experiment in duplicate. 
 
3.1.6. Conclusions 
Though the development of a colourimetric assay did not give the desired results 
further insight is necessary to determine the reason for which steroidal compounds and 
the synthesised THIQs give different results. The co-crystallisation of the enzyme with 
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one of the known inhibitors did not give the expected results but additional optimisation 
of the crystallisation conditions might lead to more successful results. In addition, when 
a strong enough crystal is obtained, the desired inhibitor can be soaked into the enzyme 
alone or with the co-factor to give the desired crystal structure. 
The reproduction of a qualitative assay for the evaluation of 17β-HSD1 inhibition, as 
well as estrogenicity and general cytotoxicity, suffered from the quality of the cell line 
used. The experiments performed to address the problems encountered during the 
development of the assay led to the conclusion that the cell line phenotypic or genetic 
instability was to be considered the most probable issue. Nevertheless, to confirm this 
hypothesis, the experiments would need to be repeated with a certified batch of cells. 
Even if the attempt to develop an in-house assay did not give the desired results, the 
compounds synthesised could be tested initially by our sponsor and subsequently 
through a collaboration with Prof. Lanisnik's group. The whole cell assay performed at 
Ipsen laboratories not only proved that the compounds tested could inhibit the enzyme 
but also demonstrated that they can penetrate inside the cell where the enzyme resides. 
Even though the assay performed by the group of Prof. Lanisnik was less sensitive 
than the one performed at Ipsen, the two assays largely agreed in the relative rank 
ordering of the compounds. From the data obtained through the testing it was possible 
to draw some preliminary conclusions about the structure activity relationship of the 
compounds. 
The hydroxyl group in position 6 was a key feature and position 5 accepted both 
lipophilic or hydrophilic groups but more examples are needed to clarify if this 
happened via the same binding mode (Figure 87). Position 7 had been shown to accept 
both lipophilic or hydrophilic groups but a polar group in this position occasionally led 
to a loss of activity (Figure 87). Position 2' should be free of any substituent probably 
because the planarity of the molecule plays an important role in the interaction of the 
compound with the enzyme (Figure 87). Position 4' and 3' benefited from electron 
withdrawing groups but also a hydroxyl group in position 3' seemed to have a beneficial 
effect (Figure 87). Small lipophilic groups in position 3 had been tolerated with only a 
minor loss in activity. Position 1 suffered from small lipophilic substitution but activity 
was increased again with larger groups (Figure 87). This could probably occur through 
a change in binding mode because when large lipophilic substituent were present in 
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position 1, the preference for the substitution in position 4' changed from the chlorine to 
the hydroxyl group (Figure 87). Position 4 benefited from lipophilic groups and a 
hydroxyl group in this position was not tolerated (Figure 87). The effect seemed to be 
size dependant and in the series tested the isopropyl group gave the best results. 
Geminal disubstitution in this position gave positive results as well as removing the 
chirality and further examples in this direction should be considered. The introduction 
of an ethyl group in position 4 was able to restore the activity lost through the insertion 
of a benzyl group in position 1 (Figure 87). Lastly, though it was not essential for the 
activity in some cases, the THIQ ring exerted a positive effect on the activity of the 
compounds probably by both forcing the planarity of the molecule and directing the 
substituents in positions 1, 3 and 4 (Figure 87). 
 
Figure 87. Picture of the SAR conclusions for each position of the THIQ. 
The strongest inhibitor was compound 234e with an IC50 of 336 nM and a good 
chemicophysical profile. Even if the Lipinski's rule of five is probably the most known, 
there are several rules that attempt to describe the drug-likeness of compounds using 
different parameters. These rules are not absolute but are useful for the developer to 
keep under control some important properties that have been too often considered 
secondary e.g. solubility. Compound 234e satisfied most of the rules and only slightly 
exceeded the limits for LogP and LogD (Table 46). This is something important to 
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consider when the next series of compounds is developed and introduction of polar 
substituents such as, for instance, a hydroxyl group in position 3' should be evaluated. 












≤ 500  160 ≤ X ≤ 480 ≤ 450 301.81 
LogP ≤ 5  -0.4 ≤ X ≤ 5.6  5.241 
H-bond 
donor 
≤ 5   ≤ 5 1 
H-bond 
acceptor 
≤ 10   ≤ 8 2 
Number of 
atoms 
  20 ≤ X ≤ 70  41 
Molecular 
refractivity 




 ≤ 10  ≤ 10 2 
Polar 
surface area 
 ≤ 140   23.47 
LogD
7,4
    -4 ≤ X ≤ 4 5.241 
Number of 
rings 
   ≤ 4 3 
In green are highlighted the rules that are being fulfilled while in red are highlighted the rules that are exceeded. 
1CLogP and CLogD, Calculated with MarvinSketch; 2Molecular refractivity, Calculated with ChemBioDraw. 
 
3.2.  Estrogen receptor-related receptor α (ERRα) 
ERRα is a constitutively active transcription factor and as such, differently from 
enzymes, does not have substrates and products. ERRα requires the binding of the 
co-activator PGC1a to initiate DNA transcription. The commercially available 
LanthaScreen
TM
 ERRα TR-FRET co-activator assay kit upon this interaction is based. 
Among the commercially available assays, the kit was chosen for its cost effectiveness 





3.2.1.  LanthaScreenTM TR-FRET assay description 
The assay is a Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET) 
which is an advanced method of FRET. In normal fluorescence, the chromophore 
absorbs light and an electron passes from a ground state to an excited state at a higher 
energy level. After vibrational relaxation the electron pass from the ground state of a 
higher energy level to the ground state of a lower energy level and emits a photon (A, 
Figure 88). In FRET, two different chromophores are involved and the chromophore 
that absorbs the light (donor) transfers its energy to a nearby chromophore (acceptor). 
The excited acceptor subsequently emits a photon when returning to its ground state 
generating the fluorescence (B, Figure 88). 
 
Figure 88. Scheme representing the excitation-relaxation steps coupled with the absorbance and emission of light in 
normal fluorescence (A) and in FRET (B). 
The transfer of energy between the donor and the acceptor occurs without radiation 
in a range smaller than the wavelength and for this reason FRET phenomena require the 
two chromophores to be near in space, usually 1-10 nm. Therefore, FRET can be used 
to determine the proximity of two chromophores, as it can only occur when the donor 
and acceptor are close to each other. 
TR-FRET is an enhancement of a standard FRET, with the main difference that there 
is a time lapse between the excitation and the reading of the fluorescence generated. In 
fact, in standard FRET the time between absorption and final emission is on the 
nanosecond timescale while TR-FRET works on the microsecond timescale. Because 
interference from auto-fluorescent compounds and scattered light is on the nanosecond 
timescale, these might generate inaccuracies in a FRET assay. The removal of these 
interferences in TR-FRET leads to a cleaner background and to more accurate readings. 
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To be able to measure fluorescence after such a delay, special long-lifetime lanthanide 
chelates are used as donor species. 
The ERRα assay uses an anti-GST antibody labelled with terbium (Tb) and a GST-
labelled ERRα while the cofactor PGC-1α is labelled with fluorescein. The antibody 
binds to GST and ERRα binds PGC-1α bringing terbium and fluorescein near enough in 
space for the energy transfer. Terbium absorbs light at 340 nm and transfers the energy 
to fluorescein which in return emits light at 520 nm (left side of Figure 89). When an 
inverse agonist binds to the receptor, it induces a conformational change that displaces 
PGC-1α. Because the acceptor is no longer in proximity to the terbium, this cannot 
transfer its energy and as a consequence emits light at 495 nm (right side of Figure 89). 
 
Figure 89. Representation of the ERRα TR-FRET assay. The binding of the inverse agonist induces a conformational 
change that displaces PGC-1α and prevent the energy transfer from Terbium to fluorescein. Tb = Terbium; Ab = 
Terbium labelled Anti-GST antibody; GST = Glutathione S-transferase; F = Fluorescein. 
The ratio of the emission at the two wavelengths (520:495) is used to quantify the 
activity of the inverse agonist. 
An initial binding saturation analysis of the known inverse agonist XCT790 103 
(Figure 27, page 36) was performed to decide the concentration of full activity. The 
assay is carried out in 384 well plates, the total volume per well is 20 µL and no mixing 
is performed. The same plate was read after 1 h and 2 h since its preparation and both 
readings resulted in very similar graphs (Figure 90). After two hours the readings were 
more homogenous leading to smaller error bars and this was probably due to the longer 
equilibration time. As the equilibration is left to simple diffusion, a longer time might 
be needed for a more uniform reading from the different wells. It was therefore decided 
to proceed with reading after two hours to minimise internal errors. The control 
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compound XCT790 103 was used at 10 µM which showed to be the binding saturation 
concentration (Figure 90). The compounds synthesised were initially evaluated at 
10 µM but the activity registered was too low (Table 48, page 14). Therefore, it was 
decided to increase the concentration to 100 µM to be able to deduce some basic SAR 
information for the set of compounds. The EC50 of XCT790 was 242 nM and to have a 
reference that was in the same range of the tested compounds diethylstilbestrol 97 
(DES, Figure 24, page 35) was also evaluated in the same assay. DES resulted in 
64.2% ± 8.4% efficacy at 100 µM which was closer to the values for the tested 
compounds. 
XCT790 binding saturation curve




























Figure 90. Binding saturation curve of ERRα for XCT790. In blue are reported the values read after 1 h and in red 
the values read after 2 h. Complete binding occurred at a Log10 value of 4, which corresponds to a concentration of 
104 nM or 10 µM. The EC50 calculated from the curve is 242 nM and was in line with the values reported in the assay 
protocol. Values reported were obtained with a single experiment in four replicates. 
 
3.2.2. Structure activity relationship of the synthesised compounds against ERRα. 
All the compounds that were synthesised and obtained in a sufficient amount were 
tested for activity against ERRα (Figure 91, Table 47). Compounds were tested for 
percentage of inhibition at 100 µM. DES (Figure 24, page 35) was also tested as 




Figure 91. Structure and substitution pattern of the compounds selected and tested against ERRα. Refer to Table 47 
for compound substitution. 
Table 47. Full list of compounds tested against ERRα, their relative substitutions and their activity expressed in 
percentage of inhibition. 
Cmpd R1 R2 R3 R4 R5 X Y Z 
% Efficacy    
(100 µM) 
163a H H H H H H H H -7.8 ± 3.2 
163e H MeO H H H H H H -4.7 ± 2.7 
163q H MeO H H 4-Me H H H -5.4 ± 0.6 
163i H MeO H H 4-Cl H H H -4.3 ± 1.6 
163s H MeO H H 4-MeO H H H 30.5 ± 0.4 
170e H OH H H H H H H 18.8 ± 1.3 
170q H OH H H 4-Me H H H 15.1 ± 3.0 
170i H OH H H 4-Cl H H H 24.8 ± 1.9 
163o H OH H H 4-MeO H H H 13.9 ± 3.9 
170s H OH H H 4-OH H H H 33.7 ± 2.5 
163u H MeO H H 3-MeO H H H 8.9 ± 2.7 
163w H MeO H H 2-MeO H H H -9.2 ± 4.8 
163t H MeO H H 3-Cl H H H 2.5 ± 5.4 
163v H MeO H H 2-Cl H H H -1.3 ± 4.4 
165j MeO H H H 4-Cl H H H 10.9 ± 3.7 
164j H H MeO H 4-Cl H H H 6.7 ± 3.0 
172 OH H H H 4-Cl H H H 22.7 ± 3.2 
171 H H OH H 4-Cl H H H 6.8 ± 3.4 
163aa H MeO H H 3,4-Cl2 H H H 6.7 ± 4.2 
163r H MeO H H 4-Et H H H -4.1 ± 2.8 
143z H H H H 4-Cl H H OH -8.8 ± 1.5 
163z H H H H 4-Cl H H H 1.9 ± 1.9 
166i H MeO H H 4-Cl H Me H 0.3 ± 4.7 
170aa H OH H H 3,4-Cl2 H H H 21.6 ± 1.8 
170t H OH H H 3-Cl H H H 21.6 ± 2.0 
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170u H OH H H 3-OH H H H -6.6 ± 1.9 
167 H MeO MeO H 4-MeO H H H -1.9 ± 3.0 
168 MeO MeO MeO H 4-MeO H H H 11.7 ± 1.1 
146x H MeO MeO H 4-MeO H H OH 10.5 ± 1.1 
173 H OH OH H 4-OH H H H -9.2 ± 0.4 
174 OH OH OH H 4-OH H H H -0.9 ± 2.8 
166s H MeO H H 4-MeO H Me H -20.5 ± 2.8 
176x H MeO MeO H 4-MeO H H OBn 37.3 ± 1.4 
181a H MeO H H 4-Cl Me H H 12.4 ± 1.2 
181b H MeO H H 4-Cl Et H H 16.8 ± 1.2 
181e H MeO H H 4-Cl Ph H H 12.8 ± 1.0 
181f H MeO H H 4-Cl Bn H H 19.7 ± 4.4 
190f H H H MeO 4-Cl Bn H H 6.5 ± 0.6 
191a H OH H H 4-Cl Me H H 9.6 ± 2.0 
191b H OH H H 4-Cl Et H H 4.5 ± 0.8 
191c H OH H H 4-Cl i-Pr H H 46.7 ± 1.6 
191e H OH H H 4-Cl Ph H H 17.2 ± 1.4 
191f H OH H H 4-Cl Bn H H 53.2 ± 0.7 
143n H OH H H 4-Cl H H OH 18.4 ± 3.7 
175n H OBn H H 4-Cl H H OBn 17.3 ± 3.6 
145h Br H H H H H H OH 2.6 ± 0.9 
144h H H Br H H H H OH 9.4 ± 0.4 
181g H MeO H H 4-Cl (CH2)2Ph H H 16.0 ± 3.6 
190h H H H MeO H Bn H H 21.1 ± 2.7 
181h H MeO H H H Bn H H 19.2 ± 3.6 
190i H H H MeO 4-MeO Bn H H 30.0 ± 1.7 
190i H MeO H H 4-MeO Bn H H 18.2 ± 3.6 
166i H MeO H H 4-Cl H Me H 13.7 ± 2.0 
211b H MeO H H 4-Cl H Et H 20.9 ± 3.5 
228a H MeO H H 4-Cl H H Me 12.9 ± 6.6 
228b H MeO H H 4-Cl H H Et 17.6 ± 1.6 
228c H MeO H H 4-Cl H H i-Pr 23.3 ± 1.3 
228e H MeO H H 4-Cl H H 2-(MeO)Et 21.6 ± 2.4 
228d H MeO H H 4-Cl H H Bn 15.8 ± 0.8 





H MeO H H 4-Cl Bn H Me 8.6 ± 0.7 
trans-
232b 
H MeO H H 4-Cl Bn H Et 17.3 ± 3.1 
trans-
233b 
H H H MeO 4-Cl Bn H Et 20.2 ± 3.9 
trans-
232d 
H MeO H H 4-Cl Bn H Bn 10.7 ± 2.5 
191g H OH H H 4-Cl (CH2)2Ph H H 35.5 ± 1.4 
191h H OH H H H Bn H H 49.1 ± 1.6 
191i H OH H H 4-OH Bn H H 35.8 ± 1.2 
234a H OH H H 4-Cl H Me H 17.8 ± 2.1 
234b H OH H H 4-Cl H Et H 14.8 ± 1.3 
234c H OH H H 4-Cl H H Me 44.8 ± 2.5 
234d H OH H H 4-Cl H H Et 37.3 ± 3.7 
234e H OH H H 4-Cl H H i-Pr 33.5 ± 1.2 
234f H OH H H 4-Cl H H Bn 49.8 ± 1.1 
234h H OH H H 4-Cl H H Me2 30.7 ± 1.5 
trans-
234i 
H OH H H 4-Cl Bn H Me 79.2 ± 0.7 
trans-
234j 
H OH H H 4-Cl Bn H Et 35.7 ± 4.0 
trans-
234k 
H OH H H 4-Cl Bn H Bn 14.9 ± 3.0 
DES 
        
64.2 ± 8.4 
The percentage of efficacy reported were the result of a single experiment in four replicates. 
3.2.2.1.  Effects of the nature of substituents on the N-phenyl ring 
Introducing a methoxy group in position 6 of the inactive compound 163a (Figure 
92, Table 48) did not lead to an active compound (163e, Figure 92, Table 48). Further 
addition of lipophilic groups, i.e. methyl, ethyl and chlorine in position 4' (163q, 163r 
and 63i, respectively, Figure 92, Table 48), did not increase the activity but the 
introduction of a second methoxy group in this position (163s, Figure 92, Table 48) 
gave an active compound with an efficacy of 30.5%. With a hydroxyl group in position 
6 and no substituent in position 4' (170e, Figure 92, Table 48), the efficacy was ca.19%. 
Introducing a methyl or a methoxy group in position 4' (170q and 163o, respectively, 
Figure 92, Table 48) led to a mild loss in activity. In contrast, a chlorine in the same 
position 4' (170i, Figure 92, Table 48) led to a mild increase in activity compared to 
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170e (Figure 92, Table 48) and the activity was even higher when a hydroxyl group in 
position 4' was present instead (170s, Figure 92, Table 48).  
 
Figure 92. Structure of the compounds tested to evaluate the effect of the nature of groups R1 and R2. Refer to Table 
48 for R1 and R2 descriptions. 
Table 48. Results of the two series of 4'-substituted compounds tested against ERRα.  
Compound R1 R2 
% of efficacy 
@ 100 µM @ 10 µM 
163a H H Inactive Inactive 
163e OMe H Inactive Inactive 
163q OMe Me Inactive Inactive 
163r OMe Et Inactive Inactive 
163i OMe Cl Inactive Inactive 
163s OMe OMe 30.5 ± 0.4 Inactive 
    
 
170e OH H 18.8 ± 1.3 Inactive 
170q OH Me 15.1 ± 3.0 6.0 ± 2.0 
170i OH Cl 24.8 ± 1.9 8.1 ± 2.4 
163o OH OMe 13.9 ± 3.9 Inactive 
170s OH OH 33.7 ± 2.5 13.5 ± 7.4 
The percentage of efficacy reported were the result of a single experiment in four replicates. 
Using a Craig plot to visualise the effects of substituents in position 4', it became 
clear how the 6-methoxy and 6-hydroxy series presented some differences. For the 
6-methoxy series, the dimethoxy compound 163s (Figure 92, Table 48) was the only 





Figure 93. Craig plot graph used to highlight the effects of substitution in position 4' of the 6-methoxy series. Arrows 
point towards the group with the next higher activity. 
When the effects of the substitution on position 4' of the hydroxyl series were 
visualised on the Craig plot, a complete different trend was observed (Figure 94). The 
efficacy increased with the increasing values of σ and π effects but the introduction of a 
hydroxyl group (170s, Figure 92, Table 48), which had completely different σ and π 
values led to a further increase in activity. It is reasonable to assume that the latter 
compound might have a different binding mode than the others of its series. 
 
Figure 94. Craig plot graph used to highlight the effects of substitution in position 4' of the 6-hydroxy series. Arrows 
point towards the group with the next higher activity. 
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3.2.2.2.  Effect of the position of the substituent on the N-phenyl ring 
For the 6-methoxy series, moving the methoxy group from position 4' (163s, Table 
49) to 3' (163u, Table 49) drastically reduced the activity and, if further shifted to 
position 2' (163w, Table 49), it was completely lost.  In addition, for the 6-methoxy 
series, compounds with a chlorine in position 4', 3' or 2' (163i, 163t and 163v, Table 49) 
were inactive and also the introduction of a second chlorine (163aa, Table 49) led to an 
inactive compound. Similarly, for the 6-hydroxy series, moving the hydroxyl group 
from position 4' (170s, Table 49) to position 3' (170u, Table 49) made the compound 
completely inactive. Conversely, in the 6-hydroxy series, when the chlorine was moved 
from position 4' (170i, Table 49) to position 3' (170t, Table 49) or if a second chlorine 
was introduced in position 3' (170aa, Table 49) the activity did not vary greatly. 
 
Figure 95. Structure of the compounds tested to evaluate the effect of the position of substituent R2
 on the N-phenyl 
ring. Refer to Table 49 for R1 and R2 descriptions. 
Table 49. Effect of the position of substituent R2 on the activity of the two series of compounds tested. 
Compound R1 R2 
% of efficacy 
(@ 100 µM) 
163s OMe 4-OMe 30.5 ± 0.4 
163u OMe 3-OMe 8.9 ± 2.7 
163w OMe 2-OMe Inactive 
163i OMe 4-Cl Inactive 
163t OMe 3-Cl Inactive 
163v OMe 2-Cl Inactive 
163aa OMe 3,4-Cl2 Inactive 
    
170i OH 4-Cl 24.8 ± 1.9 
170t OH 3-Cl 21.6 ± 2.7 
170aa OH 3,4-Cl2 21.6 ± 2.7 
170s OH 4-OH 33.7 ± 2.5 
170u OH 3-OH Inactive 
The percentage of efficacy reported were the result of a single experiment in four replicates. 
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3.2.2.3.  Effect of substituents in positions 4, 5, 6, 7 and 8 of the THIQ ring 
Compound 163i (Table 50) with a methoxy group in position 6 and a chlorine in 
position 4' was inactive. If the 6-methoxy group was moved to position 7 (164j, Table 
50) no activity was gained but if the methoxy group was moved to position 5 (165j, 
Table 50) then a moderate increase in activity was observed. In contrast, compound 
170i (Table 50) with a hydroxyl group in position 6 was active. The activity was 
retained if the hydroxyl group was moved to position 5 (172, Table 50). However, if the 
hydroxyl group was moved to position 7 (171, Table 50) or to position 4 (143z, Table 
50), the activity was lost. Removing the hydroxyl group led also to an inactive 
compound (163z, Table 50). 
 
Figure 96. Structure of the compounds used to evaluate the effect of substituents in positions 4, 5, 6 and 7. Refer to 
Table 50 for R description. 
Table 50. Effect on the activity of the position of the substituent R on the THIQ ring. 
Compound R 
% of efficacy 
(@ 100 µM) 
165j 5-OMe 10.9 ± 3.7 
163i 6-OMe Inactive 
164j 7-OMe Inactive 
   
143z 4-OH Inactive 
172 5-OH 22.7 ± 3.2 
170i 6-OH 24.8 ± 1.9 
171 7-OH Inactive 
163z H Inactive 
The percentage of efficacy reported were the result of a single experiment in four replicates. 
3.2.2.4.  Effect of multiple substituents in positions 4, 5, 6 and 7 of the THIQ ring 
The activity of compound 163s (Table 51), which had a methoxy group in position 4' 
of the N-phenyl ring and a single methoxy on the THIQ ring in position 6, was 30.5%. 
This activity was completely lost when a second methoxy group was introduced in 
position 7 of the THIQ ring(167, Table 51) and only partly restored when either a third 
methoxy group in position 5 (168, Table 51) or a hydroxyl group in position 4 (146x, 
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Table 51) were introduced. However, the activity was greater than for compound 163s 
with the introduction of a benzyloxy group in position 4 (176x, Table 51). It seemed 
that the benzyloxy group in position 4 was able to overcome the negative effect of the 
methoxy group in position 7 and would have thus been interesting to know the activity 
of a compound similar to 176x (Table 51) but lacking the methoxy group in position 7. 
Conversely, the activity of compound 170s (Table 51) was again lost when a second 
hydroxyl group was introduced in position 7 (173, Table 51) but it was not restored by 
the introduction of a third hydroxyl group in position 5 (174, Table 51).  
 
Figure 97. Structure of the compounds used to evaluate the effect of multiple substituents in positions 4, 5, 6 and 7. 
Refer to Table 51 for R1, R2, R3, R4 and R5 description. 
Table 51. Effect of the presence of multiple substituents on the THIQ ring. 
Compound R1 R2 R3 R4 R5 % of efficacy 
163s H OMe H H OMe 30.5 ± 0.4 
167 OMe OMe H H OMe Inactive 
168 OMe OMe OMe H OMe 11.7 ± 1.1 
146x OMe OMe H OH OMe 10.5 ± 1.1 
176x OMe OMe H OBn OMe 37.3 ± 1.4 
       
170s H OH H H OH 33.7 ± 2.5 
173 OH OH H H OH Inactive 
174 OH OH OH H OH Inactive 
The percentage of efficacy reported were the result of a single experiment in four replicates. 
3.2.2.5.  Effect of hydroxyl in position 4 
When a second hydroxyl group was introduced in position 4 of compound 170i 
(143n, Figure 98) the activity was somewhat lower and very interestingly when both 
hydroxyl group were benzylated (175n, Figure 98) no change in activity was observed. 
Although the activity of compound 175n was very low, the small amount of activity 




Figure 98. Structure and relative efficacy of compounds 170i, 143n and 175n. Despite the diverse substitution, the 
three compounds show very similar activities. The percentage of efficacy reported were the result of a single 
experiment in four replicates. 
Compound 145h (Figure 99) was completely inactive but moving the bromine from 
position 5 to position 7 led to a slightly active compound (144h, Figure 99). 
Unfortunately, it was not possible to do any direct correlation with the previous 
compounds because substitution position 4 of the THIQ ring had sometime positive and 
sometime negative effects (146x, Table 51 and 143n, Figure 98, respectively), 
depending on the substitution pattern on the rest of the molecule. Thus, it was difficult 
to anticipate if the hydroxyl in position 4 for compounds 144h and 145h (Figure 98) had 
a positive or negative effect. 
 
Figure 99. Structure and relative efficacy of compounds 144h and 145h. The percentage of efficacy reported were 
the result of a single experiment in four replicates. 
 
3.2.2.6.  Effect of substitution in position 1 
Compound 163i (Table 52), with a methoxy group in position 6 was inactive, 
whereas compound 171i (Table 52), with a hydroxyl in the same position had an 
activity of 24.8%. For the 6-methoxy series, adding a substituent in position 1 
(181a,b,e-g, Table 52) led to low activity compounds but this might not be size 
dependent, with every group from the methyl to the phenylethyl having very similar 
activities. For the 6-hydroxy series, the activity gained by addition of substituents in 
position 1 (191a-c,e-g, Table 52) was significant and appeared to be size dependent as 
the 1-methyl substituted compound (191a, Table 52) was the weakest of the series and 
the 1-benzyl substituted (191f, Table 52) the strongest. The phenethyl group in 
compound 191g (Table 52) was probably near the maximum size that could be 
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accommodated or was spatially not well oriented, leading to a loss in activity compared 
to compound 191f (Table 52). The 1-phenyl substituted compound 191e (Table 52), was 
the only compound of the series with the substituent in position 1 perpendicularly to the 
plane of the THIQ. This could lead to steric hindrance or less optimal binding, which 
might explain the lower activity than the other compounds of the series. 
 
Figure 100. Structure of tested compounds used to evaluate substituents in position 1. Refer to Table 52 for R1 and 
R2 substitution. 
Table 52. Effects of the substituent in position 1 for the two series of compounds tested. 
Compound R1 R2 % of efficacy 
163i OMe H Inactive 
181a OMe Me 12.4 ± 1.2 
181b OMe Et 16.8 ± 1.2 
181e OMe Ph 12.8 ± 1.0 
181f OMe Bn 19.7 ± 4.4 
181g OMe (CH2)2Ph 16.0 ± 3.6 
    
171i OH H 24.8 ± 1.9 
191a OH Me 9.6 ± 2.0 
181b OH Et 41.5 ± 0.8 
191c OH i-Pr 46.7 ± 1.6 
191e OH Ph 17.2 ± 1.4 
191f OH Bn 53.2 ± 0.7 
191g OH (CH2)2Ph 35.5 ± 1.4 
The percentage of efficacy reported were the result of a single experiment in four replicates. 
3.2.2.7.  Effect of substitution on the N-phenyl ring for the 1-substituted THIQs 
When there was a chlorine in position 4', for both the 6-methoxy and the 6-hydroxy 
series, a benzyl group in position 1 gave the highest activity. Retaining the 1-benzyl 
group, a re-evaluation of the substituent in position 4' of the N-phenyl ring of the 6-
methoxy substituted 181f did not lead to any significant change in activity for either no 
substituent (181h, Table 53) or a 4'-hydroxyl group (181i, Table 53). This suggested 
that the effect of the chlorine in 181f was negligible. When the chlorine of 6-hydroxy 
compound 191f was removed (191h, Table 53) the activity was retained but the 
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introduction of a hydroxyl group in the same 4' position (191i, Table 53) led to a 
significant loss in activity. Conversely, when the substituent in position 6 was replaced 
by a methoxy group in position 8, the 4'-chloro substituted compound (190f, Table 53) 
had the lowest activity and the 4'-methoxy derivative (190i, Table 53) the highest. In 
addition, 190f was significantly worse than 181f while 190i was significantly better than 
181i (Table 53). 
 
Figure 101. Structure of the compounds used to re-evaluate the influence of the substituent on the N-phenyl ring and 
to evaluate the influence of the substituent in position 8. Refer to Table 53 for R1, R2 and R3 substitution. 
Table 53. Effect of the substituent in 4' position of the 1-benzyl substituted compounds. 
Compound R1 R2 R3 % of efficacy 
181f OMe H Cl 19.7 ± 4.4 
181h OMe H H 19.2 ± 3.6 
181i OMe H OMe 18.2 ± 3.6 
190f H OMe Cl 6.5 ± 0.6 
190h H OMe H 21.1 ± 2.7 
190i H OMe OMe 30.0 ± 1.7 
     
191f OH H Cl 53.2 ± 0.7 
191h OH H H 49.1 ± 1.6 
191i OH H OH 35.8 ± 1.2 
The percentage of efficacy reported were the result of a single experiment in four replicates. 
3.2.2.8.  Effect of substitution in position 3 
For the 6-methoxy series, the compound with a chlorine in position 4' was inactive 
with no substituent in position 3 (163i, Table 54).  However, some activity was obtained 
by introducing a substituent in position 3 (166i, 211b, Table 54). In the 6-hydroxyl 
series with a chlorine in position 4', the presence of a substituent in position 3 (234a, 
234b, Table 54) led only to a small loss in activity. Very interestingly, when the 
substituents in 6 and 4' are methoxy groups, the introduction of a methyl group in 
position 3 (166s, Table 54) led to an inversion of activity. In the assay, compounds were 
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tested as inverse agonists where the signal from the untreated receptor was considered 
zero. Thus, an increase in activity of the receptor was reported as a negative value.  
 
Figure 102. Structure of compounds used to evaluate the effect of substituents in position 3. Refer to Table 54 for 
R1, R2 and R3 substitution. 
Table 54. Effect of the substituents in position 3. 
Compound R1 R2 R3 % of efficacy 
163i OMe H Cl Inactive 
166i OMe Me Cl 13.7 ± 2.0 
211b OMe Et Cl 20.9 ± 3.5 
     
163s OMe H OMe 30.5 ± 0.4 
166s OMe Me OMe -20.5 ± 2.8 
     
170i OH H Cl 24.8 ± 1.9 
234a OH Me Cl 17.8 ± 2.1 
234b OH Et Cl 14.8 ± 1.3 
The percentage of efficacy reported were the result of a single experiment in four replicates. 
3.2.2.9.  Effect of substitution in position 4 
Although every 4-substituted compound of the 6-methoxy-4'-chloro series was more 
active than the parent compound 163i (Table 55), the activity was small with a 
maximum of 23% of efficacy for the 4-isopropyl substituted compound 228c (Table 
55). The type of substitution did not influence the activity significantly but the geminal 
disubstituted 228f (Table 55) had the lowest activity of the series. This effect might 
indicate that one of the two stereoisomers of the 4-substituted compounds could not be 
accepted well into the binding pocket. More interesting results were found for the 
6-hydroxyl-4'-chloro series where the 4-methyl group (234c, Table 55) showed a 
significant increase in activity over the unsubstituted compound 170i (Table 55). This 
activity was reduced slightly with a 4-ethyl group (234d, Table 55) and a little further 
with a 4-isopropyl group (234e, Table 55). A benzyl group in the same position 4 gave 
the highest activity for the series of 49.8%. The effect of substitution in position 4 for 
the 6-hydroxyl-4'-chloro series was not size dependant and did not have a clear 
explanation. The geminal dimethyl derivative 234h (Table 55) had a lower activity than 
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compound 234c (Table 55) which had a single methyl group. This might implied that 
one of the two enantiomer of 234c (Table 55) could not be well accommodated in the 
binding pocket. As previously discussed (Figure 84, page 133) though, this is just 
speculation and the two separate enantiomers should be tested individually to evaluate 
the real effect that each has on the activity. 
 
Figure 103. Structure of compounds used to evaluate the effect of substituents in position 4. Refer to Table 55 for R1 
and R2 substitution. 
Table 55. Effect of the substituents in position 4. 
Compound R1 R2 % of efficacy 
163i OMe H Inactive 
228a OMe Me 12.9 ± 6.6 
228b OMe Et 17.6 ± 1.6 
228c OMe i-Pr 23.3 ± 1.3 
228e OMe (CH2)2OMe 21.6 ± 2.4 
228d OMe Bn 15.8 ± 0.8 
228f OMe Me2 9.2 ± 1.9 
    
170i OH H 24.8 ± 1.9 
234c OH Me 44.8 ± 2.5 
234d OH Et 37.3 ± 3.7 
234e OH i-Pr 33.5 ± 1.2 
234f OH Bn 49.8 ± 1.1 
234h OH Me2 30.7 ± 1.5 
The percentage of efficacy reported were the result of a single experiment in four replicates. 
3.2.2.10. Effect of disubstitution in position 1 and 4 
In the 1-benzyl-6-methoxy series introducing a group in position 4 did not give any 
positive effect on activity, instead a small loss of activity was observed (232a, 232b, 
232d, Table 56). In contrast, in the 1-benzyl-6-hydroxyl series a methyl group in 
position 4 (234i, Table 56) significantly increased the efficacy to 79.2% but the activity 





Scheme 72. Structure of the 1,4-disubstituted compounds used to evaluate the effects of the substituent in position 4. 
Refer to Table 56 for R1and R2 substitutions. 
Table 56. Effect of the substituents in position 4 of the 1-benzyl substituted compounds. 
Compound R1 R2 % of efficacy 
181f OMe H 19.7 ± 4.4 
232a OMe Me 8.6 ± 0.7 
232b OMe Et 17.7 ± 3.1 
232d OMe Bn 10.7 ± 2.5 
    
191f OH H 53.2 ± 0.7 
234i OH Me 79.2 ± 0.7 
234j OH Et 35.7 ± 4.0 
234k OH Bn 14.9 ± 3.0 
The percentage of efficacy reported were the result of a single experiment in four replicates. 
3.2.2.11. Comparison between THIQs and the open ring analogues 
To determine whether the THIQ ring was necessary for the activity, the open ring 
compounds 122n and 122p (Figure 104) were tested and compared with the analogue 
THIQs, 170i and 170s, respectively. Both the open ring derivatives 122n and 122p were 
active, although with a lower efficacy compared to the corresponding THIQs. These 
results showed that the rigidity introduced by the THIQ ring was not essential for the 




Figure 104. Structure and relative efficacy of the THIQs 170i,s and the respective open ring derivative 122n,p. The 
percentage of efficacy reported were the result of a single experiment in four replicates. 
 
3.2.3.  Conclusions 
It is difficult to draw specific conclusions on the structure activity relationship of the 
compounds tested against ERRα. A trend was observed, where by altering the 
substituent at one position the  structure activity relationship of substituents at a 
different position could be modified. For example, this was the case for the substitution 
in position 4' of the 6-methoxy, 8-methoxy and 6-hydroxy series (Table 53, page 151). 
Similarly, substitution in position 4 of the 6-methoxy and 6-hydroxy series (Table 55, 
page 153) had contrasting effect.  
From all the compounds synthesised and tested, the best inverse agonist 234i (Figure 
105) had a percentage of efficacy of 79.2% ± 0.7% at 100 µM. This was moderately 
higher than that observed for DES at the same concentration, i.e. 64.2% ± 8.4%. The 
EC50 of DES reported in the literature is ca. 10 µM, while the EC50 of XCT790 is ca. 
250 nM. Even if more active than DES, compound 234i (Figure 105) presented already 
issues of high lipophilicity, which would need to be one of the primary aspects to be 
addressed in future. In fact, high lipophilicity is inversely correlated with solubility and 
directly correlated, instead, with aspecific toxicity.  
 Considering the difference in lipophilicity between 191f and 191i (Figure 105), the 
activity of a compound like 235 (Figure 105) should be investigated. A simplification of 
the structure as in 236 (Figure 105) should also be considered where no significant loss 
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of activity is observed. As well as solubility maybe becoming a significant issue when 
trying to increase the activity of the compounds down to a low nM range, the cellular 
localisation of the target also needs to be considered. ERRα is located in the nucleus, 
therefore an active compound needs to penetrate the nucleus to be able to interact with 
the receptor. Thus, any inverse agonist will have to possess a significant degree of 
lipophilicity to be able to penetrate the nucleus and exert its activity. 
 
Figure 105. Structure and relative activity and CLogP values of compounds 191f, 191i and 234i, and compounds of 
possible future interest 235 and 236. The percentage of efficacy reported were the result of a single experiment in 
four replicates. 
An interesting result was the effect of a methyl group in position 3 of the dimethoxy 
substituted compound 166s (Figure 106), which completely inverted the activity of 
compound 163s (Figure 106) from an inverse agonist into an agonist. This effect was 





Figure 106. Structure and relative activity of compounds 163s and 166s, respectively an inverse agonist and an 
agonist of ERRα. The percentage of efficacy reported were the result of a single experiment in four replicates. 
 
3.3. Nuclear Hormone Receptors (NHRs) screening. 
A panel of 19 NHR was used to prove that the THIQ structure is a good 
steroidomimetic nucleus and at the same time evaluate possible off-target activity. In 
addition, through this service, it was possible to evaluate the activity of selected 
compounds in a whole cell assay against both ERRα and ERα. 
Three selected compounds were tested against a wide range of NHRs to obtain 
information about their selectivity. The three selected compounds were 170i, 170s and 
191c (Figure 107) and they were chosen based on their differences and similarities. In 
fact, to be able to correlate the data obtained with the structure of the compound it was 
decided to test compounds that would not differ for more than one substituent. 
 
Figure 107. Structure of the three compounds tested against a wide range of NHRs. 
 The testing was outsourced to DiscoveRx which has developed its own whole-cell 
assay named PathHunter. The principle on which the assay is based is somewhat similar 
to the LanthaScreen
TM
 TR-FRET. The PathHunter assay uses cells that contain tagged 
hormone receptor and co-activator peptide, which are both required for signalling 
transduction and gene expression. Both receptor and co-activator contain half of a 
β-galactosidase enzyme and when the receptor is activated, it is translocated to the 
nucleus where it recruits the co-activator peptide in order to initiate gene transcription. 
In this way, the two parts of the enzyme are put in proximity to one another, the enzyme 
β-galactosidase becomes active. The active enzyme converts an inactive dye (structural 
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analogue of galactose) into a chemiluminescent compound, thus producing the response 
signal (Figure 108). 
 
Figure 108. Schematic representation of the PathHunter assay from DiscoveRx. NHR = Nuclear hormone receptor; 
A = Agonist; CA = Co-activator; β-Gal = β-Galactosidase 
In agonist mode, activity is expressed as percentage of activity compared to the 
activity of a control agonist which is set by definition at 100%. In antagonist mode 
compounds where tested challenging an EC80 concentration of the control agonist. The 
activity of the control was set by definition to 100%. By definition, the values of the 
vehicles are set to 0%. 
In agonist mode, a negative value describes a compound that reduces the activity 
compared to the one observed by the vehicle only. Thus, negative values in agonist 
mode describe an inverse agonist. Values above 100% are observed instead for 
compounds that induce activity higher than the control agonist used. Conversely, ERRα 
is constitutively active and the control used is an inverse agonist. Thus, activity above 
100% are referred to compounds that are stronger than the control inverse agonist. This 
means that compounds that have an efficacy higher than 100% reduce the activity of the 
enzyme more than the control inverse agonist. Vice versa, activity values below 0% 
indicate an agonist. 
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In antagonist mode, activity values above 100% describe compounds that reduce the 
activity below the activity of the control vehicle. Thus activity values above 100% 
describe inverse agonists. Conversely, values below 0% describe compounds that 
increase the activity of the compounds above the activity of the control agonist. Thus, 
activity values below 0% describe agonist compounds. Being ERRα constitutively 
active, values observed for this receptor reflects opposite effects compared to the other 
receptors in the panel. Hence, negative values describe inverse agonists that deactivate 
the receptor more than the inverse agonist control. Vice versa, values above 100% 
describe agonist compounds that activate the receptor more than the vehicle control. 
The three compounds were tested in agonist and antagonist mode against the 
following NHRs: 
- Androgen receptor (AR) 
- Estrogen receptor alpha (ERα) 
- Estrogen receptor-related receptor alpha (ERRα) 
- Farnesoid X receptor (FXR) 
- Glucocorticoid receptor (GR) 
- Liver X receptors (LXRα, LXRβ) 
- Mineralocorticoid receptor (MR) 
- Peroxisome proliferator-activated receptors (PPARα, PPARβ, PPARγ) 
- Progesterone receptors (PRα, PRβ) 
- Retinoic acid receptors (RARα, RARβ) 
- Retinoid X receptors (RXRα, RXRγ) 
- Thyroid hormone receptors (THRα, THRβ) 
When the compounds were tested in agonist mode 191c was found to be always a 
weak inverse agonist against every receptor except ERRα for which it had 115% 
efficacy as inverse agonist (Table 57). Another important aspect was that 191c was also 
non-estrogenic even at 100 µM showing only 10.7% activity against ERα. This is a 
basic requirement for a 17β-HSD1 inhibitor. Conversely, 170i was the most estrogenic 
and, in addition, activated also PPARδ to ca. 65% while 170s did not show any general 
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agonist activity apart from a significant degree of estrogenicity (Table 57). What is 
extremely important to consider is that very simple substitutions can change the effect 
of the compounds, e.g. from ERα agonist (170i) to an ERRα inverse agonist (191c). 
Table 57. Results of the screening against the NHRs panel in agonist mode. Colours are used to visualise the worst 
(red), the intermediate (yellow) and the best (green) agonist among the three compounds. 
 
Agonist mode 
(% of activity) 
 170i 170s 191c 
AR 8.9 -0.7 -3.6 
ERRα 5.5 27.4 115.4 
ERα 114.7 60.7 10.7 
FXR -3.7 -6.6 -8.1 
GR 0.9 1.2 0.2 
LXRß 10.6 -3.0 -6.9 
LXRα 0.5 -1.9 -4.2 
MR -1.4 -0.1 -3.4 
PPARα 0.1 -2.0 -2.4 
PPARγ -4.6 -3.8 -11.7 
PPARδ 64.8 -5.9 -30.9 
PRß -2.1 -2.2 -5.6 
PRα -0.7 1.9 -13.5 
RARß -31.3 -0.2 -45.9 
RARα -2.1 1.3 -15.8 
RXRα 30.4 3.8 -12.8 
RXRγ -0.7 0.3 -17.6 
THRß 4.6 -2.7 -9.9 
THRα 10.1 0.3 -4.0 
 
When tested in antagonist mode 170s showed only a low to moderate level of 
competition while 191c was able to fully inhibit almost every receptor (Table 58). 
Again, ERRα is an exception because is constitutively active and 191c was competing 
against an inverse agonist. At this concentration 191c was unable to discriminate among 
the different receptors but 170i, which was a weaker antagonist, showed different 
degrees of inhibition against the different targets. Noteworthy is also the activity of 170i 
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against RXRs where it acted as a full antagonist against RXRγ (Table 58), but acted as a 
partial agonist against RXRα (Table 57, Table 58) showing activity as both agonist and 
antagonist. Moreover, 170i acted as an antagonist against PPARγ (Table 58) but as an 
agonist against PPARδ (Table 57). 
Table 58. Results of the screening against the NHRs panel in Antagonist mode. Colours are used to visualise the 
worst (red), the intermediate (yellow) and the best (green) agonist among the three compounds. 
 
Antagonist mode 
(% of inhibition) 
 170i 170s 191c 
AR 77.4 24.3 99.3 
ERRα -8.4 -29.2 -49.7 
ERα -18.1 -53.4 86.5 
FXR 95.5 49.0 95.5 
GR 76.1 12.3 91.5 
LXRß 41.1 17.8 103.3 
LXRα 89.1 16.9 102.3 
MR 93.9 14.3 100.4 
PPARα 11.2 -28.7 98.2 
PPARγ 91.7 33.2 110.0 
PPARδ 8.9 25.7 127.8 
PRß 96.4 40.9 102.5 
PRα 80.5 39.4 109.6 
RARß 131.9 -8.1 174.3 
RARα 96.9 36.1 125.3 
RXRα 50.0 16.1 115.1 
RXRγ 71.8 17.4 115.0 
THRß 87.5 16.3 118.0 
THRα 72.8 31.6 101.8 
The ability to affect all of the NHRs considered in the assay might present major 
risks in the future development of an inhibitor of 17β-HSD1 and inverse agonists of 
ERRα. The data obtained demonstrated that the selectivity against the different NHRs 
should be continuously evaluated during the different stages of lead optimisation. This 
awareness would prevent the development of potent compounds which cannot be 
implemented in therapy due to side effects originating from their lack of selectivity. 
162 
 
From a different point of view, the results prove that the THIQ core is capable of 
interacting with all the NHRs tested and that simple substitutions have significant 
effects on the selectivity against the different targets. Hence, even if off-target effects 
are a risk, selectivity can possibly be achieved with the right substitution pattern. In 
addition, the THIQ core may prove to be an interesting scaffold for undertaking further 
studies against the different NHRs. 
 
3.4. National Cancer Institute of America (NCI) – Developmental Therapeutics 
Program (DTP) 
The NCI-DTP 60 cell line panel is a project the development of which started in the 
late 1980s and finalised in 1990. The project was designed to identify novel antitumoral 
compounds to treat a wide range of cancer types. The screening service is free of charge 
and is open to both academic and industrial laboratories. After an electronic submission, 
compounds are selected based upon structure novelty and diversity and secondly on 
drug-like properties. When a novel natural product or synthetic compound is accepted, it 
is initially screened at 10 µM against every cell line. If the screening results show active 
compounds, then the test is repeated with a five concentration dose response. 
The 60 cell lines are collected from nine different types of cancer and together 
represent a powerful tool, not only for the discovery of new anticancer drugs, but also 
for unravelling their mechanism of action. The cell lines are characterised by different 
responses to the same antitumoural compound and the effect of a compound on the 
different cell lines is a “fingerprint” of its mechanism of action. Comparing the effect of 
an unknown compound with the effect of other drugs, which mechanism of action has 
been previously described, it is possible to determine how the new compound may exert 
its effects. 
Among the compounds synthesised, 54 (Figure 109, Table 59) were selected for the 
initial screening and three proceeded to the 5 dose assay.  
 




Table 59. List of the 54 compounds tested on the NCI 60 cell line panel with relative substituents description. 
Cmpd R1 R2 R3 R4 R5 X Y Z 
163e H OMe H H H H H H 
163i H OMe H H 4-Cl H H H 
163q H OMe H H 4-Me H H H 
163s H OMe H H 4-OMe H H H 
170e H OH H H H H H H 
170i H OH H H 4-Cl H H H 
170q H OH H H 4-Me H H H 
170s H OH H H 4-OH H H H 
163u H OMe H H 3-OMe H H H 
163w H OMe H H 2-OMe H H H 
163t H OMe H H 3-Cl H H H 
163v H OMe H H 2-Cl H H H 
164j H H OMe H 4-Cl H H H 
165j OMe H H H 4-Cl H H H 
163aa H OMe H H 3,4-Cl2 H H H 
143z H H H H 4-Cl H H OH 
166i H OMe H H 4-Cl H Me H 
170aa H OH H H 3,4-Cl2 H H H 
170t H OH H H 3-Cl H H H 
170u H OH H H 3-OH H H H 
146x H OMe OMe H 4-OMe H H OH 
167 H OMe OMe H 4-OMe H H H 
168 OMe OMe OMe H 4-OMe H H H 
166s H OMe H H 4-OMe H Me H 
176x H OMe OMe H 4-OMe H H OBn 
181a H OMe H H 4-Cl Me H H 
181e H OMe H H 4-Cl Ph H H 
181f H OMe H H 4-Cl Bn H H 
191a H OH H H 4-Cl Me H H 
191e H OH H H 4-Cl Ph H H 
190f H H H OMe 4-Cl Bn H H 
181c H OMe H H 4-Cl i-Pr H H 
191b H OH H H 4-Cl Et H H 
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191c H OH H H 4-Cl i-Pr H H 
191f H OH H H 4-Cl Bn H H 
173 H OH OH H 4-OH H H H 
174 OH OH OH H 4-OH H H H 
143n H OH H H 4-Cl H H OH 
175n H OBn H H 4-Cl H H OBn 
145h Br H H H H H H OH 
144h H H Br H H H H OH 
181g H OMe H H 4-Cl (CH2)2Ph H H 
181i H OMe H H 4-OMe Bn H H 
228a H OMe H H 4-Cl H H Me 
228b H OMe H H 4-Cl H H Et 
228d H OMe H H 4-Cl H H Bn 
234e H OH H H 4-Cl H H i-Pr 
234a H OH H H 4-Cl H Me H 
234c H OH H H 4-Cl H H Me 
234f H OH H H 4-Cl H H Bn 
234h H OH H H 4-Cl H H Me2 
191g H OH H H 4-Cl (CH2)2Ph H H 
191h H OH H H H Bn H H 
191i H OH H H 4-OH Bn H H 
The selected compounds were tested for general toxicity against the 60 cell lines. 
Cytotoxicity is undesirable for an inhibitor of 17β-HSD1 because such compounds are 
aimed for long term treatment in recurrence prevention. Nevertheless, compounds with 
exceptional cytotoxicity might generate unexpected hits for future development. 
In general, the compounds tested did not exhibit significant activity at 10 µM and 
this is shown by the graph (Figure 110, page 166) where the coloured bars were 
contained below 50% of growth inhibition and negative values, which practically 
represent growth stimulation.  
The two visual characteristics of the graph (Figure 110) describe the activity of the 
compounds are the height of the peaks and the density of the peaks. The height of the 
peaks represents the strength of inhibition, and the density of the peaks represents the 
number of cell lines affected by the compound. The compounds selected for the 5 doses 
screening were 164j, 176x and 175n, which correspond to a high density of high peaks 
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and showed an average growth inhibition of 41.3% ± 56.0%, 30.2% ± 24.5% and 88.1% 
± 42.1%, respectively. The remaining tested compounds showed an average growth 
inhibition of 3.5% ± 13.0%. 
The five dose curves for compounds 164j (Figure 111, page 167) and 176x (Figure 
112, page 167) show how the activity of the compounds drops very rapidly with sample 
dilution and become almost completely inactive at concentrations near 1 µM. 
Compound 175n is at present still in the testing queue for the 5 doses assay and for this 
reason its final results are not yet available. 
The COMPARE algorithm is a developmental tool offered by the NCI-DTP to allow 
the comparison of the pattern of activity of the test compound against the different cell 
line with the activity of known drugs. This allows the prediction of the most probable 
mechanism of action for the compound. The algorithm classifies the activity pattern and 
returns a value which is a reflection of the probability of a matching mechanism 
between the two compounds considered. The analyses on the results from 164j and 
176x led to really poor scores and no further investigation of the possible mechanism of 




Figure 110. Results from the NCI 60 cell line panel for every compound tested reported in a single graph. Each 




Figure 111. Five dose curve response against the all 60 cell line panel for compound 164j. 
 
Figure 112. Five dose curve response against the all 60 cell line panel for compound 176x. 
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The majority of the compounds tested did not have significant cytotoxic effects and 
this is a rather positive feature considering the purpose of the compounds as inhibitors 
of 17β-HSD1. This kind of therapeutic approach would not aim to a widespread 
cytotoxic effect but rather induce lower intracellular concentrations of E2 for prevention 
of rebound. Under this light, cytotoxicity would actually be a major issue rather than a 
positive aspect. 
 
3.5. Eli Lilly – Open Innovation Drug Discovery (OIDD) 
Eli Lilly and company has recently developed a project named Open Innovation 
Drug Discovery (OIDD) which aims to expand the collaboration between industry and 
academics. Similar to the NCI DTP, the submitted structures are initially screened 
before acceptance. In contrast to NCI, the initial screening for the OIDD is performed in 
silico, based on chemicophysical parameters that describes drug-like features and initial 
structural requirements previously set up in the screening software. Once the structures 
are accepted, compounds are screened free of charge on two different panels, i.e. Target 
Drug Discovery (TargetD
2







 are complementary approaches, the first aiming at the 
development of new therapeutics against already established molecular targets of 
interest, while the second aiming to discover molecules with multi-target synergic 





divided into three main areas: endocrine/cardiovascular, oncology and neuroscience 
(Table 60). 
Table 60. Area of research and relative targets for both TargetD2 and PD2.* 
 Endocrine/Cardiovascular Oncology Neuroscience 
PD
2 
 Wnt pathway activator 
 GLP-1 secretion 







 GPR119 Receptor 
agonist 
 Apelin Receptor (APJ) 
agonist 
 Enhancer of Zeste 
Homolog 2 (EZH2) 
inhibitor 
 Hexokinase 2 
inhibitor 
 mGluR2 receptor 
allosteric antagonist 
 CGRP receptor 
antagonist 
*The underlined assays refer to discontinued modules that where only initially implemented. 
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Amongst the compounds synthesised, 28 compounds (Figure 113, Table 61) were 
selected for screening and were tested against the different targets of the panel. A brief 
description of the target and the results are reported in the following sections. 
 
Figure 113. General structure for the compounds tested on the Eli Lilly OIDD screening panel. Refer to Table 61 for 
compound substitutions. 
Table 61. List of the 28 compounds tested on the Eli Lilly OIDD screening panel with relative substituents 
description. 
Compound R1 R2 R3 R4 R5 X Y Z 
165j MeO H H H 4-Cl H H H 
163aa H MeO H H 3,4-Cl2 H H H 
143z H H H H 4-Cl H H OH 
166i H MeO H H 4-Cl H Me H 
170aa H OH H H 3,4-Cl2 H H H 
146x H MeO MeO H 4-MeO H H OH 
166s H MeO H H 4-MeO H Me H 
181b H MeO H H 4-Cl Et H H 
190f H H H MeO 4-Cl Bn H H 
191b H OH H H 4-Cl Et H H 
175n H OBn H H 4-Cl H H OBn 
211b H MeO H H 4-Cl H Et H 
228b H MeO H H 4-Cl H H Et 
228d H MeO H H 4-Cl H H Bn 
181g H MeO H H 4-Cl (CH2)2Ph H H 
181i H MeO H H H Bn H H 
232a H MeO H H 4-Cl Bn H Me 
232b H MeO H H 4-Cl Bn H Et 
191g H OH H H 4-Cl (CH2)2Ph H H 
191h H OH H H H Bn H H 
191i H OH H H 4-OH Bn H H 
234b H OH H H 4-Cl H Et H 
234d H OH H H 4-Cl H H Et 
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234e H OH H H 4-Cl H H i-Pr 
234f H OH H H 4-Cl H H Bn 
234i H OH H H 4-Cl Bn H Me 
234j H OH H H 4-Cl Bn H Et 
234k H OH H H 4-Cl Bn H Bn 
 
3.5.1. PD2 – Wnt pathway activator 
The Wnt pathway activator assay module tests compounds for their ability to 
differentiate murine C2C12 cells into an osteoblast-like phenotype through a β-catenin 
dependant stimulation of alkaline phosphatase activity.
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Every compound tested on this assay has proved inactive at 2 µM and only few 
compounds showed low activity at 10 µM with 143z, 191g and 191h (Figure 113, Table 
61, page 169) resulting in a maximum simulation of 15-25% (Table 62). 
 
3.5.2. PD2 – GLP1 secretion 
Glucagon-like peptide 1 (GLP1) is secreted in response to the presence of nutrients 
in the lumen of the small intestine and is a potent anti-hyperglycaemic hormone 
inducing glucose-dependant insulin secretion and suppressing glucagon secretion. The 
glucose dependency make this mechanism a safer way to control hyper-glycaemia as it 
does not reduce glucose levels below the safety threshold.
164, 165
 Exentide and liraglutide 
are already commercially available GLP1-like peptides but as peptides the only 
administration method possible is by injection. 
Every compound tested in this assay proved inactive at both 2 µM and 20 µM except 
compound 143z (Figure 113, Table 61, page 169), which showed 50% stimulation at 20 
µM. Compound 143z was therefore assayed in both the human (hNCI-H716) and 
murine (mSTC-1) systems to obtain EC50 values. The EC50 calculated in the murine 
system was 12.98 µM but in the human system it was higher than 40 µM (Table 62). 
 
3.5.3.  PD2 – Kras/Wnt synthetic lethal 
Most colorectal cancers develop from benign lesions that are initiated by 
adenomatous polyposis coli (APC). Progression to colorectal cancer requires a second 
event such as an activating KRAS mutation. The aim of the assay module is to identify 
171 
 




Tested compounds showed a wide range of activity against the different cell lines 
from being almost completely inactive, to complete inhibition at 20 µM. The activity 
was generally lost at 2 µM and none of the compounds showed significant activity at 
0.2 µM (Table 62). The activity of compounds 143z, 191g and 234d at 0.2 µM was 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.5.4. TargetD2 – GPR119 receptor antagonist 
GPR119 is a G protein coupled receptor with a limited tissue distribution and is 
expressed only in the pancreas and intestine. In the pancreas, activation of the receptor 
results in a potentiation of glucose-induced insulin secretion, while in the intestine 
activation of the receptor increases secretion of incretin peptides, namely GLP1 and 




None of the compounds tested have shown any significant stimulation of the receptor 
at 10 µM with the maximum being only 10.5% for 191b (Table 63). 
 
3.5.5.  TargetD2 – Apelin Receptor (APJ) agonist 
The apelin receptor is a G protein coupled-receptor implicated in a variety of 




None of the compounds tested have shown any significant stimulation of the receptor 
at 10 µM, with the maximum stimulation being 15.4% for 191i (Table 63). 
 
3.5.6. TargetD2 – Calcitonin Gene-Related Peptide receptor (CGRP) antagonist 
CGRP is a neuropeptide involved in the patho-physiology of migraine. CGRP 
plasma levels have been reported to increase during a migraine attack and to normalise 
when the migraine is successfully treated with a triptan. Infusion of CGRP into 
individuals with past history of migraine can induce an attack and CGRP receptor 
antagonists have proved to be able to treat migraine attacks.
172, 173
 
Three compounds (191b, 234e and 234f, Table 63) showed average inhibition at 30 
µM with compound 191b (Table 63) showing 73.4% of inhibition. The calculated IC50s 
for compounds 234e and 234f were respectively 79.3 µM and 12.4 µM (Table 63). 
 
3.5.7.  TargetD2 – Metabotropic glutamate receptor 2 (mGluR2) allosteric 
antagonist 
Glutamate is the major excitatory neurotransmitter in the mammalian central nervous 
system, acting at both ligand gated ion channels and G-protein coupled receptors, the 
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latter known as metabotropic glutamate receptor (mGluR). Antagonists of mGluR2 and 




Among the compounds tested, 165j, 166i, 165n, 191g and 234f (Figure 113, Table 
61, page 169) have shown strong inhibition of the receptor, with the highest being 
305.8% at 50 µM. Nevertheless, the IC50 values for these compounds were higher than 
25 µM. 
 
3.5.8.  TargetD2 – Hexokinase 2 (HK2) inhibitor 
It is well known that tumour cells often rely on glycolysis for energy production and 
this phenomenon is known as Warburg effect. Hexokinase 2 catalyses the conversion of 
glucose into glucose-6-phosphate and this step is essential for both glucose intake and to 
initiate glycolysis. HK2 is highly expressed in many tumour types and is correlated to 
tumour aggressiveness and poor survival prognosis.
176
 
Among the compounds tested, 190f, 175n, 181i and 191g (Figure 113, Table 61, 
page 169) have shown enzyme inhibition higher than 50%. The IC50 values for these 
compounds were though higher than 20 µM. 
 
3.5.9.  TargetD2 – Enhancer of Zeste Homolog 2 (EZH2) inhibitor 
EZH2 is a histone methyltransferase and EZH2-mediated methylation results in 
silencing of tumour suppressor gene expression. EZH2 overexpression has been 
correlated with tumour growth, metastasis and chemo-resistance. Thus, it has been 




The tests for the majority of the compounds is still in progress and therefore results 
for only few of them are currently available. Among the compounds tested, 170aa 
(Figure 113, Table 61, page 169) showed 80% inhibition at 100 µM and might proceed 
to further screening steps.  
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Table 63. Table of the activity of the tested compounds against the TargetD2 assay modules.* 
 
*TIP = test in progress 
 
3.5.10.  Conclusions 
During the screening on the OIDD panel some possible hits have been found against 
CGRP receptor, Hexokinase 2, GLP1 secretion and maybe EZH2 but mainly against 
mGlu2R. In fact, concerning GLP1 secretion, one compound (143z) has shown higher 
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181b 0 -4,4 -22,2 41,3 -9,1 TIP
190f -1 -22,3 -16,6 54,2 >25.0 63,4 >20.0 TIP
191b 10,5 3,1 73,4 Fit Error -14,7 -32,5 TIP
175n -6,7 14,6 -15,6 153,8 >25.0 67,4 >20.0 TIP
211b -1,9 -1,2 -51,3 40,4 6,7 TIP
228b 1 -14,3 -79,6 93 >25.0 -20,7 TIP
228d -4,8 -8,2 16,6 22,8 42,3 TIP
181g -1 -3,7 -28,1 15,4 39,1 TIP
181i -5,7 -12,6 -87,8 38 59,4 >20.0 TIP
232a -6,7 11,9 29,2 47,8 -26 TIP
232b -1,9 -2 -7,9 36,9 -4,4 TIP
191g 6,7 -16,3 5,2 163,8 >25.0 54,1 >20.0 TIP
191h -2,9 -58,8 19,4 -3,1 28,7 TIP
191i 2,9 15,4 -17,2 12,6 23,5 TIP
234b 1,9 8,3 5,6 3,2 -17,9 TIP
234d -1 -12,7 21,7 60,1 >25.0 24,5 TIP
234e -1,9 -10 44,4 79,32 39,4 -6,7 TIP
234f -5,7 -17,8 43,4 12,436 205,2 >25.0 27,7 TIP
234i -4,8 -24,1 19,5 56 >25.0 5,3 TIP
234j 1,9 8 -12,7 >25.0 TIP
234k 3,8 -3,5 -19,7 TIP
CGRP Receptor 
Antagonist




inactive. Thus, the compound might possess the key functionalisation needed for a good 
interaction and much space has been left for further investigation and optimisation. For 
mGlu2R inhibition, a few compounds have shown really high percentage of inhibition 
and, even though they did not meet the criteria set from Eli Lilly concerning further 
investigation, they still represent promising examples. 
Neuropsychiatric disorders and diabetes are therapeutic areas that are very attractive 
from an industrial point of view. In fact, they occupy a very wide area of the 
pharmaceutical market and this is shown also from the interest that Eli Lilly put into the 
discovery of new therapeutics for these type of diseases. 
 
3.6.  Summary 
Estrogens play an important role in the development of the majority of breast 
cancers, which often develop in a hormone-sensitive form. Treatment of hormone-
dependent breast cancer (HDBC) is clinically performed with the use of estrogen 
signalling or biosynthesis disruptors in addition to surgery, radiotherapy and 
chemotherapy. The use of tamoxifen, a selective estrogen receptor modulator (SERM), 
and anastrozole, an aromatase inhibitor, is common practice in therapy for the treatment 
of HDBC. Inhibition of other steroidogenic enzymes like 17β-hydroxysteroid 
dehydrogenase type 1 (17β-HSD1) is a novel approach for the treatment of HDBC. 
Estrogen receptor-related receptor α (ERRα) is an orphan nuclear receptor that shares 
a high homology with the estrogen receptor α (ERα). Contrarily to ERα, ERRα does not 
bind estradiol (E2) and is constitutively active. ERRα seems able to take over the 
functions of ERα in hormone independent breast cancer (HIBC) and is an emerging 
target for the treatment of HIBC. In addition, ERRα is involved in the metabolic 
adaptation to hypoxia in cancer cells. 
As a route to discovery of new steroidomimetic templates with attractive 
pharmaceutical properties, that might form the basis for new drug candidates, 
1,2,3,4-tetrahydroisoquinoline (THIQ) was chosen as a core structure that would be 
easy to access and could be broadly substituted. The choice was influenced by the 
structural similarities between THIQ and both E2 and diethylstilbestrol (DES), the 




Figure 114. The comparison between the structure of THIQ, E2 and DES gave the rationale for choosing THIQ as 
core structure. 
The synthetic routes were built around three cyclisation methods: Pomeranz-Fritsch 
(PF), Pictet-Spengler (PS) and Bischler-Napieralski (BN). The synthetic approaches 
used were specifically chosen to permit simple access to a fairly large number of 
steroidomimetic compounds, decorated in a fashion that would enhance target 
interaction and provide clear strategies for optimisation. In this way, 77 final THIQs, 
substituted in every position, were obtained. Improvements in yield and robustness of 
the reactions may be achieved with further attention to the reaction conditions, but for 
the purpose of this work the main emphasis was on creating structural diversity. The use 
of clean and high-yielding reactions allowed multiple steps to be performed without 
purification after the workup or to combine two steps in one pot. Where possible, the 
use of air stable and easy-to-handle reagents generated synthetic processes that may be 
easily scaled up. Similarly, the use of reactions near to room temperature, will allow for 
easier future industrial development. 
Interestingly, electronic effects were shown to play an important role during the PF 
reaction and the following reductive dehydroxylation. In fact, compounds lacking a 
methoxy group para to the cyclisation position could only be cyclised using 70% 
perchloric acid. 
Often, it was possible to recover two different regioisomers from one cyclisation step 
and separate them by flash chromatography. 5- And 7-methoxy THIQs could be 
obtained from the same PF reaction and similarly it was possible to obtain 6- and 8-
methoxy THIQ from a single PS or BN reaction (Figure 115). Further investigation of 
other factors controlling such cyclisations, such as temperature, may allow greater 




Figure 115. During both the PF and PS reactions, it was sometime possible to isolate two regioisomers in one single 
cyclisation step. The BN reaction gave results similar to the PS reaction. 
The syntheses proceeded with decent overall yields and for one of the most complex 
compounds (such as the 1,4-disubstituted compound 234a, Table 34, page 99) the 
overall yield of the 6 step synthesis was ca. 6.8%. For each compound bearing a 
substituent in position 1, 3 or 4, only the racemic mixture was isolated. Attempts to 
synthesise enantiomerically pure 1-substituted THIQs failed at the cyclisation step. 
Furthermore, for compound 234a (Table 34, page 99), as for some others bearing 
substituents in both position 1 and 4 (Figure 116), additional stereochemical issues were 
raised. NOESY analysis confirmed that the relative stereochemistry of the compound 
was effectively trans, while chiral HPLC and a chiral shift NMR experiment confirmed 
the presence of only two enantiomers, showing that chiral discrimination had occurred.  
 
Figure 116. TOP: structure of compound 234a. BOTTOM: Cyclisation of the amides 231a,b,d under the BN 
conditions led to only the trans diastereoisomer. 
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Three THIQs (170i, 170s and 191c, Figure 117) were selected for their structural 
differences and screened against a panel of 19 nuclear hormone receptors (NHRs) at 
100 µM. The simple differences in substitution among the three compounds tested 
showed significant structure-dependent activity and selectivity against NHR subtypes. 
For instance, 170i was a strong agonist against ERα, while 191c was a strong antagonist 
(Table 57-Table 58, pages 160-161). 170s showed agonist activity only against ERα and 
ERRα but only antagonist activity against all the other receptors (Table 57-Table 58, 
pages 160-161). The same compound 170s was reported in the literature to show Ki of 
1000 nM against ERα and of 375 nM against Erβ.187 The differing selectivity obtained 
with such small substitutions demonstrates that the THIQ core structure may be an 
effective template for structure-activity relationship (SAR) investigation against many 
diverse NHRs. Hence, desirable NHR selectivity might in principle be achieved with 
the appropriate substitution pattern around the THIQ core. 
 
Figure 117. Structure of the three compounds selected for the NHR screening. Compounds 191c and 170s differ to 
170i by one single substituent, thus allowing comparison of the results obtained in the screening process, 
54 of the synthesised THIQs were selected by the National Cancer Institute of 
America (NCI) and were evaluated for potential off-target anti-cancer activity against a 
panel of 60 cell lines. Three compounds, 164j, 176x and 175n (Figure 118) showed a 
general growth inhibition at 10 µM against the 60 cell lines of 41.3% ± 56.0%, 30.2% ± 
24.5% and 88.1% ± 42.1%, respectively. The remaining 51 compounds showed only an 
average of 3.5% ± 11.8% inhibition at the same concentration. Cytotoxicity is 
undesirable for a 17β-HSD1 inhibitor as the type of targeted clinical approach under 
consideration is aimed at hormone-dependent tumours, by blocking the availability of 
active hormone, rather than by exerting tumour cytotoxicity. However, the three 
compounds that were found to be cytotoxic may be worth pursuing independently, to 
optimise potency and selectivity, although it is unclear at this stage what their specific 
targets might be. A single crystal X-ray structure of active compound 164j (Figure 75, 




Figure 118. Structure of the three compounds that showed cytotoxic activity in the NCI 60 cell line panel. 
Further screening for wider off-target activity through the Eli Lilly Open Innovation 
in Drug Discovery (OIDD) initiative led to interesting results against some surprising 
targets. Compound 143z showed 50% stimulation of glucagon-like peptide 1 (GLP-1) 
secretion at 20 µM. This compound was the only one of the 28 compounds selected by 
Lilly to show any activity against this target, probably meaning that the hydroxyl group 
in position 4 is highly important for activity. Three compounds showed average 
inhibition of the calcitonin gene-related peptide (CGRP) receptor at 30 µM with 191b 
showing 73.4% inhibition and 234e,f showing an IC50 of 79.3 µM and 12.4 µM, 
respectively. In addition, a few compounds showed high activity against metabotropic 
glutamate receptor 2 (mGluR2) with allosteric inhibition higher than 100% at 50 µM. 
However, the relative IC50 values were greater than 25 µM. Limited by the number of 
compounds tested (28 THIQs) and by the lack of direct control  in the selection of the 
compounds, it was not possible to establish an SAR profile for the different targets. 
However, the hits identified are novel leads and might be worth further optimisation for 
specific target activity. 
The activity of the synthesised THIQs was investigated against ERRα using a 
commercially available TR-FRET assay kit. The results obtained were complex and 
compounds showed only modest to average activity at 100 µM. However, the best 
inverse agonist, 234i (Table 56, page 154), showed an efficacy  of 79% against ERRα at 
100 µM, where the known inhibitor DES showed only 64% efficacy at the same 
concentration. A unique SAR profile could not be determined because the SAR of some 
positions of the THIQs were strictly dependent on the substituent in other positions. For 
example, this was the case for the substitution in position 4' of the 6-methoxy, 8-
methoxy and 6-hydroxy series (Table 53, page 151). Similarly, substitution in position 4 
of the 6-methoxy and 6-hydroxy series (Table 55, page 153) had a contrasting effect. 
Similarly, a methyl group in position 3 of the dimethoxy substituted compound 166s 
(Figure 106, page 157) led to completely inverted activity compared to compound 163s 
(Figure 106, page 157) from an inverse agonist into an agonist. This effect was not 
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encountered in any of the other compounds tested and would be worth future 
investigation. The same substitution on the 4-chloro-6-methoxy or 4-chloro-6-hydroxy 
compounds (166i and 234a, respectively, Table 54, page 152) did not lead to any 
similar effect. Compound 234i (Table 56, page 154) was active at 100 µM; since this 
compound possesses significant lipophilicity with a moderate activity, structural 
simplifications or modifications that reduce lipophilicity should be considered as first 
priority for future development. 
The information that may be obtained from a crystal structure of the target enzyme 
17β-HSD1 with a THIQ would be invaluable in facilitating lead optimization. 17β-
HSD1 Was expressed in a bacterial system and the protein was purified in mg amounts. 
Co-crystals of 17β-HSD1 bound to compound 170i were achieved, but attempts to 
obtain an X-ray crystal structure failed due to the fragility of the crystal obtained, 
although attempts to obtain a diffraction pattern were made at the Diamond source. 
Though the conditions used successfully gave crystals, further effort needs to be 
invested to obtain stronger crystals. This is particularly important for eventual activity 
correlation and optimisation, since clearly multiple binding modes could be envisaged 
for  a THIQ template.  
An in-house cellular assay was devised to obtain general information on toxicity, 
estrogenicity, anti-estrogenicity, and activity against 17β-HSD1. T47-D cells were 
cultured and treated with an initial set of active THIQs, in the presence or absence of 
estrone (E1) or E2. However, in general this did not give positive results for those 
evaluated. T47-D is a cell line that naturally expresses a high level of 17β-HSD1, but 
has generally proved prone to phenotypic selections or mutations. The cells used were 
insensitive to estrogenic stimulation and showed anomalies in growth levels over time. 
In future, the use of certified cells may overcome the problems encountered. 
Alternatively, the same problem could be overcome using genetically engineered cells 
that express high levels of 17β-HSD1 and are hormone-sensitive. 
The attempted use of an in-house colourimetric assay did not allow the screening of 
the synthesised THIQs against 17β-HSD1, as was hoped. The assay was developed as a 
colourimetric assay to try to overcome the limitations of the radiochemical assays 
normally performed. Even though the assay was reliable when testing steroidal 
derivatives, such as the known potent 17β-HSD1 inhibitor STX1040 from our group, it 
proved not sensitive enough  for the THIQ lead compounds. The same compounds were 
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also tested by our industrial colleagues at  Ipsen, France in a radiochemical assay and 
though the steroidal inhibitors showed similar trends in both the colourimetric and 
radiochemical assays, the THIQ derivatives did not. THIQs were mostly inactive in the 
colourimetric assay, but generally active in the radiochemical assay. For instance, 
compound 170i showed 77% inhibition at 750 nM in the whole-cell radiochemical 
assay performed by Ipsen and 64% at 6 µM in a cell lysate radiochemical assay 
performed by another  collaborator, Prof. Tea Lanisnik-Rizner (Table 40, page 123). 
However, compound 170i showed only 23% inhibition at 1 mM in the colourimetric 
assay (Figure 57, page 112). Understanding the reasons that make the assay so 
insensitive may lead to its optimisation and as a consequence, to simple and quick 
access to inhibition data, which would be very useful. 
Some THIQs synthesised, however, were indeed active in both the whole-cell and 
cell lysate radiochemical assays. This proved that the compounds can penetrate the cell 
membrane to inhibit the enzyme and suggested that the THIQs possess a reasonable 
physicochemical profile, as hoped. Screening of the compounds against the target 
enzyme in the cell lysate radiochemical assay led to the generation of a SAR profile 
around the core structure (Figure 119 and chapter 3.1.6, pages 134-137) and to the 
identification of the best lead compound to date from this work, 234e, that showed an 
IC50 value of 336 nM against 17β-HSD1. 
 
Figure 119. SAR for 17β-HSD1 of substitutions around the core THIQ structure. 
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Thus, in this study THIQs have proved to be valuable steroidomimetic core 
structures  against several different targets, even including targets apparently unrelated 
to steroids. The physicochemical properties of the core structure allowed the 
introduction of complexity, while maintaining drug-like properties, as described by e.g. 
the Lipinski rules. This is important for the future development of the compounds 
prepared, because it decreases the chances for any potential drug to fail at a later stage 
of clinical testing. It is important that such properties are maintained while further 
developing these compounds for enhanced target activity. An attractive and potent 17β-
HSD1 inhibitor was successfully designed that, with some further potency optimisation, 
should exemplify the success of our new THIQ approach and permit essential pre-




















4.1. Chemistry: materials and methods 
All chemicals were purchased from Aldrich Chemical Co. or Alfa Aesar. All organic 
solvents of A. R. grade were supplied by Fisher Scientific. Thin-layer chromatography 
(TLC) was performed on precoated plates (Merck TLC aluminium sheets silica gel 60 
F254). Product(s) and starting material(s) were detected by either TLC and/or LC-MS. 
Flash column chromatography was performed on RediSep® prepacked columns 
(normal phase and reversed phase) with an Isco CombiFlash® Rf. 
1
H NMR (400 MHz 
or 500 MHz) spectra were recorded with a Bruker and chemical shifts are reported in 
parts per million (ppm). HPLC and low resolution mass spectra analyses were obtained 
on a Waters Micromass ZQ equipped with a Waters 996 PDA detector using either a 
Waters Radialpack C18 reversed phase column (8 × 100 mm), or a Symmetry C18 
reverse phase column (4.6 × 150 mm) eluting with the solvent system specified at 1.0 
mL/min. High-resolution mass spectra were recorded at the Mass Spectrometry Service 
Centre, University of Bath on a Bruker microTOF. Elemental analyses were performed 
by the Science Centre at London Metropolitan University. Melting points were 
determined using an Optimelt block and are uncorrected. 
2,2-Dimethoxyacetaldehyde was purchased as aqueous solution and was extracted in 
CHCl3 before use. Petroleum ether (pet. ether) used for chromatography was the 




C and 2D NMR analyses of the final THIQ hydrobromide or hydrochloride were 
performed on the free bases unless specified otherwise. 
 
4.1.1. General reaction procedures 
General method for the double reductive amination reaction (Method A): 
Benzaldehyde (1.0 mL, 10 mmol) and aniline (1.1 mL, 12 mmol) were dissolved in 
CHCl3 (60 mL) then treated with NaBH4(OAc)3 (3.3 g, 15 mmol). After stirring for 1 h 
at rt, 2,2-dimethoxyacetaldehyde (30 mmol) was introduced into the reaction mixture 
followed by NaBH(OAc)3 (3.3 g, 15.0 mmol). After stirring for 8 h at rt the mixture was 
quenched with a saturated aqueous solution of K2CO3. The aqueous layer was extracted 
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with CHCl3 (30 mL). The combined organics were dried with MgSO4, filtered and 
evaporated to give a pale yellow oil (3.87 g). 
General method for the PF cyclisation with HClO4 (Method B): Compound 123a 
(3.0 g, 11.1 mmol) was dissolved in 70% HClO4 (33 mL) and stirred for 1 h at rt. The 
mixture was then diluted with water (30 mL) and basified with Na2CO3. The aqueous 
layer was then extracted with EtOAc (3 x 30 mL). The combined organics were dried 
with MgSO4, filtered and evaporated to give a brown foam (2.97 g). 
General method for the PF cyclisation with HCl (Method C): Compound 123f 
(500 mg, 1.66 mmol) was dissolved in conc. HCl (2 ml) and stirred at rt for 1 h during 
which time the mixture turned red. The reaction mixture was cooled to 0 °C and then 
quenched slowly with aq. 3 N NaOH (10 mL) (a white suspension with a yellow 
precipitate formed) and extracted with EtOAc (20 mL). The organic layer was dried 
with MgSO4, filtered and evaporated to give a yellow-brown oil (445 mg). 
General method for the reductive dehydroxylation (Method D): The crude 
compound 143a (2.77 g) was dissolved in DCM (60 mL) and Et3SiH (6.0 mL, 36.9 
mmol) and BF3·Et2O (9.8 mL, 36.9 mmol) were introduced in the order. After refluxing 
for 18 h, the mixture was cooled to rt and quenched with a saturated aqueous solution of 
Na2CO3 (50 mL). The aqueous layer was then extracted with EtOAc (2 x 50 mL). The 
combined organics were dried with MgSO4, filtered and evaporated to give a green oil 
(2.03 g). 
General method for the reductive dehydroxylation (Method E): NaBH4 (1.53 g, 
39.7 mmol) was added to a stirring solution of 146x (2.50 g, 7.93 mmol) in DCM (30 
mL) followed by the dropwise addition of TFA (3.1 mL) and the mixture was stirred at 
rt for 3 h. The mixture was then diluted with DCM (30 mL) and washed with a sat. aq. 
solution of Na2CO3 (2 x 60 mL) and dried with MgSO4, filtered and evaporated to give 
a pale yellow solid (2.45 g). 
General method for methoxy deprotection (Method F): 163e (200 mg, 836 μmol) 
was suspended in 46% HBr (3 mL) and stirred for 3 h at 120 °C. The mixture became a 
solution upon heating. The mixture was then cooled to rt and filtered to give the product 
as a white precipitate (230 mg, 90%). 
General method for methoxy deprotection (Method G): 1.0 M solution of BBr3 
(6.7 mL, 6.68 mmol) in DCM was added to a stirring solution of 167x (200 mg, 0.668 
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mmol) in anhydrous DCM (1 mL) at 0 °C under inert atmosphere. The mixture was 
stirred for 2 h letting it reach rt then quenched with a minimum amount of ice and 
stirred for 10 min. The mixture was filtered and the precipitate was washed with DCM 
then dried to give the product as a yellow solid (168 mg, 74%). 
General method for the synthesis of amides 178a-h (Method H): SOCl2 (14.6 mL, 
200 mmol) was added to a stirring solution of 3-methoxyphenylacetic acid (3.39 g, 20.0 
mmol) in anhydrous DCM (40 mL) and the mixture was stirred at rt for 4 h. The 
mixture was then evaporated and the residue was dissolved in anhydrous toluene 
(40 mL) and N,N-diisopropylethylamine (7.0 mL, 40.0 mmol), aniline (2.7 mL, 30.0 
mmol) and a catalytic amount of DMAP were introduced in the order. The mixture was 
refluxed under inert atmosphere overnight and the solvent was then evaporated. The 
residue was dissolved in EtOAc (150 mL) and washed with 1 N HCl (3 x 100 mL), 1 N 
NaOH (3 x 100 mL) and brine (2 x 100 mL) then dried with MgSO4, filtered and 
evaporated to give a yellow solid (2.73 g). 
General method for the reduction of the amides (method I): A solution of 178a 
(2.0 g, 8.29 mmol) in anhydrous THF (41 mL) was added to a stirring suspension of 
LiAlH4 (521 mg, 12.4 mmol) in THF (10 mL) under inert atmosphere and the mixture 
was stirred at 80 °C for 4 h during which time the mixture turned green. The mixture 
was then cooled to 0 °C, diluted with Et2O (50 mL) and carefully quenched with water 
(0.6 mL) under inert atmosphere. The mixture was stirred for 15 min, during which time 
a black precipitate formed. 15% NaOH (0.6 mL) was introduced and the mixture was 
stirred for 15 min, during which time the precipitate turned white. Water (1.2 mL) was 
added and after stirring for 15 min the mixture was dried with MgSO4, filtered and 
evaporated to give a brown oil (1.7 g). 
General method for the PS cyclisation (method J): Compound 179f (1.0 g, 3.82 
mmol) was dissolved in toluene (18 mL) and treated with paraformaldehyde (573 mg, 
19.1 mmol) and PTSA (32 mg, 0.191 mmol). After stirring at 90 °C for 18 h, the 
mixture was cooled to rt and filtered. The solvent was evaporated and the residue was 
dissolved in DCM (30 mL). The organic layer was washed with 1 N NaOH (20 mL) 
then dried with MgSO4, filtered and evaporated to give a yellow oil (996 mg). 
General method for the BN cyclisation (Method K): POCl3 (836 µl, 8.88 mmol) 
was added to a stirring solution of 180a (450 mg, 1.48 mmol) in anhydrous toluene (15 
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mL) and the mixture was stirred at 100 °C overnight. The mixture was then cooled to rt 
and the solvent was evaporated. The residue was dissolved in MeOH (15 mL) and 
NaBH4 (343 mg, 8.88 mmol) was added. The yellow solution started foaming and 
turned colourless. The mixture was stirred at rt for 1 h then the solvent was evaporated 
and the residue was dissolved in EtOAc (50 mL). The organic layer was washed with 1 
N NaOH (2 x 50 mL) then dried with MgSO4, filtered and evaporated to give a yellow 
oil (979 mg). 
General method for the Weinreb reaction (Method L): 1.4 M solution of 
MeMgBr (1.2 mL, 1.67 mmol) in toluene/THF (3:1) was added to a stirring solution of 
208 (290 mg, 1.39 mmol) in anhydrous THF (14 mL) under inert atmosphere and the 
mixture was stirred at rt for 1 h. The mixture was quenched with 1N HCl (3 mL) and 
extracted with EtOAc (3 x 30 mL). The combined organics were dried with MgSO4, 
filtered and evaporated to give the product as a yellow oil (211 mg, 93%). 
General method for the alkylation of the ester 226 (method M): 2.0 M LDA (3.3 
mL, 6.66 mmol) was added to a stirring solution of 226 (1.0 g, 5.55 mmol) in anhydrous 
THF (50 mL) at -78 °C under inert atmosphere and the mixture was stirred for 1 h. 
Methyl iodide (384 µL, 6.11 mmol) was added and the mixture was stirred for 1 h at -78 
°C then let reach rt and stirred for further 4 h. The mixture was cooled to 0 °C and 
carefully quenched with 1 N HCl (10 mL) then the organic solvent was evaporated. The 
aqueous layer was extracted with EtOAc (3 x 50 mL) and the combined organics were 
washed with 1 N HCl (3 x 50 mL) and brine (3 x 50 mL) then dried with MgSO4, 
filtered and evaporated to give a brown oil (1.11 g). 
General method for the direct conversion of ester into amide (method N): 
4-Chloroaniline (1.10 g, 8.49 mmol) was added to a stirring solution of 
bis(trimethylaluminum)-1,4-diazabicyclo[2.2.2]octane adduct (2.20 g, 8.49 mmol) in 
anhydrous THF (15 mL) under inert atmosphere and the mixture was stirred at 40 °C for 
1 h. A solution of 227a (1.10 g, 5.66 mmol) in anhydrous THF (3 mL) was added and 
the mixture was refluxed overnight. The mixture was then evaporated and the residue 
was dissolved in EtOAc (50 mL). The organic layer was then washed with 1 N HCl 
(3 x 50 mL) and brine (50 mL) then dried with MgSO4, filtered and evaporated to give a 




4.1.2. Experimental data 
N-(2,2-Diethoxyethyl)aniline (115a) 
C12H19NO2, Mol. Wt.: 209.28 
 
Aniline (2.7 mL, 30 mmol) and 2-bromo-1,1-diethoxyethane (3.0 mL, 20 mmol) 
were dissolved in EtOH 95% (20 ml) and treated with K2CO3 (552 mg, 40 mmol). The 
mixture was refluxed for 18 h. The mixture was filtered and the filtrate was evaporated 
to give a yellow oil (5.42 g). Part of the crude (1.0 g) was purified by chromatography 
column in gradient (from 0 % to 5 % EtOAc in pet. ether) to give the product as a 




H NMR (400 MHz, CDCl3) δ 1.26 (6H, t, J = 7.2 Hz, CH3), 3.27 (2H, d, J = 5.5 Hz, 
NCH2), 3.59 (2H, dq, J = 7.2, 14.4 Hz, OCH2), 3.75 (2H, dq, J = 7.2, 14.4 Hz, CH2), 
3.91 (1H, bs, NH), 4.70 (1H, t, J = 5.5 Hz, CH(OR)2), 6.66 (2H, d, J = 8.3 Hz, ArH), 
6.73 (1H, t, J = 7.3 Hz, ArH) and 7.20 (2H, t, J = 7.6 Hz, ArH) ppm. 
13
C NMR (101 
MHz, CDCl3) δ 15.5 (CH3), 46.4 (NCH2), 62.4 (OCH2), 101.0 (CH(OR)2), 113.2 




tr = 1.83 min 
(97%), m/z 210.6 (M
+
+H); (RP, Isocratic, 90% MeOH). HRMS (ES+) calcd. for 
C12H20NO2 (M
+
+H) 210.1489, found 210.1482. 
 
N-(2,2-Dimethoxyethyl)aniline (121) 
C10H15NO2, Mol. Wt.: 181.23 
 
Aniline (456 μL, 5.0 mmol) was dissolved in CHCl3 (20 mL) and treated in the order 
with 2,2-dimethoxyacetaldehyde (750 μL, 5.0 mmol) and NaBH(OAc)3 (3.3 g, 
15.0 mmol). After stirring for 18 h at rt, the mixture was quenched with a saturated 
aqueous solution of K2CO3 (20 mL) and the aqueous layer was extracted with CHCl3 (2 
x 20 mL). The combined organics were dried with MgSO4, filtered and evaporated to 




H NMR (500 MHz, CDCl3) δ 
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3.26 (2H, d, J = 5.5 Hz, NCH2), 3.42 (6H, s, OCH3), 3.84 (1H, bs, NH), 4.58 (1H, t, J = 
5.5 Hz, CH(OR)2), 6.65 (2H, dd, J = 1.1, 8.6 Hz, ArH), 6.73 (1H, tt, J = 1.1, 7.3 Hz, 
ArH) and 7.19 (2H, dd, J = 7.3, 8.6 Hz, ArH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 45.4 
(NCH2), 53.8 (OCH3), 102.6 (CH(OR)2), 113.1 (ArCH), 117.7 (ArCH), 129.3 (ArCH) 




tr = 1.57 min (97%), m/z 182.0 (M
+
+H); (RP, 
Isocratic, 90% MeOH) HRMS (ES+) calcd. for C10H16NO2 (M
+




C14H15NO, Mol. Wt.: 213.28 
 
4-Methoxybenzaldehyde (1.2 mL, 10.0 mmol) and aniline (1.1 mL, 12.0 mmol) were 
dissolved in CHCl3 (60 mL) and treated with sodium triacetoxyborohydride (3.0 g, 14.0 
mmol). The reaction mixture was refluxed for 18 h then cooled to rt and quenched with 
a saturated aqueous solution of NaHCO3. The organic layer was washed with brine (20 
mL), dried with MgSO4, filtered and evaporated to give 153a as a yellow oil (2.16 g, 
>99%). 
1
H NMR (270 MHz, CDCl3) δ 3.82 (3H, s), 4.27 (2H, s), 6.60 – 6.82 (3H, m), 
6.87 – 6.97 (2H, m), 7.11 – 7.25 (2H, m) and 7.27 – 7.37 (2H, m) ppm. 
 
4-((4-Chlorobenzyl)amino)phenol (122n) 
C13H12ClNO, Mol. Wt.: 233.69 
 
NaBH(OAc)3 (549 mg, 2.46 mmol) was added to a stirring solution of 
p-hydroxybenzaldehyde (204 mg, 1.64 mmol) and p-chloroaniline (182 mg, 1.64 mmol) 
in CHCl3 (5 mL) and the mixture was stirred at rt for 1 h. The mixture was washed with 
a sat. aq. sol. of NaHCO3 (2 x 5 mL) and the organic layer was dried with MgSO4, 
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filtered and evaporated to give a pale yellow oil (450 mg). The product was precipitate 





H NMR (500 MHz, D6-DMSO) δ 4.09 (2H, d, J = 5.9 Hz, CH2), 6.27 (1H, 
t, J = 5.8 Hz, NH), 6.55 (2H, d, J = 8.9 Hz, 2 x ArCH, aniline), 6.70 (2H, d, J = 8.5 Hz, 
2 x ArCH, benzyl), 7.03 (2H, d, J = 8.9 Hz, 2 x ArCH, aniline), 7.12 (2H, d, J = 8.5 Hz, 
2 x ArCH, benzyl) and 9.28 (1H, bs, OH) ppm. 
13
C NMR (126 MHz, D6-DMSO) δ 46.0 
(CH2), 113.6 (2 x ArCH, aniline), 115.0 (2 x ArCH, benzyl), 118.7 (ArCCl), 128.4 (2 x 
ArCH, aniline), 128.4 (2 x ArCH, benzyl), 129.6 (ArCCH2), 147.7 (ArCN) and 156.2 











+H) 236.0651, found 236.0639. Mp 206-209 °C (as 
hydrochloride from Et2O). 
 
4-((4-Hydroxybenzyl)amino)phenol (122p) 
C13H13NO2, Mol. Wt.: 215.25 
 
NaBH(OAc)3 (549 mg, 2.46 mmol) was added to a stirring solution of 
p-hydroxybenzaldehyde (204 mg, 1.64 mmol) and p-aminophenol (183 mg, 1.64 mmol) 
in CHCl3 (5 mL) and the mixture was stirred at rt for 1 h. The mixture was washed with 
a sat. aq. sol. of NaHCO3 (2 x 5 mL) and the organic layer was dried with MgSO4, 
filtered and evaporated to give a black oil (489 mg). The product was precipitate as 




H NMR (400 MHz, D6-DMSO) δ 4.07 (2H, s), 6.48 (2H, d, J = 8.6 Hz), 6.56 (2H, d, 
J = 8.6 Hz), 6.74 (2H, d, J = 8.0 Hz), 7.18 (2H, d, J = 8.0 Hz), 8.40 (1H, s) and 9.26 
(1H, s) ppm. HRMS (ES
+
) calcd. C13H14NO2 (M
+
+H) 216.1019, found 216.1011. 
Degraded before melting (as hydrochloride from DCM). 
 
3-Chloro-N-(4-methoxybenzyl)aniline (122t) 




4-Methoxybenzaldehyde (2.5 mL, 20.0 mmol) and 3-chloroaniline (2.1 mL, 
20.0 mmol) were dissolved in CHCl3 (40 mL) then treated with NaBH4(OAc)3 (6.0 g, 
30.0 mmol). After stirring for 18 h at rt, the mixture was quenched with a saturated 
aqueous solution of Na2CO3 (50 mL). The aqueous layer was extracted with CHCl3 (50 
mL). The combined organics were dried with MgSO4, filtered and evaporated to give a 
yellow oil (4.88 g, 98%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 3.81 (3H, s, 
CH3), 4.03 (1H, bs, NH), 4.23 (2H, s, CH2), 6.49 (1H, ddd, J = 0.8, 2.1, 8.0 Hz, ArCH, 
aniline), 6.61 (1H, t, J = 2.1 Hz, ArCH, aniline), 6.67 (1H, ddd, J = 0.8, 2.1, 8.0 Hz, 
ArCH, aniline), 6.89 (2H, d, J = 8.7 Hz, ArCH, benzyl), 7.07 (1H, t, J = 8.0 Hz, ArCH, 
aniline) and 7.27 (2H, d, J = 8.7 Hz, ArCH, benzyl) ppm. 
13
C NMR (126 MHz, CDCl3) 
δ 47.5 (CH2), 55.3 (CH3), 111.1 (ArCH, aniline), 112.4 (ArCH, aniline), 114.1 (2 x 
ArCH, benzyl), 117.3 (ArCH, aniline), 128.8 (2 x ArCH, benzyl), 130.1 (ArCH, 





tr = 2.22 min (89 %), m/z 248.0 (M
+




C14H14ClNO, Mol. Wt.: 247.72 
 
4-Methoxybenzaldehyde (2.5 mL, 20.0 mmol) and 2-chloroaniline (2.1 mL, 
20.0 mmol) were dissolved in CHCl3 (40 mL) then treated with NaBH4(OAc)3 (6.0 g, 
30.0 mmol). After stirring for 18 h at rt, the mixture was quenched with a saturated 
aqueous solution of Na2CO3 (50 mL). The aqueous layer was extracted with CHCl3 (50 
mL). The combined organics were dried with MgSO4, filtered and evaporated to give 
white solid which was recrystallised from EtOH (5.16 g, >99%) and showed: 
1
H NMR 
(400 MHz, CDCl3) δ 3.85 (3H, s, CH3O), 4.37 (2H, s, CH2N), 4.75 (1H, bs, NH), 6.71 
(1H, ddd, J = 1.5, 7.3, 7.9 Hz, ArH, aniline), 6.72 (1H, dd, J = 1.5, 8.2 Hz, ArH, 
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aniline), 6.97 (2H, d, J = 8.7 Hz, ArH, benzyl), 7.18 (1H, ddd, J = 1.5, 7.3, 8.2 Hz, ArH, 
aniline), 7.34 (1H, dd, J = 1.5, 7.9 Hz, ArH, aniline) and 7.36 (2H, d, J = 8.8 Hz, ArH, 
benzyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 47.3 (CH2), 55.2(CH3), 64.9, 111.5 
(ArCH, aniline), 114.1 (2 x ArCH, benzyl), 117.3 (ArCH, aniline), 119.1 (ArCCl), 
127.8(ArCH, aniline), 128.6 (2 x ArCH, benzyl), 129.1 (ArCH, aniline), 130.7 




tr = 2.74 min (94 %), 
m/z 248.0 (M
+
















C17H21NO2, Mol. Wt.: 271.35 
 
(Method A) 
The crude compound was purified by column chromatography (eluent: from 0% to 
30% EtOAc in pet. ether) to give 123a as a colourless oil (2.92 g, 99%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 3.41 (6H, s, OCH3), 3.58 (2H, d, J = 5.1 Hz, NCH2CH), 
4.63 (1H, t, J = 5.1 Hz, CH(OR)2), 4.67 (2H, s, CH2Ar), 6.70 (1H, tt, J = 0.9, 7.4 Hz, 
ArH), 6.74 (2H, dd, J = 0.9, 8.9 Hz, ArH), 7.16 - 7.25 (5H, m, ArH) and 7.27 - 7.34 
(2H, m, ArH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 53.9 (CH2CH), 54.6 (CH3), 54.9 
(ArCH2), 103.5 (CH(OR)2), 112.3 (ArCH), 116.7 (ArCH), 126.6 (ArCH), 126.8 
(ArCH), 128.7 (ArCH), 129.4 (ArCH), 138.9 (ArCCH2) and 148.7 (ArCN) ppm. 
LC/MS (ES+)
 
tr = 1.81 min (87%), m/z 226.0 (M
+
+H); HRMS (ES+) calcd. for 
C17H22NO2 (M
+
+H) 272,16451, found 272.1651. 
 
N-Benzyl-N-(2,2-dimethoxyethyl)-3-methoxyaniline (123b) 





The crude compound was purified by column chromatography (eluent: from 0% to 
10% EtOAc in pet. ether) to give a colourless oil (2.21 g, 73%) which showed: 
1
H NMR 
(500 MHz, CDCl3) δ 3.40 (6H, s, CH(OCH3)2), 3.55 (2H, d, J = 5.1 Hz, CH2CH), 3.74 
(3H, s, ArOCH3), 4.62 (1H, t, J = 5.1 Hz, CH(OR)2), 4.65 (2H, s, ArCH2), 6.28 (1H, 
ddd, J = 0.6, 2.5, 8.2 Hz, ArH), 6.30 (1H, t, J = 2.5 Hz, ArH), 6.36 (1H, ddd, J = 0.6, 
2.5, 8.2 Hz, ArH), 7.10 (1H, t, J = 8.2 Hz, ArH), 7.19 - 7.23 (3H, m, ArH) and 7.27 - 
7.32 (2H, m, ArH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 53.9 (CH2CH), 54.7 
(CH(OCH3)2), 55.0 (ArCH2), 55.2 (ArOCH3), 99.0 (ArCH), 101.5 (ArCH), 103.5 
(CH(OR)2), 105.5 (ArCH), 126.6 (ArCH), 126.8 (ArCH), 128.7 (ArCH), 130.1 (ArCH), 




tr = 2.48 min 
(96 %), m/z 301.5 (M
+
); (RP, Isocratic, 90% MeOH). HRMS (ES+) calcd. for 
C18H24NO3 (M
+
+H) 302.1751, found 302.1738. 
 
N-Benzyl-N-(2,2-dimethoxyethyl)-3,4,5-trimethoxyaniline (123d) 
C20H27NO5, Mol. Wt.: 361.43 
 
(Method A) 
The crude compound was purified by column chromatography (eluent 0% to 30% 
EtOAc in pet. ether) to give the product as a colourless oil (3.08 g, 85%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 3.41 (6H, s, CH(OCH3)2), 3.54 (2H, d, J = 5.0 Hz, 
CH2CH), 3.74 (6H, s, ArOCH3), 3.76 (3H, s, ArOCH3), 4.59 (1H, t, J = 5.0 Hz, 
CH(OR)2), 4.60 (2H, s, ArCH2), 5.97 (2H, s, ArH), 7.21 - 7.24 (3H, m, ArH) and 7.28 - 
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7.33 (2H, m, ArH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 54.66 (CH(OCH3)2), 54.69 
(CH2CH), 55.73 (ArCH2), 56.07 (ArOCH3), 61.21 (ArOCH3), 91.0 (ArCH), 103.8 
(CH(OR)2), 126.8 (ArCH), 127.0 (ArCH), 128.7 (ArCH), 129.9 (ArCOCH3), 139.1 




tr = 1.93 min 
(89 %), m/z 361.3 (M
+
); (RP, Isocratic, 90% MeOH). HRMS (ES+) calcd. for 
C20H28NO5 (M
+
+H) 362.1962, found 362.1948. 
 
N-(2,2-Dimethoxyethyl)-N-(4-methoxybenzyl)aniline (123e) 
C18H23NO3, Mol. Wt.: 301.38 
 
(Method A) 
The crude compound was purified by column chromatography (from 0% to 10% 
EtOAc in pet. ether) to give the product as a yellowish oil (2.09 g, 69%). 
1
H NMR (400 
MHz, CDCl3) δ 3.41 (6H, s, CHOCH3), 3.56 (2H, d, J = 5.0 Hz, NCH2CH), 3.79 (3H, s, 
ArOCH3), 4.60 - 4.65 (3H, m, CH(OR)2, ArCH2), 6.61 - 6.73 (1H, m, ArH), 6.76 (2H, 
d, J = 8.3 Hz, ArH), 6.85 (2H, d, J = 8.3 Hz, ArH), 7.14 (2H, d, J = 8.4 Hz, ArH) and 
7.20 (2H, t, J = 7.8 Hz, ArH) ppm. 
13
C NMR (101 MHz, CDCl3) δ 53.7 (NCH2CH), 
54.3 (ArOCH3), 54.6 (CH(OCH3)2), 55.4 (ArCH2), 103.4 (CH(OR)2), 112.4 (ArCH), 
114.1 (ArCH), 116.6 (ArCH), 127.8 (ArCH), 129.3 (ArCH), 130.7 (ArCCH2), 148.7 
(ArCN) and 158.6 (ArCOCH3) ppm. LC/MS (ES+)
 
tr = 2.46 min ( 70%), m/z 302.2 
(M
+
+H); HRMS (ES+) calcd. for C18H24NO3 (M
+
+H) 302.1751, found 302.1761. 
 
N-(2,2-Dimethoxyethyl)-N-(3-methoxybenzyl)aniline (123f) 





The crude product was purified by column chromatography (from 0% to 10% EtOAc 
in pet. ether 40-60 °C) to give the product as a pale yellow oil (3.56 g, 79 %) which 
showed: 
1
H NMR (400 MHz, CDCl3) δ 3.48 (6H, s, CHOCH3), 3.65 (2H, d, J = 5.1 Hz, 
NCH2CH), 3.84 (3H, s, ArOCH3), 4.66 - 4.75 (3H, m, ArCH2, CH(OR)2), 6.67 - 6.92 
(6H, m, ArH) and 7.21 - 7.35 (3H, m, ArH) ppm. 
13
C NMR (101 MHz, CDCl3) δ 53.86 
(NCH2CH), 54.60 (CH(OCH3)2), 54.93 (ArOCH3), 55.27 (ArCH2N), 103.38 
(CH(OR)2), 112.0 (ArCH), 112.3 (ArCH), 112.4 (ArCH), 116.7 (ArCH), 118.9 (ArCH), 





tr = 2.51 min (98 %), m/z 302.2 (M
+
+H); (RP, Isocratic, 90% 
MeOH). HRMS (ES+) calcd. for C18H24NO3 (M
+
+H) 302.1751, found 302.1739. 
 
N-(4-Chlorobenzyl)-N-(2,2-dimethoxyethyl)aniline (123g) 
C17H20ClNO2, Mol. Wt.: 305.80 
 
(Method A) 
The crude compound was purified by column chromatography (eluent: pet. ether) to 
give a colourless oil (2.73 g, 88%) which showed: 
1H NMR (500 MHz, CDCl3) δ 3.40 
(6H, s) (2 x OCH3), 3.55 (2H, d, J = 5.1 Hz) (CHCH2), 4.61 (1H, t, J = 5.0 Hz) (OCH), 
4.62 (2H, s) (ArCH2N), 6.70 (2H, d, J = 8.9 Hz) (2 x ArCH, aniline), 6.71 (1H, t, J = 7.3 
Hz) (ArCH, aniline), 7.14 (2H, d, J = 8.6 Hz) (2 x ArCH, benzyl), 7.19 (2H, dd, J = 7.3, 
8.9 Hz) (2 x ArCH, aniline) and 7.26 (2H, d, J = 8.6 Hz) (2 x ArCH, benzyl) ppm. 
13
C 
NMR (126 MHz, CDCl3) δ 53.9 (CHCH2), 54.5 (ArCH2), 54.7 (2 x OCH3), 103.4 
(OCH), 112.4 (2 x ArCH, aniline), 117.0 (ArCH, aniline), 128.0 (ArCH, benzyl), 128.8 
(ArCH, benzyl), 129.5 (ArCH, aniline), 132.5 (ArCCl), 137.5 (ArCCH2) and 148.4 




tr = 3.18 min (97 %), m/z 306.2 (M
+
); (RP, Isocratic, 90% 














C17H20BrNO2, Mol. Wt.: 350.25 
 
(Method A) 
The crude compound was purified by column chromatography (eluent: 0% to 10% 
EtOAc in pet. ether) to give the product as a colourless oil (1.9 g, 54%) which showed: 
1
H NMR (400 MHz, CDCl3) δ 3.48 (6H, s, CHOCH3), 3.65 (2H, d, J = 5.1 Hz, 
NCH2CH), 3.84 (3H, s, ArOCH3), 4.66 - 4.75 (3H, m, ArCH2, CH(OR)2), 6.67 - 6.92 
(6H, m, ArH) and 7.21 - 7.35 (3H, m, ArH) ppm. 
13
C NMR (101 MHz, CDCl3) δ 53.9 
(NCH2CH), 54.6 (CH(OCH3)2), 54.9 (ArOCH3), 55.3 (ArCH2N), 103.4 (CH(OR)2), 
112.0 (ArCH), 112.3 (ArCH), 112.4 (ArCH), 116.7 (ArCH), 118.9 (ArCH), 129.3 





tr = 2.51 min (98 %), m/z 302.2 (M
+
+H); (RP, Isocratic, 90% MeOH). 
HRMS (ES+) calcd. for C18H24NO3 (M
+
+H) 302.1751, found 302.1739. 
 
4-Chloro-N-(2,2-dimethoxyethyl)-N-(4-methoxybenzyl)aniline (123i) 
C18H22ClNO3, Mol. Wt.: 335.83 
 
(Method A) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give the product as a yellow oil (9.16 g, 91%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 3.39 (6H, s, CH(OCH3)2), 3.52 (2H, d, J = 5.1 
Hz, CHCH2), 3.78 (3H, s, ArOCH3), 4.55 (1H, t, J = 5.1 Hz, CH2CH), 4.56 (2H, s, 
ArCH2N), 6.65 (2H, d, J = 9.2 Hz, ArH, aniline), 6.84 (2H, d, J = 8.7 Hz, ArH, benzyl), 




C NMR (126 MHz, CDCl3) δ 54.0 (CHCH2), 54.5 (ArCH2), 54.7 (CH(OCH3)2), 55.4 
(ArOCH3), 103.3 (CH2CH), 113.7 (2 x ArCH, aniline), 114.2 (2 x ArCH, benzyl), 
121.5 (ArCCl), 127.8 (ArCH, benzyl), 129.1 (ArCH, aniline), 130.1 (ArCCH2), 147.4 
(ArCN) and 158.7 (ArCO) ppm. LC/MS (ES+)
 
tr = 2.98 min (85 %), m/z 336.1 (M
+
+H). 









+H) 338.1331, found 338.1346. 
 
4-Chloro-N-(2,2-dimethoxyethyl)-N-(3-methoxybenzyl)aniline (123j) 
C18H22ClNO3, Mol. Wt.: 335.83 
 
(Method A) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give the product as a pale yellow oil (9.08 g, 90%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 3.40 (6H, s, CH(OCH3)2), 3.54 (2H, d, J = 5.1 
Hz, CHCH2), 3.76 (3H, s, ArOCH3), 4.58 (1H, t, J = 5.1 Hz, CHCH2), 4.60 (2H, s, 
ArCH2N), 6.63 (2H, d, J = 9.2 Hz, ArH, aniline), 6.71 – 6.74 (1H, m, ArH, benzyl), 
6.74 – 6.80 (2H, m, ArH, benzyl), 7.10 (2H, d, J = 9.2 Hz, ArH, aniline) and 7.22 (1H, 
t, J = 7.9 Hz, ArH, benzyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 54.2 (CHCH2), 54.7 
(CH(OCH3)2), 55.1 (ArCH2N), 55.3(ArOCH3), 103.3 (CH(OCH3)2), 112.0 (ArCH, 
benzyl), 112.4 (ArCH, benzyl), 113.6 (ArCH, aniline), 118.8 (ArCH, benzyl), 121.6 
(ArCCl), 129.1 (ArCH, aniline), 129.8 (ArCH, benzyl), 140.2 (ArCCH2), 147.2 (ArCN) 




tr = 2.91 min (98 %), m/z 336.0 (M
+
+H); (RP, 











+H) 338.1331, found 338.1353 
 
4-Chloro-N-(2,2-dimethoxyethyl)-N-(2-methoxybenzyl)aniline (123k) 





The crude compound was purified by column chromatography (from 0% to 30% 
EtOAc in pet. ether) to give the product as a yellow oil (4.84 g, 96%) which showed: 
1
H 
NMR (500 MHz, CDCl3) δ 3.40 (6H, s, CH(OCH3)2), 3.54 (2H, d, J = 5.1 Hz, 
NCH2CH), 3.86 (3H, s, ArOCH3), 4.59 (2H, s, ArCH2N), 4.62 (1H, t, J = 5.1 Hz, 
CH(OCH3)2), 6.66 (2H, d, J = 9.1 Hz, ArCH, aniline), 6.84 (1H, td, J = 1.3, 7.2 Hz, 
ArCH, benzyl), 6.88 (1H, d, J = 8.2 Hz, ArCH, benzyl), 6.98 (1H, d, J = 7.2 Hz, ArCH, 
benzyl), 7.10 (2H, d, J = 9.1 Hz, ArCH, aniline) and 7.22 (1H, td, J = 1.3, 8.2 Hz, 
ArCH, benzyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 50.6 (ArCH2), 54.2 (NCH2CH), 
54.7 (CH(OCH3)2), 55.1 (ArOCH3), 103.1 (CH(OCH3)2), 110.0 (ArCH, benzyl), 113.7 
(2 x ArCH, aniline), 120.3 (ArCH, benzyl), 121.8 (ArCCl), 124.9 (ArCCH2), 127.2 
(ArCH, benzyl), 127.9 (ArCH, benzyl), 128.9 (2 x ArCH, aniline), 146.7 (ArCN) and 
157.1 (ArCO) ppm. HRMS (ES
+




+H) 336.1361, found 




+H) 338.1331, found 338.1306. 
 
4-(((2,2-Dimethoxyethyl)(phenyl)amino)methyl)phenol (123l) 
C17H21NO3, Mol. Wt.: 287.35 
 
(Method A) 
The crude compound was purified by column chromatography (eluent: from 0% to 
30% of EtOAc in pet. ether) to give the product as a colourless oil (2.5 g, 90%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 3.40 (6H, s, CH3), 3.54 (2H, d, J = 5.1 Hz, 
CH2CH), 4.58 (2H, s, ArCH2), 4.61 (1H, t, J = 5.1 Hz, CH(OR)2), 5.01 (1H, bs, OH), 
6.70 (1H, t, J = 7.2 Hz, ArH), 6.74 (2H, d, J = 8.7 Hz, ArH) 6.74 (2H, d, J = 8.6 Hz, 
200 
 
ArH), 7.06 (2H, d, J = 8.6 Hz, ArH) and 7.19 (2H, dd, J = 7.2, 8.7 Hz, ArH) ppm. 
13
C 
NMR (126 MHz, CDCl3) δ 53.6 (CH2CH), 54.3 (ArCH2), 54.7 (CH3), 103.5 
(CH(OR)2), 112.4 (ArCH), 115.5 (ArCH), 116.7 (ArCH), 128.0 (ArCH), 129.4 




tr = 2.91 min (65 %), 
m/z 287.5 (M
+
); (RP, Isocratic, 80% MeOH). HRMS (ES+) calcd. for C17H22NO3 
(M
+
+H) 288.1600, found 288.1595; calcd. for C17H21NNaO3 (M
+





C18H23NO3, Mol. Wt.: 301.38 
 
(Method A) 
The crude compound was purified by column chromatography (eluent: from 0% to 
30% EtOAc in pet. ether) to give the product as a colourless oil (2.83 g, 94%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 2.24 (3H, s, ArCH3), 3.40 (6H, s, CH(OCH3)2), 
3.51 (2H, d, J = 5.1 Hz, CH2CH), 4.54 (2H, s, ArCH2), 4.59 (1H, t, J = 5.1 Hz, 
CH(OR)2), 5.10 (1H, bs, OH), 6.66 (2H, d, J = 8.6 Hz, ArH), 6.74 (2H, d, J = 8.7 Hz, 
ArH), 7.00 (2H, d, J = 8.6 Hz, ArH) and 7.06 (2H, d, J = 8.7 Hz, ArH) ppm. 
13
C NMR 
(126 MHz, CDCl3) δ 20.1 (ArCH3), 53.7 (CH2CH), 54.4 (ArCH2), 54.5 (CH(OCH3)2), 
103.4 (CH(OR)2), 112.5 (ArCH), 115.3 (ArCH), 125.7 (ArCCH3), 127.9 (ArCH), 129.7 





1.92 min (>99 %), m/z 301.5 (M
+
); (RP, Isocratic, 90% MeOH). HRMS (ES+) calcd. 
for C18H24NO3 (M
+
+H) 302.1751, found 302.1757. 
 
4-(((4-Chlorophenyl)(2,2-dimethoxyethyl)amino)methyl)phenol (123n) 





The crude compound was purified by column chromatography (eluent: from 0% to 
30% EtOAc in pet. ether) to give the product as a colourless oil (2.12 g, 66%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 3.39 (6H, s, CH3), 3.51 (2H, d, J = 5.1 Hz, 
CH2CH), 4.54 (2H, s, ArCH2), 4.56 (1H, t, J = 5.1 Hz, CH(OR)2), 5.02 (1H, bs, OH), 
6.64 (2H, d, J = 9.2 Hz, ArH), 6.76 (2H, d, J = 8.6 Hz, ArH), 7.03 (2H, d, J = 8.6 Hz, 
ArH) and 7.10 (2H, d, J = 9.1 Hz, ArH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 53.8 
(CH2CH), 54.4 (ArCH2), 54.6 (CH3), 103.2 (CH(OR)2), 113.6 (ArCH), 115.4 (ArCH), 
121.4 (ArCCl), 127.8 (ArCH), 128.9 (ArCH), 129.1 (ArCCH2), 147.2 (ArCN) and 




tr = 4.19 min (74 %), m/z 321.6 (M
+
); (RP, 
Isocratic, 80% MeOH). HRMS (ES+) calcd. for C17H21ClNO3 (M
+
+H) 322.1210, found 
322.1201; calcd. for C17H20ClNNaO3 (M
+
+Na) 344.1029, found 344.1043. 
 
4-(((2,2-dimethoxyethyl)(4-methoxyphenyl)amino)methyl)phenol (123o) 
C18H23NO4, Mol. Wt.: 317.38 
 
(Method A) 
The crude compound was purified by column chromatography (eluent 0% to 40% 
EtOAc in pet. ether) to give the product as a colourless oil (2.87 g, 90%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 3.38 (6H, s, CH(OCH3)2), 3.46 (2H, d, J = 5.1 Hz, 
CH2CH)), 3.74 (3H, s, ArOCH3), 4.48 (2H, s, ArCH2), 4.55 (1H, t, J = 5.1 Hz, 
CH(OR)2), 5.12 (1H, bs, OH), 6.71 (2H, d, J = 9.1 Hz, ArH), 6.74 (2H, d, J = 8.6 Hz, 
ArH), 6.79 (2H, d, J = 9.1 Hz, ArH) and 7.07 (2H, d, J = 8.6 Hz, ArH) ppm. 
13
C NMR 
(126 MHz, CDCl3) δ 54.4 (CH2CH), 54.5 (CH(OCH3)2), 55.3 (ArCH2), 55.9 (ArOCH3), 
202 
 
103.6 (CH(OR)2), 114.6 (ArCH), 114.9 (ArCH), 115.4 (ArCH), 128.3 (ArCH), 131.0 





= 1.56 min (97 %), m/z 317.5 (M
+
); (RP, Isocratic, 90% MeOH). HRMS (ES+) calcd. 
for C18H24NO4 (M
+
+H) 318.1700, found 318.1698. 
 
N-(2,2-Dimethoxyethyl)-N-(4-methoxybenzyl)-4-methylaniline (123q) 
C19H25NO3, Mol. Wt.: 315.41 
 
(Method A) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give the product as a yellow oil (8.6 g, 91%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 2.23 (3H, s, ArCH3), 3.39 (6H, s, CH(OCH3)2)), 
3.51 (2H, d, J = 5.1 Hz, CH2CH), 3.78 (3H, s, ArOCH3), 4.56 (2H, s, ArCH2), 4.58 (1H, 
t, J = 5.1 Hz, CHCH2), 6.66 (2H, d, J = 8.7 Hz, ArH, aniline), 6.83 (2H, d, J = 8.7 Hz, 
ArH, benzyl), 7.00 (2H, d, J = 8.7 Hz, ArH, aniline) and 7.12 (2H, d, J = 8.7 Hz, ArH, 
benzyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 20.3 (ArCH3), 53.9 (CHCH2), 54.5 
(ArCH2), 54.6 (CH(OCH3)2), 55.4 (ArOCH3), 103.5 (CHCH2), 112.6 (ArCH, aniline), 
114.2 (ArCH, benzyl), 125.9 (ArCCH3), 128.0 (ArCH, benzyl), 130.0 (ArCH, aniline), 
131.0 (ArCCH2), 146.7 (ArCN) and 158.6 (ArCO) ppm. LC/MS (ES+)
 
tr = 2.83 min 
(92 %), m/z 316.2 (M
+











The crude compound was purified by column chromatography (eluent: from 0% to 
10% EtOAc in pet. ether) to give the product as a yellow oil (3.42 g, 52%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 1.19 (3H, t, J = 7.6 Hz, CH2CH3), 2.54 (2H, q, J 
= 7.6 Hz, CH2CH3), 3.39 (6H, s, CH(OCH3)2), 3.52 (2H, d, J = 5.1 Hz, CHCH2), 3.78 
(3H, s, ArOCH3), 4.56 (2H, s, ArCH2N), 4.59 (1H, t, J = 5.1 Hz, CHCH2), 6.68 (2H, d, 
J = 8.7 Hz, ArH, aniline), 6.83 (2H, d, J = 8.7 Hz, ArH, benzyl), 7.02 (2H, d, J = 8.7 
Hz, ArH, aniline) and 7.13 (2H, d, J = 8.7 Hz, ArH, benzyl) ppm. 
13
C NMR (126 MHz, 
CDCl3) δ 15.9 (CH2CH3), 27.8 (CH2CH3), 53.9 (CHCH2), 54.5 (ArCH2N), 54.6 
(CH(OCH3)2), 55.4 (ArOCH3), 103.5 (CHCH2), 112.5 (ArCH, aniline), 114.0 (ArCH, 
benzyl), 127.9 (ArCH, benzyl), 128.7 (ArCH, aniline), 131.0 (ArCCH2N), 132.3 




tr = 3.42 min (85 %), 
m/z 330.2 (M
+
+H); (RP, Isocratic, 90% MeOH). HRMS (ES
+
) calcd. C20H28NO3 
(M
+




C19H25NO4, Mol. Wt.: 331.41 
 
(Method A) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give the product as a yellow oil (9.65 g, 97%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 3.38 (6H, s, CH(OCH3)2)), 3.47 (2H, d, J = 5.1 
Hz, CH2CH), 3.74 (3H, s, ArOCH3), 3.78 (3H, s, ArOCH3), 4.51 (2H, s, ArCH2), 4.55 
(1H, t, J = 5.1 Hz, CHCH2), 6.72 (2H, d, J = 9.2 Hz, ArH, aniline), 6.79 (2H, d, J = 9.2 
Hz, ArH, aniline), 6.83 (2H, d, J = 8.7 Hz, ArH, benzyl) and 7.13 (2H, d, J = 8.7 Hz, 
ArH, benzyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 54.4 (CHCH2), 54.5 (CH(OCH3)2)), 
55.2 (ArCH2), 55.4 (ArOCH3), 55.9 (ArOCH3), 103.6 (CHCH2), 114.0 (ArCH, benzyl), 
114.5 (ArCH, aniline), 114.9 (ArCH, aniline), 128.1 (ArCH, benzyl), 131.1 (ArCCH2), 





= 1.99 min (92 %), m/z 332.2 (M
+
+H). HRMS (ES+) calcd. for C19H26NO4 (M
+
+H) 
332.1856, found 332.1859. 
 
N-(2,2-Dimethoxyethyl)-3-methoxy-N-(4-methoxybenzyl)aniline (123u) 
C19H25NO4, Mol. Wt.: 331.41 
 
(Method A) 
As described in the general method A except that after stirring for 12 h at rt the 
mixture was concentrated in vacuo into a slurry and stirred for further 6 h. The crude 
compound was purified by column chromatography (eluent: from 0% to 10% EtOAc in 
pet. ether) to give the product as an orange oil (5.93 g, 89%) which showed: 
1
H NMR 
(500 MHz, CDCl3) δ 3.39 (6H, s, CH(OCH3)2), 3.52 (2H, d, J = 5.1 Hz, CHCH2), 3.74 
(3H, s, OCH3, benzyl), 3.78 (3H, s, OCH3, aniline), 4.58 (2H, s, ArCH2N), 4.60 (1H, t, J 
= 5.1 Hz, CHCH2), 6.27 (1H, ddd, J = 0.9, 2.5, 8.2 Hz, ArH, aniline), 6.30 (1H, t, J = 
2.5 Hz, ArH, aniline), 6.36 (1H, ddd, J = 0.9, 2.5, 8.2 Hz, ArH aniline), 6.83 (2H, d, J = 
8.9 Hz, ArH, benzyl), 7.09 (1H, t, J = 8.2 Hz, ArH, aniline) and 7.11 (2H, d, J = 8.9 Hz, 
ArH, benzyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 53.8 (CHCH2), 54.4 (ArCH2N), 54.7 
(CH(OCH3)2), 55.2 (ArOCH3, benzyl), 55.4 (ArOCH3, aniline), 99.1 (ArCH, aniline), 
101.5 (ArCH, aniline), 103.5 (CH(OCH3)2), 105.6 (ArCH, aniline), 114.1 (ArCH, 
benzyl), 127.8 (ArCH, benzyl), 130.0 (ArCH, aniline), 130.7 (ArCCH2), 150.2 (ArCN), 




tr = 2.30 min 
(96 %), m/z 332.1 (M
+





+H) 332.1856, found 332.1840. 
 
N-(2,2-Dimethoxyethyl)-2-methoxy-N-(4-methoxybenzyl)aniline (123w) 




As described in the general method A except that after stirring for 12 h at rt the 
mixture was concentrated in vacuo into a slurry and stirred for further 6 h. The crude 
compound was purified by column chromatography (eluent: from 0% to 10% EtOAc in 
pet. ether) to give the product as a yellow oil (5.34 g, 81%) which showed: 
1
H NMR 
(500 MHz, CDCl3) δ 3.25 (6H, s, CH(OCH3)2), 3.26 (2H, d, J = 5.2 Hz, CHCH2), 3.77 
(3H, s, OCH3, benzyl), 3.88 (3H, s, OCH3, aniline), 4.33 (2H, s, ArCH2N), 4.44 (1H, t, J 
= 5.2 Hz, CHCH2), 6.80 (2H, d, J = 8.8 Hz, ArH, benzyl), 6.83 (1H, dd, J = 1.6, 8.0 Hz, 
ArH, aniline), 6.87 (1H, dd, J = 1.4, 7.9 Hz, ArH, aniline), 6.91 – 6.96 (2H, m, ArH, 
aniline) and 7.21 (2H, d, J = 8.8 Hz, ArH, benzyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 
53.2 (CHCH2), 53.7 (CH(OCH3)2), 55.4 (ArOCH3, aniline), 55.7 (ArOCH3, benzyl), 
56.9 (ArCH2N), 103.8 (CH(OCH3)2), 112.2 (ArCH, aniline), 113.6 (ArCH, benzyl), 
120.9 (ArCH, aniline), 122.1 (ArCH, aniline), 122.6 (ArCH, aniline), 129.7 (ArCH, 
benzyl), 131.4 (ArCCH2), 140.0 (ArCN), 153.4 (ArCO, benzyl) and 158.6 (ArCO, 




tr = 1.87 min (99 %), m/z 332.1 (M
+
+H); (RP, Isocratic, 
90% MeOH). HRMS (ES
+
) calcd. C19H26NO4 (M
+
+H) 332.1856, found 332.1863. 
 
N-(3,4-Dimethoxybenzyl)-N-(2,2-dimethoxyethyl)-4-methoxyaniline (123x) 
C20H27NO5, Mol. Wt.: 361.43 
 
(Method A) 
The crude compound was purified by column chromatography (eluent: from 0% to 
40% EtOAc in pet. ether) to give the product as an orange oil (6.58 g, 91%) which 
showed: 
1
H NMR (400 MHz, CDCl3) δ 3.37 (6H, s), 3.45 (2H, t, J = 4.7 Hz), 3.73 (3H, 
s), 3.81 (3H, s), 3.84 (3H, s), 4.48 (2H, s), 4.56 (1H, bs) and 6.69 – 6.82 (7H, m) ppm. 
HRMS (ES
+
) calcd. C20H28NO5 (M
+





C21H29NO6, Mol. Wt.: 391.46 
 
(Method A) 
The crude compound was purified by column chromatography (eluent: from 0% to 
50% EtOAc in pet. ether) to give the product as an orange oil (7.71 g, 98%) which 
showed: 
1
H NMR (400 MHz, CDCl3) δ 3.37 (6H, s), 3.47 (2H, d, J = 5.1 Hz), 3.74 (3H, 
s), 3.78 (6H, s), 3.81 (3H, s), 4.47 (2H, s), 4.56 (1H, t, J = 5.1 Hz), 6.46 (2H, s), 6.72 
(2H, d, J = 9.2 Hz) and 6.79 (2H, d, J = 9.2 Hz) ppm. HRMS (ES
+
) calcd. C21H30NO6 
(M
+
+H) 392.2068, found 392.2081. 
 
4-Chloro-N-(2,2-dimethoxyethyl)-N-benzyl-aniline (123z) 
C17H20ClNO2, Mol. Wt.: 305.80 
 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give the product as a colourless oil (3.74 g, 82%) which 
solidified upon standing and showed: 
1
H NMR (500 MHz, CDCl3) δ 3.40 (6H, s, 
CH(OCH3)2), 3.55 (2H, d, J = 5.1 Hz, CHCH2), 4.58 (1H, t, J = 5.1 Hz, CHCH2), 4.63 
(2H, s, ArCH2N), 6.64 (2H, d, J = 9.2 Hz, ArH, aniline), 7.11 (2H, d, J = 9.2 Hz, ArH, 
aniline), 7.17 (2H, d, J = 7.0 Hz, ArH, benzyl), 7.23 (1H, t, J = 7.3 Hz, ArH, benzyl) 
and 7.30 (1H, t, J = 7.4 Hz, ArH, benzyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 54.2 
(CHCH2), 54.7 (CH(OCH3)2), 55.1 (ArCH2N), 103.3 (CHCH2), 113.6 (ArCH, aniline), 
121.5 (ArCCl), 126.5 (ArCH, benzyl), 127.0 (ArCH, benzyl), 128.8 (ArCH, benzyl), 







3.08 min (96 %), m/z 305.9 (M
+












308.1226, found 308.1244. Mp 61-63 °C (pet. ether). Anal. calcd. for C17H20ClNO2: C 
66.8, H 6.59, N 4.58% found C 66.3, H 6.52, N 4.52%. 
 
1-(2-(Benzylamino)-4,6-dimethoxyphenyl)-2,2-dimethoxyethan-1-ol (124) 
C19H25NO5, Mol. Wt.: 347.41 
 
The crude compound was purified by chromatography (eluent 0% to 40% EtOAc in 
pet. ether) to give the product as a pale yellow oil (1.94 g, 56%). 
1
H NMR (400 MHz, 
CDCl3) δ 3.28 (3H, s, CHOCH3), 3.47 (3H, s, CHOCH3), 3.70 (3H, s, ArOCH3), 3.78 
(3H, s, ArOCH3), 4.32 (2H, d, J = 2.8 Hz, ArCH2), 4.75 (1H, d, J = 6.9 Hz, CH(OR)2), 
5.24 (1H, d, J = 6.9 Hz, ArCH), 5.88 (1H, d, J = 2.2 Hz, ArH), 5.94 (1H, d, J = 2.2 Hz, 
ArH), 7.23 - 7.26 (1H, m, ArH) and 7.31 - 7.37 (4H, m, ArH) ppm. 
13
C NMR (101 
MHz, CDCl3) δ 48.0 (ArCH2), 54.9 (ArOCH3), 55.0 (CHOCH3), 55.7 (ArOCH3), 55.9 
(CHOCH3), 68.2 (ArCHOH), 88.2 (ArCH), 91.3 (ArCH), 103.7 (ArCCH), 105.2 
(CH(OR)2), 127.0 (ArCH), 127.3 (ArCH), 128.6 (ArCH), 139.7 (ArCCH2), 149.4 
(ArCN), 159.3 (ArCOCH3) and 161.1 (ArCOCH3) ppm. LC/MS (ES+)
 
tr = 1.27 min 
(95%), m/z 348.0 (M
+










2-Hydroxybenzaldehyde (320 μL, 3.00 mmol) and 3,5-dimethoxyaniline (469 mg, 
3.00 mmol) were dissolved in CHCl3 (20 mL) and treated with NaBH(OAc)3 (870 mg, 
3.90 mmol). The mixture was stirred for 4 h at rt, during which time it turned from pale 
yellow to bright yellow. NaBH(OAc)3 (870 mg, 3.90 mmol) was introduced and, after 
stirring for 1 h at rt, the mixture was quenched with a saturated aqueous solution of 
K2CO3. The aqueous layer was then extracted with CHCl3 (2 x 20 mL). The combined 
organics were dried with MgSO4, filtered and evaporated to give a bright yellow oil 
(966 mg) which showed: 
1
H NMR (500 MHz, CDCl3) δ 3.74 (6H, s, CH3), 3.95 (1H, bs, 
NH), 4.38 (2H, s, ArCH2), 6.01 (2H, d, J = 2.1 Hz, ArH), 6.04 (1H, t, J = 2.1 Hz, ArH), 
6.87 (1H, td, J = 1.2, 7.4 Hz, ArH), 6.89 (2H, dd, J = 1.2, 7.4 Hz, ArH), 7.15 (1H, dd, J 
= 1.6, 7.4 Hz, ArH), 7.22 (1H, td, J = 1.6, 7.4 Hz, ArH) and 8.06 (1H, bs, ArOH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 48.5 (ArCH2), 55.4 (CH3), 92.8 (ArCH), 94.7 (ArCH), 
116.8 (ArCH), 120.3 (ArCH), 123.0 (ArCCH2), 128.9 (ArCH), 129.4 (ArCH), 149.4 




tr = 1.21 min 
(99 %), m/z 260.0 (M
+
); (RP, Isocratic, 90% MeOH). HRMS (ES+) calcd. for 
C15H18NO3 (M
+




C19H23NO5, Mol. Wt.: 345.39 
 
 
Compound 125 (780 mg, 3.00 mmol) was dissolved in CHCl3 (5 mL) and 2,2-
dimethoxyacetaldehyde (1.0 mL, 6.7 mmol) was introduced. After stirring overnight, 
the mixture was extracted with water and the organic layer was dried with MgSO4, 
filtered and evaporated to give a pale green oil. The crude compound was purified by 
chromatography (eluent: from 0% to 30% EtOAc in pet. ether) to give the product as a 
pale green oil (55 mg, 5%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 3.39 (3H, s, 
209 
 
CHOCH3), 3.47 (3H, s, CHOCH3), 3.74 (6H, s, ArOCH3), 4.44 (1H, d, J = 16.6 Hz, 
ArCH2), 4.66 (1H, d, J = 16.6 Hz, ArCH2), 4.67 (1H, d, J = 6.7 Hz, CH(OR)2), 5.48 
(1H, dd, J = 1.5, 6.7 Hz, NCH), 6.09 (1H, t, J = 2.2 Hz, ArH), 6.28 (2H, d, J = 2.2 Hz, 
ArH), 6.89 (1H, td, J = 1.3, 7.5 Hz, ArH), 6.91 (1H, dd, J = 1.3, 8.4 Hz, ArH), 7.01 (1H, 
dd, J = 1.7, 7.5 Hz, ArH) and 7.14 (1H, td, J = 1.7, 8.4 Hz, ArH) ppm. 
13
C NMR (126 
MHz, CDCl3) δ 46.8 (ArCH2), 53.5 (CHOCH3), 55.3 (ArOCH3), 55.6 (CHOCH3), 87.0 
(NCH), 93.8 (ArCH), 98.0 (ArCH), 101.2 (CH(OR)2), 117.2 (ArCH), 120.1 (ArCCH2), 
120.9 (ArCH), 126.6 (ArCH), 128.2 (ArCH), 151.3 (ArCN), 152.5 (ArCOCH) and 




tr = 2.03 min (4%), m/z 346.1 (M
+
+H); (RP, 
Isocratic, 90% MeOH).  
 
2-((Phenylamino)methyl)phenol (128) 
C13H13NO, Mol. Wt.: 199.25 
 
Salicylaldehyde (1.1 mL, 10.0 mmol) and aniline (0.9 mL, 10.0 mmol) were 
dissolved in CHCl3 (40 mL) and treated with NaBH(OAc)3 (3.3 g, 15.0 mmol). After 
stirring for 3 h at rt, the mixture was quenched with a saturated aqueous solution of 
NaHCO3 and the aqueous layer was extracted with EtOAc (1 x 40 mL). The combined 
organics were dried with MgSO4, filtered and evaporated to give a yellow-green solid 
which showed: 
1
H NMR (500 MHz, CDCl3) δ 3.94 (1H, bs) (OH or NH), 4.42 (2H, s) 
(CH2), 6.86 (2H, dd, J = 1.0, 8.5 Hz) (ArH, Aniline), 6.87 – 6.91 (2H, m) (2 x ArH, 
benzyl), 6.92 (1H, tt, J = 1.0, 7.4 Hz) (ArH, aniline), 7.16 (1H, dd, J = 1.6, 7.4 Hz) 
(ArH, benzyl), 7.21 – 7.25 (1H, m) (ArH, benzyl), 7.25 (2H, dd, J = 7.4, 8.5 Hz) (2 x 
ArH, aniline) and 8.37 (1H, bs) (OH or NH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 48.9 
(CH2), 116.1, 116.8, 120.2, 121.0 (ArCH, Aniline), 123.0 (ArCCH2), 128.9 (ArCH, 





tr = min 1.40 ( %), m/z 199.3 (M
+
); (RP, Isocratic, 90% MeOH). 
HRMS (ES+) calcd. for C13H14NO (M
+





C17H19NO3, Mol. Wt.: 285.34 
 
 
Compound 128 (598 mg, 3.0 mmol) was dissolved in CHCl3 (20 mL) and treated 
with 2,2-dimethoxyacetaldehyde (452 μL, 3.0 mmol) and K2CO3 (828 mg, 6.0 mmol). 
After stirring for 24 h at rt, the mixture was filtered and the filtrate was evaporated to 
give the a yellow oil (782 mg). The crude compound was purified by column 
chromatography (eluent: from 0% to 20% EtOAc in pet. ether) to give the product as a 
pale yellow oil (638 mg, 75%) which showed: 
1
H NMR (400 MHz, CDCl3) δ 3.39 (3H, 
s), 3.46 (3H, s), 4.45 (1H, d, J = 16.8 Hz), 4.65 (1H, d, J = 6.6 Hz), 4.66 (1H, d, J = 
16.8 Hz), 5.46 (1H, dd, J = 1.2, 6.6 Hz), 6.90 (2H, d, J = 7.8 Hz), 6.94 (1H, t, J = 7.0 
Hz), 7.00 (1H, d, J = 7.9 Hz), 7.10 (2H, d, J = 7.9 Hz), 7.15 (1H, d, J = 7.9 Hz) and 7.24 
(2H, dd, J = 7.0, 7.8 Hz) ppm. 
 
3-Chloro-N-(2,2-diethoxyethyl)-N-(4-methoxybenzyl)aniline (131t) 
C20H26ClNO3, Mol. Wt.: 363.88 
 
The crude compound 122t (4.9 g) was dissolved in anhydrous DMF (20 mL) under 
inert atmosphere and treated with NaH (2.4 g, 60.0 mmol). The mixture was stirred for 
30 min at rt and then 2-bromo-1,1-diethoxyethane (6.2 mL, 40.0 mmol) was introduced. 
After stirring for 6 h at 60 °C, the mixture was cooled to rt, quenched with ice, and 
extracted with EtOAc (3 x 50 mL). The combined organics were washed with brine (3 x 
15 mL) then dried with MgSO4, filtered and evaporated to give a dark yellow oil (9.3 g). 
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The crude compound was purified twice by column chromatography (eluent: pet. ether) 
to give the product as a pale yellow oil (1.5 g, 21%) which showed: 
1
H NMR (500 
MHz, CDCl3) δ 1.20 (6H, t, J = 7.0 Hz, CH2CH3), 3.49 – 3.56 (4H, m, CH2CH3, 
NCH2CH), 3.72 (2H, dq, J = 7.0, 9.3 Hz, CH2CH3), 3.78 (3H, s, ArOCH3), 4.58 (2H, s, 
ArCH2N), 4.69 (1H, t, J = 5.2 Hz, CH2CH), 6.59 (1H, ddd, J = 0.5, 2.2, 8.6 Hz, ArCH, 
aniline), 6.64 (1H, ddd, J = 0.5, 2.2, 7.8 Hz, ArCH, aniline), 6.74 (1H, t, J = 0.5 Hz, 
ArCH, aniline), 6.84 (2H, d, J = 8.7 Hz, ArCH, benzyl), 7.06 (1H, t, J = 8.2 Hz, ArCH, 
aniline) and 7.09 (2H, d, J = 8.7 Hz, ArCH, benzyl) ppm. 
13
C NMR (126 MHz, CDCl3) 
δ 15.4 (CH2CH3), 54.1(ArCH2), 54.3(NCH2CH), 55.3(ArOCH3), 63.2(CH2CH3), 
101.2(CH2CH), 110.4 (ArCH, aniline), 112.1 (ArCH, aniline), 114.0 (ArCH, benzyl), 
116.2 (ArCH, aniline), 127.6 (ArCH, benzyl), 129.8 (ArCCH2), 130.0 (ArCH, aniline), 




tr = 4.13 min 
(88 %), m/z 364.0 (M
+
















C20H26ClNO3, Mol. Wt.: 363.88 
 
Compound 122v (5.2 g) was dissolved in anhydrous DMF (20 mL) under inert 
atmosphere and treated with NaH (2.4 g, 60.0 mmol). The mixture was stirred for 30 
min at 80 °C and then 2-bromo-1,1-diethoxyethane (6.2 mL, 40.0 mmol) was 
introduced. After stirring for 6 h at 60 °C, the mixture was cooled to rt, quenched with 
ice, and extracted with EtOAc (3 x 50 mL). The combined organics were washed with 
brine (3 x 15 mL) then dried with MgSO4, filtered and evaporated to give a yellow oil 
(12.2 g). The crude compound was dissolved in pet. ether and the remaining starting 
material was crystallised out. The recovered organic solvent was evaporated and the 
residue was purified by column chromatography (eluent: from 0% to 10% EtOAc in pet. 





(500 MHz, CDCl3) δ 1.12 (6H, t, J = 7.1 Hz, CH2CH3), 3.24 (2H, d, J = 5.4 Hz, 
NCH2CH), 3.41 (2H, dq, J = 7.1, 9.3 Hz, CH2CH3), 3.55 (2H, dq, J = 7.1, 9.1 Hz, 
CH2CH3), 3.78 (3H, s, OCH3), 4.31 (2H, s, ArCH2N), 4.53 (1H, t, J = 5.4 Hz, 
NCH2CH), 6.81 (2H, d, J = 8.7 Hz, 2 x ArCH, benzyl), 6.94 (1H, ddd, J = 1.8, 7.2, 7.9 
Hz, ArCH, aniline), 7.09 (1H, dd, J = 1.8, 8.0 Hz, ArCH, aniline), 7.11 – 7.16 (1H, m, 
ArCH, aniline), 7.23 (2H, d, J = 8.7 Hz, 2 x ArCH, benzyl) and 7.35 (1H, dd, J = 1.5, 
7.9 Hz, ArCH, aniline) ppm. 
13
C NMR (126 MHz, CDCl3) δ 15.3 (2 x CH2CH3), 53.5 
(NCH2CH), 55.2 (OCH3), 57.3 (NCH2CH), 62.0 (2 x CH2CH3), 101.3 (NCH2CH), 
113.5 (2 x ArCH, benzyl), 123.8 (ArCH, aniline), 124.4 (ArCH, aniline), 126.9 (ArCH, 
aniline), 129.7 (2 x ArCH, benzyl), 130.0 (ArCCH2), 130.5 (ArCCl), 130.6 (ArCH, 




tr = 3.61 min (99 %), 
m/z 364.0 (M
+
















C12H19NO3, Mol. Wt.: 225.28 
 
NaBH(OAc)3 (6.69g, 30.0 mmol) was added to a stirring solution of 
p-methoxyaniline (2.46 g, 20.0 mmol) and 2,2-dimethoxyacetone (5.0 mL, 40.0 mmol) 
in CHCl3 (40 mL) and the mixture was stirred at rt for 1 h. The mixture was washed 
with a sat. aq. solution of NaHCO3 (2 x 40 mL) and the organic layer was dried with 





H NMR (500 MHz, CDCl3) δ 1.16 (3H, d, J = 6.5 Hz, CH3CH), 3.44 (3H, s, 
CHOCH3), 3.47 (3H, s, CHOCH3), 3.50 – 3.57 (1H, m, CH2CH), 3.75 (3H, s, ArOCH3), 
4.29 (1H, d, J = 4.0 Hz, CHCHCH3), 6.65 (2H, d, J = 9.0 Hz, 2 x ArCH) and 6.77 (2H, 
d, J = 9.0 Hz, 2 x ArCH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 14.4 (CH3CH), 52.0 
(CH3CH), 55.6 (CHOCH3), 55.7 (ArOCH3), 56.5 (CHOCH3), 106.9 (CH3CHCH), 114.9 










C20H27NO4, Mol. Wt.: 345.43 
 
NaH (1.2g, 30.0 mmol) was added to a stirring solution of 136s (4.8g, 20.0 mmol) in 
anhydrous THF (40 mL) and stirred at rt for 1 h. 4-Methoxybenzyl chloride (4.2 ml, 
30.0 mmol) was added to the reaction mixture and the mixture was then refluxed 
overnight. The mixture was quenched with water and the THF was evaporated. The 
residue was dissolved in EtOAc (150 mL) and washed with sat. aq. NaHCO3 
(3 x 100 mL) then dried with MgSO4, filtered and evaporated to give a brown oil 
(1.97 g). The crude compound was purified by column chromatography (from 0% to 
10% EtOAc in pet. ether) to give the pure compound as a yellow oil (1.67 g, 24%) 
which showed: 
1
H NMR (500 MHz, CDCl3) δ 1.23 (3H, d, J = 6.3 Hz, CH3CH), 3.34 
(3H, s, CHOCH3), 3.37 (3H, s, CHOCH3), 3.72 (3H, s, ArOCH3), 3.76 (3H, s, 
ArOCH3), 3.92 – 4.05 (1H, m, CH3CH), 4.29 – 4.45 (3H, m, CH3CHCH, ArCH2), 6.74 
(4H, s, 4 x ArCH, aniline), 6.81 (2H, d, J = 8.4 Hz, 2 x ArCH, benzyl) and 7.20 (2H, d, 
J = 7.8 Hz, 2 x ArCH, benzyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 12.7, 49.3, 54.3, 
55.2, 55.4, 55.6, 56.3, 106.6, 113.7, 114.4, 116.4, 127.7, 129.3, 132.3, 143.4, 151.8 and 
158.1 ppm. HRMS (ES
+
) calcd. C20H28NO4 (M
+
+H) 346.2018, found 346.2031; calcd. 
C20H27NNaO4 (M
+
+H) 368.1838, found 368.1836. 
 
4-(((4-Chlorophenyl)(propyl)amino)methyl)phenol (139n) 




NaBH(OAc)3 (1.34 g, 6.00 mmol) was added to a stirring solution of 
4-hydroxybenzaldehyde (498 mg, 4.00 mmol) and 4-chloroaniline (525 mg, 4.00 mmol) 
in CHCl3 (20 mL) and the mixture was stirred at rt for 2 h. Propanal (351 µL, 4.80 
mmol) was introduced followed by NaBH(OAc)3 (1.34 g, 6.00 mmol) and the mixture 
was stirred at rt overnight. The mixture was washed with 1 N NaOH (3 x 20 mL) and 
the dried with MgSO4, filtered and evaporated to give an orange oil (773 mg). The 
crude compound was purified by column chromatography (eluent: from 0% to 30% 
EtOAc in pet. ether) to give the product as a yellow oil (655 mg, 59%) which showed:  
1
H NMR (500 MHz, D6-DMSO) δ 0.86 (3H, t, J = 7.4 Hz, CH2CH3), 1.47 – 1.62 (2H, 
m, CH2CH3), 3.26 – 3.33 (2H, m, NCH2CH2), 4.39 (2H, s, ArCH2N), 6.61 (2H, d, J = 
9.2 Hz, 2 x ArCH, aniline), 6.71 (2H, d, J = 8.5 Hz, 2 x ArCH, benzyl), 6.97 (2H, d, J = 
8.5 Hz, 2 x ArCH, benzyl), 7.09 (2H, d, J = 9.1 Hz, 2 x ArCH, aniline) and 9.42 (1H, 
bs, OH) ppm. 
13
C NMR (126 MHz, D6-DMSO) δ 11.2 (CH2CH3), 19.8 (CH2CH3), 52.5 
(NCH2CH2), 53.2 (ArCH2N), 113.3 (2 x ArCH, aniline), 115.3 (2 x ArCH, benzyl), 
118.7 (ArCCl), 127.6 (2 x ArCH, benzyl), 128.5 (2 x ArCH, aniline), 128.6 (ArCCH2), 











+H) 278.1120, found 278.1120. 
Mp 143-146 °C (aqueous HBr). 
 
4-(((4-Chlorophenyl)(isobutyl)amino)methyl)phenol (140n) 
C17H20ClNO, Mol. Wt.: 289.80 
 
NaBH(OAc)3 (1.34 g, 6.00 mmol) was added to a stirring solution of 
4-hydroxybenzaldehyde (498 mg, 4.00 mmol) and 4-chloroaniline (525 mg, 4.00 mmol) 
in CHCl3 (20 mL) and the mixture was stirred at rt for 2 h. Isobutyraldehyde (447 µL, 
4.80 mmol) was introduced followed by NaBH(OAc)3 (1.34 g, 6.00 mmol) and the 
mixture was stirred at rt overnight. The mixture was washed with 1 N NaOH (3 x 20 
mL) and the dried with MgSO4, filtered and evaporated to give an orange oil (1.43 g). 
The crude compound was purified by column chromatography (eluent: from 0% to 30% 
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EtOAc in pet. ether) to give the product as a yellow oil (598 mg, 52%) which showed: 
1
H NMR (500 MHz, D6-DMSO) δ 0.87 (6H, d, J = 6.7 Hz, CH(CH3)2), 1.91 – 2.06 (1H, 
m, CH(CH3)2), 3.18 (2H, d, J = 7.3 Hz, NCH2CH), 4.44 (2H, s, ArCH2N), 6.61 (2H, d, J 
= 9.2 Hz, 2 x ArCH, aniline), 6.71 (2H, d, J = 8.5 Hz, 2 x ArCH, benzyl), 6.93 (2H, d, J 
= 8.5 Hz, 2 x ArCH, benzyl), 7.07 (2H, d, J = 9.1 Hz, 2 x ArCH, aniline) and 9.58 (1H, 
bs, OH) ppm. 
13
C NMR (126 MHz, D6-DMSO) δ 20.1 (CH(CH3)2), 26.7 (CH(CH3)2), 
54.1 (ArCH2N), 58.7 (NCH2CH), 113.7 (2 x ArCH, aniline), 115.3 (2 x ArCH, benzyl), 
118.8 (ArCCl), 127.5 (2 x ArCH, benzyl), 128.1 (ArCCH2), 128.5 (2 x ArCH, aniline), 











+H) 292.1277, found 292.1281. 
Mp 135-137 °C (aqueous HBr). 
 
2-Phenyl-1,2,3,4-tetrahydroisoquinolin-4-ol (143a) 
C15H15NO, Mol. Wt.: 225.29 
 
(Method B) 
A sample of crude compound was purified by column chromatography (eluent: from 
0% to 10% EtOAc in pet. ether) to give a yellow oil which showed: 
1
H NMR (500 
MHz, CDCl3) δ 2.65 (1H, bs, OH), 3.39 (1H, dd, J = 2.6, 12.6 Hz, H3-THIQ), 3.86 (1H, 
ddd, J = 1.1, 3.8, 12.6 Hz, H3-THIQ), 4.20 (1H, d, J = 15.4 Hz, H1-THIQ), 4.49 (1H, d, 
J = 15.4 Hz, H1-THIQ), 4.79 (1H, bs, H4-THIQ), 6.94 (1H, tt, J = 1.1, 7.4 Hz, ArH, 
phenyl), 7.09 (2H, dd, J = 1.0, 8.8 Hz, ArH, phenyl), 7.17 – 7.23 (1H, m), 7.29 – 7.32 
(2H, m, H6,H7-THIQ ), 7.34 (2H, dd, J = 7.3, 8.8 Hz, ArH, phenyl) and 7.47 – 7.51 (1H, 
m) ppm. 
13
C NMR (126 MHz, CDCl3) δ 51.4 (C1-THIQ), 55.6 (C3-THIQ), 67.3 (C4-
THIQ), 116.6 (ArCH, phenyl), 120.2 (ArCH, phenyl), 126.5, 127.2, 128.2, 129.3, 129.4 




tr = 1.75 min 
(66 %), m/z 226.0 (M
+
+H); (RP, Isocratic, 90% MeOH). HRMS (ES
+
) calcd. for 
C15H16NO (M
+





C16H17NO2, Mol. Wt.: 255.31 
 
(Method B) 
The crude compound was obtained as a yellow oil (1.73 g) which showed: 
1
H NMR 
(400 MHz, CDCl3) δ 2.46 (1H, bs), 3.40 (1H, dd, J = 2.7, 12.6 Hz), 3.83 (3H, s), 3.85 
(1H, ddd, J = 0.7, 3.9, 12.6 Hz), 4.21 (1H, d, J = 15.5 Hz), 4.50 (1H, d, J = 15.5 Hz), 
4.79 (1H, s), 6.47 (1H, dd, J = 2.3, 8.2 Hz), 6.61 (1H, t, J = 2.3 Hz), 6.69 (1H, dd, J = 
2.3, 8.2 Hz), 7.17 - 7.20 (1H, m), 7.23 (1H, t, J = 8.2 Hz), 7.28 - 7.32 (2H, m) and 7.45 - 











C16H17NO2, Mol. Wt.: 255.31 
 
(Method B) 
A sample of crude compound was purified by column chromatography (eluent: from 
0% to 30% EtOAc in pet. ether) to give a yellow oil which showed: 
1
H NMR (500 
MHz, CDCl3) δ 2.54 (1H, bs, OH), 3.37 (1H, dd, J = 2.6, 12.6 Hz, H3-THIQ), 3.83 (3H, 
s, ArOCH3), 3.84 (4H, ddd, J = 1.1, 3.8, 12.6 Hz, H3-THIQ), 4.14 (1H, d, J = 14.9 Hz, 
H1-THIQ), 4.43 (1H, d, J = 14.9 Hz, H1-THIQ), 4.74 (1H, bs, H4-THIQ), 6.88 (1H, dd, 
J = 2.7, 8.4 Hz, H7-THIQ), 6.91 (1H, tt, J = 0.8, 7.4 Hz, ArH, phenyl), 7.01 (1H, d, J = 
2.7 Hz, H5-THIQ), 7.07 (2H, dd, J = 0.8, 8.7 Hz, ArH, phenyl), 7.10 (1H, d, J = 8.4 Hz, 
H8-THIQ) and 7.32 (2H, dd, J = 7.3, 8.7 Hz, ArH, phenyl) ppm. 
13
C NMR (126 MHz, 
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CDCl3) δ 50.9 (C1-THIQ), 55.5 (ArOCH3), 55.5 (C3-THIQ), 67.6 (C4-THIQ), 113.1 
(C5-THIQ), 115.3 (C7-THIQ), 116.6 (ArCH, phenyl), 120.2 (ArCH, phenyl), 126.4 
(C1CC8-THIQ), 127.6 (C8-THIQ), 129.4 (ArCH, phenyl), 137.8 (C4CC5-THIQ), 151.2 
(ArCN) and 158.7 (C6-THIQ) ppm. LC/MS (ES+)
 
tr = 1.77 min (56%), m/z 255.9 
(M
+
+H). HRMS (ES+) calcd. for C16H18NO2 (M
+
+H) 256.1332, found 256.1326. 
 
2-(4-Chlorophenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-4-ol (143i) 
C16H16ClNO2, Mol. Wt.: 289.76 
 
A sample of crude compound was purified by column chromatography (eluent: from 
0% to 30% EtOAc in pet. ether) to give a yellow oil which showed: 
1
H NMR (500 
MHz, CDCl3) δ 2.45 (1H, bs, OH), 3.36 (1H, dd, J = 2.7, 12.6 Hz, H3-THIQ), 3.77 (1H, 
ddd, J = 0.9, 3.9, 12.6 Hz, H3-THIQ), 3.83 (3H, s, ArOCH3), 4.11 (1H, d, J = 14.8 Hz, 
H1-THIQ), 4.38 (1H, d, J = 14.8 Hz, H1-THIQ), 4.74 (1H, bs, H4-THIQ), 6.88 (1H, dd, 
J = 2.7, 8.5 Hz, H7-THIQ), 6.97 (2H, d, J = 9.0 Hz, ArH, phenyl), 7.00 (1H, d, J = 2.6 
Hz, , H5-THIQ), 7.09 (1H, d, J = 8.5 Hz, H8-THIQ) and 7.25 (2H, d, J = 9.0 Hz, ArH, 
phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 50.8 (C1-THIQ), 55.5 (C3-THIQ), 55.5 
(ArOCH3), 67.5 (C4-THIQ), 113.15 (C5-THIQ), 115.45 (C7-THIQ), 117.7 (ArCH, 
phenyl), 125.0 (ArCCl), 126.0 (C1CC8), 127.65 (C8-THIQ), 129.2 (ArCH, phenyl), 




tr = 2.08 min 
(58 %), m/z 290.1 (M
+
+H); (RP, Isocratic, 90% MeOH). HRMS (ES
+










290.0756, found 290.0769 
 
2-Phenyl-1,2,3,4-tetrahydroisoquinoline-4,6-diol (143l) 





The crude compound was obtained as a brown-yellow solid (2.15 g) which showed: 
1
H NMR (400 MHz, CDCl3) δ 3.42 (1H, ddd, J = 0.6, 2.9, 12.7 Hz), 3.85 (1H, ddd, J = 
1.0, 4.0, 12.7 Hz), 4.17 (1H, d, J = 14.3 Hz), 4.46 (1H, d, J = 14.2 Hz), 4.76 (1H, s), 
6.84 (1H, dd, J = 2.7, 8.4 Hz), 6.92 - 7.05 (2H, m), 7.08 - 7.13 (3H, m) and 7.31 - 7.39 




tr = 1.22 min (81 %), m/z 242.1 (M
+
+H); (RP, Isocratic, 
90% MeOH).  
 
2-p-Tolyl-1,2,3,4-tetrahydroisoquinoline-4,6-diol (143m) 
C16H17NO2, Mol. Wt.: 255.31 
 
(Method B) 
The crude compound was obtained as a brown-yellow solid (2.05 g) which showed: 
1
H NMR (400 MHz, CDCl3) δ 3.31 (1H, dd, J = 2.5, 12.2 Hz), 3.76 (1H, dd, J = 3.5, 
12.2 Hz), 4.07 (1H, d, J = 14.9 Hz), 4.36 (1H, d, J = 14.9 Hz), 4.69 (1H, s), 6.64 (1H, d, 







1.52 min (70 %), m/z 256.1 (M
+









The crude compound was purified by column chromatography (eluent: 10% MeOH 
in DCM) to give a yellow-brown solid (1.88g, 95%) which showed: 
1
H NMR (500 
MHz, CDCl3) δ 2.63 (1H, bs, C4OH), 3.37 (1H, dd, J = 2.2, 12.6 Hz, H3-THIQ), 3.76 
(1H, dd, J = 3.6, 12.6 Hz, H3-THIQ), 4.11 (1H, d, J = 14.8 Hz, H1-THIQ), 4.38 (1H, d, J 
= 14.8 Hz, H1-THIQ), 4.72 (1H, s, H4-THIQ), 5.30 (1H, bs, C6OH), 6.81 (1H, dd, J = 
2.3, 8.3 Hz, H7-THIQ), 6.96 (1H, d, J = 2.2 Hz, H5-THIQ), 6.99 (2H, d, J = 8.7 Hz, 2 x 
ArCH, phenyl), 7.05 (1H, d, J = 8.3 Hz, H7-THIQ) and 7.27 (2H, d, J = 8.7 Hz, 2 x 
ArCH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 50.8 (C1-THIQ), 55.3 (C3-THIQ), 
67.1 (C4-THIQ), 115.1 (C5-THIQ), 115.9 (C7-THIQ), 117.6 (2 x ArCH, phenyl), 125.0 
(ArCCl), 125.9 (C1CC8-THIQ), 127.7 (C8-THIQ), 129.1 (2 x ArCH, phenyl), 137.6 




tr = 1.65 min 
(72 %), m/z 276.1 (M
+
+H); (RP, Isocratic, 90% MeOH). HRMS (ES
-
) calcd. for 
C15H13ClNO2 (M
-
-H) 274.0640, found 274.0629. Mp 168-171 °C 
 
2-(4-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline-4,6-diol (143o) 
C16H17NO3, Mol. Wt.: 271.31 
 
(Method B) 
The crude compound was obtained as a brown-yellow solid (2.17 g) which showed: 
1
H NMR (400 MHz, CDCl3) δ 3.26 (1H, dd, J = 2.5, 12.4 Hz), 3.62 (1H, ddd, J = 1.1, 
3.7, 12.2 Hz), 3.78 (3H, s), 4.00 (1H, d, J = 14.6 Hz), 4.25 (1H, d, J = 14.6 Hz), 4.66 
(1H, t, J = 3.0 Hz), 6.77 (1H, dd, J = 2.7, 8.3 Hz), 6.87 (2H, d, J = 9.0 Hz), 6.90 (1H, d, 
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= 1.35 min (98 %), m/z 271.8 (M
+
+H); (RP, Isocratic, 90% MeOH).  
 
6-Methoxy-2-(p-tolyl)-1,2,3,4-tetrahydroisoquinolin-4-ol (143q) 
C17H19NO2, Mol. Wt.: 269.34 
 
(Method B) 
A sample of crude compound was purified by column chromatography (eluent: from 
0% to 30% EtOAc in pet. ether) to give a yellow oil which showed: 
1
H NMR (500 
MHz, CDCl3) δ 2.30 (3H, s, ArCH3), 2.64 (1H, bs, OH), 3.31 (1H, dd, = 2.6, 12.5 Hz, 
H3-THIQ), 3.77 (1H, ddd, J = 1.1, 3.8, 12.5 Hz, H3-THIQ), 3.83 (3H, s, ArOCH3), 4.08 
(1H, d, J = 14.9 Hz, H1-THIQ), 4.37 (1H, d, J = 14.8 Hz, H1-THIQ), 4.72 (1H, bs, H4-
THIQ), 6.87 (1H, dd, J = 2.7, 8.5 Hz, H7-THIQ), 6.98 (2H, d, J = 8.6 Hz, ArH, phenyl), 
7.00 (1H, d, J = 2.7 Hz, H5-THIQ), 7.09 (1H, d, J = 8.5 Hz, H8-THIQ) and 7.13 (2H, d, 
J = 8.6 Hz, ArH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 20.6 (ArCH3), 51.6 (C1-
THIQ), 55.5 (ArOCH3), 56.2 (C3-THIQ), 67.6 (C4-THIQ), 113.1 (C5-THIQ), 115.3 (C7-
THIQ), 117.1 (ArCH, phenyl), 126.6 (C1CC8), 127.6 (C8-THIQ), 129.9 (ArCH, 





tr = 1.82 min (70 %), m/z 270.2 (M
+









The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give the product as an orange wax (900 mg, 31%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 1.23 (1H, t, J = 7.6 Hz, CH2CH3), 2.56 (1H, d, J 
= 10.8 Hz, OH), 2.61 (1H, q, J = 7.6 Hz, CH2CH3), 3.32 (1H, dd, J = 2.5, 12.5 Hz, 
H3-THIQ), 3.81 (1H, ddd, J = 1.0, 3.7, 12.5 Hz, H3-THIQ), 3.83 (1H, s, OCH3), 4.09 
(1H, d, J = 14.8 Hz, H1-THIQ), 4.40 (1H, d, J = 14.8 Hz, H1-THIQ), 4.73 (1H, dt, J 
= 3.1, 10.8 Hz, H4-THIQ), 6.87 (1H, dd, J = 2.7, 8.5 Hz, H7-THIQ), 7.00 (1H, d, J = 2.4 
Hz, H5-THIQ), 7.02 (1H, d, J = 8.8 Hz), 7.10 (1H, d, J = 8.5 Hz, H8-THIQ) and 7.16 
(1H, d, J = 8.6 Hz) ppm. 
13
C NMR (126 MHz, CDCl3) δ 15.8 (CH2CH3), 28.0 
(CH2CH3), 51.3 (C1-THIQ), 55.4 (OCH3), 55.9 (C3-THIQ), 67.5 (C4-THIQ), 113.0 
(C5-THIQ), 115.1 (C7-THIQ), 116.9 (ArCH, phenyl), 126.4 (C1CC8-THIQ), 127.5 
(C8-THIQ), 128.6 (ArCH, phenyl), 136.3 (ArCEt), 137.7 (C4CC6-THIQ), 149.1 (ArCN) 




tr = 2.19 min (48 %), m/z 284.2 (M
+
+H); (RP, 
Isocratic, 90% MeOH). HRMS (ES
+
) calcd. C18H22NO2 (M
+





C17H19NO3, Mol. Wt.: 285.34 
 
A sample of crude compound was purified by column chromatography (eluent: from 
0% to 30% EtOAc in pet. ether) to give a yellow oil which showed: 1H NMR (400 
MHz, CDCl3) δ 3.28 (1H, dd, J = 2.6, 12.2 Hz, H3-THIQ), 3.75 (1H, dd, J = 4.5, 12.2 
Hz), 3.79 (3H, s, OMe), 3.83 (3H, s, OMe), 4.04 (1H, d, J = 14.7 Hz, H1-THIQ), 4.29 
(1H, d, J = 14.7 Hz, H1-THIQ), 4.71 (1H, m, H4-THIQ), 6.86 (1H, dd, J = 2.5, 8.4 Hz, 
H7-THIQ), 6.89 (2H, d, J = 9.0 Hz, 2 x ArH, phenyl), 7.01 (1H, d, J = 2.5 Hz, 
H5-THIQ), 7.03 (2H, d, J = 9.0 Hz, 2 x ArH, phenyl) and 7.07 (1H, d, J = 8.4 Hz, 




tr = 1.52 min (83 %), m/z 286.0 (M
+
+H); (RP, Isocratic, 
90% MeOH). HRMS (ES
+
) calcd. for C17H20NO3 (M
+





C16H16ClNO2, Mol. Wt.: 289.76 
 
(Method B) 
The crude compound was purified by column chromatography (eluent: from 0% to 
40% EtOAc in pet. ether) to give a yellow oil (504 mg, 41%) which showed: 
1
H NMR 
(500 MHz, CDCl3) δ 2.38 (1H, bs, OH), 3.41 (1H, dd, J = 2.4, 12.9 Hz, H3-THIQ), 3.81 
(2H, ddd, J = 1.7, 4.0, 12.9 Hz, H3-THIQ), 3.83 (3H, s, OCH3), 4.16 (1H, d, J = 14.9 
Hz, H1-THIQ), 4.42 (1H, d, J = 14.9 Hz, H1-THIQ), 4.76 (1H, bs, H4-THIQ), 6.86 (1H, 
ddd, J = 0.8, 2.0, 8.1 Hz, ArH, phenyl), 6.89 (1H, dd, J = 2.8, 8.5 Hz, H7-THIQ), 6.92 
(1H, ddd, J = 0.8, 2.0, 8.1 Hz, ArH, phenyl), 7.01 (1H, d, J = 2.8 Hz, H5-THIQ), 7.01 
(1H, t, J = 2.0 Hz, ArH, phenyl), 7.11 (1H, d, J = 8.5 Hz, H8-THIQ) and 7.21 (1H, t, J = 
8.1 Hz, ArH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 50.3 (C1-THIQ), 54.9 (C3-
THIQ), 55.6 (OCH3), 67.5 (C4-THIQ), 113.0 (ArCH, phenyl), 114.2 (ArCH, phenyl), 
115.4 (C7-THIQ), 116.0 (C5-THIQ), 119.7 (ArCH, phenyl), 125.8 (C1CC8-THIQ), 127.7 
(C8-THIQ), 130.3 (ArCH, phenyl), 135.2 (ArCCl), 137.6 (C4CC5-THIQ), 152.2 (ArCN) 




tr = 2.10 min (96 %), m/z 290.0 (M
+
+H); (RP, 











+H) 292.0913, found 292.0952. 
 
6-Methoxy-2-(3-methoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-4-ol (143u) 






The crude compound was purified by column chromatography (eluent: from 0% to 
50% EtOAc in pet. ether) to give a yellow oil (1.9 g, 36%) which showed: 
1
H NMR 
(500 MHz, CDCl3) δ 2.48 (1H, d, J = 10.5 Hz, OH), 3.38 (1H, dd, J = 2.6, 12.6 Hz, H3-
THIQ), 3.83 (3H, s, OCH3, THIQ), 3.83 (1H, ddd, J = 1.0, 3.9, 12.6 Hz, H3-THIQ), 3.83 
(3H, s, OCH3, phenyl), 4.14 (1H, d, J = 14.9 Hz, H1-THIQ), 4.43 (1H, d, J = 14.9 Hz, 
H1-THIQ), 4.74 (1H, dt, J = 3.1, 10.5 Hz, H4-THIQ), 6.47 (1H, ddd, J = 0.5, 2.3, 8.2 
Hz, ArH, phenyl), 6.60 (1H, t, J = 2.3 Hz, ArH, phenyl), 6.68 (1H, ddd, J = 0.5, 2.3, 8.2 
Hz, ArH, phenyl), 6.88 (1H, dd, J = 2.7, 8.5 Hz, H7-THIQ), 7.01 (1H, d, J = 2.6 Hz, H5-
THIQ), 7.10 (1H, d, J = 8.5 Hz, H8-THIQ) and 7.23 (1H, t, J = 8.2 Hz, ArH, phenyl) 
ppm. 
13
C NMR (126 MHz, CDCl3) δ 50.8 (C1-THIQ), 55.3 (C3-THIQ), 55.4 (OCH3, 
THIQ), 55.5 (OCH3, phenyl), 67.6 (C4-THIQ), 102.9 (ArCH, phenyl), 104.9 (ArCH, 
phenyl), 109.2 (ArCH, phenyl), 113.0 (C5-THIQ), 115.3 (C7-THIQ), 126.3 
(C1CC8-THIQ), 127.6 (C8-THIQ), 130.1 (ArCH, phenyl), 137.8 (C4CC5-THIQ), 152.6 




tr = 1.75 min (94 %), 
m/z 286.0 (M
+
+H); (RP, Isocratic, 90% MeOH). HRMS (ES
+
) calcd. C17H20NO3 
(M
+
+H) 286.1438, found 286.1428. 
 
6-Methoxy-2-(2-methoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-4-ol (143w) 




The crude compound was purified by column chromatography (eluent: from 0% to 
50% EtOAc in pet. ether) to give a yellow oil (1.4 g, 26%) which showed: 
1
H NMR 
(500 MHz, CDCl3) δ 3.17 (1H, dd, J = 2.5, 12.3 Hz, H3-THIQ), 3.49 (1H, d, J = 10.1 
Hz, OH), 3.68 (1H, dd, J = 2.9, 12.1 Hz, H3-THIQ), 3.83 (3H, s, OCH3, THIQ), 3.88 
(3H, s, OCH3, phenyl), 4.12 – 4.25 (2H, m, , H1-THIQ), 4.67 (1H, dt, J = 2.7, 9.9 Hz, 
H4-THIQ), 6.85 (1H, dd, J = 2.8, 8.4 Hz, H7-THIQ), 6.91 (1H, dd, J = 1.3, 8.0 Hz, ArH, 
phenyl), 6.97 (1H, td, J = 1.4, 7.6 Hz, ArH, phenyl), 7.01 (1H, d, J = 2.7 Hz, H5-THIQ) 
and 7.04 – 7.11 (3H, m, H8-THIQ, 2 x ArH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) 
224 
 
δ 52.4 (C1-THIQ), 55.5 (OCH3, THIQ), 55.5 (OCH3, phenyl), 57.1 (C3-THIQ), 67.9 
(C4-THIQ), 111.3 (ArCH, phenyl), 113.5 (C5-THIQ), 114.9 (C7-THIQ), 119.4 (ArCH, 
phenyl), 121.1 (ArCH, phenyl), 123.6 (ArCH, phenyl), 127.1 (C1CC8-THIQ), 127.4 
(C8-THIQ), 138.2 (C4CC5-THIQ), 140.9 (ArCN), 152.7 (ArCO, phenyl) and 158.6 




tr = 1.59 min (68 %), m/z 285.9 (M
+
+H); (RP, Isocratic, 
90% MeOH). HRMS (ES
+
) calcd. C17H20NO3 (M
+
+H) 286.1438, found 286.1443. 
 
2-(4-Chlorophenyl)-1,2,3,4-tetrahydroisoquinolin-4-ol (143z) 
C15H14ClNO, Mol. Wt.: 259.73 
 
(Method B) 
The crude compound was purified by column chromatography (eluent: from 0% to 
30% EtOAc in pet. ether) to give a white solid (1.9 g, 61%). The compound was 
recrystallised from Et2O/pet. ether to give a white solid which showed: 
1
H NMR (500 
MHz, CDCl3) δ 2.43 (1H, d, J = 9.9 Hz, OH), 3.37 (1H, dd, J = 2.4, 12.6 Hz, H3-THIQ), 
3.81 (1H, ddd, J = 1.2, 3.7, 12.6 Hz, H3-THIQ), 4.18 (1H, d, J = 15.3 Hz, H1-THIQ), 
4.45 (1H, d, J = 15.3 Hz, H1-THIQ), 4.75 – 4.84 (1H, m, H4-THIQ), 6.99 (2H, d, J = 9.0 
Hz, ArH, phenyl), 7.17 – 7.21 (1H, m, H5-THIQ), 7.26 (2H, d, J = 9.0 Hz, ArH, 
phenyl), 7.31 (2H, t, J = 3.5 Hz, H6,H7-THIQ) and 7.46 – 7.50 (1H, m, H8-THIQ) ppm. 
13
C NMR (126 MHz, CDCl3) δ 51.3 (C1-THIQ), 55.6 (C3-THIQ), 67.3 (C4-THIQ), 
117.7 (ArCH, phenyl), 125.1 (ArCCl), 126.5 (C-THIQ), 127.3 (C-THIQ), 128.4 (C-
THIQ), 129.3 (ArCH, phenyl), 129.3 (C7,C6-THIQ), 134.0 (C1CC8-THIQ), 136.5 




tr = 2.01 min (99 %), m/z 259.9 
(M
+
+H); (RP, Isocratic, 90% MeOH). HRMS (ES
+









Cl) 262.0807, found 
262.0830. Mp 98-100 °C (Et2O/Pet). Anal. calcd. for C15H14ClNO: C 694, H 5.43, N 





C16H17NO2, Mol. Wt.: 255.31 
 
 (Method C) 
The crude compound was purified with chromatography (eluent: from 0% to 25% 
EtOAc in pet. ether) to give the product as a yellow oil (302 mg, 71 %) which showed: 
1
H NMR (400 MHz, CDCl3) δ 2.54 (1H, bs), 3.33 (2H, dd, J = 2.3, 12.6 Hz), 3.81 (4H, 
s), 3.87 (2H, dd, J = 3.0, 12.6 Hz), 4.14 (2H, d, J = 15.4 Hz), 4.45 (2H, d, J = 15.4 Hz), 
4.73 (1H, s), 6.69 (1H, d, J = 2.3 Hz), 6.84 (1H, dd, J = 2.3, 8.4 Hz), 6.92 (1H, t, J = 7.3 






tr = 1.71 min (75 %), m/z 255.9 (M
+
+H); (RP, Isocratic, 90% MeOH). 
HRMS (ES
+
) calcd. C16H17NNaO2 (M
+




C15H14BrNO, Mol. Wt.: 304.18 
 
(Method B) 
The crude compound was obtained as a pale yellow oil (250 mg, 48%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 3.19 (1H, dd, J = 2.1, 12.9 Hz, CH2CH), 4.07 
(1H, ddd, J = 1.6, 2.4, 12.9 Hz, CH2CH), 4.11 (1H, d, J = 15.2 Hz, ArCH2), 4.54 (1H, d, 
J = 15.5 Hz, ArCH2), 5.03 (1H, t, J = 2.3 Hz, CHOH), 6.95 (1H, tt, J = 0.9, 7.4 Hz, 
ArH), 7.10 (2H, dd, J = 0.9, 8.7 Hz, ArH), 7.16 (1H, d, J = 2.0 Hz, ArH), 7.17 (1H, d, J 
= 7.2 Hz, ArH), 7.34 (2H, dd, J = 7.4, 8.7 Hz, ArH) and 7.52 (1H, dd, J = 2.0, 7.2 Hz, 
ArH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 51.5 (ArCH2), 55.7 (CH2CH), 66.7 (CHOH), 
116.8 (ArCH), 117.0 (ArCH), 120.8 (ArCH), 125.8 (ArCBr), 126.0 (ArCH), 129.4 
226 
 














Isocratic, 90% MeOH). HRMS (ES
+









Br) 306.0311, found 306.0323. 
 
2-(4-Clorophenyl)-7-methoxy-1,2,3,4-tetrahydroisoquinolin-4-ol (144j) 
C16H16ClNO2, Mol. Wt.: 289.76 
 
(Method C) 
The crude compound was purified by column chromatography (eluent: from 0% to 
40% EtOAc in pet. ether) to give a dark yellow wax (2.39 g, 31%) which showed: 
1
H 
NMR (500 MHz, CDCl3) δ 2.36 (1H, d, J = 8.6 Hz, OH), 3.32 (2H, dd, J = 2.5, 12.6 Hz, 
H3-THIQ), 3.82 (3H, s, OCH3), 3.82 (5H, ddd, J = 1.3, 3.5, 12.8 Hz, H3-THIQ), 4.13 
(2H, d, J = 15.3 Hz, H1-THIQ), 4.42 (2H, d, J = 15.3 Hz, H1-THIQ), 4.74 (1H, bs, 
H4-THIQ), 6.69 (1H, d, J = 2.6 Hz, H8-THIQ), 6.85 (1H, dd, J = 2.6, 8.5 Hz, H6-THIQ), 
6.98 (3H, d, J = 9.0 Hz, ArH, phenyl), 7.25 (4H, d, J = 9.0 Hz, ArH, phenyl) and 7.39 
(1H, d, J = 8.5 Hz, H5-THIQ) ppm. 
13
C NMR (126 MHz, CDCl3) δ 51.3 (C1-THIQ), 
55.3 (OCH3), 55.7 (C3-THIQ), 66.7 (C4-THIQ), 110.9 (C8-THIQ), 113.4 (C6-THIQ), 
117.6 (ArCH, phenyl), 124.9 (ArCCl), 129.0 (C5CC6-THIQ), 129.1 (ArCH, phenyl), 





tr = 1.95 min (92 %), m/z 290.0 (M
+
+H); (RP, Isocratic, 90% MeOH). 
HRMS (ES
+









+H) 292.0913, found 292.0935. 
 
5-Bromo-2-phenyl-1,2,3,4-tetrahydroisoquinolin-4-ol (145h) 





The crude compound was obtained as a pale yellow oil (50 mg, 10%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 3.35 (1H, dd, J = 2.7, 12.7 Hz, CH2CH), 3.77 (1H, ddd, J 
= 1.0, 3.9, 12.7 Hz, CH2CH), 3.89 (1H, bs, OH), 4.13 (1H, d, J = 15.6 Hz, ArCH2), 4.37 
(1H, d, J = 15.6 Hz, ArCH2), 4.72 (1H, t, J = 3.3 Hz, CHOH), 6.93 (1H, tt, J = 0.9, 7.2 
Hz, ArH), 7.03 (2H, dd, J = 0.9, 8.7 Hz, ArH), 7.29 - 7.35 (4H, m, ArH) and 7.39 (1H, 
dd, J = 2.0, 8.2 Hz, ArH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 51.0 (ArCH2), 55.5 
(CH2CH), 66.6 (CHOH), 116.7 (ArCH), 120.6 (ArCH), 121.9 (ArCBr), 129.3 (ArCH), 
129.4 (ArCH), 130.3 (ArCH), 131.0 (ArCH), 135.7 (ArCCH), 136.5 (ArCCH2) and 






























The crude compound was purified by column chromatography (eluent: from 0% to 
50% EtOAc in pet. ether) to give the product as a white solid (3.54 g, 62%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 2.67 (1H, bs, OH), 3.23 (1H, dd, J = 2.3, 12.3 
Hz, H3-THIQ), 3.71 (1H, dd, J = 3.1, 12.3 Hz, H3-THIQ), 3.79 (3H, s, OCH3, phenyl), 
3.88 (3H, s, C6OCH3-THIQ), 3.90 (3H, s, C7OCH3-THIQ), 4.01 (1H, d, J = 14.8 Hz, 
H1-THIQ), 4.27 (1H, d, J = 14.8 Hz, H1-THIQ), 4.67 (1H, bs, H4-THIQ), 6.62 (1H, s, 
228 
 
H8-THIQ), 6.89 (2H, d, J = 9.0 Hz, 2 x ArCH, phenyl), 6.96 (1H, s, H5-THIQ) and 7.03 
(2H, d, J = 8.9 Hz, 2 x ArCH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 52.7 (C1-
THIQ), 55.6 (OCH3, phenyl), 55.9 (2 x OCH3, THIQ), 57.2 (C3-THIQ), 67.2 (C4-
THIQ), 108.6 (C8-THIQ), 111.6 (C5-THIQ), 114.5 (2 x ArCH, phenyl), 118.9 (2 x 
ArCH, phenyl), 126.8 (C1CC8-THIQ), 128.6 (C4CC5-THIQ), 145.3 (ArCN), 148.1 (C7-





+H) 316.1543, found 316.1543. Mp 136-137 °C (DCM/Et2O).  
 
5,6,7-Trimethoxy-2-(4-methoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-4-ol (148y) 




The crude compound was purified by column chromatography (eluent: from 0% to 
100% EtOAc in pet. ether) to give the product as a dark brown solid (5.49 g, 82%) 
which showed: 
1
H NMR (500 MHz, CDCl3) δ 2.90 (1H, bs, OH), 3.18 (1H, dd, J = 2.7, 
12.4 Hz, H3-THIQ), 3.70 (1H, dd, J = 3.5, 12.6 Hz, H3-THIQ), 3.79 (3H, s, OCH3, 
phenyl), 3.86 (3H, s, C6OCH3-THIQ), 3.87 (3H, s, C7OCH3-THIQ), 3.98 (1H, d, J = 
15.1 Hz, H1-THIQ), 4.02 (3H, s, C5OCH3-THIQ), 4.29 (1H, d, J = 15.0 Hz, H1-THIQ), 
4.98 (1H, bs, H4-THIQ), 6.45 (1H, s, H8-THIQ), 6.88 (2H, d, J = 9.0 Hz, 2 x ArCH, 
phenyl) and 7.04 (2H, d, J = 9.0 Hz, 2 x ArCH, phenyl) ppm. 
13
C NMR (126 MHz, 
CDCl3) δ 53.2 (C1-THIQ), 55.6 (OCH3, phenyl), 56.0 (C6OCH3-THIQ), 56.9 
(C3-THIQ), 60.9 (C7OCH3-THIQ), 61.5(C5OCH3-THIQ), 62.7 (C4-THIQ), 104.6 
(C8-THIQ), 114.5 (2 x ArCH, phenyl), 119.1 (2 x ArCH, phenyl), 123.0 (C1CC8-THIQ), 
130.5 (C4CC5-THIQ), 140.6 (C7-THIQ), 145.3 (ArCN), 152.2 (C5-THIQ), 153.5 (C6-
THIQ) and 154.3 (ArCO, phenyl) ppm. HRMS (ES
+
) calcd. C19H24NO5 (M
+
+H) 





C18H19NO3, Mol. Wt.: 297.35 
 
(Method B) 
The crude compound was purified by chromatography (eluent from 0% to 30% 
EtOAc in pet. ether) to yield the product as a pale yellow oil (71 mg, 22%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 3.82 (3H, s, CH3), 3.87 (3H, s, CH3), 4.13 (3H, 
s, CH3), 5.23 (2H, s, ArCH2), 6.47 (1H, s, ArH), 6.59 (1H, dd, J = 0.8, 3.2 Hz, ArH), 
6.94 - 6.97 (1H, m, ArH), 7.11 - 7.15 (2H, m, ArH) and 7.25 - 7.34 (3H, m, ArH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 50.2 (ArCH2), 56.3 (CH3), 60.7 (CH3), 61.4 (CH3), 88.2 
(ArCH), 99.2 (ArCH), 115.6 (ArCCH), 126.2 (ArCH), 126.8 (ArCH), 127.6 (ArCH), 
128.7 (ArCH), 133.4 (ArCN), 135.5 (ArCOCH3), 137.3 (ArCCH2), 145.9 (ArCOCH3) 




tr = 1.02 min (76 %), m/z 298.1 (M
+
+H); 






C19H25NO2, Mol. Wt.: 299.41 
 
2-Phenylethylamine (1.3 mL, 10.0 mmol) and benzaldehyde (1.0 mL, 10.0 mmol) 
were dissolved in CHCl3 (50 mL) and treated with NaBH(OAc)3 (3.3 g, 15.0 mmol). 
After stirring for 2 h at rt, 2,2-dimethoxyacetaldehyde (1.5 mL, 10.0 mmol) was 
introduced followed by NaBH(OAc)3 (3.30 g, 15.0 mmol). After stirring for 6 h, the 
mixture was quenched with a saturated aqueous solution of NaHCO3 and the aqueous 
layer was extracted with EtOAc (2 x 50 mL). The combine organics were dried with 







NMR (500 MHz, CDCl3) δ 2.74 (2H, d, J = 5.2 Hz, CHCH2), 2.83 (4H, s, CH2CH2), 
3.34 (6H, s, CH3), 3.77 (2H, s, ArCH2N), 4.43 (1H, t, J = 5.2 Hz, ArH), 7.15 - 7.23 (3H, 
m, ArH) and 7.24 - 7.37 (7H, m, ArH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 33.6 
(ArCH2CH2), 53.9 (CH3), 55.9 (CHCH2N), 56.7 (CH2CH2N), 59.4 (ArCH2N), 104.2 
(CH(OR)2), 126.0 (ArCH), 127.0 (ArCH), 128.3 (ArCH), 128.4 (ArCH), 129.0 (ArCH), 





1.08 min (98 %), m/z 300.2 (M
+
+H); (RP, Isocratic, 90% MeOH). HRMS (ES+) calcd. 
for C19H26NO2 (M
+
+H) 300.1958, found 300.1967. 
 
5,7,8,13-tetrahydro-6,13-methanodibenzo[c,f]azonine (158) 
C17H17N, Mol. Wt.: 235.32 
 
(Method B) 
The crude compound was obtained as a yellow oil (856 mg, 83%) which showed: 
1
H 
NMR (500 MHz, CDCl3) δ 2.35 (1H, ddd, J = 1.3, 4.4, 15.7 Hz, ArCH2CH2N), 3.10 
(1H, ddd, J = 2.2, 12.9, 15.7 Hz, ArCH2CH2N), 3.31 (1H, ddd, J = 2.2, 12.9, 15.0 Hz, 
ArCH2CH2N), 3.46 (1H, ddd, J = 1.3, 4.4, 15.0 Hz, ArCH2CH2N), 3.56 (1H, dd, J = 0.8, 
13.9 Hz, NCH2CH), 3.67 (1H, ddd, J = 1.0, 5.2, 13.9 Hz, NCH2CH), 3.88 (1H, d, J = 
5.2 Hz, CH2CH), 4.09 (1H, dd, J = 1.5, 17.1 Hz, ArCH2N), 4.61 (1H, d, J = 17.3 Hz, 
ArCH2N), 6.96 (1H, d, J = 7.4 Hz, ArH), 7.03 (1H, d, J = 8.6 Hz, ArH), 7.06 - 7.13 (3H, 
m, ArH), 7.13 - 7.22 (2H, m, ArH) and 7.32 (1H, dd, J = 1.2, 7.4 Hz, ArH) ppm. 
13
C 
NMR (126 MHz, CDCl3) δ 34.7 (ArCH2CH2N), 44.5 (CH2CH), 52.5 (NCH2CH), 53.6 
(ArCH2N), 56.2 (ArCH2CH2N), 125.1 (ArCH), 126.7 (ArCH), 126.8 (ArCH), 126.9 
(ArCH), 126.9 (ArCH), 129.0 (ArCH), 130.4 (ArCH), 130.9 (ArCH), 134.6 





tr = 0.95 min (99 %), m/z 236.0 (M
+
+H); (RP, Isocratic, 90% MeOH). HRMS 
(ES+) calcd. for C17H18N (M
+





C20H27NO4, Mol. Wt.: 345.43 
 
m-Anisaldehyde (1.2 mL, 10.0 mmol) and 2,2-dimethoxyethylamine (1.1 mL, 10.0 
mmol) were dissolved in CHCl3 (50 mL) and treated with NaBH(OAc)3 (3.3 g, 15.0 
mmol). After stirring for 2 h at rt, p-anisaldehyde (1.2 mL, 10.0 mmol) was introduced 
followed by NaBH(OAc)3 (3.30 g, 15.0 mmol). After stirring for 6 h at rt, the mixture 
was quenched with a saturated aqueous solution of NaHCO3 and the aqueous layer was 
extracted with EtOAc (2 x 50 mL). The combined organics were dried with MgSO4, 
filtered and evaporated to give a pale green oil (3.49 g). The crude compound was 
purified by column chromatography to give the product as a colourless oil (2.78 g, 80%) 
which showed: 1H NMR (500 MHz, CDCl3) δ 2.63 (2H, d, J = 5.2 Hz, CH2CH), 3.27 
(6H, s, CH(OCH3)), 3.56 - 3.66 (4H, m, ArCH2), 3.80 (3H, s, ArOCH3), 3.81 (3H, s, 
ArOCH3), 4.46 (1H, t, J = 5.2 Hz, CH(OR)2), 6.78 (1H, dd, J = 2.1, 7.8 Hz, ArH), 6.85 
(2H, d, J = 8.7 Hz, ArH), 6.95 (2H, d, J = 7.8 Hz, ArH), 6.97 - 6.98 (1H, m, ArH), 7.22 
(1H, t, J = 7.8 Hz, ArH) and 7.28 (2H, d, J = 8.7 Hz, ArH) ppm. 
13
C NMR (126 MHz, 
CDCl3) δ 53.6 CH(OCH3)2, 55.0 (CH2CH), 55.3 (ArOCH3), 55.4 (ArOCH3), 58.5 
(ArCH2), 58.9 (ArCH2), 104.0 (ArCH), 112.4 (ArCH), 113.7 (ArCH), 114.5 (ArCH), 
121.3 (ArCH), 129.2 (ArCH), 130.2 (ArCH), 131.6 (ArCCH2), 141.6 (ArCCH2), 158.8 




tr = 1.03 min (96 %), m/z 346.3 
(M
+
+H); (RP, Isocratic, 90% MeOH). HRMS (ES+) calcd. for C20H28NO4 (M
+
+H) 
346.2013, found 346.2025. 
 
7-Methoxy-2-(4-methoxybenzyl)-1,2,3,4-tetrahydroisoquinolin-4-ol (160) 





The crude compound was purified by column chromatography (eluent: from 0% to 
100% EtOAc in pet. ether) to give the product as a yellow oil (223 mg, 34%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 2.61 (1H, dd, J = 2.6, 11.6 Hz CHCH2), 2.81 
(1H, bs, OH), 3.05 (1H, ddd, J = 1.2, 3.1, 11.6 Hz, CHCH2), 3.33 (1H, d, J = 15.1 Hz, 
ArCH2 (THIQ)), 3.66 (2H, d, J = 5.1 Hz, ArCH2 (benzylic)), 3.76 (3H, s, CH3), 3.76 
(1H, d, J = 15.1 Hz, ArCH2 (THIQ)), 3.81 (3H, s, CH3), 4.56 (1H, bs), 6.53 (1H, d, J = 
2.5 Hz, ArH (THIQ)), 6.79 (1H, dd, J = 2.5, 8.4 Hz, ArH (THIQ)), 6.88 (3H, d, J = 8.7 
Hz, ArH (benzyl)), 7.28 (2H, d, J = 8.7 Hz, ArH (benzyl)) and 7.32 (1H, d, J = 8.4 Hz, 
ArH (THIQ)) ppm. 
13
C NMR (126 MHz, CDCl3) δ 55.4 (CH3), 55.4 (CH3), 56.0 
(ArCH2 (THIQ)), 58.5 (CHCH2), 62.1 (ArCH2 (benzyl)), 66.9 (CHCH2), 110.8 (ArCH 
(THIQ)), 113.3 (ArCH (THIQ)), 113.9 (ArCH (benzyl)), 129.5 (CHCH2), 129.9 (ArCH2 
(benzyl)), 130.3 (ArCH (benzyl)), 130.7 (ArCH (THIQ)), 136.5 (ArCH2 (THIQ)), 159.0 




tr = 0.88 min (69 %), m/z 300.0 (M
+
+H); 






C18H19NO2, Mol. Wt.: 281.35 
 
(Method B) 
The crude compound was purified by column chromatography (eluent: from 0% to 
30% EtOAc in pet. ether) to give the product as a brown gum (181 mg, 15%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 3.35 (1H, d, J = 7.0 Hz, CHCH2), 3.62 (1H, s, 
ArCH), 3.72 (3H, s, CH3), 3.77 (3H, s, CH3), 3.87 (1H, d, J = 14.0 Hz, ArCH2), 3.90 
(1H, d, J = 7.0 Hz, CHCH2), 3.90 (1H, d, J = 14.5 Hz, ArCH2), 4.52 (1H, d, J 
= 14.5 Hz, ArCH2), 4.55 (1H, d, J = 14.0 Hz, ArCH2), 6.52 (1H, d, J = 2.6 Hz, ArH), 
6.63 (1H, dd, J = 2.6, 8.4 Hz, ArH), 6.66 (1H, dd, J = 2.6, 8.4 Hz, ArH), 6.75 (1H, d, J 
= 2.6 Hz, ArH), 6.89 (1H, d, J = 8.4 Hz, ArH) and 7.15 (1H, d, J = 8.4 Hz, ArH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 35.9 (CHCH2), 49.4 (CHCH2), 55.2 (CH3), 55.3 (CH3), 
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56.9 (ArCH2), 57.7 (ArCH2), 110.8 (ArCH), 111.9 (ArCH), 112.4 (ArCH), 112.5 
(ArCH), 126.0 (ArCCH2), 127.1 (ArCH), 128.4 (ArCH), 132.8 (ArCCH), 135.5 





tr = 0.90 min (94 %), m/z 282.2 (M
+
+H); (RP, Isocratic, 90% MeOH). HRMS 
(ES+) calcd. for C18H20NO2 (M
+




C18H21NO3, Mol. Wt.: 299.36 
 
(Method B) 
The crude compound was not purified and showed: HRMS (ES
+
) calcd. C18H22NO3 
(M
+
+H) 300.1594, found 300.1595. 
 
2-Phenyl-1,2,3,4-tetrahydroisoquinoline (163a) 
C15H15N, Mol. Wt.: 209.29 
 
(Method D) 
The crude product was purified by column chromatography (eluent: pet. ether) to 





H NMR (500 MHz, CDCl3) δ 3.00 (2H, t, J = 5.8 Hz, H4-THIQ), 
3.57 (2H, t, J = 5.8 Hz, H3-THIQ), 4.42 (2H, s, H1-THIQ), 6.83 (1H, t, J = 7.3 Hz, ArH, 
phenyl), 6.99 (2H, d, J = 8.7 Hz, ArH, phenyl), 7.14 – 7.21 (4H, m, H5,H6,H7,H8-THIQ) 
and 7.30 (2H, dd, J = 7.3, 8.7 Hz, ArH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 
29.27 (C4-THIQ), 46.67 (C3-THIQ), 50.89 (C1-THIQ), 115.29 (ArCH, phenyl), 118.8 
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(ArCH, phenyl), 126.2 (ArCH, THIQ), 126.5 (ArCH, THIQ), 126.7 (ArCH, THIQ), 
128.7 (ArCH, THIQ), 129.4 (ArCH, phenyl), 134.6 (C1CC8-THIQ), 135.0 (C5CC6-




tr = 2.79 min (97 %), m/z 209.9 (M
+
+H); 
(RP, Isocratic, 90% MeOH). HRMS (ES
+
) calcd. for C15H16N (M
+
+H) 210.1277, found 
210.1284. Mp 44-45 °C (pet. ether). Anal. calcd. for C15H15N: C 86.1, H 7.22, N 6.69. 
Found: C 85.3, H 7.11, N 6.59%. 
 
2-(3-Methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (163b) 
C16H17NO, Mol. Wt.: 239.31 
 
(Method D) 
The crude product was purified by column chromatography (eluent 0% to 30% 





H NMR (500 MHz, CDCl3) δ 2.99 (2H, t, J = 5.9 Hz, ArCH2CH2), 3.56 
(2H, t, J = 5.9 Hz, NCH2CH2), 3.82 (3H, s, ArOCH3), 4.41 (2H, s, ArCH2N), 6.39 (1H, 
dd, J = 2.4, 8.1 Hz, ArH), 6.52 (1H, t, J = 2.4 Hz, ArH), 6.60 (1H, dd, J = 2.4, 8.1 Hz, 
ArH) and 7.14 - 7.22 (5H, m, ArH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 29.3 
(ArCH2CH2), 46.5 (NCH2CH2), 50.8 (ArCH2N), 55.3 (ArOCH3), 101.6 (ArCH), 103.4 
(ArCH), 108.0 (ArCH), 126.2 (ArCH), 126.5 (ArCH) 126.7 (ArCH), 128.6 (ArCH), 
130.0 (ArCH), 134.6 (ArCCH2N), 135.1 (ArCCH2CH2), 152.0 (ArCN) and 160.9 




tr = 2.84 min (84%), m/z 240.0 (M
+
+H); (RP, Isocratic, 
90% MeOH). HRMS (ES+) calcd. for C16H18NO (M
+
+H) 240.1383, found 240.1373. 
 
6-Methoxy-2-phenyl-1,2,3,4-tetrahydroisoquinoline (163e) 





The crude product was purified by column chromatography (eluent: from 0% to 
0.5% EtOAc in pet. ether) to yield the product as a colourless oil (1.3 g, 25%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 2.96 (2H, t, J = 5.8 Hz, H4-THIQ), 3.55 (2H, t, J 
= 5.8 Hz, H3-THIQ), 3.80 (3H, s, ArOCH3), 4.36 (2H, s, H1-THIQ), 6.70 (1H, d, J = 2.6 
Hz, H5-THIQ), 6.77 (1H, dd, J = 2.6, 8.4 Hz, H7-THIQ), 6.83 (1H, tt, J = 1.0, 7.3 Hz, 
ArH, phenyl), 6.98 (2H, dd, J = 1.0, 8.8 Hz, ArH, phenyl), 7.08 (1H, d, J = 8.4 Hz, H8-
THIQ) and 7.29 (2H, dd, J = 7.3, 8.8 Hz, ArH, phenyl) ppm. 
13
C NMR (126 MHz, 
CDCl3) δ 29.6 (C4-THIQ), 46.6 (C3-THIQ), 50.3 (C1-THIQ), 55.4 (ArOCH3), 112.5 
(C7-THIQ), 113.4 (C5-THIQ), 115.3 (ArCH, phenyl), 118.8 (ArCH, phenyl), 126.8 
(C1CC8-THIQ), 127.6 (C8-THIQ), 129.3 (ArCH, phenyl), 136.2 (C5CC6-THIQ), 150.7 




tr = 2.48 min (97 %), m/z 239.9 
(M
+
+H); (RP, Isocratic, 90% MeOH). HRMS (ES+) calcd. for C16H18NO (M
+
+H) 
240.1383, found 240.1372. Mp 72-73 °C (pet. ether). Anal. calcd. for C16H17NO: C 
80.3, H 7.16, N 5.85. Found: C 80.2, H 7.16, N 5.73%. 
 
2-(4-Chlorophenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline (163i) 
C16H16ClNO, Mol. Wt.: 273.76 
 
(Method D) 
The crude product was purified by column chromatography (eluent: from 0% to 30% 





H NMR (500 MHz, CDCl3) δ 2.95 (2H, t, J = 5.8 Hz, H4-THIQ), 3.51 (2H, 
t, J = 5.9 Hz, H3-THIQ), 3.80 (3H, s, ArOCH3), 4.31 (2H, s, H1-THIQ), 6.70 (1H, d, J 
= 2.6 Hz, H5-THIQ), 6.77 (1H, dd, J = 2.7, 8.4 Hz, H7-THIQ), 6.87 (2H, d, J = 9.1 Hz, 
ArH, phenyl), 7.06 (1H, d, J = 8.4 Hz, H8-THIQ) and 7.21 (2H, d, J = 9.1 Hz, ArH, 
phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 29.4 (C4-THIQ), 46.6 (C3-THIQ), 50.3 
(C1-THIQ), 55.5 (ArOCH3), 112.6 (C7-THIQ), 113.4 (C5-THIQ), 116.3 (ArCH, phenyl), 
123.4 (ArCCl), 126.4 (C1CC8-THIQ), 127.6 (C8-THIQ), 129.1 (ArCH, phenyl), 136.0 
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tr = 3.56 min 








Cl); (RP, Isocratic, 90% MeOH). 









+H) 276.0964, found 274.0980. Mp 99-100 °C (pet. ether). Anal. 
calcd. for C16H16ClNO: C 70.2, H 5.89, N 5.12. Found: C 69.3, H 5.83, N 5.14 %. 
 
2-(4-Methoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (163o) 
C16H17NO2, Mol. Wt.: 255.31 
 
(Method D) 
The crude compound was purified by reversed phase column chromatography 
(eluent: from 5% to 100% MeOH in water) to get the compound as a yellow oil (503 
mg, 20%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 2.93 (2H, t, J = 5.9 Hz, 
ArCH2CH2), 3.42 (2H, t, J = 5.9 Hz, ArCH2CH2), 3.78 (3H, s, ArOCH3), 4.22 (2H, s, 
ArCH2N), 6.62 (1H, d, J = 2.5 Hz, ArH), 6.67 (1H, dd, J = 2.5, 8.2 Hz, ArH), 6.86 (2H, 
d, J = 9.1 Hz, ArH), 6.97 (2H, d, J = 9.1 Hz, ArH) and 7.00 (1H, d, J = 8.2 Hz, ArH) 
ppm. 
13
C NMR (126 MHz, CDCl3) δ 29.1 (ArCH2CH2), 48.4 (NCH2CH2), 52.2 
(ArCH2N), 55.6 (ArOCH3), 113.4 (ArCH), 114.6 (ArCH), 114.9 (ArCH), 118.1 
(ArCH), 126.7 (ArCCH2N), 127.6 (ArCH), 131.0 (Ar CCH2CH2), 145.5 (ArCN), 153.5 




tr = 1.17 min (96%), m/z 255.7 
(M
+
+H); (RP, Isocratic, 90% MeOH). HRMS (ES+) calcd. for C16H18NO2 (M
+
+H) 
256.1332, found 256.1336. Mp 192-194 °C (Hydrochloride from MeOH/Et2O). Anal. 
calcd. for C16H18ClNO2: C 65.9, H 6.22, N 4.80% found C 64.4, H 6.09, N 4.57%. 
 
6-Methoxy-2-(p-tolyl)-1,2,3,4-tetrahydroisoquinoline (163q) 





The crude product was purified by column chromatography (eluent: from 0% to 10% 
EtOAc in pet. ether) to yield the product as a white solid (1.65 g, 25%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 2.28 (3H, s, ArCH3), 2.95 (2H, t, J = 5.8 Hz, H4-THIQ), 
3.49 (2H, t, J = 5.8 Hz, H3-THIQ), 3.79 (3H, s, ArOCH3), 4.30 (2H, s, H1-THIQ), 6.69 
(1H, d, J = 2.6 Hz, H5-THIQ), 6.76 (1H, dd, J = 2.6, 8.4 Hz, H7-THIQ), 6.91 (2H, d, J = 
8.6 Hz, ArH, phenyl), 7.06 (1H, d, J = 8.4 Hz, H8-THIQ) and 7.09 (2H, d, J = 8.6 Hz, 
ArH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 20.5 (ArCH3), 29.5 (C4-THIQ), 47.4 
(C3-THIQ), 51.1 (C1-THIQ), 55.4 (ArOCH3), 112.5 (C7-THIQ), 113.4 (C5-THIQ), 
116.0 (ArCH, phenyl), 126.9 (C1CC8-THIQ), 127.6 (C8-THIQ), 128.5 (ArCCH3), 129.8 





tr = 2.62 min (97 %), m/z 254.0 (M
+
+H); (RP, Isocratic, 90% MeOH). 
HRMS (ES+) calcd. for C17H20NO (M
+
+H) 254.1539, found 254.1535. Mp 69-70 °C 
(pet. ether). Anal. calcd. for C17H19NO: C 80.6, H 7.56, N 5.53. Found: C 80.4, H 7.55, 
N 5.44 %. 
 
2-(4-Ethylphenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline (163r) 
C18H21NO, Mol. Wt.: 267.36 
 
(Method D) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to get the product as a yellow solid (409 mg, 51%) which was 
recrystallised from pet. ether and showed: 
1
H NMR (500 MHz, CDCl3) δ 1.22 (3H, t, 
J = 7.6 Hz, CH2CH3), 2.59 (2H, q, J = 7.6 Hz, CH2CH3), 2.97 (2H, t, J = 5.8 Hz, 
H4-THIQ), 3.51 (2H, t, J = 5.8 Hz, H3-THIQ), 3.80 (3H, s, OCH3), 4.32 (2H, s, 
H1-THIQ), 6.70 (1H, d, J = 2.5 Hz, H5-THIQ), 6.77 (1H, dd, J = 2.5, 8.4 Hz, H7-THIQ), 
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6.96 (2H, d, J = 8.3 Hz, 2 x ArCH, phenyl), 7.07 (1H, d, J = 8.4 Hz, H8-THIQ) and 7.13 
(2H, d, J = 8.6 Hz, 2 x ArCH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 15.8 
(CH2CH3), 27.9 (CH2CH3), 29.3 (C4-THIQ), 47.2 (C3-THIQ), 50.9 (C1-THIQ), 55.3 
(OCH3), 112.3 (C7-THIQ), 113.2 (C5-THIQ), 115.8 (2 x ArCH, phenyl), 126.6 
(C1CC8-THIQ), 127.5 (C8-THIQ), 128.5 (2 x ArCH, phenyl), 135.0 (ArCCH2CH3), 





+H) 268.1696, found 268.1694. Mp 78-80 °C (pet. ether). Anal. calcd. 
for C18H21NO: C 80.86, H 7.92, N 5.24 %. Found: C 80.91, H 8.00, N 5.14 %. 
 
6-Methoxy-2-(4-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (163s) 
C17H19NO2, Mol. Wt.: 269.34 
 
(Method D) 
The crude product was purified by column chromatography (eluent: from 0% to 15% 





H NMR (500 MHz, CDCl3) δ 2.96 (2H, t, J = 5.8 Hz, H4-THIQ), 3.43 (2H, 
t, J = 5.8 Hz, H3-THIQ), 3.78 (3H, s, ArOCH3), 3.79 (3H, s, ArOCH3), 4.24 (2H, s, 
H1-THIQ), 6.68 (1H, d, J = 2.6 Hz, H5-THIQ), 6.75 (1H, dd, J = 2.6, 8.4 Hz, H7-THIQ), 
6.86 (2H, d, J = 9.1 Hz, ArH, phenyl), 6.97 (2H, d, J = 9.1 Hz, ArH, phenyl) and 7.04 
(1H, d, J = 8.4 Hz, H8-THIQ) ppm. 
13
C NMR (126 MHz, CDCl3) δ 29.5 (C4-THIQ), 
48.5 (C3-THIQ), 52.3 (C1-THIQ), 55.4 (ArOCH3), 55.8 (ArOCH3), 112.5 (C7-THIQ), 
113.4 (C5-THIQ), 114.7 (ArCH, phenyl), 118.2 (ArCH, phenyl), 127.0 (C1CC8-THIQ), 
127.6 (C8-THIQ), 135.9 (C5CC6-THIQ), 145.6 (ArCN), 153.6 (ArCO, phenyl) and 




tr = 1.47 min (90 %), m/z 270.0 (M
+
+H); (RP, 
Isocratic, 90% MeOH). HRMS (ES+) calcd. for C17H20NO2 (M
+
+H) 270.1489, found 
270.1477. Mp 124-125 °C (pet. ether). Anal. calcd. for C17H19NO: C 75.81, H 7.11, N 





C16H16ClNO, Mol. Wt.: 273.76 
 
(Method D) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to get the product as a colourless oil (247 mg, 52%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 2.95 (1H, t, J = 5.8 Hz, H4-THIQ), 3.54 (1H, t, J 
= 5.8 Hz, H3-THIQ), 3.80 (1H, s, OCH3), 4.35 (1H, s, H1-THIQ), 6.71 (1H, d, J = 2.5 
Hz, H5-THIQ), 6.76 (1H, ddd, J = 0.9, 2.2, 8.1 Hz, ArH, phenyl), 6.77 (1H, dd, J = 2.5, 
8.4 Hz, H7-THIQ), 6.81 (1H, ddd, J = 0.9, 2.2, 8.1 Hz, ArH, phenyl), 6.90 (1H, t, J = 2.2 
Hz, ArH, phenyl), 7.08 (1H, d, J = 8.4 Hz, H8-THIQ) and 7.17 (1H, t, J = 8.1 Hz, ArH, 
phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 29.4 (C4-THIQ), 46.0 (C3-THIQ), 49.7 
(C1-THIQ), 55.5 (OCH3), 112.6 (C7-THIQ), 112.7 (ArCH, phenyl), 113.3 (C5-THIQ), 
114.5 (ArCH, phenyl), 118.1 (ArCH, phenyl), 126.3 (C1CC8-THIQ), 127.6 (C8-THIQ), 





tr = 3.84 min (95 %), m/z 273.9 (M
+












+H) 276.0964, found 276.0974. Mp 112-114 °C (as hydrochloride 
from Et2O).  
 
6-Methoxy-2-(3-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (163u) 
C17H19NO2, Mol. Wt.: 269.34 
 
(Method D) 
The crude compound was purified by column chromatography (eluent: from 0% to 





H NMR (500 MHz, CDCl3) δ 2.95 (2H, t, J = 5.9 Hz, H4-THIQ), 3.54 (2H, t, J 
= 5.9 Hz, H3-THIQ), 3.80 (3H, s, ArOCH3, THIQ), 3.81 (3H, s, ArOCH3, phenyl), 4.35 
(2H, s, H1-THIQ), 6.39 (1H, ddd, J = 0.9, 2.5, 8.4 Hz, ArH, phenyl), 6.50 (1H, t, J = 2.5 
Hz, ArH, phenyl), 6.59 (1H, ddd, J = 0.9, 2.5, 8.4 Hz, ArH, phenyl), 6.70 (1H, d, J = 2.6 
Hz, H5-THIQ), 6.76 (1H, dd, J = 2.7, 8.4 Hz, H7-THIQ), 7.07 (1H, d, J = 8.4 Hz, H8-
THIQ) and 7.19 (1H, t, J = 8.4 Hz, ArH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 
29.5 (C4-THIQ), 46.4 (C3-THIQ), 50.2 (C1-THIQ), 55.3 (OCH3, phenyl), 55.4 (OCH3, 
THIQ), 101.6 (ArCH, phenyl), 103.4 (ArCH, phenyl), 108.0 (ArCH, phenyl), 112.5 (C7-
THIQ), 113.3 (C5-THIQ), 126.7 (C1CC8-THIQ), 127.6 (C8-THIQ), 130.0 (ArCH, 
phenyl), 136.2 (C4CC5-THIQ), 152.0 (ArCN), 158.2 (C6-THIQ) and 160.8 (ArCO, 
phenyl) ppm. HRMS (ES
+
) calcd. C17H20NO2 (M
+
+H) 270.1489, found 270.1479. Mp 
119-120 °C (pet. ether).  
 
2-(2-Chlorophenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline (163v) 
C16H16ClNO, Mol. Wt.: 273.76 
 
(Method J) 
The crude compound was purified by column chromatography (eluent: from 0% to 
10% EtOAc in pet. ether) to give a colourless oil (600 mg, 57%) which was crystallised 




C NMR data refer to the free base): 
1
H NMR (500 MHz, CDCl3) δ 3.00 (2H, t, J = 5.8 Hz, H4-THIQ), 3.38 (2H, t, J 
= 5.8 Hz, H3-THIQ), 3.80 (3H, s, OCH3), 4.22 (2H, s, H1-THIQ), 6.71 (1H, d, J = 2.6 
Hz, H5-THIQ), 6.75 (1H, dd, J = 2.6, 8.4 Hz, H7-THIQ), 6.98 (1H, ddd, J = 1.5, 7.4, 7.8 
Hz, ArH, phenyl), 7.02 (1H, d, J = 8.4 Hz, H8-THIQ), 7.12 (1H, dd, J = 1.5, 8.0 Hz, 
ArH, phenyl), 7.22 (1H, ddd, J = 1.5, 7.4, 8.0 Hz, ArH, phenyl) and 7.39 (1H, dd, J = 
1.5, 7.8 Hz, ArH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 29.4 (C4-THIQ), 49.8 
(C3-THIQ), 52.7 (C2-THIQ), 55.3 (CH3O), 112.2 (C7-THIQ), 113.5 (C5-THIQ), 120.6, 
123.5, 126.9 (C1CC8-THIQ), 127.3, 127.5, 128.8 (ArCCl), 130.7, 135.7 (C4CC5-THIQ), 
149.1 (ArCN), 158.1 (C6-THIQ) ppm. HRMS (ES
+











+H) 276.0964, found 276.0974. 
Mp 59-61 °C (pet. ether). 
 
6-Methoxy-2-(2-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (163w) 
C17H19NO2, Mol. Wt.: 269.34 
 
(Method D) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to get the product as a colourless oil (143 mg, 38%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 2.95 (2H, t, J = 5.8 Hz, H4-THIQ), 3.39 (2H, t, J 
= 5.9 Hz, H3-THIQ), 3.79 (3H, s, H1-THIQ), 3.89 (3H, s, OCH3), 4.23 (2H, s, OCH3), 
6.67 (1H, d, J = 2.3 Hz, H5-THIQ), 6.74 (1H, dd, J = 2.6, 8.4 Hz, H7-THIQ), 6.88 – 6.94 
(2H, m, 2 x ArH, phenyl) and 6.98 – 7.05 (3H, m, H8-THIQ and 2 x ArH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 29.1 (C4-THIQ), 48.8 (C3-THIQ), 52.5 (C1-THIQ), 55.2 
(CH3O-), 55.4 (CH3O-), 111.2 (ArCH, phenyl), 112.1 (C7-THIQ), 113.4 (C5-THIQ), 
118.9 (ArCH, phenyl), 120.9 (ArCH, phenyl), 122.9 (ArCH, phenyl), 127.3 (C6-THIQ), 
127.4 (C1CC8-THIQ), 135.7 (C4CC5-THIQ), 141.1 (ArCN), 152.5 (COCH3) and 157.9 
(COCH3) ppm. HRMS (ES
+
) calcd. C17H20NO2 (M
+
+H) 270.1489, found 270.1499. Mp 
199-200 °C (as hydrochloride from Et2O).  
 
2-(4-Chlorophenyl)-1,2,3,4-tetrahydroisoquinoline (163z) 
C15H14ClN, Mol. Wt.: 243.73 
 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to get the product as a white solid which was recrystallised 




H NMR (500 MHz, CDCl3) δ 2.98 (2H, t, 
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J = 5.9 Hz, H4-THIQ), 3.53 (2H, t, J = 5.9 Hz, H3-THIQ), 4.38 (2H, s, H1-THIQ), 6.89 
(2H, d, J = 9.1 Hz, ArH, phenyl), 7.12 – 7.21 (4H, m, H5,H6,H7,H8 -THIQ) and 7.22 
(2H, d, J = 9.1 Hz, ArH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 29.1 (C4-THIQ), 
46.7 (C3-THIQ), 50.8 (C1-THIQ), 116.3 (ArCH, phenyl), 123.5, 126.3 (C8-THIQ), 
126.6 (ArCH-THIQ), 126.7 (ArCH-THIQ), 128.7 (C5-THIQ), 129.2 (ArCH, phenyl), 












246.0858, found 246.0866. 
 
2-(3,4-Dichlorophenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline (163aa) 
C16H15Cl2NO, Mol. Wt.: 308.20 
 
(Method J) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give yellow solid (631 mg, 55%) which showed: 
1
H NMR 
(500 MHz, CDCl3) δ 2.94 (2H, t, J = 5.9 Hz, H4-THIQ), 3.51 (2H, t, J = 5.9 Hz, H3-
THIQ), 3.80 (3H, s, OCH3), 4.32 (2H, s, H1-THIQ), 6.70 (1H, d, J = 2.5 Hz), 6.75 (1H, 
dd, J = 2.9, 8.9 Hz), 6.77 (1H, dd, J = 2.3, 8.1 Hz), 6.97 (1H, d, J = 2.9 Hz), 7.07 (1H, 
d, J = 8.4 Hz) and 7.27 (1H, d, J = 8.9 Hz) ppm. 
13
C NMR (126 MHz, CDCl3) δ 29.1, 
45.8, 49.5, 55.3, 112.5, 113.2, 113.9, 115.7, 120.6, 125.8, 127.5, 130.4, 132.8, 135.8 
and 158.3 ppm. HRMS (ES
+




+H) 306.0447, found 











+H) 308.0417, found 308.0390. Mp 81-82 °C (pet. ether). Anal. 
calcd. for C16H15Cl2NO: C 62.35, H 4.91, N 4.54%. Found: C 62.18, H 4.83, N 4.42%. 
 
2-(4-Chlorophenyl)-7-methoxy-1,2,3,4-tetrahydroisoquinoline (164j) 





The crude compound was purified by column chromatography (eluent: from 0% to 
30% EtOAc in pet. ether) to get the product as a white solid (1.1 g, 51%) which was 
recrystallised from pet. ether and showed: 
1
H NMR (500 MHz, CDCl3) δ 2.90 (2H, t, J 
= 5.9 Hz, H4-THIQ), 3.52 (2H, t, J = 5.9 Hz, H3-THIQ), 3.80 (3H, s, OCH3), 4.35 (2H, 
s, H1-THIQ), 6.70 (1H, d, J = 2.6 Hz, H8-THIQ), 6.76 (1H, dd, J = 2.6, 8.4 Hz, 
H7-THIQ), 6.88 (2H, d, J = 9.1 Hz, ArH, phenyl), 7.07 (1H, d, J = 8.4 Hz, H5-THIQ) 
and 7.22 (2H, d, J = 9.1 Hz, ArH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 28.1 
(C4-THIQ), 47.0 (C3-THIQ), 51.0 (C1-THIQ), 55.5 (OCH3), 111.4 (C8-THIQ), 112.8 
(C6-THIQ), 116.4 (ArCH, phenyl), 123.5 (ArCCl), 126.9 (C5CC6-THIQ), 129.1 (ArCH, 





tr = 3.49 min (99 %), m/z 273.9 (M
+












+H) 276.0964, found 276.0987. Mp 79-80 °C (pet. ether). 
 
2-(4-Chlorophenyl)-5-methoxy-1,2,3,4-tetrahydroisoquinoline (165j) 
C16H16ClNO, Mol. Wt.: 273.76 
 
(Method E) 
The crude compound was purified by column chromatography (eluent: from 0% to 
30% EtOAc in pet. ether) to get the product as a white solid (230 mg, 11%) which was 
recrystallised from pet. ether and showed: 
1
H NMR (500 MHz, CDCl3) δ 2.87 (2H, t, J 
= 6.0 Hz, H4-THIQ), 3.52 (2H, t, J = 6.0 Hz, H3-THIQ), 3.83 (3H, s, OCH3), 4.35 (2H, 
s, H1-THIQ), 6.72 (1H, d, J = 8.1 Hz, H6-THIQ), 6.77 (1H, d, J = 7.7 Hz, H8-THIQ), 
6.91 (2H, d, J = 9.0 Hz, ArH, phenyl), 7.17 (1H, t, J = 8.0 Hz, H7-THIQ) and 7.21 (2H, 
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d, J = 9.0 Hz, ArH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 23.0 (C4-THIQ), 46.8 
(C3-THIQ), 51.0 (C1-THIQ), 55.5 (OCH3), 107.8 (C6-THIQ), 116.8 (ArCH, phenyl), 
118.8 (C8-THIQ), 123.6 (C5CC6-THIQ), 123.7 (ArCCl), 126.8 (C7-THIQ), 129.1 











C17H18ClNO, Mol. Wt.: 287.78 
 
(method E) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give the product as a white solid (120 mg, 28%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 1.04 (3H, d, J = 6.6 Hz, CHCH3), 2.66 (1H, dd, 
J = 2.0, 15.6 Hz, H4-THIQ), 3.23 (1H, dd, J = 5.4, 15.6 Hz, H4-THIQ), 3.81 (3H, s, 
OCH3), 4.17 (1H, d, J = 15.0 Hz, H1-THIQ), 4.24 – 4.32 (1H, m, H3-THIQ), 4.35 (1H, 
d, J = 15.0 Hz, H1-THIQ), 6.72 (1H, d, J = 2.6 Hz, H5-THIQ), 6.79 (1H, dd, J = 2.6, 8.4 
Hz, H7-THIQ), 6.85 (2H, d, J = 9.0 Hz, 2 x ArCH, phenyl), 7.09 (1H, d, J = 8.4 Hz, H8-
THIQ) and 7.23 (2H, d, J = 9.0 Hz, 2 x ArCH, phenyl) ppm. 
13
C NMR (126 MHz, 
CDCl3) δ 15.5 (CHCH3), 35.7 (C4-THIQ), 45.7 (C1-THIQ), 48.8 (C3-THIQ), 55.2 
(OCH3), 112.2 (C7-THIQ), 113.8 (C5-THIQ), 115.4 (2 x ArCH, phenyl), 122.4 (ArCCl), 
125.3 (C1CC8-THIQ), 127.3 (C8-THIQ), 129.0 (2 x ArCH, phenyl), 134.3 







+H) 288.1150, found 288.1156. Mp 86-90 °C (pet. ether). 
 
6-Methoxy-2-(4-methoxyphenyl)-3-methyl-1,2,3,4-tetrahydroisoquinoline (166s) 





The crude compound was purified by column chromatography (eluent: form 0% to 
20% EtOAc in pet. ether) to give the product as a yellow solid (170 mg, 6%, yield of the 
last two steps) which showed: 
1
H NMR (500 MHz, CDCl3) δ 1.02 (3H, d, J = 6.6 Hz, 
CHCH3), 2.63 (1H, dd, J = 3.0, 15.9 Hz, H4-THIQ), 3.21 (1H, dd, J = 5.3, 15.9 Hz, H4-
THIQ), 3.78 (3H, s, OCH3, phenyl), 3.80 (3H, s, C6OCH3-THIQ), 4.04 – 4.13 (1H, m, 
H3-THIQ), 4.16 (1H, d, J = 15.1 Hz, H1-THIQ), 4.26 (1H, d, J = 15.1 Hz, H1-THIQ), 
6.68 (1H, d, J = 2.4 Hz, H5-THIQ), 6.76 (1H, dd, J = 2.6, 8.3 Hz, H7-THIQ), 6.86 (2H, 
d, J = 9.1 Hz, 2 x ArCH, phenyl), 6.95 (2H, d, J = 9.1 Hz, 2 x ArCH, phenyl) and 7.06 
(1H, d, J = 8.4 Hz, H8-THIQ) ppm. 
13
C NMR (126 MHz, CDCl3) δ 15.3 (CHCH3), 35.8 
(C4-THIQ), 47.2 (C1-THIQ), 50.6 (C3-THIQ), 55.2 (OCH3), 55.6 (OCH3), 112.1 (C6-
THIQ), 113.8 (C5-THIQ), 114.5 (2 x ArCH, phenyl), 118.2 (2 x ArCH, phenyl), 126.1 
(C1CC8-THIQ), 127.2 (H8-THIQ), 134.6 (C4CC5-THIQ), 144.1 (ArCN), 153.1 (ArCO, 
phenyl) and 158.1 (C6-THIQ) ppm. HRMS (ES
+
) calcd. C18H22NO2 (M
+
+H) 284.1645, 
found 284.1647; calcd. C18H21NNaO2 (M
+
+Na) 306.1465, found 306.1470. Mp 108-110 
°C (pet. ether). Anal. calcd. for C18H21NO2: C 76.30, H 7.47, N 4.94. Found: C 76.25, H 
7.36, N 4.85%. 
 
6,7-Dimethoxy-2-(4-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (167x) 
C18H21NO3, Mol. Wt.: 299.36 
 
(Method E) 
The crude compound was purified by column chromatography (eluent: form 0% to 





H NMR (500 MHz, CDCl3) δ 2.89 (2H, t, J = 5.7 Hz, H4-THIQ), 3.43 (2H, 
t, J = 5.7 Hz, H3-THIQ), 3.78 (3H, s, OCH3, phenyl), 3.86 (3H, s, OCH3-THIQ), 3.87 
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(3H, s, OCH3-THIQ), 4.22 (2H, s, H1-THIQ), 6.62 (1H, s), 6.63 (1H, s), 6.86 (2H, d, J = 
9.0 Hz, 2 x ArCH, phenyl) and 6.98 (2H, d, J = 9.0 Hz, 2 x ArCH, phenyl) ppm. 
13
C 
NMR (126 MHz, CDCl3) δ 28.5 (C4-THIQ), 48.6 (C3-THIQ), 52.4 (C1-THIQ), 55.6 
(OCH3, phenyl), 55.9 (OCH3-THIQ), 56.0 (OCH3-THIQ), 109.3 (Cy-THIQ), 111.4 
(Cy-THIQ), 114.5 (2 x ArCH, phenyl), 118.1 (2 x ArCH, phenyl), 126.3 (C1CC8-THIQ), 
126.4 (C4CC5-THIQ), 145.3 (ArCN), 147.4 (C-THIQ), 147.6 (C-THIQ) and 153.5 
(ArCO, phenyl) ppm. HRMS (ES
+
) calcd. C18H22NO3 (M
+
+H) 300.1594, found 
300.1581. Mp 138-140 °C (DCM/Et2O). 
 
5,6,7-Trimethoxy-2-(4-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (168y) 
C19H23NO4, Mol. Wt.: 329.39 
 
(Method E) 
The crude compound was purified by column chromatography (eluent: form 0% to 
70% EtOAc in pet. ether) to give the product as a white solid (1.13 g, 49%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 2.86 (2H, t, J = 5.9 Hz, H4-THIQ), 3.39 (2H, t, J 
= 5.9 Hz, H3-THIQ), 3.78 (3H, s, OCH3, phenyl), 3.85 (3H, s, C5OCH3), 3.86 (3H, s, 
C7OCH3), 3.87 (3H, s, C6OCH3), 4.20 (2H, s, H1-THIQ), 6.45 (1H, s, H8-THIQ), 6.86 
(2H, d, J = 9.1 Hz, 2 x ArCH, phenyl) and 6.98 (2H, d, J = 9.0 Hz, 2 x ArCH, phenyl) 
ppm. 
13
C NMR (126 MHz, CDCl3) δ 23.3 (C4-THIQ), 48.5 (C3-THIQ), 52.9 (C1-THIQ), 
55.6 (OCH3, phenyl), 56.0 (C5OCH3), 60.5 (C7OCH3), 60.9 (C6OCH3), 105.2 
(C8-THIQ), 114.5 (2 x ArCH, phenyl), 118.4 (2 x ArCH, phenyl), 120.7 (C4CC5-THIQ), 
130.1 (C1CC8-THIQ), 140.5 (C7-THIQ), 145.4 (ArCN), 151.2 (C6-THIQ), 151.9 (C5-
THIQ) and 153.7 (ArCO, phenyl) ppm. HRMS (ES
+
) calcd. C19H24NO4 (M
+
+H) 
330.1700, found 330.1697. Mp 103-104 °C (DCM/Et2O). Anal. calcd. for C19H23NO4: 
C 69.28, H 7.04, N 4.25. Found: C 69.36, H 6.95, N 4.13 %. 
 
2-(4-Chlorophenyl)-1,2,3,4-tetrahydroisoquinoline-4,6-diyl diacetate (169) 
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C19H18ClNO4, Mol. Wt.: 359.80 
 
A solution of acetyl chloride (39 µL, 0.544 mmol) in EtOAc (1 mL) was added to a 
stirring solution of 143l (150 mg, 0.544 mmol) and Et3N (76 µL, 0.544 mmol) in EtOAc 
(1 mL) at 0 °C and the mixture was stirred for 1 h. The mixture was then let reach rt, 
filtered and the filtrate was evaporated to give a brown oil (166 mg). The crude 
compound was purified by column chromatography (eluent: from 0% to 40% EtOAc in 
pet. ether) to give a yellow oil (54 mg, 28%) which showed: 
1
H NMR (500 MHz, 
CDCl3) δ 2.11 (3H, s, C6OCOCH3), 2.30 (3H, s, C4OCOCH3), 3.59 (1H, dd, J = 3.8, 
13.1 Hz, H3-THIQ), 3.70 (1H, dd, J = 3.8, 13.2 Hz, H3-THIQ), 4.25 (1H, d, J = 15.5 Hz, 
H1-THIQ), 4.47 (1H, d, J = 15.5 Hz, H1-THIQ), 6.00 (1H, t, J = 3.8 Hz, H4-THIQ), 6.88 
(2H, d, J = 8.8 Hz, 2 x ArCH, phenyl), 7.07 (1H, dd, J = 1.9, 8.3 Hz, H7-THIQ), 7.14 
(1H, d, J = 2.4 Hz, H5-THIQ), 7.21 (1H, d, J = 8.3 Hz, H8-THIQ) and 7.23 (2H, d, J = 
8.8 Hz, 2 x ArCH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 21.0 (C4OCOCH3), 
21.2 (C6OCOCH3), 50.2 (C1-THIQ), 51.1 (C3-THIQ), 68.1 (C4-THIQ), 116.7 (2 x 
ArCH, phenyl), 121.7 (C5-THIQ), 122.1 (C7-THIQ), 124.4 (ArCCl), 127.4 (C8-THIQ), 
129.1 (2 x ArCH, phenyl), 132.5 (C4CC5-THIQ), 133.7 (C1CC8-THIQ), 148.6 (ArCN), 
149.3 (C6-THIQ), 169.4 (C4OCOCH3) and 170.9 (C6OCOCH3) ppm. 
 
2-Phenyl-1,2,3,4-tetrahydroisoquinolin-6-ol hydrobromide (170e) 
C15H16BrNO, Mol. Wt.: 306.20 
 
(Method F) 





C NMR data refer to the free base): 
1
H NMR (500 MHz, CDCl3) δ 2.93 (2H, t, J = 
5.8 Hz, H4-THIQ), 3.54 (2H, t, J = 5.8 Hz, H3-THIQ), 4.34 (2H, s, H1-THIQ), 4.75 (1H, 
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bs, OH), 6.63 (1H, d, J = 2.6 Hz, H5-THIQ), 6.68 (1H, dd, J = 2.6, 8.2 Hz, H7-THIQ), 
6.83 (1H, t, J = 7.3 Hz, ArH, phenyl), 6.97 (2H, d, J = 8.8 Hz, ArH, phenyl), 7.03 (1H, 
d, J = 8.2 Hz, H8-THIQ) and 7.29 (2H, dd, J = 7.3, 8.8 Hz, ArH, phenyl) ppm. 
13
C NMR 
(126 MHz, CDCl3) δ 29.3 (C4-THIQ), 46.6 (C3-THIQ), 50.4 (C1-THIQ), 113.6 (C7-
THIQ), 115.0 (C5-THIQ), 115.4 (ArCH, phenyl), 118.9 (ArCH, phenyl), 126.9 (C1CC8-
THIQ), 127.9 (C8-THIQ), 129.3 (ArCH, phenyl), 136.5 (C5CC6-THIQ), 150.7 (ArCN) 




tr = 2.14 min (98 %), m/z 225.9 (M
+
+H); (RP, 
Isocratic, 80% MeOH). HRMS (ES
+
) calcd. for C15H16NO (M
+
+H) 226.1226, found 
226.1258. Mp 220-221 °C (aqueous HBr). Anal. calcd. for C15H16BrNO: C 58.54, H 
5.27, N 4.57. Found: C 58.6, H 5.25, N 4.44 %. 
 
2-(4-Chlorophenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol hydrobromide (170i) 
C15H15BrClNO, Mol. Wt.: 340.64 
 
(Method F) 
The product was obtained as a yellow precipitate (196 mg, 79%) which showed: 
1
H 
NMR (500 MHz, CDCl3) δ 2.92 (2H, t, J = 5.9 Hz, H4-THIQ), 3.50 (2H, t, J = 5.9 Hz, 
H3-THIQ), 4.30 (2H, s, H1-THIQ), 4.79 (1H, bs, OH), 6.64 (1H, d, J = 2.6 Hz, H5-
THIQ), 6.68 (1H, dd, J = 2.6, 8.2 Hz, H7-THIQ), 6.87 (2H, d, J = 9.1 Hz, ArH, phenyl), 
7.02 (1H, d, J = 8.2 Hz, H8-THIQ) and 7.21 (2H, d, J = 9.1 Hz, ArH, phenyl) ppm. 
13
C 
NMR (126 MHz, CDCl3) δ 29.2 (C4-THIQ), 46.6 (C3-THIQ), 50.3 (C1-THIQ), 113.7 
(C7-THIQ), 115.0 (C5-THIQ), 116.3 (ArCH, phenyl), 123.5 (ArCCl), 126.5 (C1CC8-
THIQ), 127.8 (C8-THIQ), 129.1 (ArCH, phenyl), 136.3 (C5CC6-THIQ), 149.2 (ArCN) 




tr = 4.39 min (97 %), m/z 259.8 (M
+
+H); (RP, 











+H) 262.0807, found 262.0845. Mp 196-197 °C 
(aqueous HBr). Anal. calcd. for C15H15BrClNO: C 52.89, H 4.44, N 5.39. Found: C 




2-(p-Tolyl)-1,2,3,4-tetrahydroisoquinolin-6-ol hydrobromide (170q) 
C16H18BrNO, Mol. Wt.: 320.22 
 
(Method F) 
The product was obtained as a yellow precipitate (240 mg, 95%) which showed: 
1
H 
NMR (500 MHz, CDCl3) δ 2.28 (3H, s, CH3), 2.92 (2H, t, J = 5.8 Hz, H4-THIQ), 3.48 
(2H, t, J = 5.9 Hz, H3-THIQ), 4.28 (2H, s, H1-THIQ), 4.77 (1H, bs), 6.62 (1H, d, J = 2.5 
Hz, H5-THIQ), 6.67 (1H, dd, J = 2.5, 8.2 Hz, H7-THIQ), 6.91 (2H, d, J = 8.6 Hz, ArH, 
phenyl), 7.01 (1H, d, J = 8.2 Hz, H8-THIQ) and 7.09 (2H, d, J = 8.6 Hz, ArH, phenyl) 
ppm. 
13
C NMR (126 MHz, CDCl3) δ 20.5 (CH3), 29.3 (C4-THIQ), 47.4 (C3-THIQ), 51.2 
(C1-THIQ), 113.5 (C7-THIQ), 115.0 (C5-THIQ), 116.1 (ArCH, phenyl), 127.0 (C1CC8-
THIQ), 127.8 (C8-THIQ), 128.6 (ArCCH3), 129.8 (ArCH, phenyl), 136.4 (C5CC6-




tr = 1.73 min (97 %), 
m/z 239.9 (M
+
+H); (RP, Isocratic, 80% MeOH). HRMS (ES
+
) calcd. C16H17NO 
(M
+
+H) 240.1383, found 240.1380. Mp 224-225 °C (aqueous HBr). Anal. calcd. for 
C16H18BrClNO: C 60.0, H 5.67, N 4.37. Found: C 59.5, H 5.69, N 4.32 %. 
 
2-(4-Hydroxyphenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol hydrobromide (170s) 
C15H16BrNO2, Mol. Wt.: 322.20 
 
(Method F) 




H NMR (500 MHz, D6-DMSO) δ 2.78 (2H, t, J = 5.7 Hz, H4-THIQ), 3.27 (2H, t, J 
= 5.9 Hz, H3-THIQ), 4.05 (2H, s, H1-THIQ), 6.52 (1H, d, J = 2.5 Hz, H5-THIQ), 6.56 
(1H, dd, J = 2.5, 8.2 Hz, H7-THIQ), 6.66 (2H, d, J = 8.9 Hz, ArH, phenyl), 6.84 (2H, d, 
J = 8.9 Hz, ArH, phenyl), 6.94 (1H, d, J = 8.2 Hz, H8-THIQ), 8.80 (1H, bs, OH, phenyl) 
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and 9.15 (1H, bs, OH-THIQ) ppm. 
13
C NMR (126 MHz, D6-DMSO) δ 28.6 (C4-THIQ), 
47.8 (C3-THIQ), 51.7 (C1-THIQ), 113.3 (C7-THIQ), 114.6 (C5-THIQ), 115.6 (ArCH, 
phenyl), 117.7 (ArCH, phenyl), 125.0 (C1CC8-THIQ), 127.4 (C8-THIQ), 135.3 (C5CC6-




tr = 1.96 min (95 %), m/z 241.8 (M
+





+H) 242.1176, found 242.1178. Mp 245-246 °C (aqueous HBr). 
Anal. calcd. for C15H16BrNO2: C 55.9, H 5.01, N 4.35. Found: C 55.7, H 4.99, N 
4.17 %. 
 
2-(3-Chlorophenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol hydrobromide (170t) 
C15H15BrClNO, Mol. Wt.: 340.64 
 
(Method F) 
The product was obtained as a yellow solid (35 mg, 64%) which showed: 
1
H NMR 
(500 MHz, D6-DMSO) δ 2.79 (2H, t, J = 5.7 Hz, H4-THIQ), 3.48 (9H, t, J = 5.7 Hz, H3-
THIQ), 4.27 (2H, s, H1-THIQ), 6.57 (1H, s, H5-THIQ), 6.60 (1H, dd, J = 2.3, 8.2 Hz, 
H7-THIQ), 6.70 (1H, d, J = 7.8 Hz, ArCH, phenyl), 6.89 (1H, dd, J = 2.2, 8.4 Hz, 
ArCH, phenyl), 6.92 (1H, s, ArCH, phenyl), 7.01 (1H, d, J = 8.2 Hz, H8-THIQ), 7.20 
(1H, t, J = 8.1 Hz, ArCH, phenyl) and 9.29 (1H, bs, OH) ppm. 
13
C NMR (126 MHz, D6-
DMSO) δ 28.2 (C4-THIQ), 45.1 (C3-THIQ), 48.7 (C1-THIQ), 112.6 (ArCH, phenyl), 
113.4 (ArCH, phenyl), 113.5 (C7-THIQ), 114.5 (C5-THIQ), 116.8 (ArCH, phenyl), 
124.4 (C1CC8-THIQ), 127.5 (C8-THIQ), 130.5 (ArCH, phenyl), 134.0 (ArCCl), 135.7 












262.0807, found 262.0805. Mp 211-215 °C.  
 
2-(3-Hydroxyphenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol hydrobromide (170u) 





The product was obtained as a black solid (20 mg, 67%) which showed: 
1
H NMR 
(400 MHz, CDCl3) δ 2.90 (2H, t, J = 5.8 Hz), 3.51 (2H, t, J = 5.9 Hz), 4.32 (2H, s), 4.66 
(2H, bs), 6.27 (1H, ddd, J = 0.7, 2.3, 8.0 Hz), 6.42 (1H, t, J = 2.3 Hz), 6.54 (1H, dd, J = 
2.1, 8.0 Hz), 6.63 (1H, d, J = 2.6 Hz), 6.67 (1H, dd, J = 2.7, 8.2 Hz), 7.01 (1H, d, J = 
8.3 Hz) and 7.12 (1H, t, J = 8.1 Hz) ppm. HRMS (ES
+
) calcd. C15H16NO2 (M
+
+H) 
242.1176, found 242.1187; 
 
2-(4-Chlorophenyl)-1,2,3,4-tetrahydroisoquinolin-7-ol hydrobromide (171) 
C15H15BrClNO, Mol. Wt.: 340.64 
 
(Method F) 
The product was obtained as a yellow precipitate (92 mg, 74%) which showed: 
1
H 
NMR (500 MHz, D6-DMSO) δ 2.75 (2H, t, J = 5.9 Hz, H4-THIQ), 3.48 (2H, t, J 
= 5.9 Hz, H3-THIQ), 4.27 (2H, s, H1-THIQ), 6.58 (1H, dd, J = 2.4, 8.2 Hz, H6-THIQ), 
6.60 (1H, d, J = 2.4 Hz, H8-THIQ), 6.94 (1H, d, J = 8.2 Hz, H5-THIQ), 6.97 (2H, d, J = 
9.1 Hz, ArH, phenyl), 7.22 (2H, d, J = 9.1 Hz, ArH, phenyl) and 9.20 (1H, bs, OH) 
ppm. 
13
C NMR (126 MHz, D6-DMSO) δ 27.0 (C4-THIQ), 45.9 (C3-THIQ), 49.7 (C1-
THIQ), 112.8 (C8-THIQ), 113.8 (C6-THIQ), 116.0 (ArCH, phenyl), 121.2 (ArCCl), 
124.6 (C4CC5-THIQ), 128.7 (ArCH, phenyl), 129.2 (C5-THIQ), 135.0 (C1CC8-THIQ), 











+H) 262.0807, found 262.0831. 
Mp 225-228 °C. 
 
2-(4-Chlorophenyl)-1,2,3,4-tetrahydroisoquinolin-5-ol hydrobromide (172) 
252 
 
C15H15BrClNO, Mol. Wt.: 340.64 
 
(Method F) 
The product was obtained as a brown precipitate (47 mg, 75%) which showed: 
1
H 
NMR (500 MHz, D6-DMSO) δ 2.69 (2H, t, J = 5.9 Hz, H4-THIQ), 3.51 (2H, t, J 
= 5.9 Hz, H3-THIQ), 4.31 (2H, s, H1-THIQ), 6.64 (1H, d, J = 7.9 Hz, H6-THIQ), 6.65 
(1H, d, J = 7.9 Hz, H8-THIQ), 6.97 (1H, t, J = 7.9 Hz, H7-THIQ), 7.00 (2H, d, J = 9.1 
Hz, ArH, phenyl), 7.22 (2H, d, J = 9.1 Hz, ArH, phenyl) and 9.37 (1H, bs, OH) ppm. 
13
C NMR (126 MHz, D6-DMSO) δ 22.2 (C4-THIQ), 45.6 (C3-THIQ), 49.9 (C1-THIQ), 
112.2 (C6-THIQ), 116.4 (ArCH, phenyl), 117.1 (C8-THIQ), 121.3 (C4CC5-THIQ), 121.4 
(ArCCl), 126.3 (C7-THIQ), 128.7 (ArCH, phenyl), 135.4 (C1CC8-THIQ), 149.0 (ArCN) 
















C15H16BrNO3, Mol. Wt.: 338.20 
 
(Method G) 
The product was obtained as a yellow solid (168 mg, 74%) which showed: 
1
H NMR 
(500 MHz, D2O) δ 3.18 (2H, t, J = 6.0 Hz, H4-THIQ), 3.93 (2H, t, J = 6.0 Hz, H3-
THIQ), 4.63 (2H, s, H1-THIQ), 6.74 (1H, s, H8-THIQ), 6.84 (1H, s, H5-THIQ), 7.06 
(2H, d, J = 8.3 Hz, 2 x ArCH, phenyl) and 7.50 (2H, d, J = 8.3 Hz, 2 x ArCH, phenyl) 
ppm. 
13
C NMR (126 MHz, D2O) δ 24.9 (C4-THIQ), 53.4 (C3-THIQ), 56.5 (C1-THIQ), 
113.4 (C8-THIQ), 115.7 (C5-THIQ), 116.8 (2 x ArCH, phenyl), 120.0 (C1CC8-THIQ), 
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122.5 (2 x ArCH, phenyl), 122.9 (C4CC5-THIQ), 133.5 (ArCN), 143.2 (C6-THIQ), 
144.2 (C7-THIQ) and 156.9 (ArCO, phenyl) ppm. HRMS (ES
+
) calcd. C15H16NO3 
(M
+




C15H16BrNO4, Mol. Wt.: 354.20 
 
(Method G) 
The product was obtained as a yellow solid (245 mg, 99%) which showed: 
1
H NMR 
(500 MHz, D2O) δ 3.10 (2H, t, J = 6.3 Hz, H4-THIQ), 3.94 (2H, t, J = 6.4 Hz, H3-
THIQ), 4.61 (2H, s, H1-THIQ), 6.40 (1H, s, H8-THIQ), 7.07 (2H, d, J = 9.1 Hz, 2 x 
ArCH, phenyl) and 7.49 (2H, d, J = 9.1 Hz, 2 x ArCH, phenyl) ppm. 
13
C NMR (126 
MHz, D2O) δ 20.6 (C4-THIQ), 53.1 (C3-THIQ), 56.4 (C1-THIQ), 105.5 (C8-THIQ), 
111.4 (C4CC5-THIQ), 116.8 (2 x ArCH, phenyl), 120.4 (C1CC8-THIQ), 122.4 (2 x 
ArCH, phenyl), 132.3 (C6-THIQ), 133.6 (ArCN), 143.0 (C5-THIQ), 144.5 (C7-THIQ) 
and 156.8 (ArCO, phenyl) ppm. Mp 178-181 °C. 
 
4,6-Bis(benzyloxy)-2-(4-chlorophenyl)-1,2,3,4-tetrahydroisoquinoline (175n) 
C29H26ClNO2, Mol. Wt.: 455.98 
 
NaH (54 mg, 1.36 mmol) was added to a stirring solution of 143n (150 mg, 0.544 
mmol) in anhydrous THF (2 mL) under inert atmosphere followed by 15-crown-5 
(216 µL, 1.09 mmol) and the mixture was stirred for 30 min at rt during which time the 
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mixture turned dark brown. Benzyl bromide (139 µL, 1.14 mmol) was introduced and 
the mixture was stirred for 2 h at rt. The mixture was then quenched with water then 
dried with MgSO4, filtered and evaporated to give a brown oil (154 mg). The crude 
compound was purified by column chromatography (eluent: from 0% to 10% EtOAc in 
pet. ether) to give the product as a pale yellow oil (49 mg, 20%) which solidified upon 
standing and showed: 
1
H NMR (500 MHz, CDCl3) δ 3.55 – 3.66 (2H, m, H3-THIQ), 
4.25 (1H, d, J = 14.6 Hz, H1-THIQ), 4.40 (1H, d, J = 14.6 Hz, H1-THIQ), 4.65 (1H, t, J 
= 4.5 Hz, H4-THIQ), 4.69 (2H, s, C4OCH2), 5.07 (2H, d, J = 2.4 Hz, C6OCH2), 6.83 
(2H, d, J = 8.8 Hz, 2 x ArCH, phenyl), 6.93 (1H, dd, J = 2.2, 8.4 Hz, H7-THIQ), 7.03 
(1H, d, J = 2.2 Hz, H5-THIQ), 7.11 (1H, d, J = 8.4 Hz, H8-THIQ), 7.22 (2H, d, J = 8.8 
Hz, 2 x ArCH, phenyl) and 7.29 – 7.48 (10H, m, 10 x ArCH, benzyl) ppm. 13C NMR 
(126 MHz, CDCl3) δ 49.6 (C1-THIQ), 50.8 (C3-THIQ), 70.1 (C6OCH3), 71.0 (C4OCH3), 
73.3 (C1-THIQ), 113.8 (C5-THIQ), 115.2 (C7-THIQ), 115.7 (2 x ArCH, phenyl), 123.3 
(ArCCl), 126.9 (C1CC8-THIQ), 127.5, 127.8, 127.9, 128.0, 128.5, 128.6, 128.7, 129.0, 
135.8 (C4CC5-THIQ), 136.9 (ArCCH2OC6), 138.3 (ArCCH2OC4), 148.9 (ArCN) and 




C25H27NO4, Mol. Wt.: 405.49 
 
NaH (23 mg, 0.580 mmol) was added to a stirring solution of 146x (100 mg, 0.290 
mmol) in anhydrous THF (3 mL) under inert atmosphere. After stirring at rt for 30 min 
benzyl bromide (51 µL, 0.435 mmol) was added and the mixture was stirred at rt for 
further 6 h. The mixture was then quenched with water and the organic solvent was 
evaporated. The aqueous layer was extracted with EtOAc (3 x 10 mL) and the combined 
organics were then dried with MgSO4, filtered and evaporated to give a yellow oil 
(238 mg). The crude compound was purified by column chromatography (eluent: form 





H NMR (500 MHz, CDCl3) δ 3.50 (1H, dd, J = 4.5, 12.3 Hz, H3-
THIQ), 3.57 (1H, dd, J = 4.5, 12.3 Hz, H3-THIQ), 3.79 (3H, s, C7OCH3, phenyl), 3.85 
(3H, s, C6OCH3-THIQ), 3.88 (3H, s, OCH3-THIQ), 4.12 (1H, d, J = 14.8 Hz, H1-
THIQ), 4.29 (1H, d, J = 14.8 Hz, H1-THIQ), 4.67 (1H, t, J = 4.5 Hz, H4-THIQ), 4.72 
(1H, d, J = 12.1 Hz, CH2O), 4.77 (1H, d, J = 12.1 Hz, CH2O), 6.63 (1H, s, H8-THIQ), 
6.86 (1H, s, H5-THIQ), 6.88 (2H, d, J = 9.1 Hz, 2 x ArCH, phenyl), 6.98 (2H, d, J = 9.1 
Hz, 2 x ArCH, phenyl), 7.31 (1H, t, J = 7.3 Hz, ArCH, benzyl), 7.37 (2H, t, J = 7.3 Hz, 
2 x ArCH, benzyl) and 7.43 (2H, d, J = 7.3 Hz, 2 x ArCH, benzyl) ppm. 
13
C NMR (126 
MHz, CDCl3) δ 52.2 (C1-THIQ), 53.0 (C3-THIQ), 55.6 (OCH3, phenyl), 55.8 (OCH3-
THIQ), 55.9 (OCH3-THIQ), 70.7 (CH2O), 73.2 (C4-THIQ), 108.5 (C8-THIQ), 110.9 
(C5-THIQ), 114.5 (2 x ArCH, phenyl), 118.1 (2 x ArCH, phenyl), 126.5 (C1CC8-THIQ), 
127.5 (C4CC5-THIQ), 127.6 (ArCH, benzyl), 127.9 (2 x ArCH, benzyl), 128.4 
(2 x ArCH, benzyl), 138.7 (ArCCH2O), 145.2 (ArCN), 147.7 (C7-THIQ), 148.7 (C6-
THIQ) and 153.6 (ArCO, phenyl) ppm. HRMS (ES
+
) calcd. C25H28NO4 (M
+
+Na) 
406.2013, found 406.2024. 
 
2-(3-Methoxyphenyl)-N-phenylacetamide (178a) 
C15H15NO2, Mol. Wt.: 241.29 
 
(Method H) 
The crude compound was purified by column chromatography (eluent: from 0% to 





H NMR (400 MHz, CDCl3) δ 3.71 (2H, s), 3.82 (3H, s), 6.81 – 6.89 
(2H, m), 6.91 (1H, d, J = 7.5 Hz), 7.08 (1H, dd, J = 4.2, 10.5 Hz), 7.14 (1H, bs), 7.26 – 
7.35 (2H, m) and 7.41 (2H, dd, J = 1.0, 8.5 Hz) ppm. HRMS (ES
+
) calcd. C15H16NO2 
(M
+
+H) 242.1176, found 242.1184. Mp 109-110 °C (as hydrochloride from Et2O). 
 
N-(4-Chlorophenyl)-2-(3-methoxyphenyl)acetamide (178b) 





The crude compound was recrystallised from EtOAc/pet. ether to give a white solid 




H NMR (500 MHz, CDCl3) δ 3.77 (2H, s, CH2CO), 3.83 
(3H, s, CH3O), 6.88 – 6.92 (2H, m, phenyl), 6.95 (1H, d, J = 7.5 Hz, ArCH, phenyl), 
7.00 (1H, td, J = 1.5, 7.9 Hz, aniline), 7.24 (1H, dd, J = 0.9, 8.2 Hz, aniline), 7.28 (1H, 
dd, J = 1.4, 8.0 Hz, aniline), 7.34 (1H, dd, J = 7.5, 9.0 Hz, ArCH, phenyl), 7.72 (1H, bs, 
NH) and 8.36 (1H, d, J = 7.5 Hz, ArCH, aniline) ppm. 
13
C NMR (126 MHz, CDCl3) δ 
45.4 (CCO), 55.4 (CH3O), 113.7 (ArCH, phenyl), 115.2 (ArCH, phenyl), 121.4 (ArCH, 
aniline), 122.0 (ArCH, phenyl), 122.9 (ArCCl), 124.8 (ArCH, aniline), 127.8 (ArCH, 
aniline), 129.1 (ArCH, aniline), 130.6 (ArCH, phenyl), 134.6 (ArCN), 135.5 (ArCCH2), 




tr = 1.66 min (95 %), m/z 276.1 
(M
+
+H); (RP, Isocratic, 90% MeOH). HRMS (ES
+










found 300.0590. Mp 224-225 °C (EtOAc/pet. ether). 
 
2-(3-methoxyphenyl)-N-(4-methoxyphenyl)acetamide (178c) 
C16H17NO3, Mol. Wt.: 271.31 
 
(Method H) 
The crude compound was purified by column chromatography (eluent: from 0% to 





H NMR (400 MHz, CDCl3) δ 3.69 (2H, s), 3.76 (3H, s), 3.81 (3H, s), 
6.81 (2H, d, J = 9.0 Hz), 6.84 – 6.89 (2H, m), 6.91 (1H, d, J = 7.5 Hz), 7.07 (1H, bs) 
and 7.27 – 7.35 (3H, m) ppm. HRMS (ES+) calcd. C16H18NO3 (M
+
+H) 272.1281, found 





C15H14ClNO2, Mol. Wt.: 275.73 
 
(Method H) 





H NMR (500 MHz, CDCl3) δ 3.70 (2H, s, ArCH2), 3.82 (3H, s, 
ArOCH3), 6.84 – 6.86 (1H, m, ArCH, benzyl), 6.87 – 6.93 (2H, m, 2 x ArCH, benzyl), 
7.05 (1H, dd, J = 1.7, 8.1 Hz, ArCH, aniline), 7.16 (1H, bs, NH), 7.19 (1H, t, J = 8.1 
Hz, ArCH, aniline), 7.27 (1H, dd, J = 1.7, 8.1 Hz, ArCH, aniline), 7.32 (1H, t, J = 8.0 
Hz, ArCH, benzyl) and 7.52 (1H, t, J = 1.7 Hz, ArCH, aniline) ppm. 
13
C NMR (126 
MHz, CDCl3) δ 44.9 (ArCH2), 55.3 (ArOCH3), 113.2 (ArCH, benzyl), 115.2 (ArCH, 
benzyl), 117.7 (ArCH, aniline), 119.8 (ArCH, aniline), 121.6 (ArCH, benzyl), 124.4 
(ArCH, benzyl), 129.9 (ArCH, aniline), 130.4 (ArCH, aniline), 134.6 (ArCCl), 135.5 
















C16H17NO3, Mol. Wt.: 271.31 
 
(Method H) 





H NMR (500 MHz, CDCl3) δ 3.71 (2H, s, ArCH2), 3.78 (3H, s, 
ArOCH3, aniline), 3.82 (3H, s, ArOCH3, benzyl), 6.64 (1H, dd, J = 2.4, 8.2 Hz, ArCH, 
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aniline), 6.84 (1H, dd, J = 2.4, 8.2 Hz, ArCH, aniline), 6.87 (1H, m, ArCH, benzyl), 
6.88 – 6.93 (2H, m, ArCH, benzyl), 7.07 (1H, bs, NH), 7.16 (1H, t, J = 8.2 Hz, ArCH, 
aniline), 7.22 (1H, t, J = 2.4 Hz, ArCH, aniline) and 7.32 (1H, t, J = 7.8 Hz, ArCH, 
benzyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 45.0 (ArCH2), 55.2 (ArOCH3, aniline), 
55.3 (ArOCH3, benzyl), 105.5 (ArCH, aniline), 110.3 (ArCH, aniline), 111.8 (ArCH, 
aniline), 113.2 (ArCH, benzyl), 115.1 (ArCH, benzyl), 121.7 (ArCH, benzyl), 129.6 
(ArCH, aniline), 130.3 (ArCH, benzyl), 135.7 (ArCCH2), 138.8 (ArCN, aniline), 160.1 





+H) 272.1281, found 272.1288. Mp 79-81 °C (EtOAc/pet. ether). 
 
N-(2-Chlorophenyl)-2-(3-methoxyphenyl)acetamide (178f) 
C15H14ClNO2, Mol. Wt.: 275.73 
 
(Method H) 




H NMR (500 MHz, CDCl3) δ 3.77 (2H, s, CH2CO), 3.83 (3H, s, CH3O), 6.88 – 6.92 
(2H, m, phenyl), 6.95 (1H, d, J = 7.5 Hz, ArCH, phenyl), 7.00 (1H, td, J = 1.5, 7.9 Hz, 
aniline), 7.24 (1H, dd, J = 0.9, 8.2 Hz, aniline), 7.28 (1H, dd, J = 1.4, 8.0 Hz, aniline), 
7.34 (1H, dd, J = 7.5, 9.0 Hz, ArCH, phenyl), 7.72 (1H, bs, NH), 8.36 (1H, d, J = 7.5 
Hz, ArCH, aniline) ppm. 
13
C NMR (126 MHz, CDCl3) δ 45.4 (CCO), 55.4 (CH3O), 
113.7 (ArCH, phenyl), 115.2 (ArCH, phenyl), 121.4 (ArCH, aniline), 122.0 (ArCH, 
phenyl), 122.9 (ArCCl), 124.8 (ArCH, aniline), 127.8 (ArCH, aniline), 129.1 (ArCH, 
aniline), 130.6 (ArCH, phenyl), 134.6 (ArCN), 135.5 (ArCCH2), 160.4 (COCH3) and 




tr = 1.66 min (95 %), m/z 276.1 (M
+
+H); (RP, 
Isocratic, 90% MeOH) HRMS (ES
+









+Na) 300.0575, found 300.0590. Mp 





C16H17NO3, Mol. Wt.: 271.31 
 
(Method H) 
The crude compounds was obtained as a pale brown oil which solidified upon 
standing (2.52 g, 93%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 3.73 (2H, s, 
ArCH2), 3.73 (3H, s, ArOCH3, aniline), 3.83 (3H, s, ArOCH3, benzyl), 6.80 (1H, dd, J = 
1.2, 8.1 Hz, ArCH, aniline), 6.85 – 6.91 (2H, m, ArCH, benzyl), 6.91 – 6.97 (2H, m, 
ArCH, aniline, ArCH, benzyl), 7.01 (1H, td, J = 1.6, 7.8 Hz, ArCH, aniline), 7.31 (1H, 
t, J = 7.8 Hz, ArCH, benzyl), 7.84 (1H, bs, CONH) and 8.34 (1H, dd, J = 1.5, 8.0 Hz, 
ArCH, aniline) ppm. 
13
C NMR (126 MHz, CDCl3) δ 45.2 (ArCH2), 55.2 (ArOCH3, 
benzyl), 55.6 (ArOCH3, aniline), 109.9 (ArCH, aniline), 113.2 (ArCH, benzyl), 114.9 
(ArCH, benzyl), 119.5 (ArCH, aniline), 121.1 (ArCH, benzyl), 121.8 (ArCH, aniline), 
123.7 (ArCH, aniline), 127.5 (ArCN), 130.0 (ArCH, benzyl), 136.0 (ArCCH2), 147.9 
(ArCO), 160.1 (ArCO) and 168.7 (CH2CONH) ppm. HRMS (ES
+
) calc. for C16H18NO3 
(M
+
+H) 272.1281, found 272.1292. Mp 52-54 °C (EtOAc/pet. ether). 
 
N-(3,4-Dichlorophenyl)-2-(3-methoxyphenyl)acetamide (178h) 
C15H13Cl2NO2, Mol. Wt.: 310.18 
 
(Method H) 
The crude compound was obtained as a white solid (4.7 g, 76%) which showed: 
1
H 
NMR (500 MHz, CDCl3) δ 3.71 (2H, s, CH2CO), 3.83 (3H, s, CH3O), 6.85 (1H, t, J = 
2.1 Hz, ArH, phenyl), 6.89 (2H, dd, J = 2.1, 8.0 Hz, ArH, phenyl), 7.08 (1H, bs, NH), 
7.25 (1H, dd, J = 2.4, 9.0 Hz, ArH, aniline), 7.32 (1H, d, J = 9.0 Hz, ArH, Aniline), 7.33 
(1H, t, J = 8.0 Hz, ArH, phenyl) and 7.64 (1H, d, J = 2.4 Hz, ArH, aniline) ppm. 
13
C 
NMR (126 MHz, CDCl3) δ 44.8 (CH2CO), 55.3 (CH3O), 113.3 (ArCH, phenyl), 115.2 
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(ArCH, phenyl), 118.9 (ArCH, aniline), 121.4 (ArCH, aniline), 121.6 (ArCH, phenyl), 
127.6 (ArCN), 130.4 (ArCH, phenyl), 130.5 (ArCH, aniline), 132.7 (ArCCl), 135.3 





2.10 min (92 %), m/z (not ionised) (M
+


















C15H17NO, Mol. Wt.: 227.30 
 
(Method I) 
The crude compound was purified by column chromatography (eluent: from 0% to 





H NMR (500 MHz, CDCl3) δ 2.91 (2H, t, J = 7.1 Hz, CH2CH2N), 3.41 (2H, 
t, J = 7.1 Hz, CH2CH2N), 3.80 (3H, s, ArOCH3), 6.67 (2H, d, J = 7.8 Hz, 2 x ArCH, 
aniline), 6.74 (1H, t, J = 7.8 Hz, ArCH, aniline), 6.76 – 6.80 (2H, m, 2 x ArCH, 
phenethyl), 6.82 (1H, d, J = 7.5 Hz, ArCH, phenethyl), 7.20 (2H, t, J = 7.8 Hz, 
2 x ArCH, aniline) and 7.24 (1H, t, J = 7.9 Hz, ArCH, phenethyl) ppm. 
13
C NMR (126 
MHz, CDCl3) δ 35.3 (CH2CH2N), 45.3 (CH2CH2N), 55.2 (ArOCH3), 111.7 (ArCH, 
phenethyl), 113.4 (2 x ArCH, aniline), 114.5 (ArCH, phenethyl), 118.0 (ArCH, aniline), 
121.1 (ArCH, phenethyl), 129.3 (2 x ArCH, aniline), 129.6 (ArCH, phenethyl), 140.7 
(ArCCH2), 147.4 (ArCN) and 159.7 (ArCO) ppm. HRMS (ES
+
) calcd. C15H17NNaO 
(M
+
+Na) 250.1208, found 250.1201. Mp 98-100 °C (as hydrochloride from Et2O). 
 
4-Chloro-N-(3-methoxyphenethyl)aniline (179b) 





The compound was precipitate as hydrochloride from Et2O to give a pale yellow 




H NMR (400 MHz, CDCl3) δ 2.87 (2H, t, J = 6.9 
Hz), 3.36 (2H, t, J = 6.9 Hz), 3.79 (3H, s), 6.52 (2H, d, J = 8.8 Hz), 6.74 (1H, s), 6.76 – 









C16H19NO2, Mol. Wt.: 257.33 
 
(Method I) 
The crude compound was purified by column chromatography (eluent: from 0% to 





H NMR (500 MHz, CDCl3) δ 2.89 (2H, t, J = 7.0 Hz, CH2CH2N), 3.36 (2H, 
t, J = 7.0 Hz, CH2CH2N), 3.75 (3H, s, ArOCH3, aniline), 3.80 (3H, s, ArOCH3, 
phenethyl), 6.63 (2H, d, J = 8.8 Hz, 2 x ArCH, aniline), 6.74 – 6.83 (5H, m, 3 x ArCH, 
phenethyl, 2 x ArCH, aniline) and 7.23 (1H, t, J = 7.8 Hz, ArCH, phenethyl) ppm. 
13
C 
NMR (126 MHz, CDCl3) δ 35.4 (CH2CH2N), 46.2 (CH2CH2N), 55.2 (ArOCH3, 
phenethyl), 55.8 (ArOCH3, aniline), 111.7 (ArCH, phenethyl), 114.5 (ArCH, 
phenethyl), 114.8 (2 x ArCH, aniline), 114.9 (2 x ArCH, aniline), 121.1 (ArCH, 
phenethyl), 129.6 (ArCH, phenethyl), 140.8 (ArCCH2), 141.6 (ArCN), 152.4 (ArCO, 
aniline) and 159.7 (ArCO, phenethyl) ppm. HRMS (ES
+
) calcd. C16H19NNaO2 (M
+
+Na) 
280.1308, found 280.1312.  Mp 108-111 °C (as hydrochloride from Et2O). 
 
3-Chloro-N-(3-methoxyphenethyl)aniline (179d) 





The crude compound was purified by column chromatography (from 0% to 20% 
EtOAc in pet. ether) to give the product as a yellow oil (1.32 g, 66%) which showed: 
1
H 
NMR (500 MHz, CDCl3) δ 2.89 (2H, t, J = 6.9 Hz, ArCH2CH2), 3.38 (2H, t, J = 6.9 Hz, 
CH2CH2N), 3.76 (1H, bs, NH), 3.80 (3H, s, ArOCH3), 6.46 (1H, ddd, J = 0.8, 2.1, 8.0 
Hz, ArCH, aniline), 6.58 (1H, t, J = 2.1 Hz, ArCH, aniline), 6.66 (1H, ddd, J = 0.8, 2.1, 
8.0 Hz, ArCH, aniline), 6.73 – 6.77 (1H, m, ArCH, phenethyl), 6.77 – 6.83 (2H, m, 
ArCH, phenethyl), 7.07 (1H, t, J = 8.0 Hz, ArCH, aniline) and 7.24 (1H, t, J = 7.9 Hz, 
ArCH, phenethyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 35.3 (ArCH2CH2), 44.6 
(ArCH2CH2), 55.2 (ArOCH3), 111.3 (ArCH, aniline), 111.8 (ArCH, phenethyl), 112.5 
(ArCH, aniline), 114.6 (ArCH, phenethyl), 117.2 (ArCH, aniline), 121.1 (ArCH, 
phenethyl), 129.7 (ArCH, phenethyl), 130.2 (ArCH, aniline), 135.0 (ArCCl), 140.5 
(ArCCH2), 149.1 (ArCN) and 159.8 (ArCO) ppm. HRMS (ES
+









+H) 264.0964, found 
264.0966. Mp 136-138 °C (as hydrochloride from Et2O). 
 
3-Methoxy-N-(3-methoxyphenethyl)aniline (179e) 
C16H19NO2, Mol. Wt.: 257.33 
 
(Method I) 
The crude compound was purified by column chromatography (from 0% to 20% 




H NMR (500 MHz, CDCl3) δ 2.89 (2H, t, J = 7.0 Hz, ArCH2CH2), 3.39 (2H, t, J = 7.0 
Hz, CH2CH2N), 3.72 (1H, bs, NH), 3.77 (3H, s, ArOCH3, aniline), 3.80 (3H, s, 
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ArOCH3, phenethyl), 6.18 (1H, t, J = 2.3 Hz, ArCH, aniline), 6.23 (1H, ddd, J = 0.7, 
2.3, 8.1 Hz, ArCH, aniline), 6.28 (1H, ddd, J = 0.7, 2.3, 8.1 Hz, ArCH, aniline), 6.76 – 
6.80 (2H, m, ArCH, phenethyl), 6.80 – 6.84 (1H, m, ArCH, phenethyl), 7.08 (1H, t, J = 
8.1 Hz, ArCH, aniline) and 7.24 (1H, t, J = 7.8 Hz, ArCH, phenethyl) ppm. 
13
C NMR 
(126 MHz, CDCl3) δ 35.5 (ArCH2CH2), 44.9 (CH2CH2N), 55.1 (ArOCH3, aniline), 55.2 
(ArOCH3, phenethyl), 98.9 (ArCH, aniline), 102.6 (ArCH, aniline), 106.2 (ArCH, 
aniline), 111.7 (ArCH, phenethyl), 114.5 (ArCH, phenethyl), 121.1 (ArCH, phenethyl), 
129.6 (ArCH, phenethyl), 130.0 (ArCH, aniline), 140.9 (ArCCH2), 149.4 (ArCN), 159.8 
(ArCO, phenethyl) and 160.9 (ArCO, aniline) ppm. HRMS (ES
+
) calc. for C16H20NO2 
(M
+
+H) 258.1489, found 258.1490. Mp 99-101 °C (as hydrochloride from Et2O). 
 
2-Chloro-N-(3-methoxyphenethyl)aniline (179f) 
C15H16ClNO, Mol. Wt.: 261.75 
 
(Method I) 





NMR (500 MHz, CDCl3) δ 2.93 (2H, t, J = 7.1 Hz, ArCH2), 3.44 (2H, t, J = 7.1 Hz, 
CH2N), 3.81 (3H, s), 4.38 (1H, bs, NH), 6.63 (1H, td, J = 1.5, 7.6 Hz, ArH, aniline), 
6.70 (1H, dd, J = 1.3, 8.2 Hz, ArH, aniline), 6.76 – 6.78 (1H, m, ArH, benzyl), 6.80 
(1H, ddd, J = 0.7, 2.5, 8.2 Hz, ArH, benzyl), 6.81 – 6.85 (1H, m, ArH, benzyl), 7.12 – 
7.18 (1H, m, ArH, aniline) and 7.25 (2H, td, J = 1.3, 7.8 Hz, ArH, aniline and ArH, 
benzyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 35.4 (ArCH2), 44.8 (CH2N), 55.2 (OCH3), 
111.2 (ArCH, aniline), 111.9 (ArCH, benzyl), 114.4 (ArCH, benzyl), 117.2 (ArCH, 
aniline), 119.3 (ArCCl), 121.1 (ArCH, benzyl), 127.8 (ArCH, aniline), 129.2 (ArCH, 





tr = 3.12 min (85 %), m/z 262.1 (M
+
+H); (RP, Isocratic, 90% MeOH). 
HRMS (ES
+















C16H19NO2, Mol. Wt.: 257.33 
 
(Method I) 
The crude compound was purified by column chromatography (from 0% to 20% 
EtOAc in pet. ether) to give the product as a yellow oil (721 mg, 31%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 2.93 (2H, t, J = 7.3 Hz, ArCH2CH2), 3.41 (2H, t, J = 7.3 
Hz, CH2CH2N), 3.80 (1H, s, ArOCH3, phenethyl), 3.82 (3H, s, ArOCH3, aniline), 4.35 
(1H, bs, NH), 6.67 (1H, d, J = 7.7 Hz, ArCH, aniline), 6.69 (1H, dd, J = 1.5, 7.4 Hz, 
ArCH, aniline), 6.75 – 6.80 (3H, m, 3 x ArCH, phenethyl), 6.83 (1H, d, J = 7.4 Hz, 
ArCH, aniline), 6.89 (1H, td, J = 1.5, 7.7 Hz, ArCH, aniline) and 7.24 (1H, dd, J = 7.5, 
8.9 Hz, ArCH, phenethyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 35.7 (ArCH2CH2), 44.9 
(CH2CH2N), 55.1 (ArOCH3, phenethyl), 55.4 (ArOCH3, phenethyl), 109.5 (ArCH, 
phenethyl), 110.0 (ArCH, aniline), 111.7 (ArCH, phenethyl), 114.4 (ArCH, phenethyl), 
116.5 (ArCH, aniline), 121.1 (ArCH, aniline), 121.3 (ArCH, aniline), 129.5 (ArCH, 
phenethyl), 137.9 (ArCN), 141.1 (ArCCH2), 146.9 (ArOCH3, aniline) and 159.7 
(ArOCH3, phenethyl) ppm. HRMS (ES
+
) calc. for C16H20NO2 (M
+
+H) 258.1489, found 
258.1499. Mp 132-134 °C (as hydrochloride from Et2O). 
 
3,4-Dichloro-N-(3-methoxyphenethyl)aniline (179h) 





The crude compound was purified by column chromatography (eluent: from 0% to 
30% EtOAc in pet. ether) to get the product as a yellow oil (1.6 g, 75%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 2.88 (2H, t, J = 6.9 Hz, ArCH2CH2), 3.36 (2H, t, J = 6.9 
Hz, CH2CH2N), 3.80 (3H, s, OCH3), 6.42 (1H, dd, J = 2.7, 8.7 Hz, ArCH, aniline), 6.66 
(1H, d, J = 2.7 Hz, ArCH, aniline), 6.75 (1H, t, J = 2.1, ArCH, phenethyl), 6.80 (2H, dd, 
J = 2.1, 7.9 Hz, 2 x ArCH, phenethyl), 7.17 (1H, d, J = 8.7 Hz, ArCH, aniline) and 7.25 
(1H, t, J = 7.9 Hz, ArCH, phenethyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 35.2 
(ArCH2CH2), 44.7 (CH2CH2N), 55.2 (OCH3), 111.8 (ArCH, phenethyl), 112.7 (ArCH, 
aniline), 113.9 (ArCH, aniline), 114.6 (ArCH, phenethyl), 119.8 (ArCCl), 121.0 (ArCH, 
phenethyl), 129.7 (ArCH, phenethyl), 130.6 (ArCH, aniline), 132.8 (ArCCl), 140.3 













Cl); (RP, Isocratic, 90% MeOH) HRMS 
(ES
+











+H) 298.0580, found 298.0592. Mp 134-136 °C (as 
hydrochloride from Et2O).  
 
N-(4-Chlorophenyl)-N-(3-methoxyphenethyl)acetamide (180a) 
C17H18ClNO2, Mol. Wt.: 303.78 
 
Compound 179b (150 mg, 0.503 mmol) was dissolved in a mixture of EtOAc (2 mL) 
and Pyridine (123 µL, 1.51 mmol) and Acetylchloride (13.3 µL, 1.01 mmol) was added 
dropwise. The mixture was stirred for 1 h at rt during which time a white precipitate 
formed. The mixture was filtered and the filtrate was diluted with EtOAc (5 ml) washed 
with 1N HCl (5 mL) and 1N NaOH (5 mL). The organic layer was then dried with 
MgSO4, filtered and evaporated to give a white solid (132 mg, 86%) which showed: 
1
H 
NMR (500 MHz, CDCl3) δ 1.83 (3H, s, COCH3), 2.83 (2H, t, J = 7.8 Hz, ArCH2CH2), 
3.77 (3H, s, ArOCH3), 3.90 (2H, t, J = 7.8 Hz, CH2CH2N), 6.70 (1H, s, ArCH, 
phenethyl), 6.74 (2H, d, J = 8.3 Hz, 2 x ArCH, phenethyl), 6.98 (2H, d, J = 8.5 Hz, 2 x 
ArCH, aniline), 7.17 (1H, t, J = 7.8 Hz, ArCH, phenethyl) and 7.36 (2H, d, J = 8.5 Hz, 2 
x ArCH, aniline) ppm. 
13
C NMR (126 MHz, CDCl3) δ 22.9 (NCOCH3), 34.0 
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(ArCH2CH2), 50.6 (CH2CH2N), 55.2 (ArOCH3), 112.0 (ArCH, phenethyl), 114.3 
(ArCH, phenethyl), 121.2 (ArCH, phenethyl), 129.4 (ArCH, aniline), 129.4 (ArCH, 
phenethyl), 129.9 (ArCH, aniline), 133.7 (ArCCl), 140.2 (ArCCH2), 141.8 (ArCN), 















C18H20ClNO2, Mol. Wt.: 317.81 
 
Propanoyl chloride (90 µL, 1.01 mmol) was added to a stirring solution of 179b (150 
mg, 0.503 mmol) and pyridine (123 µL, 1.51 mmol) in DCM (2 mL) and the mixture 
was stirred at rt for 10 h. A white precipitate formed after the first ten minutes. The 
mixture was then diluted with DCM (10 mL) washed with a sat. aq. solution of 
NaHCO3 (2 x 10 mL) and 1N HCl (2 x 10 mL) and the organic layer was dried with 
MgSO4, filtered and evaporated to give the product as a pale yellow oil (114 mg, 71%) 
which showed: 
1
H NMR (500 MHz, CDCl3) δ 1.05 (3H, t, J = 7.4 Hz, CH2CH3), 2.02 
(2H, q, J = 7.4 Hz, CH2CH3), 2.78 – 2.91 (2H, m, CH2CH2N), 3.77 (3H, s, OCH3), 3.82 
– 3.96 (2H, m, CH2CH2N), 6.69 – 6.72 (1H, m, ArCH, benzyl), 6.72 – 6.79 (2H, m, 2 x 
ArCH, benzyl), 6.97 (2H, d, J = 8.4 Hz, 2 x ArCH, aniline), 7.17 (1H, t, J = 7.9 Hz, 
ArCH, benzyl) and 7.36 (2H, d, J = 8.6 Hz, ArCH, aniline) ppm. 
13
C NMR (126 MHz, 
CDCl3) δ 9.5 (CH2CH3), 27.9 (CH2CH3), 34.1 (CH2CH2N), 50.9 (CH2CH2N), 55.2 
(OCH3), 112.0 (ArCH, phenethyl), 114.3 (ArCH, phenethyl), 121.2 (ArCH, phenethyl), 
129.4 (ArCH, phenethyl), 129.6 (ArCH, aniline), 129.9 (ArCH, aniline), 133.7 (ArCCl), 

















C19H22ClNO2, Mol. Wt.: 331.84 
 
Isobutyryl chloride (108 µL, 1.01 mmol) was added to a stirring solution of 179b 
(150 mg, 0.503 mmol) and pyridine (123 µL, 1.51 mmol) in DCM (2 mL) and the 
mixture was stirred at rt for 10 h. A white precipitate formed after the first ten minutes. 
The mixture was then diluted with DCM (10 mL) washed with a sat. aq. solution of 
NaHCO3 (2 x 10 mL) and 1N HCl (2 x 10 mL) and the organic layer was dried with 
MgSO4, filtered and evaporated to give the product as a pale yellow solid (113 mg, 
68%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 1.01 (6H, d, J = 6.7 Hz, 
(CH3)2CH), 2.38 (1H, septet, J = 6.7 Hz, (CH3)2CH), 2.85 (2H, t, J = 7.8 Hz, 
CH2CH2N), 3.77 (3H, s, OCH3), 3.86 (2H, t, J = 7.8 Hz, CH2CH2N), 6.71 (1H, s, ArCH, 
phenethyl), 6.74 (2H, d, J = 8.0 Hz, 2 x ArCH, phenethyl), 6.95 (2H, d, J = 8.4 Hz, 2 x 
ArCH, aniline), 7.17 (1H, t, J = 7.8 Hz, ArCH, phenethyl) and 7.35 (2H, d, J = 8.6 Hz, 2 
x ArCH, aniline) ppm. 
13
C NMR (126 MHz, CDCl3) δ 19.6 ((CH3)2CH), 31.3 
((CH3)2CH), 34.0 (CH2CH2N), 51.0 (CH2CH2N), 55.2 (CH3O), 112.1 (ArCH, 
phenethyl), 114.3 (ArCH, phenethyl), 121.2 (ArCH, phenethyl), 129.4 (ArCH, 
phenethyl), 129.5 (2 x ArCH, aniline), 129.8 (2 x ArCH, aniline), 133.7 (ArCCl), 140.3 












334.1382, found 334.1394. 
 
N-(4-Chlorophenyl)-N-(3-methoxyphenethyl)pivalamide (180d) 
C20H24ClNO2, Mol. Wt.: 345.86 
 
Pivaloyl chloride (126 µL, 1.01 mmol) was added to a stirring solution of 179b (150 
mg, 0.503 mmol) and pyridine (123 µL, 1.51 mmol) in DCM (2 mL) and the mixture 
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was stirred at rt for 10 h. A white precipitate formed after the first ten minutes. The 
mixture was then diluted with DCM (10 mL) washed with a sat. aq. solution of 
NaHCO3 (2 x 10 mL) and 1N HCl (2 x 10 mL) and the organic layer was dried with 
MgSO4, filtered and evaporated to give the product as a yellow solid (122 mg, 70%) 
which showed: 
1
H NMR (500 MHz, CDCl3) δ 1.03 (9H, s, C(CH3)3), 2.79 – 2.92 (1H, 
m, CH2CH2N), 3.68 – 3.83 (2H, m, CH2CH2N), 3.77 (3H, s, CH3O), 6.69 – 6.72 (1H, m, 
ArCH, phenethyl), 6.74 (1H, dd, J = 2.0, 8.0 Hz, 2 x ArCH, phenethyl), 6.99 (2H, d, J = 
8.6 Hz, ArCH, aniline), 7.17 (1H, t, J = 7.9 Hz, ArCH, aniline) and 7.33 (2H, d, J = 8.6 
Hz, ArCH, aniline) ppm. 
13
C NMR (126 MHz, CDCl3) δ 29.5 (C(CH3)3), 33.7 
(CH2CH2N), 41.0 (C(CH3)3), 55.0 (CH2CH2N), 55.2 (OCH3), 112.0 (ArCH, phenethyl), 
114.4 (ArCH, phenethyl), 121.3 (ArCH, phenethyl), 129.3 (2 x ArCH, aniline), 129.4 
(ArCH, phenethyl), 130.9 (2 x ArCH, aniline), 133.7 (ArCCl), 140.5 (ArCCH2), 142.5 















C22H20ClNO2, Mol. Wt.: 365.85 
 
Benzoyl chloride (118 µL, 1.01 mmol) was added to a stirring solution of 179b (150 
mg, 0.503 mmol) and pyridine (123 µL, 1.51 mmol) in DCM (2 mL) and the mixture 
was stirred at rt for 10 h. A white precipitate was formed after the first ten minutes. The 
mixture was then diluted with DCM (10 mL) washed with a sat. aq. solution of 
NaHCO3 (2 x 10 mL) and 1N HCl (2 x 10 mL) and the organic layer was dried with 
MgSO4, filtered and evaporated to give a yellow oil (263 mg). The crude compound 
was purified by column chromatography (from 0% to 30% EtOAc in pet. ether) to give 
the product as a pale yellow oil (89 mg, 48%) which showed: 
1
H NMR (500 MHz, 
CDCl3) δ 2.98 (2H, t, J = 6.8 Hz, CH2CH2N), 3.77 (3H, s, OCH3), 4.10 (2H, t, J = 6.8 
Hz, CH2CH2N), 6.70 – 6.85 (5H, m), 7.14 (2H, d, J = 8.6 Hz), 7.20 (3H, td, J = 7.0, 
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14.4 Hz) and 7.25 – 7.31 (3H, m) ppm. 13C NMR (126 MHz, CDCl3) δ 33.8 
(CH2CH2N), 52.4 (CH2CH2N), 55.1 (OCH3), 112.1, 114.4, 121.3, 127.9, 128.6, 128.7, 
129.2, 129.5, 129.8, 132.1 (ArCCl), 135.7 (ArCCO), 140.3 (ArCCH2), 142.3 (ArCN), 











+H) 368.1226, found 368.1250. 
 
N-(4-Chlorophenyl)-N-(3-methoxyphenethyl)-2-phenylacetamide (180f) 
C23H22ClNO2, Mol. Wt.: 379.88 
 
Phenacetyl chloride (136 µL, 1.01 mmol) was added to a stirring solution of 179b 
(150 mg, 0.503 mmol) and pyridine (123 µL, 1.51 mmol) in DCM (2 mL) and the 
mixture was stirred at rt for 10 h. A white precipitate was formed after the first ten 
minutes. The mixture was then diluted with DCM (10 mL) washed with a sat. aq. 
solution of NaHCO3 (2 x 10 mL) and 1N HCl (2 x 10 mL) and the organic layer was 
dried with MgSO4, filtered and evaporated to give a yellow oil (140 mg). The crude 
compound was purified by column chromatography (from 0% to 30% EtOAc in pet. 
ether) to give the product as a pale yellow oil (34 mg, 18%) which showed: 
1
H NMR 
(500 MHz, CDCl3) δ 2.84 (2H, t, J = 7.7 Hz, CH2CH2N), 3.41 (2H, s, ArCH2CO), 3.75 
(3H, s, OCH3), 3.90 (2H, t, J = 7.7 Hz, CH2CH2N), 6.65 – 6.80 (3H, m, 3 x ArCH, 
phenethyl), 6.88 (2H, d, J = 8.5 Hz, 2 x ArCH, aniline), 7.02 (2H, d, J = 7.0 Hz, 2 x 
ArCH, phenacetyl), 7.15 (1H, t, J = 7.8 Hz, ArCH, phenethyl), 7.18 – 7.27 (3H, m, 3 x 
ArCH, phenacetyl) and 7.32 (2H, d, J = 8.5 Hz, 2 x ArCH, aniline) ppm. 
13
C NMR (126 
MHz, CDCl3) δ 33.9 (CH2CH2N), 41.3 (ArCH2CO), 51.1 (CH2CH2N), 55.1 (OCH3), 
112.0 (ArCH, phenethyl), 114.2 (ArCH, phenethyl), 121.2 (ArCH, phenethyl), 126.6 
(ArCH, phenacetyl), 128.4 (2 x ArCH, phenacetyl), 128.9 (2 x ArCH, phenacetyl), 
129.4 (ArCH, phenethyl), 129.7 (2 x ArCH, aniline), 129.8 (2 x ArCH, aniline), 133.8 
(ArCCl), 135.0 (ArCCH2CO), 140.0 (ArCCH2CH2), 141.1 (ArCN), 159.7 (ArCO) and 
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+H) 382.1382, found 382.1383. 
 
N-(4-Chlorophenyl)-N-(3-methoxyphenethyl)-3-phenylpropanamide (180g) 
C24H24ClNO2, Mol. Wt.: 393.91 
 
3-Phenylpropanoyl chloride (153 µL, 1.01 mmol) was added to a stirring solution of 
179b (300 mg, 1.01 mmol) and Et3N (353 µL, 2.53 mmol) in DCM (3 mL) and the 
mixture was stirred at rt overnight. The mixture was then diluted with DCM (10 mL) 
and washed with 1 N HCl (3 x 10 mL), 1 N NaOH (3 x 10 mL) and brine (3 x 10 mL) 
then dried with MgSO4, filtered and evaporated to give a yellow oil (364 mg) which 
partly solidify upon standing. The crude compound was purified by column 
chromatography (eluent: from 0% to 30% EtOAc in pet. ether) to give the product as a 
pale yellow solid (301 mg, 76%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 2.31 
(1H, t, J = 6.5 Hz, CH2CH2CO), 2.81 (1H, t, J = 7.8 Hz, CH2CH2N), 2.91 (1H, t, J = 6.5 
Hz, CH2CH2CO), 3.77 (1H, s, ArOCH3), 3.87 (1H, t, J = 7.6 Hz, CH2CH2N), 6.66 – 
6.79 (2H, m), 7.04 – 7.10 (1H, m), 7.14 – 7.21 (1H, m), 7.21 – 7.25 (1H, m) and 7.26 – 
7.33 (1H, m) ppm. 
13
C NMR (126 MHz, CDCl3) δ 31.7 (CH2CH2CO), 34.0 
(CH2CH2N), 36.3 (CH2CH2CO), 51.0 (CH2CH2N), 55.2 (ArOCH3), 112.0 (2 x ArCH), 
114.3 (ArCH), 121.2 (ArCH), 126.1 (ArCH), 128.4 (2 x ArCH), 128.5 (2 x ArCH), 
129.4 (ArCH), 129.6 (ArCH), 129.8 (2 x ArCH), 133.7 (ArCCl), 140.1 
(ArCCH2CH2N), 141.0 (ArCCH2CH2CO), 141.1 (ArCN), 159.7 (ArCO) and 171.8 











+H) 396.1539, found 396.1549. 
 
N-(3-Methoxyphenethyl)-N,2-diphenylacetamide (180h) 




Phenacetyl chloride (154 µL, 1.14 mmol) was added to a stirring solution of 179a 
(300 mg, 1.14 mmol) and Et3N (398 µL, 2.85 mmol) in DCM (3 mL) and the mixture 
was stirred at rt overnight. The mixture was then diluted with DCM (10 mL) and 
washed with 1 N HCl (3 x 10 mL), 1 N NaOH (3 x 10 mL) and brine (3 x 10 mL) then 
dried with MgSO4, filtered and evaporated to give a yellow oil (336 mg) which partly 
solidify upon standing. The crude compound was purified by column chromatography 
(eluent: from 0% to 30% EtOAc in pet. ether) to give the product as a pale yellow-




H NMR (500 MHz, CDCl3) δ 2.87 (2H, t, J 
= 6.7 Hz, CH2CH2N), 3.42 (2H, s, CH2CO), 3.75 (3H, s, ArOCH3), 3.93 (2H, t, J = 6.7 
Hz, CH2CH2N), 6.69 – 6.79 (3H, m, 3 x ArCH), 6.97 – 7.09 (3H, m, 3 x ArCH), 7.11 – 
7.25 (5H, m, 5 x ArCH) and 7.33 – 7.42 (3H, m, 3 x ArCH) ppm. 13C NMR (126 MHz, 
CDCl3) δ 34.0 (CH2CH2N), 41.4 (CH2CO), 51.2 (CH2CH2N), 55.2 (ArOCH3), 112.0 
(ArCH), 114.2 (ArCH), 121.2 (ArCH), 126.5 (ArCH), 128.0 (ArCH), 128.3 (2 x ArCH), 
128.6 (2 x ArCH), 129.1 (2 x ArCH), 129.4 (ArCH), 129.6 (2 x ArCH), 135.4 
(ArCCH2CO), 140.3 (ArCCH2CH2), 142.6 (ArCN), 159.7 (ArCO) and 170.8 (CON) 
ppm. HRMS (ES
+
) calcd. C23H24NO2 (M
+
+H) 346.1835, found 346.1832; C23H23NNaO2 
(M
+
+Na) 368.1621, found 368.1639. 
 
N-(3-Methoxyphenethyl)-N-(4-methoxyphenyl)-2-phenylacetamide (180i) 
C24H25NO3, Mol. Wt.: 375.46 
 
Phenacetyl chloride (138 µL, 1.02 mmol) was added to a stirring solution of 179c 
(300 mg, 1.02 mmol) and Et3N (356 µL, 2.55 mmol) in DCM (3 mL) and the mixture 
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was stirred at rt overnight. The mixture was then diluted with DCM (10 mL) and 
washed with 1 N HCl (3 x 10 mL), 1 N NaOH (3 x 10 mL) and brine (3 x 10 mL) then 
dried with MgSO4, filtered and evaporated to give a yellow oil (379 mg) which partly 
solidify upon standing. The crude compound was purified by column chromatography 
(eluent: from 0% to 30% EtOAc in pet. ether) to give the product as a pale yellow oil 




H NMR (500 MHz, CDCl3) δ 2.85 (2H, t, J = 7.9 Hz, 
CH2CH2N), 3.42 (2H, s, CH2CO), 3.75 (3H, s, ArOCH3, phenethyl), 3.84 (3H, s, 
ArOCH3, aniline), 3.89 (2H, t, J = 7.9 Hz, CH2CH2N), 6.68 - 6.79 (3H, m, 3 x ArCH, 
phenethyl), 6.88 (2H, d, J = 17.4 Hz, 2 x ArCH, aniline), 6.90 (2H, d, J = 17.4 Hz, 2 x 
ArCH, aniline), 7.04 (2H, d, J = 7.2 Hz, 2 x ArCH, phenacetyl), 7.15 (1H, t, J = 7.8 Hz, 
ArCH, phenethyl), 7.21 (1H, t, J = 6.9 Hz, ArCH, phenacetyl) and 7.23 (2H, t, J = 6.9 
Hz, 2 x ArCH, phenacetyl ) ppm. 
13
C NMR (126 MHz, CDCl3) δ 33.9 (CH2CH2N), 41.1 
(CH2CO), 51.1 (CH2CH2N), 55.1 (ArOCH3, phenethyl), 55.5 (ArOCH3, aniline), 112.0 
(ArCH, phenethyl), 114.2 (ArCH, phenethyl), 114.6 (2 x ArCH, aniline), 121.2 (ArCH, 
phenethyl), 126.5 (ArCH, phenacetyl), 128.3 (2 x ArCH, phenacetyl), 129.0 (2 x ArCH, 
phenacetyl), 129.3 (ArCH, phenethyl), 129.5 (2 x ArCH, aniline), 135.3 (ArCN), 135.5 
(ArCCH2CO), 140.3 (ArCCH2CH2), 159.0 (ArCO, aniline), 159.6 (ArCO, phenethyl) 
and 171.2 (CON) ppm. HRMS (ES
+
) calcd. C24H26NO3 (M
+




C22H21ClN2O2, Mol. Wt.: 380.87 
 
A solution of 179b (500 mg, 1.91 mmol) in DCM (3 mL) was added to a stirring 
solution of 2-(pyridin-4-yl)acetic acid hydrochloride (372 mg, 2.10 mmol), EDCI (935 
mg, 4.78 mmol) and Et3N (533 µL, 3.82 mmol) in DCM (6 mL) and the mixture was 
stirred overnight at rt. The mixture was diluted with DCM (20 mL) and washed with 1 
N NaOH (3 x 25 mL) and brine (25 mL) then dried with MgSO4, filtered and 
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evaporated to give a yellow oil (825 mg). The crude compound was purified by column 
chromatography (eluent: from 0% to 10% MeOH in DCM) to give the product as a 
yellow oil (463 mg, 64%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 2.86 (2H, t, J = 
7.5 Hz, CH2CH2N), 3.45 (2H, s, CH2CO), 3.77 (3H, s, OCH3), 3.95 (2H, t, J = 7.5 Hz, 
CH2CH2N), 6.70 (1H, s, ArCH, phenyl), 6.74 (1H, d, J = 7.7 Hz, ArCH, phenyl), 6.77 
(1H, d, J = 7.7 Hz, ArCH, phenyl), 6.92 (2H, d, J = 7.8 Hz, 2 x ArCH, aniline), 7.14 
(2H, d, J = 4.6 Hz, 2 x ArCH, pyridine), 7.18 (1H, t, J = 7.7 Hz, ArCH, phenyl), 7.38 
(2H, d, J = 7.8 Hz, 2 x ArCH, aniline) and 8.52 (2H, d, J = 4.6 Hz, 2 x ArCH, pyridine) 
ppm. 
13
C NMR (126 MHz, CDCl3) δ 33.8 (CH2CH2N), 40.8 (CH2CO), 51.0 
(CH2CH2N), 55.2 (OCH3), 112.0 (ArCH, phenyl), 114.5 (ArCH, phenyl), 121.2 (ArCH, 
phenyl), 125.1 (2 x ArCH, pyridine), 129.5 (ArCH, phenyl), 129.6 (2 x ArCH, aniline), 
130.2 (2 x ArCH, aniline), 134.5 (ArCCl), 139.7 (ArCCH2, phenyl), 140.6 (ArCN), 




C22H21ClN2O2, Mol. Wt.: 380.87 
 
A solution of 179b (500 mg, 1.91 mmol) in DCM (3 mL) was added to a stirring 
solution of 2-(pyridin-3-yl)acetic acid hydrochloride (372 mg, 2.10 mmol), EDCI (935 
mg, 4.78 mmol) and Et3N (533 µL, 3.82 mmol) in DCM (6 mL) and the mixture was 
stirred overnight at rt. The mixture was diluted with DCM (20 mL) and washed with 1 
N NaOH (3 x 25 mL) and brine (25 mL) then dried with MgSO4, filtered and 
evaporated to give a yellow oil (763 mg). The crude compound was purified by column 
chromatography (eluent: from 0% to 10% MeOH in DCM) to give the product as a 
yellow oil (437 mg, 60%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 2.86 (2H, t, J = 
7.7 Hz, CH2CH2N), 3.43 (2H, s, CH2CO), 3.77 (3H, s, OCH3), 3.93 (2H, t, J = 7.7 Hz, 
CH2CH2N), 6.70 (1H, d, J = 2.1 Hz, ArCH, phenyl), 6.73 (1H, d, J = 7.9 Hz, ArCH, 
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phenyl), 6.77 (1H, dd, J = 2.1, 7.9 Hz, ArCH, phenyl), 6.96 (2H, d, J = 8.5 Hz, 2 x 
ArCH, aniline), 7.18 (1H, t, J = 7.9 Hz, ArCH, phenyl), 7.34 (1H, dd, J = 5.0, 7.8 Hz, 
ArCH, pyridine), 7.41 (2H, d, J = 8.5 Hz, 2 x ArCH, aniline), 7.68 (1H, d, J = 7.8 Hz, 
ArCH, pyridine), 8.26 (1H, s, ArCH, pyridine) and 8.52 (1H, d, J = 5.0 Hz, ArCH, 
pyridine) ppm. 
13
C NMR (126 MHz, CDCl3) δ 33.9 (CH2CH2N), 38.3 (CH2CO), 51.2 
(CH2CH2N), 55.2 (OCH3), 112.0 (ArCH, phenyl), 114.4 (ArCH, phenyl), 121.2 (ArCH, 
phenyl), 123.9 (ArCH, pyridine), 129.5 (ArCH, phenyl), 129.7 (2 x ArCH, aniline), 
130.2 (2 x ArCH, aniline), 131.8 (ArCCH2, pyridine), 134.5 (ArCCl), 138.6 (ArCH, 
pyridine), 139.8 (ArCCH2, phenyl), 140.7 (ArCN), 146.5 (ArCH, pyridine), 148.5 
(ArCH, pyridine), 159.8 (ArCO) and 169.1 (CON) ppm. 
 
N-(4-Chlorophenyl)-N-(3-methoxyphenethyl)-2-(pyridin-2-yl)acetamide (180l) 
C22H21ClN2O2, Mol. Wt.: 380.87 
 
A solution of 179b (500 mg, 1.91 mmol) in DCM (3 mL) was added to a stirring 
solution of 2-(pyridin-2-yl)acetic acid hydrochloride (372 mg, 2.10 mmol), EDCI (935 
mg, 4.78 mmol) and Et3N (533 µL, 3.82 mmol) in DCM (6 mL) and the mixture was 
stirred overnight at rt. The mixture was diluted with DCM (20 mL) and washed with 1 
N NaOH (3 x 25 mL) and brine (25 mL) then dried with MgSO4, filtered and 
evaporated to give a yellow oil (869 mg). The crude compound was purified by column 
chromatography (eluent: from 0% to 10% MeOH in DCM) to give the product as a 
yellow oil (485 mg, 67%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 2.81 – 2.97 
(2H, m, CH2CH2N), 3.69 (2H, s, CH2CO), 3.77 (3H, s, OCH3), 3.90 – 4.00 (2H, m, 
CH2CH2N), 6.73 (1H, s, ArCH, phenyl), 6.76 (1H, d, J = 7.9 Hz, ArCH, phenyl), 6.77 
(1H, d, J = 7.9 Hz, ArCH, phenyl), 7.07 (2H, d, J = 8.5 Hz, 2 x ArCH, aniline), 7.18 
(1H, t, J = 7.9 Hz, ArCH, phenyl), 7.20 – 7.26 (2H, m, 2 x ArCH, pyridine), 7.36 (2H, 
d, J = 8.5 Hz, 2 x ArCH, aniline), 7.63 - 7.73 (1H, m, ArCH, pyridine) and 8.51 (1H, d, 
J = 4.5 Hz, ArCH, pyridine) ppm. 
13
C NMR (126 MHz, CDCl3) δ 34.0 (CH2CH2N), 
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43.5 (CH2N), 51.2 (CH2CH2N), 55.2 (OCH3), 112.1 (ArCH, phenyl), 114.3 (ArCH, 
phenyl), 121.2 (ArCH, phenyl), 122.1 (ArCH, pyridine), 124.5 (ArCH, pyridine), 129.5 
(ArCH, phenyl), 129.8 (2 x ArCH, aniline), 129.9 (2 x ArCH, aniline), 134.1 (ArCCl), 
137.3 (ArCH, pyridine), 140.1 (ArCCH2), 140.9 (ArCN), 148.3 (ArCH, pyridine), 155.2 




C24H24ClNO3, Mol. Wt.: 409.91 
 
A solution of 179b (500 mg, 1.91 mmol) in DCM (3 mL) was added to a stirring 
solution of (S)-2-methoxy-2-phenylacetic acid (352 mg, 2.10 mmol), EDCI (935 mg, 
4.78 mmol) and Et3N (533 µL, 3.82 mmol) in DCM (6 mL) and the mixture was stirred 
overnight at rt. The mixture was diluted with DCM (20 mL) and washed with 1 N 
NaOH (3 x 25 mL) and brine (25 mL) then dried with MgSO4, filtered and evaporated 
to give a yellow oil (668 mg). The crude compound was purified by column 
chromatography (eluent: from 0% to 40% EtOAc in pet. ether) to give the product as a 
yellow oil (422 mg, 54%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 2.77 – 2.94 
(2H, m, CH2CH2N), 3.23 (3H, s, CHOCH3), 3.78 (3H, s, ArOCH3), 3.81 – 3.92 (1H, m, 
CH2CH2N), 3.92 – 4.05 (1H, m, CH2CH2N), 4.57 (1H, s, CHOCH3), 6.65 – 6.73 (2H, 
m, 2 x ArCH, methoxyphenyl), 6.73 – 6.85 (2H, m, ArCH, methoxyphenyl, ArCH), 
7.10 (2H, d, J = 6.8 Hz, 2 x ArCH), 7.16 (1H, t, J = 8.1 Hz, ArCH, methoxyphenyl) and 
7.31 (6H, dd, J = 2.2, 6.8 Hz, 6 x ArCH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 33.8 
(CH2CH2N), 51.5 (CH2CH2N), 55.2 (ArOCH3), 56.8 (CHOCH3), 80.9 (CHOCH3), 
112.1 (ArCH, methoxyphenyl), 114.3 (ArCH, methoxyphenyl), 121.3 (ArCH, 
methoxyphenyl), 128.2 (2 x ArCH), 128.4 (2 x ArCH), 128.7 (ArCH), 129.4 (ArCH, 
methoxyphenyl), 129.7 (2 x ArCH), 130.3 (2 x ArCH), 134.2 (ArCCl), 136.1 (ArCCH), 






C25H24ClNO4, Mol. Wt.: 437.92 
 
A solution of 179b (100 mg, 0.335 mmol) in DCM (2 mL) was added to a stirring 
solution of (S)-2-methoxy-2-phenylacetic acid (66 mg, 0.335 mmol), EDCI (131 mg, 
0.670 mmol) and Et3N (106 µL, 0.764 mmol) in DCM (2 mL) and the mixture was 
stirred overnight at rt. The mixture was diluted with DCM (20 mL) and washed with 1 
N NaOH (3 x 25 mL) and brine (25 mL) then dried with MgSO4, filtered and 
evaporated to give a yellow oil (115 mg) which showed:
 1
H NMR (400 MHz, CDCl3) δ 
2.14 (3H, s), 2.72 – 2.90 (2H, m), 3.74 (3H, s), 3.85 (2H, t, J = 7.8 Hz), 5.66 (1H, s), 
6.63 – 6.69 (2H, m), 6.69 – 6.75 (1H, m), 7.04 (2H, d, J = 7.1 Hz), 7.11 (1H, t, J = 8.0 





460.1286, found 460.1311. 
 
2-(4-Chlorophenyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (181a)  
C17H18ClNO, Mol. Wt.: 287.78 
 
(Method K) 
The crude compound was purified by column chromatography (eluent: 100% pet. 
ether) to give white solid (292 mg, 69%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 
1.39 (3H, d, J = 6.6 Hz, CHCH3), 2.77 – 2.93 (1H, m, H4-THIQ), 2.93 – 3.06 (1H, m, 
H4-THIQ), 3.41 – 3.50 (1H, m, H3-THIQ), 3.50 – 3.62 (1H, m, H3-THIQ), 3.79 (3H, s, 
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OCH3), 4.81 (1H, q, J = 6.6 Hz, CHCH3), 6.68 (1H, d, J = 2.6 Hz, H5-THIQ), 6.76 (1H, 
dd, J = 2.6, 8.4 Hz, H7-THIQ), 6.84 (2H, bs, 2 x ArCH, phenyl), 7.04 (1H, d, J = 8.4 
Hz, H8-THIQ) and 7.19 (2H, d, J = 8.9 Hz, 2 x ArCH, phenyl) ppm. 
13
C NMR (126 
MHz, CDCl3) δ 20.8 (C1CH3), 28.6 (C4-THIQ), 41.2 (C3-THIQ), 54.0 (C1-THIQ), 55.3 
(OCH3), 112.4 (C7-THIQ), 113.2 (C5-THIQ), 115.8 (2 x ArCH, phenyl), 122.2 (ArCCl), 
127.7 (C8-THIQ), 129.0 (2 x ArCH, phenyl), 131.9 (C8CC1), 135.4 (C5CC4), 147.9 











+H) 290.1120, found 290.1142. 
Mp 186-189 °C (as a hydrochloride from Et2O). 
 
2-(4-Chlorophenyl)-1-ethyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline (181b) 
C18H20ClNO, Mol. Wt.: 301.81 
 
(Method K) 
The crude compound was purified by column chromatography (eluent: 100 % pet. 
ether) to give the product as a colourless oil (335 mg, 71%) which showed: 
1
H NMR 
(500 MHz, CDCl3) δ 0.99 (3H, t, J = 7.4 Hz, CH3CH2), 1.71 (1H, ddq, J = 7.0, 7.4, 14.2 
Hz, CH3CH2), 1.94 (1H, ddq, J = 7.0, 7.4, 14.2 Hz, CH3CH2), 2.86 (1H, dd, J = 5.7, 
15.8 Hz, H4-THIQ), 2.97 (1H, ddd, J = 5.3, 7.8, 15.8 Hz, H4-THIQ), 3.43 - 3.55 (1H, m, 
H3-THIQ), 3.58 (1H, ddd, J = 5.0, 7.8, 12.6 Hz, H4-THIQ), 3.80 (3H, s, OCH3), 4.45 
(1H, t, J = 7.0 Hz, H1-THIQ), 6.71 (1H, d, J = 2.6 Hz, H5-THIQ), 6.75 (1H, dd, J = 2.6, 
8.4 Hz, H7-THIQ), 6.78 (2H, d, J = 9.1 Hz, 2 x ARCH, phenyl), 7.04 (1H, d, J = 8.4 Hz, 
H8-THIQ) and 7.18 (2H, d, J = 9.1 Hz, 2 x ARCH, phenyl) ppm. 
13
C NMR (126 MHz, 
CDCl3) δ 11.3 (CH3CH2), 27.5 (C4-THIQ), 29.5 (CH3CH2), 42.1 (C3-THIQ), 55.2 
(OCH3), 60.2 (C1-THIQ), 111.7 (C7-THIQ), 113.3 (C5-THIQ), 114.6 (2 x ArCH, 
phenyl), 121.4 (ArCCl), 128.3 (C8-THIQ), 128.9 (2 x ArCH, phenyl), 130.7 (C1CC8-


















C19H22ClNO, Mol. Wt.: 315.84 
 
(Method K) 
The crude compound was purified by column chromatography (eluent: 100% pet. 
ether) to give a colourless oil (267 mg, 56%) which showed: 
1
H NMR (500 MHz, 
CDCl3) δ 0.92 (3H, d, J = 6.6 Hz, (CH3)2CH), 1.03 (3H, d, J = 6.9 Hz, (CH3)2CH)), 2.03 
– 2.13 (1H, m, (CH3)2CH)), 2.92 – 3.01 (2H, m, H4-THIQ), 3.36 – 3.46 (1H, m, H3-
THIQ), 3.68 (1H, dt, J = 6.1, 12.2 Hz, H3-THIQ), 3.79 (3H, s, OCH3), 4.26 (1H, d, J = 
8.1 Hz, H1-THIQ), 6.68 – 6.72 (2H, m, H5,H7-THIQ), 6.76 (2H, d, J = 9.1 Hz, 2 x 
ArCH, phenyl), 7.02 (1H, d, J = 7.9 Hz, H8-THIQ) and 7.14 (2H, d, J = 9.1 Hz, 2 x 
ArCH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 20.0 ((CH3)2CH), 20.5 
((CH3)2CH), 27.5 (C4-THIQ), 34.4 ((CH3)2CH), 42.9 (C3-THIQ), 55.2 (OCH3), 64.2 
(C1-THIQ), 111.0 (C7-THIQ), 113.4 (C5-THIQ), 114.3 (2 x ArCH, phenyl), 121.1 
(ArCCl), 128.8 (2 x ArCH, phenyl), 129.2 (C8-THIQ), 129.6 (C1CC8-THIQ), 136.3 












318.1433, found 318.1448. 
 
2-(4-Chlorophenyl)-6-methoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline (181e)  





The crude compound was purified by column chromatography (eluent: 100% pet. 
ether) to give a colourless oil (342 mg, 68%) which showed: 
1
H NMR (400 MHz, 
CDCl3) δ 2.80 – 2.97 (2H, m, H4-THIQ), 3.45 (1H, ddd, J = 5.7, 8.0, 11.4 Hz, H3-
THIQ), 3.66 (1H, dt, J = 5.5, 11.2 Hz, H3-THIQ), 3.79 (3H, s, OCH3), 5.71 (1H, s, H1-
THIQ), 6.71 (1H, d, J = 2.6 Hz, H5-THIQ), 6.74 (2H, d, J = 9.1 Hz, 2 x ArCH, N-
phenyl), 6.77 (2H, dd, J = 2.5, 8.3 Hz, H7-THIQ), 7.14 (2H, d, J = 9.1 Hz, 2 x ArCH, N-
phenyl) and 7.16 – 7.25 (6H, m, H8-THIQ, 5 x ArCH, C1-phenyl) ppm. 
13
C NMR (101 
MHz, CDCl3) δ 28.2 (C4-THIQ), 43.8 (C3-THIQ), 55.2 (OCH3), 62.3 (C1-THIQ), 111.9 
(C7-THIQ), 113.2 (C5-THIQ), 115.1 (2 x ArCH, N-phenyl), 122.2 (ArCCl), 126.8 
(ArCH), 127.1 (2 x ArCH, C1-phenyl), 128.2 (2 x ArCH, C1-phenyl), 128.7 (ArCH), 
128.9 (2 x ArCH, N-phenyl), 129.9 (C1CC8-THIQ), 136.7 (C4CC5-THIQ), 143.0 
(ArCC1, C1-phenyl), 148.1 (ArCN) and 158.6 (C6-THIQ) ppm. Mp 188-191 °C (pet. 
ether) 
 
1-Benzyl-2-(4-chlorophenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline (181f)  
C23H22ClNO, Mol. Wt.: 363.88 
 
(Method K) 
The crude compound was purified by column chromatography (eluent: 100% pet. 
ether) to give a yellow oil (437 mg, 78%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 
2.92 – 3.05 (1H, m), 3.05 – 3.19 (1H, m), 3.29 – 3.43 (1H, m), 3.67 – 3.78 (1H, m), 3.80 
(3H, s), 3.83 – 3.92 (1H, m), 3.92 – 4.03 (1H, m), 4.86 – 4.96 (1H, m), 6.57 (1H, d, J = 
7.8 Hz), 6.66 (1H, dd, J = 2.6, 8.6 Hz), 6.74 (1H, d, J = 2.5 Hz), 7.03 – 7.12 (2H, m), 
7.19 – 7.25 (3H, m), 7.32 – 7.40 (2H, m) and 7.61 (2H, d, J = 8.4 Hz) ppm. 13C NMR 
(126 MHz, CDCl3) δ 25.2, 40.1, 51.4, 55.3, 66.2, 107.0, 113.2, 113.5, 123.5, 123.9, 
127.1, 128.4, 128.7, 129.6, 130.1, 134.8, 136.0, 140.4, 142.2 and 159.5 ppm. Mp 149-






C24H24ClNO, Mol. Wt.: 377.91 
 
(Method K) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give a yellow oil (194 mg, 67%) which showed: 
1
H NMR 
(500 MHz, CDCl3) δ 1.94 - 2.05 (1H, m, CHH2CH2), 2.17 - 2.34 (1H, m, CHCH2CH2), 
2.66 - 2.79 (2H, m, CHCH2CH2), 2.80 - 2.90 (1H, m, H4-THIQ), 2.90 - 3.03 (1H, m H4-
THIQ), 3.52 -3.68 (2H, m H3-THIQ), 3.79 (3H, s, OCH3), 4.55 (1H, t, J = 6.9 Hz, H1-
THIQ), 6.68 (1H, d, J = 2.4 Hz, H5-THIQ), 6.71 - 6.83 (3H, m, H7-THIQ, 2 x ArCH, N-
phenyl), 7.05 (1H, d, J = 8.4 Hz, H8-THIQ), 7.10 - 7.22 (5H, m, 3 x ArCH, phenethyl, 2 
x ArCH, N-phenyl) and 7.25 - 7.31 (2H, m, 2 x ArCH, phenethyl) ppm. 
13
C NMR (126 
MHz, CDCl3) δ 26.9 (C4-THIQ), 32.7 (CHCH2CH2), 38.0 (CHCH2CH2), 43.2 (C3-
THIQ), 55.3 (OCH3), 59.0 (C1-THIQ), 112.1, 113.5 (C5-THIQ), 121.0, 125.9, 128.2 
(C8-THIQ), 128.4 (2 x ArCH), 128.5 (2 x ArCH), 129.0, 135.9 (C1CC8-THIQ), 141.6 







+H) 380.1590, found 380.1615. 
 
1-Benzyl-6-methoxy-2-phenyl-1,2,3,4-tetrahydroisoquinoline (181h) 





The crude compound was purified by column chromatography (eluent: from 0% to 





NMR (500 MHz, CDCl3) δ 2.64 – 2.83 (1H, m, 1 x H4-THIQ), 2.87 – 3.06 (2H, m, 1 x 
H4-THIQ, 1 x CHCH2), 3.11 – 3.34 (1H, m, 1 x CHCH2), 3.44 – 3.58 (1H, m, H3-
THIQ), 3.58 – 3.70 (1H, m, H3-THIQ), 3.78 (3H, s, OCH3), 4.86 (1H, t, J = 6.5 Hz, H1-
THIQ), 6.60 (1H, dd, J = 2.4, 8.4 Hz, H7-THIQ), 6.63 (1H, d, J = 8.4 Hz, H8-THIQ), 
6.67 (1H, d, J = 1.8 Hz, H5-THIQ), 6.70 – 6.79 (1H, m), 6.79 - 6.94 (2H, m), 7.02 (2H, 
d, J = 6.5 Hz) and 7.15 – 7.25 (5H, m) ppm. 13C NMR (126 MHz, CDCl3) δ 27.8 (C4-
THIQ), 42.1 (C3-THIQ), 42.4 (CHCH2), 55.2 (OCH3), 61.0 (C1-THIQ), 111.5 (C7-
THIQ), 113.0 (C5-THIQ), 113.7 (2 x ArCH), 117.3 (ArCH), 126.2 (ArCH), 128.1 (2 x 
ArCH), 128.6 (C8-THIQ), 129.2 (2 x ArCH), 129.6 (C1CC8-THIQ), 129.8 (2 x ArCH), 
136.2 (C4CC5-THIQ), 138.7 (ArCCH2CH), 149.1 (ArCN) and 158.1 (C6-THIQ) ppm. 
 
1-Benzyl-6-methoxy-2-(4-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (181i) 
C24H25NO2, Mol. Wt.: 359.46 
 
(Method K) 
The crude compound was purified by column chromatography (eluent: from 0% to 





NMR (500 MHz, CDCl3) δ 2.62 – 2.79 (1H, m, 1 x H4-THIQ), 2.86 – 3.05 (2H, m, 1 x 
H4-THIQ, 1 x CHCH2), 3.20 (1H, dd, J = 5.4, 13.5 Hz, 1 x CHCH2), 3.43 - 3.55 (1H, m, 
H3-THIQ), 3.60 (1H, ddd, J = 4.5, 9.0, 13.5 Hz, H3-THIQ), 3.77 (3H, s, OCH3), 3.79 
(3H, s, OCH3), 4.76 (1H, t, J = 6.5 Hz, H1-THIQ), 6.59 – 6.66 (2H, m, H7-THIQ, H8-
THIQ), 6.67 (1H, d, J = 1.7 Hz, H5-THIQ), 6.78 – 6.92 (4H, m), 7.04 (2H, d, J = 6.8 
Hz) and 7.15 – 7.29 (3H, m) ppm. 13C NMR (126 MHz, CDCl3) δ 27.5 (C4-THIQ), 42.0 
(CHCH2), 42.4 (C3-THIQ), 55.1 (OCH3), 55.6 (OCH3), 61.8 (C1-THIQ), 111.5 (C7-
THIQ), 113.1 (C5-THIQ), 114.6 (2 x ArCH), 116.8 (2 x ArCH), 126.0 (ArCH), 128.0 (2 
x ArCH), 128.6 (C8-THIQ), 129.7 (2 x ArCH), 130.0 (C1CC8-THIQ), 136.0 (C4CC5-
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C16H16ClNO, Mol. Wt.: 273.76 
 
(Method J) 
The crude compound was purified by column chromatography (eluent: from 0% to 
10% EtOAc in pet. ether) to give a pale yellow oil (46 mg, 4%) which showed: 
1
H 
NMR (400 MHz, CDCl3) δ 3.01 (2H, t, J = 5.7 Hz), 3.36 (2H, t, J = 5.7 Hz), 3.82 (3H, 
s), 4.21 (2H, s), 6.70 (1H, d, J = 8.1 Hz), 6.78 (1H, d, J = 7.6 Hz), 6.94 – 7.00 (1H, m), 





tr = 4.13 min (82 %), m/z 274.1 (M
+
+H); (RP, Isocratic, 90% MeOH)
 
 
 2-(3,4-Dichlorophenyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline (185aa) 
C16H15Cl2NO, Mol. Wt.: 308.20 
 
(Method J) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give pale yellow oil (36 mg, 4%) which showed: 
1
H NMR 
(500 MHz, CDCl3) δ 2.95 (2H, t, J = 5.8 Hz, H4-THIQ), 3.50 (2H, t, J = 5.8 Hz, H3-
THIQ), 3.87 (3H, s, OCH3), 4.28 (2H, s, H1-THIQ), 6.73 (1H, d, J = 8.1 Hz, H7-THIQ), 
6.78 (1H, d, J = 7.6 Hz, H5-THIQ), 6.82 (1H, dd, J = 2.9, 9.0 Hz, ArCH, phenyl), 7.04 
(1H, d, J = 2.9 Hz, ArCH, phenyl), 7.17 (1H, t, J = 7.9 Hz, H6-THIQ) and 7.28 (1H, d, J 
= 9.0 Hz, ArCH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 29.1, 45.6, 45.7, 55.4, 
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tr = 6.12 min (12 %), m/z 308.1 (M
+




C18H20ClNO, Mol. Wt.: 301.81 
 
(Method K) 
The crude compound was purified by column chromatography (eluent: 100% pet. 
ether) to give a colourless oil (24 mg, 5%) which showed: 
1
H NMR (400 MHz, CDCl3) 
δ 0.97 (3H, t, J = 7.4 Hz, CH3CH2), 1.74 – 1.91 (2H, m, CH3CH2), 2.78 (1H, dt, J = 5.1, 
16.2 Hz, H4-THIQ), 2.97 (1H, ddd, J = 5.9, 8.8, 15.0 Hz, H4-THIQ), 3.49 – 3.68 (2H, 
m, H3-THIQ), 3.83 (3H, s, OCH3), 4.87 (1H, dd, J = 5.7, 8.0 Hz, H1-THIQ), 6.71 (1H, 
d, J = 7.9 Hz, H5 or H7-THIQ), 6.72 (1H, d, J = 7.9 Hz, H5 or H7-THIQ), 6.80 (2H, d, J 
= 9.1 Hz, 2 x ArCH, phenyl), 7.11 (1H, t, J = 7.9 Hz, H6-THIQ) and 7.13 (2H, d, J = 9.2 
Hz, 2 x ArCH, phenyl) ppm. 
13
C NMR (101 MHz, CDCl3) δ 11.3 (CH3CH2), 26.3 (C4-
THIQ), 27.6 (CH3CH2), 41.1 (C3-THIQ), 54.6 (C1-THIQ), 55.2 (OCH3), 107.8 (C5 or 
C7-THIQ), 115.0 (2 x ArCH, phenyl), 120.8 (C5 or C7-THIQ), 121.3 (ArCCl), 126.9 
(C6-THIQ), 127.7 (C1CC8-THIQ), 128.8 (2 x ArCH, phenyl), 135.9 (C4CC5-THIQ), 









The crude compound was purified by column chromatography (eluent: 100% pet. 
ether) to give a white solid (57 mg, 12%) which showed: 
1
H NMR (400 MHz, CDCl3) δ 
0.86 (3H, d, J = 6.7 Hz, (CH3)2CH), 1.02 (3H, d, J = 6.8 Hz, (CH3)2CH), 2.08 (1H, ddt, 
J = 6.8, 9.4, 13.6 Hz, (CH3)2CH), 2.92 (1H, ddd, J = 4.5, 6.3, 15.8 Hz, H4-THIQ), 3.02 
– 3.18 (1H, m, H4-THIQ), 3.31 (1H, ddd, J = 6.3, 9.3, 11.4 Hz, H3-THIQ), 3.68 (1H, 
ddd, J = 4.5, 6.8, 11.4 Hz, H4-THIQ), 3.81 (3H, s, OCH3), 4.95 (1H, d, J = 9.3 Hz, H1-
THIQ), 6.72 (1H, d, J = 7.4 Hz, H5 or H7-THIQ), 6.75 (1H, d, J = 7.4 Hz, H5 or 
H7-THIQ), 6.76 (2H, d, J = 9.2 Hz, 2 x ArCH, phenyl), 7.12 (2H, d, J = 9.2 Hz, 2 x 
ArCH, phenyl) and 7.13 (1H, t, J = 7.4 Hz, H6-THIQ) ppm. 
13
C NMR (101 MHz, 
CDCl3) δ 19.8 ((CH3)2CH), 20.9 ((CH3)2CH), 27.2 (C4-THIQ), 34.9 ((CH3)2CH), 43.3 
(C3-THIQ), 55.1 (OCH3), 56.5 (C1-THIQ), 108.0 (C5 or C7-THIQ), 113.8 (2 x ArCH, 
phenyl), 120.3 (C5 or C7-THIQ), 120.5 (ArCCl), 127.2 (C6-THIQ), 127.6 (C1CC8-
THIQ), 128.6 (2 x ArCH, phenyl), 136.3 (C4CC5-THIQ), 148.8 (ArCN) and 155.6 (C8-
THIQ) ppm. HRMS (ES
+
) calcd. C19H23ClNO (M
+
+H) 316.1463, found 316.1475. 
 
1-Benzyl-2-(4-chlorophenyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline (190f) 
C23H22ClNO, Mol. Wt.: 363.88 
 
(Method K) 
The crude compound was purified by column chromatography (eluent: 100% pet. 
ether) to give a colourless oil (62 mg, 11%) which showed: 
1
H NMR (400 MHz, CDCl3) 
δ 2.55 (1H, dt, J = 5.1, 16.2 Hz), 2.87 – 2.99 (1H, m), 3.04 (1H, dd, J = 7.8, 13.5 Hz), 
3.15 (1H, dd, J = 4.5, 13.5 Hz), 3.51 – 3.60 (1H, m), 3.66 – 3.74 (1H, m), 3.78 (3H, s), 
5.15 (1H, dd, J = 4.5, 7.7 Hz), 6.60 (2H, d, J = 9.1 Hz), 6.66 – 6.75 (2H, m), 7.04 (2H, 
d, J = 9.1 Hz) and 7.09 – 7.24 (6H, m) ppm. 
 
1-Benzyl-8-methoxy-2-phenyl-1,2,3,4-tetrahydroisoquinoline (190h) 





The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give a white solid (16 mg, 6%) which showed: 
1
H NMR 
(500 MHz, CDCl3) δ 2.46 - 2.73 (1H, m, H4-THIQ), 2.89 - 3.03 (1H, m, H4-THIQ), 3.03 
- 3.24 (2H, m, CHCH2), 3.53 - 3.64 (1H, m, H3-THIQ), 3.67 - 3.82 (4H, m, OCH3, H3-
THIQ), 5.23 (1H, t, J = 6.1 Hz, H1-THIQ), 6.69 (2H, d, J = 8.1 Hz), 6.72 (1H, d, J = 7.6 
Hz), 6.74 – 6.85 (2H, m), 7.09 - 7.17 (6H, m) and 7.17 - 7.23 (2H, m) ppm. 13C NMR 
(126 MHz, CDCl3) δ 26.3 (C4-THIQ), 40.2 (CHCH2), 41.1 (C3-THIQ), 55.1 (OCH3), 
56.5 (C1-THIQ), 107.7 (ArCH), 114.1 (2 x ArCH), 120.7 (2 x ArCH), 125.9 (ArCH), 
126.8 (Cq), 127.9 (2 x ArCH), 129.0 (ArCH), 129.5 (2 x ArCH), 129.7 (ArCH), 130.9 
(ArCH), 136.1 (C4CC5-THIQ), 139.8 (Cq), 149.4 (Cq) and 155.6 (C8-THIQ) ppm. 
HRMS (ES
+
) calcd. C23H24NO (M
+




C24H25NO2, Mol. Wt.: 359.46 
 
(Method K) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give a yellow oil (25 mg, 8%) which showed: 
1
H NMR 
(500 MHz, CDCl3) δ 2.41 – 2.65 (1H, m, H4-THIQ), 2.84 – 2.99 (1H, m, H4-THIQ), 
2.99 – 3.23 (2H, m, CHCH2), 3.44 – 3.63 (1H, m, H3-THIQ), 3.70 (3H, s, OCH3), 3.71 
– 3.75 (1H, m, H3-THIQ), 3.78 (3H, s, J = 30.7 Hz, OCH3), 5.05 (1H, bs, H1-THIQ), 
6.61 – 6.77 (6H, m), 7.09 – 7.18 (4H, m) and 7.18 – 7.25 (2H, m) ppm. 13C NMR (126 
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MHz, CDCl3) δ 25.8 (C4-THIQ), 40.2 (CHCH2), 41.6 (C3-THIQ), 55.1 (OCH3), 55.7 
(OCH3), 57.1 (H1-THIQ), 107.5 (ArCH), 114.4 (2 x ArCH), 116.5 (ArCH), 120.9 (2 x 
ArCH), 125.8 (ArCH), 127.0 (ArCH), 127.9 (2 x ArCH), 129.6 (2 x ArCH), 136.2 (Cq), 
140.5 (Cq), 144.5 (Cq), 146.9 (ArCN), 151.9 (ArCO) and 155.7 (ArCO) ppm. HRMS 
(ES
+
) calcd. C24H26NO2 (M
+





C16H17BrClNO, Mol. Wt.: 354.67 
 
(Method G) 
The product was obtained as a white solid (130 mg, 41%) which showed: 
1
H NMR 
(500 MHz, CDCl3) δ 1.37 (3H, d, J = 6.7 Hz, CH3), 2.81 (1H, dt, J = 4.6, 16.0 Hz, H4-
THIQ), 2.88 – 3.05 (1H, m, H4-THIQ), 3.35 – 3.49 (1H, m, H3-THIQ), 3.54 (1H, dt, J = 
5.2, 12.2 Hz, H3-THIQ), 4.79 (1H, q, J = 6.7 Hz, H1THIQ), 6.63 (1H, d, J = 2.5 Hz, H5-
THIQ), 6.68 (1H, dd, J = 2.6, 8.3 Hz, H7-THIQ), 6.81 (2H, d, J = 9.1 Hz, 2 x ArCH, 
phenyl), 6.99 (1H, d, J = 8.3 Hz, H8-THIQ) and 7.19 (2H, d, J = 9.1 Hz, 2 x ArCH, 
phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 20.8 (CH3), 28.4 (C4-THIQ), 41.0 (C3-
THIQ), 54.0 (C1-THIQ), 113.5 (C7-THIQ), 114.8 (C5-THIQ), 115.8 (2 x ArCH, 
phenyl), 122.3 (ArCCl), 128.0 (C8-THIQ), 129.0 (2 x ArCH, phenyl), 132.0 (C1CC8-












276.0964, found 276.0981. Mp 210-213 °C.  
 
2-(4-Chlorophenyl)-1-ethyl-1,2,3,4-tetrahydroisoquinolin-6-ol hydrobromide  
(191b) 





The product was obtained as a white solid (57 mg, 61%) which showed: 
1
H NMR 
(500 MHz, D6-DMSO) δ 0.88 (3H, t, J = 7.3 Hz, CH3), 1.52 – 1.68 (1H, m, CH3CH2), 
1.72 – 1.87 (1H, m, CH3CH2), 2.73 (1H, dt, J = 5.5, 16.0 Hz, H4-THIQ), 2.83 (1H, dt, J 
= 6.5, 13.3 Hz, H4-THIQ), 3.43 – 3.50 (2H, m, H3-THIQ), 4.49 (1H, t, J = 7.0 Hz, H1-
THIQ), 6.48 – 6.63 (2H, m, H5, H7-THIQ), 6.84 (2H, d, J = 8.8 Hz, 2 x ArCH, phenyl), 
6.96 (1H, d, J = 8.0 Hz, H8-THIQ), 7.17 (2H, d, J = 8.8 Hz, 2 x ArCH, phenyl) and 9.33 
(1H, bs, OH) ppm. 
13
C NMR (126 MHz, D6-DMSO) δ 11.1 (CH3), 26.4 (C4-THIQ), 
28.9 (CH3CH2), 41.0 (C3-THIQ), 58.9 (C1-THIQ), 112.9 (C5 or C7-THIQ), 114.4 (2 x 
ArCH, phenyl), 114.6 (C5 or C7-THIQ), 119.5 (ArCCl), 128.3 (C8-THIQ), 128.6 
(C1CC8-THIQ), 128.7 (2 x ArCH, phenyl), 135.6 (C4CC5-THIQ), 148.1 (ArCN) and 






+H) 290.1120, found 




C18H21BrClNO, Mol. Wt.: 382.72 
 
(Method G) 
The product was obtained as a pale grey solid (37 mg, 58%) which showed: 
1
H NMR 
(500 MHz, D6-DMSO) δ 0.86 (3H, d, J = 6.3 Hz, (CH3)2CH), 0.93 (3H, d, J = 6.9 Hz, 
(CH3)2CH), 1.98 (1H, td, J = 6.8, 13.8 Hz, (CH3)2CH), 2.76 – 2.94 (2H, m, H4-THIQ), 
3.37 – 3.40 (1H, m, H3-THIQ), 3.58 (1H, dt, J = 6.1, 12.4 Hz, H3-THIQ), 4.31 (1H, d, J 
= 8.6 Hz, H1-THIQ), 6.54 (1H, d, J = 8.2 Hz, H7-THIQ), 6.56 (1H, s, H5-THIQ), 6.86 
(2H, d, J = 8.6 Hz, 2 x ArCH, phenyl), 6.95 (1H, d, J = 8.2 Hz, H8-THIQ), 7.14 (2H, d, 
J = 8.0 Hz, 2 x ArCH, phenyl) and 9.30 (1H, bs, OH) ppm. 
13
C NMR (126 MHz, D6-
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DMSO) δ 19.9 ((CH3)2CH), 20.3 ((CH3)2CH), 26.4 (C4-THIQ), 33.6 ((CH3)2CH), 41.9 
(C3-THIQ), 62.9 (C1-THIQ), 112.2 (C7-THIQ), 114.2 (2 x ArCH, phenyl), 114.7 (C5-
THIQ), 119.2 (ArCCl), 127.7 (C1CC8-THIQ), 128.5 (2 x ArCH, phenyl), 129.1 















C21H19BrClNO, Mol. Wt.: 416.74 
 
(Method G) 
The product was obtained as a white solid (247 mg, 79%) which showed: 
1
H NMR 
(500 MHz, CDCl3) δ 2.80 – 2.94 (2H, m, H4-THIQ), 3.44 (1H, ddd, J = 5.7, 8.1, 11.4 
Hz, H3-THIQ), 3.65 (1H, dt, J = 5.5, 11.2 Hz, H3-THIQ), 4.69 (1H, bs, OH), 5.70 (1H, 
s, H1-THIQ), 6.65 (1H, d, J = 2.5 H, H5-THIQ), 6.70 (1H, dd, J = 2.5, 8.2 Hz, H7-
THIQ), 6.74 (2H, d, J = 9.0 Hz, 2 x ArCH, N-phenyl), 7.14 (1H, d, J = 8.2 Hz, H8-
THIQ), 7.15 (2H, d, J = 9.0 Hz, 2 x ArCH, N-phenyl), 7.19 (2H, d, J = 6.9 Hz, 2 x 
ArCH, C1-phenyl) and 7.22 – 7.27 (3H, m, 3 x ArCH, C1-phenyl) ppm. 
13
C NMR (126 
MHz, CDCl3) δ 28.0 (C4-THIQ), 43.8 (C3-THIQ), 62.3 (C1-THIQ), 113.3 (C7-THIQ), 
114.7 (C5-THIQ), 115.1 (2 x ArCH, N-phenyl), 122.3 (ArCCl), 126.9 (ArCH, C1-
phenyl), 127.2 (2 x ArCH, C1-phenyl), 128.3 (2 x ArCH, C1-phenyl), 128.9 (2 x ArCH, 
N-phenyl), 129.0 (C8-THIQ), 130.1 (C1CC8-THIQ), 137.1 (C4CC5-THIQ), 142.9 


















C22H21BrClNO, Mol. Wt.: 430.77 
 
(Method G) 





NMR (400 MHz, CDCl3) δ 2.64 (1H, dt, J = 5.7, 15.9 Hz), 2.80 – 2.91 (1H, m), 2.94 
(1H, dd, J = 7.1, 13.3 Hz), 3.15 (1H, dd, J = 6.0, 13.3 Hz), 3.38 – 3.49 (1H, m), 
3.50 - 3.61 (1H, m), 4.75 (1H, t, J = 6.5 Hz), 6.53 – 6.62 (2H, m), 6.64 (1H, d, J = 2.1 
Hz), 6.69 (2H, d, J = 9.1 Hz), 6.99 (2H, dd, J = 1.8, 7.5 Hz), 7.13 (2H, d, J = 9.1 Hz) 














C23H23BrClNO, Mol. Wt.: 444.79 
 
(Method G) 
The product was obtained as a white precipitate (98 mg, 61%) which showed: 
1
H 
NMR (500 MHz, D6-DMSO) δ 1.85 – 2.01 (1H, m, ArCH2CH2CH), 2.01 – 2.13 (1H, m, 
ArCH2CH2CH), 2.58 – 2.70 (2H, m, ArCH2CH2CH), 2.74 (1H, dt, J = 6.1, 14.0 Hz, H4-
THIQ), 2.85 (1H, dt, J = 6.1, 14.0 Hz, H4-THIQ), 3.53 (2H, t, J = 6.1 Hz, H3-THIQ), 
4.62 (1H, t, J = 7.0 Hz, H1-THIQ), 6.56 (1H, d, J = 2.3 Hz, H5-THIQ), 6.59 (1H, dd, J = 
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2.3, 8.3 Hz, H5-THIQ), 6.82 (2H, d, J = 9.1 Hz, 2 x ArCH, N-phenyl), 7.02 (1H, d, J = 
8.3 Hz, H8-THIQ), 7.12 – 7.18 (3H, m, 2 x ArCH, N-phenyl, ArCH, phenyl), 7.19 (2H, 
d, J = 7.4 Hz, 2 x ArCH, phenyl), 7.27 (2H, t, J = 7.5 Hz, 2 x ArCH, phenyl) and 9.27 
(1H, bs, OH) ppm. 
13
C NMR (126 MHz, D6-DMSO) δ 26.1 (C4-THIQ), 32.2 
(ArCH2CH2CH), 37.9 (ArCH2CH2CH), 40.8 (C3-THIQ), 57.1 (C1-THIQ), 113.0 (C7-
THIQ), 114.6 (C5-THIQ), 114.7 (2 x ArCH, N-phenyl), 119.8 (ArCCl), 125.7 (ArCH, 
phenyl), 128.1 (C8-THIQ), 128.2 (2 x ArCH, phenyl), 128.3 (2 x ArCH, phenyl), 128.6 
(C1CC8-THIQ), 128.7 (2 x ArCH, N-phenyl), 135.7 (C4CC5-THIQ), 141.7 (ArCCH2, 











+H) 366.1433, found 
366.1465. Mp 190-192 °C. 
 
1-Benzyl-2-phenyl-1,2,3,4-tetrahydroisoquinolin-6-ol hydrobromide (191h) 
C22H22BrNO, Mol. Wt.: 396.32 
 
(Method G) 





H NMR (500 MHz, D6-DMSO) δ 2.62 (1H, dt, J = 4.7, 16.2 Hz, H4-THIQ), 
2.78 – 2.90 (1H, m, H4-THIQ), 2.95 (1H, dd, J = 6.8, 13.4 Hz, CH2CH), 3.11 (1H, dd, J 
= 6.8, 13.4 Hz, CH2CH), 3.49 – 3.64 (2H, m, H3-THIQ), 4.87 (1H, t, J = 6.8 Hz, H1-
THIQ), 6.48 (1H, dd, J = 2.2, 8.2 Hz, H7-THIQ), 6.53 (1H, d, J = 2.2 Hz, H5-THIQ), 
6.59 (1H, t, J = 7.2 Hz, ArCH), 6.72 – 6.81 (3H, m, 2 x ArCH, H8-THIQ), 7.11 (2H, t, J 
= 7.9 Hz, 2 x ArCH), 7.13 – 7.19 (3H, m, 3 x ArCH), 7.23 (2H, t, J = 7.3 Hz, 2 x ArCH) 
and 9.21 (1H, bs, OH) ppm. 
13
C NMR (126 MHz, D6-DMSO) δ 26.1 (C4-THIQ), 40.3 
(C3-THIQ), 41.7 (CH2CH), 59.8 (C1-THIQ), 112.7 (C7-THIQ), 113.3 (2 x ArCH), 114.5 
(C5-THIQ), 116.5 (ArCH), 125.9 (ArCH), 127.9 (2 x ArCH), 128.1 (C1CC8-THIQ), 
128.3 (C8-THIQ), 129.0 (2 x ArCH), 129.5 (2 x ArCH), 135.8 (C4CC5-THIQ), 139.1 




1-benzyl-2-(4-hydroxyphenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol hydrobromide  
(191i) 
C22H22BrNO2, Mol. Wt.: 412.32 
 
(Method G) 





H NMR (500 MHz, D6-DMSO) δ 2.51 – 2.57 (1H, m, H4-THIQ), 2.79 (1H, 
ddd, J = 6.0, 10.0, 16.0 Hz, H4-THIQ), 2.86 (1H, dd, J = 6.1, 13.5 Hz, CH2CH), 3.04 
(1H, dd, J = 7.6, 13.5 Hz, CH2CH), 3.39 – 3.47 (1H, m, H3-THIQ), 3.47 – 3.56 (1H, m, 
H3-THIQ), 4.66 (1H, t, J = 6.7 Hz, H1-THIQ), 6.47 (1H, dd, J = 2.2, 8.3 Hz, H7-THIQ), 
6.49 (1H, d, J = 2.2 Hz, H5-THIQ), 6.57 (2H, d, J = 8.9 Hz, 2 x ArCH, N-phenyl), 6.64 
(2H, d, J = 8.9 Hz, 2 x ArCH, N-phenyl), 6.71 (1H, d, J = 8.3 Hz, H8-THIQ), 7.12 (2H, 
d, J = 7.3 Hz, 2 x ArCH, phenyl), 7.15 (1H, t, J = 7.3 Hz, 2 x ArCH, phenyl), 7.22 (2H, 
t, J = 7.3 Hz, ArCH, phenyl), 8.66 (1H, bs, OH) and 9.16 (1H, bs, OH) ppm. 
13
C NMR 
(126 MHz, D6-DMSO) δ 25.9 (C4-THIQ), 41.1 (C3-THIQ), 41.5 (CH2CH), 60.7 (C1-
THIQ), 112.7 (C7-THIQ), 114.6 (C5-THIQ), 115.5 (2 x ArCH, N-phenyl), 116.7 (2 x 
ArCH, N-phenyl), 125.8 (ArCH, phenyl), 127.8 (2 x ArCH, phenyl), 128.3 (C8-THIQ), 
128.4 (C1CC8-THIQ), 129.4 (2 x ArCH, phenyl), 135.6 (C4CC5-THIQ), 139.6 















POCl3 (304 µL, 3.22 mmol) was added to a stirring suspension of 178h (100 mg, 
0.322 mmol) in toluene (6 mL) and stirred at 100 °C overnight. The solvent and the 
excess of POCl3 were evaporated under reduced pressure and the residue was dissolved 
in toluene (6 mL) and treated with a 3.0 M solution of MeMgBr (161 µL, 0.483 mmol) 
in THF. The mixture was stirred at rt overnight and then refluxed for one further day. 
The mixture was then cooled to rt, quenched with water and extracted with EtOAc (3 x 
15 mL). The combined organics were dried with MgSO4, filtered and evaporated to give 
a yellow oil (186 mg). The crude compound was purified by column chromatography 
(eluent: from 0% to 20% EtOAc in pet. ether) to give the product as a yellow oil (21 
mg, 20%) which showed: 
1
H NMR (400 MHz, CDCl3) δ 1.58 (3H, d, J = 7.2 Hz), 3.67 
(1H, q, J = 7.2 Hz), 3.81 (3H, s), 6.83 – 6.88 (2H, m), 6.88 – 6.95 (1H, m), 7.03 (1H, 
bs), 7.22 (1H, dd, J = 2.5, 8.7 Hz), 7.30 (1H, d, J = 8.7 Hz), 7.31 (1H, dt, J = 1.6, 7.5 
Hz) and 7.65 (1H, d, J = 2.4 Hz) ppm. HRMS (ES+) calcd. C16H1535Cl2NNaO2 (M++Na) 
346.0372, found 346.0360. 
 
N-(3,4-Dichlorophenyl)-2-hydroxy-2-(3-methoxyphenyl)acetamide (197) 
C15H13Cl2NO3, Mol. Wt.: 326.17 
 
POCl3 (304 µL, 3.22 mmol) was added to a stirring suspension of 178h (100 mg, 
0.322 mmol) in toluene (6 mL) and stirred at 100 °C overnight. The solvent and the 
excess of POCl3 were evaporated under reduced pressure and the residue was dissolved 
in toluene (6 mL) and treated with a 3.0 M solution of MeMgBr (161 µL, 0.483 mmol) 
in THF. The mixture was stirred at rt overnight and then refluxed for one further day. 
The mixture was then cooled to rt, quenched with water and extracted with EtOAc (3 x 
15 mL). The combined organics were dried with MgSO4, filtered and evaporated to give 
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a yellow oil (186 mg). The crude compound was purified by column chromatography 
(eluent: from 0% to 20% EtOAc in pet. ether) to give the product as a yellow oil (28 
mg, 27%) which showed: 
1
H NMR (400 MHz, CDCl3) δ 3.80 (3H, s), 5.16 (1H, s), 6.64 
– 6.70 (1H, m), 6.89 (1H, ddd, J = 0.9, 2.6, 8.3 Hz), 6.98 – 7.01 (1H, m), 7.02 – 7.05 
(1H, m), 7.28 – 7.33 (1H, m), 7.35 (1H, d, J = 1.3 Hz), 7.74 – 7.79 (1H, m) and 8.28 







+Na) 350.0135, found 350.0146. 
 
N-Methoxy-2-(3-methoxyphenyl)-N-methylacetamide (208) 
C11H15NO3, Mol. Wt.: 209.24 
 
A solution of PCl3 (3.5 mL, 40.0 mmol) in anhydrous toluene (50 mL) was added to 
a stirring suspension of N,O-dimethylhydroxylamine hydrochloride (12.3 g, 
124.0 mmol) and Et3N (39 mL, 280 mmol) at 0 °C under inert atmosphere and the 
mixture was stirred at rt overnight. 3-Methoxyphenylacetic acid (13.7 g, 80.0 mmol) 
was added and the mixture was stirred overnight at 120 °C under inert atmosphere. The 
mixture was evaporated and the residue was dissolved with EtOAc (150 mL). The 
organic layer was washed with 1 N HCl (3 x 100 mL) and brine (3 x 100 mL), then 
dried with MgSO4, filtered and evaporated to give a brown oil (6.40 g). The crude 
compound was purified by column chromatography (eluent: from 0% to 40% EtOAc in 





(400 MHz, CDCl3) δ 3.19 (3H, s), 3.60 (3H, s), 3.74 (2H, s), 3.79 (3H, s), 6.78 (1H, dd, 
J = 2.3, 8.2 Hz), 6.83 – 6.91 (2H, m) and 7.22 (1H, t, J = 7.8 Hz) ppm. HRMS (ES+) 
calcd. C11H16NO3 (M
+
+H) 210.1125, found 210.1125. 
 
1-(3-Methoxyphenyl)propan-2-one (209a) 










(500 MHz, CDCl3) δ 2.15 (3H, s, CH3CO), 3.66 (2H, s, CH2CO), 3.80 (3H, s, ArOCH3), 
6.73 – 6.76 (1H, m, ArCH), 6.77 – 6.80 (1H, m, ArCH), 6.80 – 6.84 (1H, m, ArCH) and 
7.25 (1H, t, J = 7.9 Hz, ArCH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 29.2 (CH3CO), 
51.1 (CH2CO), 55.2 (ArOCH3), 112.5 (ArCH), 115.0 (ArCH), 121.7 (ArCH), 129.8 











C11H14O2, Mol. Wt.: 178.23 
 
(Method L) 
The crude compound was purified by column chromatography (eluent: from 0% to 





NMR (500 MHz, CDCl3) δ 1.02 (3H, t, J = 7.3 Hz, CH2CH3), 2.47 (2H, q, J = 7.3 Hz, 
CH2CH3), 3.65 (2H, s, ArCH2), 3.80 (3H, s, OCH3), 6.73 – 6.77 (1H, m, ArCH), 6.77 – 
6.84 (2H, m, 2 x ArCH) and 7.24 (1H, t, J = 8.0 Hz, ArCH) ppm. 
13
C NMR (126 MHz, 
CDCl3) δ 7.8 (CH2CH3), 35.1 (CH2CH3), 49.9 (ArCH2), 55.2 (OCH3), 112.4 (ArCH), 
115.0 (ArCH), 121.7 (ArCH), 129.7 (ArCH), 135.9 (ArCCH2), 159.8 (ArCO) and 208.9 
(CH2CO) ppm. HRMS (ES
+
) calcd. C11H15O2 (M
+
+H) 179.1067, found 179.1075. 
 
2-(3-Methoxyphenyl)-1-phenylethanone (209d) 





The crude compound was purified by column chromatography (eluent: pet. ether) to 
give the product as a yellow oil (356 mg, 66%) which showed: 
1
H NMR (500 MHz, 
CDCl3) δ 3.79 (3H, s ArOCH3), 4.26 (2H, s, CH2), 6.80 (1H, d, J = 8.2 Hz, ArCH, 
methoxyphenyl), 6.82 (1H, s, ArCH, methoxyphenyl), 6.86 (1H, d, J = 7.5 Hz, ArCH, 
methoxyphenyl), 7.24 (1H, t, J = 8.0 Hz, ArCH, methoxyphenyl), 7.46 (2H, t, J = 7.7 
Hz, 2 x ArCH, phenyl), 7.56 (1H, t, J = 7.7 Hz, ArCH, phenyl) and 8.01 (2H, d, J = 7.7 
Hz, 2 x ArCH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 45.6 (CH2), 55.2 
(ArOCH3), 112.4 (ArCH, methoxyphenyl), 115.1 (ArCH, methoxyphenyl), 121.8 
(ArCH, methoxyphenyl), 128.6 (4 x ArCH, phenyl), 129.6 (ArCH, methoxyphenyl), 
133.2 (ArCH, phenyl), 136.0 (ArCCH2), 136.6 (ArCCO), 159.8 (ArCO) and 197.5 
(CH2CO) ppm. HRMS (ES
+
) calcd. C15H15O2 (M
+
+H) 227.1072, found 227.1082; calcd. 
C15H14NaO2 (M
+
+Na) 249.0891, found 249.0901. 
 
1-(3-Methoxyphenyl)-3-phenylpropan-2-one (209e) 
C16H16O2, Mol. Wt.: 240.30 
 
(Method L) 
The crude compound was purified by column chromatography (eluent: pet. ether) to 




H NMR (500 
MHz, CDCl3) δ 3.69 (2H, s, CH2, methoxyphenyl), 3.72 (2H, s, CH2, phenyl), 3.78 (3H, 
s, ArOCH3), 6.69 (1H, s, ArCH, methoxyphenyl), 6.75 (1H, d, J = 7.5 Hz, ArCH, 
methoxyphenyl), 6.81 (1H, dd, J = 1.9, 7.9 Hz, ArCH, methoxyphenyl), 7.15 (2H, d, J = 
7.4 Hz, 2 x ArCH, phenyl), 7.24 (1H, t, J = 7.9 Hz, ArCH, methoxyphenyl), 7.26 – 7.29 
(1H, m, ArCH, phenyl) and 7.32 (2H, t, J = 7.4 Hz, 2 x ArCH, phenyl) ppm. 
13
C NMR 
(126 MHz, CDCl3) δ 49.0 (CH2, phenyl), 49.2 (CH2, methoxyphenyl), 55.2 (ArOCH3), 
112.7 (ArCH, methoxyphenyl), 115.0 (ArCH, methoxyphenyl), 121.8 (ArCH, 
methoxyphenyl), 127.0 (ArCH, phenyl), 128.7 (2 x ArCH, phenyl), 129.5 (2 x ArCH, 
phenyl), 129.7 (ArCH, methoxyphenyl), 134.0 (ArCCH2, phenyl), 135.4 (ArCCH2, 





C16H18ClNO, Mol. Wt.: 275.77 
 
NaBH(OAc)3 (306 mg, 1.37 mmol) was added to a stirring solution of 209a (105 mg, 
0.914 mmol) and 4-chloroaniline (117 mg, 0.914 mmol) in CHCl3 (5 mL) and the 
mixture was stirred at rt for 6 h. The mixture was diluted with CHCl3 (15 mL) and 
washed with sat. aq.Na2CO3 (3 x 10 mL), then dried with MgSO4, filtered and 
evaporated to give a yellow oil (205 mg). The crude compound was purified by column 
chromatography (eluent: from 0% to 30 % EtOAc in pet. ether) to get the product as a 
yellow oil (53 mg, 21%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 1.16 (3H, d, J = 
6.4 Hz, CHCH3), 2.70 (1H, dd, J = 7.4, 13.4 Hz, CH2CH), 2.91 (1H, dd, J = 4.7, 13.4 
Hz, CH2CH), 3.67 – 3.75 (1H, m, CHCH3), 3.79 (3H, s, OCH3), 6.61 (2H, d, J = 8.5 Hz, 
2 x ArCH, aniline), 6.70 (1H, s, ArCH, phenyl), 6.73 – 6.81 (2H, m, 2 x ArCH, phenyl), 
7.14 (2H, d, J = 8.7 Hz, 2 x ArCH, aniline) and 7.22 (1H, t, J = 7.9 Hz, ArCH, phenyl) 
ppm. 
13
C NMR (126 MHz, CDCl3) δ 19.8 (CHCH3), 41.9 (CH2CH), 50.2 (CHCH3), 
55.1 (OCH3), 111.5 (ArCH, phenyl), 115.2 (2 x ArCH, aniline), 115.3 (ArCH, phenyl), 
121.8 (ArCH, phenyl), 122.5 (ArCCl), 129.2 (2 x ArCH, aniline), 129.3 (ArCH, 
phenyl), 139.6 (ArCCH2), 144.9 (ArCN) and 159.6 (ArCO) ppm. 
 
4-Chloro-N-(1-(3-methoxyphenyl)butan-2-yl)aniline (210b) 
C17H20ClNO, Mol. Wt.: 289.80 
 
NaBH(OAc)3 (445 mg, 2.10 mmol) was added to a stirring solution of 209b (250 mg, 
1.40 mmol) and 4-chloroaniline (268 mg, 2.10 mmol) in CHCl3 (15 mL) and the 
mixture was stirred at rt overnight. The mixture was diluted with CHCl3 (15 mL) and 
washed with sat. aq. Na2CO3 (2 x 30 mL) then dried with MgSO4, filtered and 
evaporated to give a yellow oil (383 mg). the crude compound was purified by column 
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chromatography (eluent: from 0% to 20% EtOAc in pet. ether) to give the product as a 
colourless oil (67 mg, 19%) which showed: 
1
H NMR (500 MHz, CDCl3) δ 0.99 (3H, t, J 
= 7.4 Hz, CH2CH3), 1.35 – 1.51 (1H, m, CH2CH3), 1.57 – 1.71 (1H, m, CH2CH3), 2.74 
– 2.90 (2H, m, ArCH2), 3.47 – 3.60 (1H, m, CHN), 3.80 (3H, s, OCH3), 6.57 (2H, d, J = 
8.7 Hz, 2 x ArCH, aniline), 6.72 (1H, s, ArCH, phenyl), 6.77 (1H, d, J = 8.7 Hz, ArCH, 
phenyl), 6.79 (1H, d, J = 8.7 Hz, ArCH, phenyl), 7.14 (2H, d, J = 8.7 Hz, ArCH, 
phenyl) and 7.23 (1H, t, J = 7.9 Hz) ppm. 
13
C NMR (126 MHz, CDCl3) δ 10.4 
(CH2CH3), 26.6 (CH2CH3), 39.6 (ArCH2), 55.1 (OCH3), 55.5 (CHN), 111.4 (ArCH, 
phenyl), 114.5 (2 x ArCH, aniline), 115.4 (ArCH, phenyl), 121.8 (ArCCl), 121.9 
(ArCH, phenyl), 129.2 (2 x ArCH, aniline), 129.3 (ArCH, phenyl), 139.8 (ArCCH2), 











-H) 290.1131, found 290.1119. 
 
4-Chloro-N-(1-(3-methoxyphenyl)-3-phenylpropan-2-yl)aniline (210e) 
C22H22ClNO, Mol. Wt.: 351.87 
 
NaBH(OAc)3 (393 mg, 1.76 mmol) was added to a stirring solution of 209e (280 mg, 
1.17 mmol) and 4-chloroaniline (149 mg, 1.17 mmol) in dichloroethane (3.0 mL). 
Glacial acetic acid (67 µL, 1.17 mmol) was introduced and the mixture was stirred at rt 
overnight during which time the suspension turned into a solution. The mixture was 
diluted with DCM (10 mL) and washed with 1 N NaOH (1 x 10 mL) then dried with 
MgSO4, filtered and evaporated to give a yellow oil (305 mg). The crude compound 
was purified by column chromatography (eluent: from 0% to 40 % EtOAc in pet. ether) 
to give the product as a yellow oil (116 mg, 28%) which showed: 
1
H NMR (400 MHz, 
CDCl3) δ 2.64 – 2.95 (4H,z m), 3.77 (3H, m), 3.85 – 4.01 (1H, m), 6.51 (2H, d, J = 8.9 
Hz), 6.69 – 6.72 (1H, m), 6.73 – 6.79 (2H, m), 7.09 (2H, d, J = 8.9 Hz), 7.15 – 7.19 












352.1288, found 352.1301; 
 
2-(4-Chlorophenyl)-3-ethyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline (211b) 
C18H20ClNO, Mol. Wt.: 301.81 
 
(Method J) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give the product as a colourless oil (92 mg, 44%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 0.87 (3H, t, J = 7.4 Hz, CH2CH3), 1.27 – 1.37 
(1H, m, CH2CH3), 1.49 – 1.60 (1H, m, CH2CH3), 2.78 (1H, dd, J = 1.5, 15.8 Hz, H4-
THIQ), 3.11 (1H, dd, J = 5.4, 15.7 Hz, H4-THIQ), 3.81 (3H, s, OCH3), 3.95 – 4.03 (1H, 
m, H3-THIQ), 4.20 (1H, d, J = 15.2 Hz, H1-THIQ), 4.35 (1H, d, J = 15.1 Hz, H1-THIQ), 
6.70 (1H, d, J = 2.2 Hz, H5-THIQ), 6.78 (1H, dd, J = 2.5, 8.4 Hz, H7-THIQ), 6.81 (2H, 
d, J = 9.0 Hz, 2 x ArCH, phenyl), 7.08 (1H, d, J = 8.4 Hz, H8-THIQ) and 7.20 (2H, d, J 
= 9.0 Hz, 2 x ArCH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 11.4 (CH2CH3), 23.2 
(CH2CH3), 32.3 (C4-THIQ), 45.7 (C1-THIQ), 55.1 (C3-THIQ), 55.2 (OCH3), 112.1 (C7-
THIQ), 113.9 (C5-THIQ), 115.0 (2 x ArCH, phenyl), 121.9 (ArCCl), 125.6 (C1CC8-
THIQ), 127.2 (C8-THIQ), 129.0 (2 x ArCH, phenyl), 134.5 (C4CC5-THIQ), 148.3 
(ArCN) and 158.2 (C6-THIQ) ppm. 
 
2-(3-Methoxyphenyl)-N-methylacetamide (218) 
C10H13NO2, Mol. Wt.: 179.22 
 
2.0 M solution of isopropylmagnesium chloride (1.72 mL, 3.44 mmol) in THF was 
added to a stirring solution of 208 (600 mg, 2.87 mmol) in anhydrous THF (29 mL) 
under inert atmosphere and the mixture was stirred at rt for 1 h. The mixture was 
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quenched with 1N HCl (6 mL) and extracted with EtOAc (3 x 50 mL). The combined 
organics were dried with MgSO4, filtered and evaporated to give a yellow oil (486 mg). 
The crude compound was purified by column chromatography (eluent: from 0% to 50% 




H NMR (500 MHz, CDCl3) δ 2.75 (3H, d, J = 4.8 Hz, NCH3), 3.55 (2H, s, ArCH2), 
3.81 (3H, s, OCH3), 5.40 (1H, bs, NH), 6.77 – 6.81 (1H, m, ArCH), 6.81 – 6.86 (2H, m, 
2 x ArCH) and 7.25 – 7.31 (1H, m, ArCH) ppm. 13C NMR (126 MHz, CDCl3) δ 26.5 
(NCH3), 43.8 (ArCH2), 55.2 (OCH3), 112.8 (ArCH), 115.2 (ArCH), 121.8 (ArCH), 





+H) 180.1019, found 180.1016. 
 
2-(4-Chlorophenyl)-3-ethyl-8-methoxy-1,2,3,4-tetrahydroisoquinoline (219b) 
C18H20ClNO, Mol. Wt.: 301.81 
 
(Method J) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give the product as a colourless oil (8 mg, 4%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 0.85 (3H, t, J = 7.4 Hz, CH2CH3), 1.27 – 1.42 
(1H, m, CH2CH3), 1.47 – 1.59 (1H, m, CH2CH3), 2.79 (1H, d, J = 15.9 Hz, H4-THIQ), 
3.13 (1H, dd, J = 5.4, 15.9 Hz, H4-THIQ), 3.87 (3H, s, OCH3), 3.99 – 4.06 (1H, m, 
H3-THIQ), 4.09 (1H, d, J = 17.4 Hz, H1-THIQ), 4.37 (1H, d, J = 16.8 Hz, H1-THIQ), 
6.73 (1H, d, J = 7.9 Hz, H7-THIQ), 6.76 (1H, d, J = 7.9 Hz, H5-THIQ), 6.88 (2H, d, J = 
9.1 Hz, 2 x ArCH, phenyl), 7.17 (1H, t, J = 7.9 Hz, H6-THIQ) and 7.20 (2H, d, J = 9.1 
Hz, 2 x ArCH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 11.5 (CH2CH3), 22.6 
(CH2CH3), 32.0 (C4-THIQ), 41.5 (C1-THIQ), 54.5 (C3-THIQ), 55.2 (OCH3), 107.2 (C7-
THIQ), 115.3 (2 x ArCH, phenyl), 121.3 (C5-THIQ), 121.9 (ArCCl), 122.0 (C1CC8-
THIQ), 126.9 (C6-THIQ), 128.9 (2 x ArCH, phenyl), 134.2 (C4CC5-THIQ), 148.6 





C16H16ClNO2, Mol. Wt.: 289.76 
 
(Method N) 
The crude compound was purified by column chromatography (eluent: from 0% to 
40% EtOAc in pet. ether) to give the product as a yellow oil (418 mg, 25%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 1.58 (3H, d, J = 7.1 Hz, CHCH3), 3.68 (1H, q, J 
= 7.1 Hz, CHCH3), 3.81 (3H, s, OCH3), 6.85 (1H, dd, J = 2.3, 7.9 Hz, ArCH, 
phenacetyl), 6.87 – 6.90 (1H, m, ArCH, phenacetyl), 6.93 (1H, d, J = 7.9 Hz, ArCH, 
phenacetyl), 7.08 (1H, bs, NH), 7.22 (2H, d, J = 8.8 Hz, ArCH, aniline), 7.30 (1H, t, J = 
7.9 Hz, ArCH, phenacetyl) and 7.36 (2H, d, J = 8.8 Hz, ArCH, aniline) ppm. 
13
C NMR 
(126 MHz, CDCl3) δ 18.3 (CHCH3), 48.1 (CHCH3), 55.3 (OCH3), 112.9 (ArCH, 
phenacetyl), 113.5 (ArCH, phenacetyl), 119.9 (ArCH, phenacetyl), 120.9 (2 x ArCH, 
aniline), 128.9 (2 x ArCH, aniline), 129.2 (ArCCl), 130.3 (ArCH, phenacetyl), 136.4 












292.0913, found 292.0961. 
 
N-(4-Chlorophenyl)-2-(3-methoxyphenyl)butanamide (224b) 
C17H18ClNO2, Mol. Wt.: 303.78 
 
(Method N) 
The crude compound was purified by column chromatography (eluent: from 0% to 
40% EtOAc in pet. ether) to give the product as a yellow solid (400 mg, 24%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 0.92 (3H, t, J = 7.4 Hz, CH2CH3), 1.77 – 1.96 
(1H, m, CHCH2), 2.16 – 2.35 (1H, m, CHCH2), 3.35 (1H, t, J = 7.5 Hz, CHCH2), 3.81 
(3H, s OCH3), 6.84 (1H, dd, J = 2.1, 8.2 Hz, ArCH, phenacetyl), 6.87 – 6.90 (1H, m, 
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ArCH, phenacetyl), 6.92 (1H, d, J = 7.6 Hz, ArCH, phenacetyl), 7.08 (1H, bs, NH), 7.23 
(2H, d, J = 8.8 Hz, ArCH, aniline), 7.29 (1H, t, J = 7.9 Hz, ArCH, phenacetyl) and 7.38 
(2H, d, J = 8.8 Hz, ArCH, aniline) ppm. 
13
C NMR (126 MHz, CDCl3) δ 12.3 (CH2CH3), 
26.2 (CHCH2), 55.2 (OCH3), 56.1 (CHCH2), 112.8 (ArCH, phenacetyl), 113.8 (ArCH, 
phenacetyl), 120.3 (ArCH, phenacetyl), 120.9 (2 x ArCH, aniline), 128.9 (2 x ArCH, 
aniline), 129.2 (ArCCl), 130.1 (ArCH, phenacetyl), 136.4 (ArCN), 140.8 (ArCCH), 











+H) 306.1069, found 306.1098. 
 
N-(4-Chlorophenyl)-2-(3-methoxyphenyl)-3-methylbutanamide (224c) 
C18H20ClNO2, Mol. Wt.: 317.81  
 
(Method N) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20 % EtOAc in pet. ether) to give the product as a yellow oil (212 mg, 42%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 0.76 (3H, d, J = 6.6 Hz, (CH3)2CH), 1.09 (3H, 
d, J = 6.5 Hz, (CH3)2CH), 2.40 – 2.56 (1H, m, , (CH3)2CH), 2.95 (1H, d, J = 10.0 Hz, 
(CH3)2CHCH), 3.80 (3H, s, OCH3), 6.81 (1H, dd, J = 1.9, 8.2 Hz, ArCH, phenacetyl), 
6.87 – 6.96 (2H, m, 2 x ArCH, phenacetyl), 7.18 (1H, bs, NH), 7.20 – 7.25 (3H, m, 2 x 
ArCH, aniline, ArCH, phenacetyl) and 7.42 (2H, d, J = 8.7 Hz m, 2 x ArCH, aniline) 
ppm. 
13
C NMR (126 MHz, CDCl3) δ 20.3 ((CH3)2CH), 21.7 ((CH3)2CH), 31.5 
((CH3)2CH), 55.2 (OCH3), 62.8 ((CH3)2CHCH), 112.7 (ArCH, phenacetyl), 113.9 
(ArCH, phenacetyl), 120.7 (ArCH, phenacetyl), 121.0 (2 x ArCH, aniline), 128.9 (2 x 
ArCH, aniline), 129.2 (ArCCl), 129.7 (ArCH, phenacetyl), 136.4 (ArCN), 140.2 
(ArCCH), 159.8 (ArCO) and 171.4 (CON) ppm. 
 
N-(4-Chlorophenyl)-2-(3-methoxyphenyl)-3-phenylpropanamide (224d) 





The crude compound was purified by column chromatography (eluent: from 0% to 
40% EtOAc in pet. ether) to give the product as a yellow oil (145 mg, 9%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 3.04 (1H, dd, J = 7.4, 13.6 Hz, CHCH2), 3.60 
(1H, dd, J = 7.4, 13.6 Hz, CHCH2), 3.69 (1H, t, J = 7.4 Hz, CHCH2), 3.78 (3H, s, 
OCH3), 6.82 (1H, dd, J = 2.2, 8.2 Hz, ArCH, methoxyphenyl), 6.84 – 6.88 (1H, m, 
ArCH, methoxyphenyl), 6.90 (1H, d, J = 7.6 Hz, ArCH, methoxyphenyl) 6.98 (1H, bs, 
NH), 7.13 (2H, d, J = 7.3 Hz, 2 x ArCH, phenyl), 7.17 (1H, t, J = 7.3 Hz, ArCH, 
phenyl), 7.21 (3H, d, J = 8.8 Hz, 2 x ArCH, aniline), 7.23 (2H, d, J = 7.3 Hz, ArCH, 
phenyl), 7.26 (1H, d, J = 7.8 Hz, ArCH, methoxyphenyl) and 7.32 (2H, d, J = 8.7 Hz, 
ArCH, aniline) ppm. 
13
C NMR (126 MHz, CDCl3) δ 39.5 (CHCH2), 55.3 (OCH3), 56.5 
(CHCH2), 113.1 (ArCH, methoxyphenyl), 113.8 (ArCH, methoxyphenyl), 120.4 
(ArCH, methoxyphenyl), 121.1 (2 x ArCH, aniline), 126.4 (ArCH, phenyl), 128.4 (2 x 
ArCH, aniline), 128.9 (2 x ArCH, phenyl), 129.0 (2 x ArCH, aniline), 129.3 (ArCCl), 
130.0 (ArCH, methoxyphenyl), 136.2 (ArCN), 139.3 (ArCCH2), 140.4 (ArCCH), 160.0 











+H) 368.1226, found 368.1250. 
 
N-(4-Chlorophenyl)-4-methoxy-2-(3-methoxyphenyl)butanamide (224e) 
C18H20ClNO3, Mol. Wt.: 333.81  
 
(Method N) 
The crude compound was purified by column chromatography (eluent: from 0% to 





H NMR (500 MHz, CDCl3) δ 1.98 – 2.10 (1H, m, CHCH2), 2.39 – 2.52 (1H, 
m, CHCH2), 3.25 – 3.31 (1H, m, CH2O), 3.31 (3H, s, CH2OCH3), 3.40 – 3.49 (1H, m, 
CHCH2), 3.72 (1H, t, J = 7.4 Hz, CHCH2), 3.80 (3H, s, ArOCH3), 6.83 (1H, dd, J = 2.1, 
8.2 Hz, ArCH, phenacetyl), 6.88 – 6.92 (1H, m, ArCH, phenacetyl), 6.94 (1H, d, J = 7.6 
Hz, ArCH, phenacetyl), 7.23 (2H, d, J = 8.8 Hz, 2 x ArCH, aniline), 7.27 (2H, t, J = 8.0 
Hz, ArCH, phenacetyl), 7.35 (1H, bs, NH) and 7.40 (2H, d, J = 8.8 Hz, 2 x ArCH, 
aniline) ppm. 
13
C NMR (126 MHz, CDCl3) δ 33.1 (CHCH2), 50.3 (CHCH2), 55.2 
(ArOCH3), 58.6 (CH2OCH3), 69.8 (CH2OCH3), 112.9 (ArCH, phenacetyl), 113.8 
(ArCH, phenacetyl), 120.4 (ArCH, phenacetyl), 120.9 (2 x ArCH, aniline), 128.9 (2 x 
ArCH, aniline), 129.1, 130.0 (ArCH, phenacetyl), 136.5 (ArCN), 140.6 (ArCCH), 160.0 











+H) 336.1175, found 336.1190. 
 
N-(4-Chlorophenyl)-2-(3-methoxyphenyl)-2-methylpropanamide (224f) 
C17H18ClNO2, Mol. Wt.: 303.78  
 
(Method N) 
The crude compound was not purified and showed: 
1
H NMR (500 MHz, CDCl3) δ 
1.64 (6H, s, (CH3)2C), 3.82 (3H, s, OCH3), 6.81 (1H, bs, NH), 6.86 (1H, dd, J = 2.1, 7.9 
Hz, ArCH, phenacetyl), 6.96 (1H, t, J = 2.1 Hz, ArCH, phenacetyl), 7.01 (1H, dd, J = 
2.1, 7.9 Hz, ArCH, phenacetyl), 7.21 (2H, d, J = 8.8 Hz, 2 x ArCH, aniline), 7.31 (2H, 
d, J = 8.8 Hz, 2 x ArCH, aniline) and 7.33 (2H, t, J = 7.9 Hz, ArCH, phenacetyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 26.9 ((CH3)2C), 48.1 ((CH3)2C), 55.3 (OCH3), 112.2 
(ArCH, phenacetyl), 112.9 (ArCH, phenacetyl), 118.8 (ArCH, phenacetyl), 120.9 (2 x 
ArCH, aniline), 128.8 (2 x ArCH, aniline), 129.1 (ArCCl), 130.1 (ArCH, phenacetyl), 

















C16H18ClNO, Mol. Wt.: 275.77 
 
(Method I) 
The crude compound was not purified and showed: 
1
H NMR (500 MHz, CDCl3) δ 
1.33 (3H, d, J = 6.9 Hz, CHCH3), 2.97 – 3.11 (1H, m, CHCH3), 3.20 (1H, dd, J = 8.3, 
12.4 Hz, CHCH2), 3.31 (1H, dd, J = 6.2, 12.4 Hz, CHCH2), 3.80 (3H, s, OCH3), 6.57 
(2H, d, J = 8.8 Hz, 2 x ArCH, aniline), 6.74 – 6.76 (1H, m, ArCH, phenyl), 6.76 – 6.83 
(2H, m, 2 x ArCH, phenyl), 7.11 (2H, d, J = 8.8 Hz, 2 x ArCH, aniline) and 7.25 (2H, t, 
J = 7.9 Hz, ArCH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 19.7 (CHCH3), 39.0 
(CHCH3), 51.6 (CHCH2), 55.2 (OCH3), 111.7 (ArCH, phenyl), 113.2 (ArCH, phenyl), 
115.0 (2 x ArCH, aniline), 119.5 (ArCH, phenyl), 123.0 (ArCCl), 129.1 (2 x ArCH, 
aniline), 129.7 (ArCH, phenyl), 145.5 (ArCN), 145.7 (ArCCH) and 159.9 (ArCO) ppm. 
 
4-Chloro-N-(2-(3-methoxyphenyl)butyl)aniline (225b) 
C17H20ClNO, Mol. Wt.: 289.80 
 
(Method I) 
The crude compound was not purified and showed: 
1
H NMR (500 MHz, CDCl3) δ 
0.83 (3H, t, J = 7.4 Hz, CH2CH3), 1.56 – 1.67 (1H, m, CH2CH3), 1.73 – 1.85 (1H, m, 
CH2CH3), 2.70 – 2.83 (1H, m, CHCH2CH3), 3.18 (1H, dd, J = 9.1, 12.3 Hz, CH2N), 
3.41 (1H, dd, J = 5.6, 12.4 Hz, CH2N), 3.80 (3H, s, OCH3), 6.56 (2H, d, J = 8.8 Hz, 2 x 
ArCH, aniline), 6.69 – 6.72 (1H, m, ArCH, phenyl), 6.76 (1H, d, J = 8.0 Hz, ArCH, 
phenyl), 6.78 (1H, dd, J = 2.4, 8.0 Hz, ArCH, phenyl), 7.10 (2H, d, J = 8.8 Hz, 2 x 
ArCH, aniline) and 7.24 (1H, t, J = 8.0 Hz, ArCH, phenyl) ppm. 
13
C NMR (126 MHz, 
CDCl3) δ 12.0 (CH2CH3), 27.0 (CH2CH3), 46.8 (CHCH2CH3), 50.4 (CH2N), 55.2 
(OCH3), 111.7 (ArCH, phenyl), 113.9 (ArCH, phenyl), 115.2 (2 x ArCH, aniline), 120.2 
(ArCH, phenyl), 123.2 (ArCCl), 129.1 (2 x ArCH, aniline), 129.7 (ArCH, phenyl), 
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292.1277, found 292.1268. 
 
4-Chloro-N-(2-(3-methoxyphenyl)-3-methylbutyl)aniline (225c) 
C18H22ClNO, Mol. Wt.: 303.83 
 
(Method I) 
The crude compound was not purified and showed: 
1
H NMR (500 MHz, CDCl3) δ 
0.77 (3H, d, J = 6.7 Hz, CH(CH3)2), 1.05 (3H, d, J = 6.6 Hz, CH(CH3)2), 1.84 – 1.99 
(1H, m, CH(CH3)2), 2.55 (1H, ddd, J = 4.4, 8.4, 10.5 Hz, CHCH2), 3.16 (1H, dd, J = 
10.7, 11.8 Hz, CHCH2), 3.37 (1H, bs, NH), 3.56 (1H, dd, J = 4.2, 11.9 Hz, CHCH2), 
3.79 (3H, s, OCH3), 6.44 (2H, d, J = 8.9 Hz, 2 x ArCH, aniline), 6.68 – 6.70 (1H, m, 
ArCH, phenethyl), 6.72 – 6.76 (1H, m, ArCH, phenethyl), 6.79 (1H, ddd, J = 0.8, 2.6, 
8.2 Hz, ArCH, phenethyl), 7.07 (2H, d, J = 8.9 Hz, 2 x ArCH, aniline) and 7.20 – 7.26 
(1H, m, ArCH, phenethyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ  21.1(CH(CH3)2), 
21.2(CH(CH3)2), 31.9 (CH(CH3)2), 47.0 (CHCH2), 52.6 (CHCH2), 55.3 (OCH3), 111.8 
(ArCH, phenethyl), 114.3 (2 x ArCH, aniline), 114.7 (ArCH, phenethyl), 121.0 (ArCH, 
phenethyl), 121.9 (ArCCl), 129.1 (2 x ArCH, aniline), 129.6 (ArCH, phenethyl), 143.8 




















The crude compound was not purified and showed: 
1
H NMR (500 MHz, CDCl3) δ 
2.97 (2H, d, J = 7.3 Hz, ArCH2, phenyl), 3.13 – 3.20 (1H, m, CHCH2), 3.23 (1H, dd, J = 
8.9, 12.2 Hz, CH2N), 3.41 (1H, dd, J = 4.9, 12.2 Hz, CH2N), 3.77 (3H, s, OCH3), 6.43 
(2H, d, J = 8.8 Hz, 2 x ArCH, aniline), 6.67 – 6.71 (1H, m, ArCH, methoxyphenyl), 
6.74 – 6.80 (2H, m, 2 x ArCH, methoxyphenyl), 7.06 (2H, d, J = 8.8 Hz, 2 x ArCH, 
aniline), 7.09 (2H, d, J = 7.1 Hz, 2 x ArCH, phenyl) and 7.18 – 7.26 (4H, m, 3 x ArCH, 
phenyl, ArCH, methoxyphenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 40.8 (ArCH2, 
phenyl), 46.6 (CHCH2), 49.3 (CH2N), 55.2 (OCH3), 112.0 (ArCH, methoxyphenyl), 
113.8 (ArCH, methoxyphenyl), 115.0 (2 x ArCH, aniline), 120.0 (ArCH, 
methoxyphenyl), 123.1 (ArCCl), 126.3 (ArCH, phenyl), 127.7, 128.3 (2 x ArCH, 
phenyl), 129.0 (2 x ArCH, phenyl), 129.1 (2 x ArCH, aniline), 129.7 (ArCH, 












-H) 352.1288, found 352.1275. 
 
4-Chloro-N-(4-methoxy-2-(3-methoxyphenyl)butyl)aniline (225e) 
C18H22ClNO2, Mol. Wt.: 319.83  
 
(Method I) 

















C17H20ClNO, Mol. Wt.: 289.80 
 
(Method I) 
The crude compound was not purified and showed: 
1
H NMR (500 MHz, CDCl3) δ 
1.32 (6H, s, (CH3)2C), 3.15 (2H, s, CH2N), 3.74 (3H, s, OCH3), 6.40 (2H, d, J = 8.7 Hz, 
2 x ArCH, aniline), 6.71 (1H, dd, J = 2.4, 8.0 Hz, ArCH, phenyl), 6.83 – 6.87 (1H, m, 
ArCH, phenyl), 6.89 (1H, d, J = 8.0 Hz, ArCH, phenyl), 6.99 (2H, d, J = 8.7 Hz, 2 x 
ArCH, aniline) and 7.20 (1H, t, J = 8.0 Hz, ArCH, phenyl) ppm. 
13
C NMR (126 MHz, 
CDCl3) δ 27.2 ((CH3)2C), 38.8 ((CH3)2C), 55.2 (OCH3), 57.9 (CH2N), 111.0 (ArCH, 
phenyl), 112.9 (ArCH, phenyl), 116.3 (2 x ArCH, aniline), 118.4 (ArCH, phenyl), 124.2 
(ArCCl), 129.1 (2 x ArCH, aniline), 129.6 (ArCH, phenyl), 147.4 (ArCN), 147.7 







290.1306, found 290.1320. 
 
Methyl 2-(3-methoxyphenyl)acetate (226) 
C10H12O3, Mol. Wt.: 180.20 
 
Conc. H2SO4 (1.2 mL) was added dropwise to a stirring solution of 
3-methoxyphenylacetic acid (6.78 g, 40.0 mmol) in MeOH (80 mL) and the mixture 
was refluxed for 3 days. Product did not form according to TLC. The mixture was then 
stirred for 3 h under reflux and inert atmosphere using a Soxhlet extractor containing 
CaH2 as dehydrating agent. The mixture was then neutralised with Na2CO3, filtered and 
evaporated. The residue was dissolved in EtOAc (100 mL) and washed with 1 N NaOH 
(3 x 100 mL) and brine (100 mL) then dried with MgSO4, filtered and evaporated to 
give the product as a colourless oil (6.36 g, 88%) which showed: 
1
H NMR (400 MHz, 
CDCl3) δ 3.60 (2H, s), 3.69 (3H, s), 3.80 (3H, s), 6.79 – 6.84 (2H, m), 6.86 (1H, d, J = 




Methyl 2-(3-methoxyphenyl)propanoate (227a) 
C11H14O3, Mol. Wt.: 194.23 
 
(Method M) 
The crude compound was not purified and showed: 
1
H NMR (500 MHz, CDCl3) δ 
1.49 (3H, d, J = 7.1 Hz, CHCH3), 3.66 (3H, s, COOCH3), 3.70 (1H, q, J = 7.1 Hz, 
CHCH3), 3.80 (3H, s, ArOCH3), 6.80 (1H, dd, J = 2.3, 8.2 Hz, ArCH), 6.84 (1H, t, J = 
2.3 Hz, ArCH), 6.88 (1H, dd, J = 2.3, 8.2 Hz, ArCH) and 7.24 (1H, t, J = 8.0 Hz, ArCH) 
ppm. 
13
C NMR (126 MHz, CDCl3) δ 18.5 (CHCH3), 45.4 (CHCH3), 52.0 (COOCH3), 
55.2 (ArOCH3), 112.4 (ArCH), 113.2 (ArCH), 119.8 (ArCH), 129.6 (ArCH), 142.0 
(ArCCH), 159.7 (ArCO) and 174.8 (COO) ppm. HRMS (ES
+
) calcd. C11H15O3 (M
+
+H) 
195.1021, found 195.1014; calcd. C11H14NaO3 (M
+
+H) 217.0841, found 217.0831.  
 
Methyl 2-(3-methoxyphenyl)butanoate (227b) 
C12H16O3, Mol. Wt.: 208.25 
 
(Method M) 
The crude compound was not purified and showed: 
1
H NMR (500 MHz, CDCl3) δ 
0.89 (3H, t, J = 7.4 Hz, CH2CH3), 1.72 – 1.86 (1H, m, CHCH2), 2.03 – 2.14 (1H, m, 
CHCH2), 3.42 (1H, t, J = 7.7 Hz, CHCH2), 3.66 (3H, s, COOCH3), 3.80 (3H, s, 
ArOCH3), 6.80 (1H, ddd, J = 0.6, 2.5, 7.9 Hz, ArCH), 6.83 – 6.86 (1H, m, ArCH), 6.88 
(1H, d, J = 7.9 Hz, ArCH) and 7.23 (1H, t, J = 7.9 Hz, ArCH) ppm. 
13
C NMR (126 
MHz, CDCl3) δ 12.1 (CH2CH3), 26.7 (CHCH2), 51.9 (COOCH3), 53.4 (CHCH2), 55.2 
(ArOCH3), 112.5 (ArCH), 113.6 (ArCH), 120.4 (ArCH), 129.5 (ArCH), 140.6 
(ArCCH), 159.7 (ArCO) and 174.4 (COO) ppm. HRMS (ES
+
) calcd. C12H17O3 (M
+
+H) 
209.1178, found 209.1163; calcd. C12H16NaO3 (M
+




Methyl 2-(3-methoxyphenyl)-3-methylbutanoate (227c) 
C13H18O3, Mol. Wt.: 222.28 
 
(Method M) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give the product as a yellow oil (243mg, 20%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 0.71 (3H, d, J = 6.7 Hz, (CH3)2CH), 1.02 (3H, 
d, J = 6.5 Hz, (CH3)2CH), 2.24 – 2.41 (1H, m, (CH3)2CH), 3.12 (1H, d, J = 10.6 Hz, 
(CH3)2CHCH), 3.65 (3H, s, COOCH3), 3.80 (3H, s, ArOCH3), 6.80 (1H, dd, J = 1.7, 8.2 
Hz, ArCH), 6.90 (2H, d, J = 7.8 Hz, 2 x ArCH) and 7.22 (1H, t, J = 7.8 Hz, ArCH) 
ppm. 
13
C NMR (126 MHz, CDCl3) δ 20.2 ((CH3)2CH), 21.5 ((CH3)2CH), 31.9 
((CH3)2CH), 51.7 (COOCH3), 55.2 (ArOCH3), 60.0 ((CH3)2CHCH), 112.5 (ArCH), 
114.1 (ArCH), 121.0 (ArCH), 129.3 (ArCH), 139.9 (ArCCH), 159.6 (ArCO) and 174.3 
(COO) ppm. HRMS (ES
+
) calcd. C13H19O3 (M
+
+H) 223.1334, found 223.1325; calcd. 
C13H18NaO3 (M
+
+H) 245.1153, found 245.1133. 
 
Methyl 2-(3-methoxyphenyl)-3-phenylpropanoate (227d) 
C17H18O3, Mol. Wt.: 270.32 
 
(Method M) 
The crude compound was purified by column chromatography (eluent: from 0% to 
10% EtOAc in pet. ether) to give the product as a colourless oil (1.29 g, 86 %) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 3.02 (1H, dd, J = 6.7, 13.7 Hz, CH2CH), 3.41 
(1H, dd, J = 8.8, 13.7 Hz, CH2CH), 3.61 (3H, s, COOCH3), 3.79 (3H, s, ArOCH3), 3.83 
310 
 
(1H, dd, J = 6.7, 8.8 Hz, CH2CH), 6.81 (1H, dd, J = 2.4, 8.2 Hz, ArCH, 
methoxyphenyl), 6.84 – 6.88 (1H, m, ArCH, methoxyphenyl), 6.89 (1H, d, J = 7.7 Hz, 
ArCH, methoxyphenyl), 7.13 (2H, d, J = 7.1 Hz, 2 x ArCH, phenyl) and 7.16 – 7.26 
(4H, m, 3 x ArCH, phenyl, ArCH, methoxyphenyl) ppm. 
13
C NMR (126 MHz, CDCl3) 
δ 39.7 (CH2CH), 52.0 (COOCH3), 53.6 (CH2CH), 55.2 (ArOCH3), 112.8 (ArCH, 
methoxyphenyl), 113.6 (ArCH, methoxyphenyl), 120.3 (ArCH, methoxyphenyl), 126.4 
(ArCH, phenyl), 128.3 (2 x ArCH, phenyl), 128.9 (2 x ArCH, phenyl), 129.6 (ArCH, 
methoxyphenyl), 139.0 (ArCCH2), 140.1 (ArCCH), 159.7 (ArCO) and 173.7 (COO) 
ppm. HRMS (ES
+
) calcd. C17H19O3 (M
+
+H) 271.1334, found 271.1320; calcd. 
C17H18NaO3 (M
+
+H) 293.1154, found 293.1149. 
 
Methyl 4-methoxy-2-(3-methoxyphenyl)butanoate (227e) 
C13H18O4, Mol. Wt.: 238.28 
 
(Method M) 
The crude compound was purified by column chromatography (eluent: from 0% to 
10% EtOAc in pet. ether) to give the product as a yellow oil (430 mg, 33%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 1.91 – 2.05 (1H, m, CHCH2), 2.29 – 2.42 (1H, 
m, CHCH2), 3.22 – 3.28 (1H, m, CH2O), 3.29 (3H, s, CH2OCH3), 3.36 (1H, dt, J = 5.8, 
11.3 Hz, CH2O), 3.66 (3H, s, COOCH3), 3.71 – 3.76 (1H, m, CHCH2), 3.80 (3H, s, 
ArOCH3), 6.78 – 6.83 (1H, m, ArCH), 6.85 (1H, s, ArCH), 6.89 (1H, d, J = 8.0 Hz, 
ArCH) and 7.23 (1H, t, J = 8.0 Hz, ArCH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 33.2 
(CHCH2), 47.9 (CHCH2), 52.0 (COOCH3), 55.2 (ArOCH3), 58.6 (CH2OCH3), 69.9 
(CH2OCH3), 112.7 (ArCH), 113.6 (ArCH), 120.4 (ArCH), 129.6 (ArCH), 140.2 
(ArCCH), 159.8 (ArCO) and 174.2 (COO) ppm. HRMS (ES
+
) calcd. C13H18NaO4 
(M
+
+H) 261.1103, found 261.1116. 
 
Methyl 2-(3-methoxyphenyl)-2-methylpropanoate (227f) 
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C12H16O3, Mol. Wt.: 208.25 
 
(Method M) 




H NMR (500 MHz, CDCl3) δ 
1.57 (6H, s, C(CH3)2), 3.65 (3H, s, COOCH3), 3.80 (3H, s, ArOCH3), 6.78 (1H, dd, J = 
2.2, 7.9 Hz, ArCH), 6.88 (1H, t, J = 2.2 Hz, ArCH), 6.92 (1H, dd, J = 2.2, 7.9 Hz, 
ArCH) and 7.25 (1H, t, J = 7.9 Hz, ArCH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 26.5 
(C(CH3)2), 46.5 (C(CH3)2), 52.2 (COOCH3), 55.2 (ArOCH3), 111.4 (ArCH), 112.1 
(ArCH), 118.0 (ArCH), 129.3 (ArCH), 146.3 (ArCC(CH3)2), 159.5 (ArCO) and 177.1 
(COO) ppm. HRMS (ES
+
) calcd. C12H16NaO3 (M
+





The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give the product as a white solid (302 mg, 58%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 1.29 (3H, d, J = 6.9 Hz, CHCH3), 2.96 – 3.06 
(1H, m, H4-THIQ), 3.19 (1H, dd, J = 6.2, 12.0 Hz, H3-THIQ), 3.40 (1H, dd, J = 4.3, 
12.0 Hz, H3-THIQ), 3.74 (3H, s, OCH3), 4.18 (1H, d, J = 14.7 Hz, H1-THIQ), 4.27 (1H, 
d, J = 14.7 Hz, H1-THIQ), 6.69 (1H, dd, J = 2.6, 8.3 Hz, H7-THIQ), 6.72 (1H, d, J 
= 2.6 Hz, H5-THIQ), 6.78 (2H, d, J = 9.0 Hz, 2 x ArCH, phenyl), 7.00 (1H, d, J = 8.3 
Hz, H8-THIQ) and 7.14 (2H, d, J = 9.0 Hz, 2 x ArCH, phenyl) ppm. 
13
C NMR (126 
MHz, CDCl3) δ 19.6 (CHCH3), 33.5 (C4-THIQ), 50.0 (C1-THIQ), 53.4 (C3-THIQ), 55.3 
(OCH3), 112.0 (C5-THIQ), 112.3 (C7-THIQ), 115.7 (2 x ArCH, phenyl), 122.9 (ArCCl), 
125.8 (C1CC8-THIQ), 127.4 (C8-THIQ), 129.0 (2 x ArCH, phenyl), 141.2 (C4CC5-





C18H20ClNO, Mol. Wt.: 301.81 
 
(Method J) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give the product as a yellow oil (384 mg, 74%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 0.97 (3H, t, J = 7.4 Hz, CH2CH3), 1.59 – 1.72 
(2H, m, CH2CH3), 2.67 – 2.75 (1H, m, H4-THIQ), 3.24 (1H, dd, J = 3.8, 12.1 Hz, H3-
THIQ), 3.53 (1H, dd, J = 4.1, 12.1 Hz, H3-THIQ), 3.74 (3H, s, OCH3), 4.10 (1H, d, J 
= 14.6 Hz, H1-THIQ), 4.32 (1H, d, J = 14.7 Hz, H1-THIQ), 6.68 (1H, d, J = 2.4 Hz, H5-
THIQ), 6.70 (1H, dd, J = 2.6, 8.3 Hz, H7-THIQ), 6.77 (2H, d, J = 9.0 Hz, 2 x ArCH, 
phenyl), 7.00 (1H, d, J = 8.3 Hz, H8-THIQ) and 7.15 (2H, d, J = 9.0 Hz, 2 x ArCH, 
phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 12.3 (CH2CH3), 27.2 (CH2CH3), 41.0 (C4-
THIQ), 49.5 (C3-THIQ), 49.7(C1-THIQ), 55.3 (OCH3), 112.2 (C7-THIQ), 113.1(C5-
THIQ), 115.2 (2 x ArCH, phenyl), 122.6 (ArCCl), 125.7 (C1CC8-THIQ), 127.5(C8-










The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give the product as a colourless oil (53 mg, 36%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 0.94 (3H, d, J = 6.8 Hz, (CH3)2CH), 0.98 (3H, 
d, J = 6.8 Hz, (CH3)2CH), 1.93 – 2.04 (1H, m, (CH3)2CH), 2.61 (1H, dt, J = 3.6, 7.2 Hz, 
H4-THIQ), 3.23 (1H, dd, J = 3.6, 12.1 Hz, H3-THIQ), 3.79 (1H, dd, J = 3.6, 12.1 Hz, 
H3-THIQ), 3.81 (3H, s, OCH3), 4.16 (1H, d, J = 14.6 Hz, H1-THIQ), 4.44 (1H, d, J 
= 14.6 Hz, H1-THIQ), 6.73 (1H, d, J = 2.6 Hz, H5-THIQ), 6.79 (1H, dd, J = 2.6, 8.4 Hz, 
H7-THIQ), 6.81 (2H, d, J = 9.1 Hz, 2 x ArCH, phenyl), 7.08 (1H, d, J = 8.4 Hz, H8-
THIQ) and 7.22 (2H, d, J = 9.0 Hz, 2 x ArCH, phenyl) ppm. 
13
C NMR (126 MHz, 
CDCl3) δ 20.1 ((CH3)2CH), 21.5 ((CH3)2CH), 30.7 ((CH3)2CH), 46.2 (C4-THIQ), 46.4 
(C3-THIQ), 49.4 (C1-THIQ), 55.3 (OCH3), 112.1 (C7-THIQ), 114.0 (C5-THIQ), 114.3 
(2 x ArCH, phenyl), 122.0 (ArCCl), 125.9 (C1CC8-THIQ), 127.6 (C8-THIQ), 128.8, 




C23H22ClNO, Mol. Wt.: 363.88 
 
(Method J) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give the product as a white solid (327 mg, 63%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 2.86 (1H, dd, J = 10.1, 13.7 Hz, ArCH2CH), 
2.97 (1H, dd, J = 5.3, 13.7 Hz, ArCH2CH), 3.03 (1H, dd, J = 3.4, 12.2 Hz, H3-THIQ), 
3.06 - 3.12 (1H, m, H4-THIQ), 3.48 (1H, dd, J = 3.0, 12.2 Hz, H3-THIQ), 3.68 (3H, s, 
OCH3), 4.07 (1H, d, J = 14.8 Hz, H1-THIQ), 4.44 (1H, d, J = 14.7 Hz, H1-THIQ), 6.57 
(1H, d, J = 2.5 Hz, H5-THIQ), 6.70 (2H, d, J = 9.0 Hz, 2 x ArCH, N-phenyl), 6.73 (1H, 
dd, J = 2.6, 8.5 Hz, H7-THIQ), 7.03 (1H, d, J = 8.4 Hz, H8-THIQ), 7.08 - 7.15 (4H, m, 2 
x ArCH, N-phenyl, 2 x ArCH, C4-phenyl), 7.17 – 7.19 (1H, m, ArCH, C4-phenyl) and 
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7.25 (2H, t, J = 7.3 Hz, 2 x ArCH, C4-phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 41.3 
(ArCH2CH), 41.6 (C4-THIQ), 48.5 (C3-THIQ), 49.9 (C1-THIQ), 55.3 (OCH3), 112.9 
(C7-THIQ), 113.0 (C5-THIQ), 115.4 (2 x ArCH, N-phenyl), 122.9 (ArCCl), 125.5 
(C1CC8-THIQ), 126.4 (ArCH, C4-phenyl), 127.6 (C8-THIQ), 128.5 (2 x ArCH, C4-
phenyl), 128.9 (2 x ArCH), 129.4 (2 x ArCH), 139.4 (C4CC5-THIQ), 140.1 (ArCCH2, 




C19H22ClNO2, Mol. Wt.: 331.84  
 
(Method J) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give the product as a yellow oil (76 mg, 37%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 1.88 – 2.03 (2H, m, CHCH2), 3.06 – 3.13 (1H, 
m, H4-THIQ), 3.28 (1H, dd, J = 3.5, 12.1 Hz, H3-THIQ), 3.39 (3H, s, CH2OCH3), 
3.42 - 3.55 (2H, m, CH2O), 3.67 (1H, dd, J = 3.3, 12.1 Hz, H3-THIQ), 3.81 (3H, s, 
ArOCH3), 4.15 (1H, d, J = 14.7 Hz, H1-THIQ), 4.43 (1H, d, J = 14.7 Hz, H1-THIQ), 
6.76 (1H, d, J = 2.6 Hz, H5-THIQ), 6.79 (1H, dd, J = 2.6, 8.3 Hz, H7-THIQ), 6.85 (2H, 
d, J = 9.0 Hz, 2 x ArCH, phenyl), 7.08 (1H, d, J = 8.3 Hz, H8-THIQ) and 7.22 (2H, d, J 
= 9.0 Hz, 2 x ArCH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 34.3 (CHCH2), 36.4 
(C4-THIQ), 49.6 (C1-THIQ), 50.0 (C3-THIQ), 55.3 (ArOCH3), 58.7 (CH2OCH3), 70.6 
(CH2O), 112.6 (C7-THIQ), 113.1 (C5-THIQ), 115.2 (2 x ArCH, phenyl), 122.7 (ArCCl), 
125.6 (C1CC8-THIQ), 127.6 (C8-THIQ), 128.9 (2 x ArCH, phenyl), 139.6 (C4CC5-






C18H20ClNO, Mol. Wt.: 301.81 
 
(Method J) 
The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give the product as a white solid (94 mg, 23%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 1.28 (6H, s, (CH3)2C), 3.14 (2H, s, H3-THIQ), 
3.74 (3H, s, OCH3), 4.22 (2H, s, H1-THIQ), 6.68 (1H, dd, J = 2.6, 8.4 Hz, H7-THIQ), 
6.79 (2H, d, J = 9.0 Hz, 2 x ArCH, phenyl), 6.83 (1H, d, J = 2.6 Hz, H5-THIQ), 6.98 
(1H, d, J = 8.4 Hz, H8-THIQ) and 7.15 (2H, d, J = 9.0 Hz, 2 x ArCH, phenyl) ppm. 
13
C 
NMR (126 MHz, CDCl3) δ 28.1 ((CH3)2C), 35.8 (C4-THIQ), 50.5 (C1-THIQ), 55.3 
(OCH3), 59.9 (C3-THIQ), 110.9 (C5-THIQ), 111.6 (C7-THIQ), 115.7 (2 x ArCH, 
phenyl), 123.0 (ArCCl), 125.1 (C1CC8-THIQ), 127.4 (C8-THIQ), 129.0 (2 x ArCH, 






The crude compound was purified by column chromatography (eluent: from 0% to 
20% EtOAc in pet. ether) to give the product as a colourless oil (19 mg, 4%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 2.81 – 2.88 (1H, m, ArCH2CH), 2.93 – 2.99 
(2H, m, ArCH2CH, H3-THIQ), 3.08 – 3.16 (1H, m, H4-THIQ), 3.49 (1H, dd, J = 2.6, 
12.3 Hz, H3-THIQ), 3.81 (3H, s, OCH3), 3.97 (1H, d, J = 16.4 Hz, H1-THIQ), 4.44 (1H, 
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d, J = 16.4 Hz, H1-THIQ), 6.69 (1H, d, J = 8.1 Hz, H5 or H7-THIQ), 6.76 (3H, d, J = 8.9 
Hz, 2 x ArCH, N-phenyl, H5 or H7-THIQ), 7.10 – 7.16 (5H, m, 2 x ArCH, N-phenyl, 2 x 
ArCH, C4-phenyl, H6-THIQ), 7.18 (1H, t, J = 7.2 Hz, ArCH, C4-phenyl) and 7.25 (2H, 
t, J = 7.3 Hz, 2 x ArCH, C4-phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 41.4 (C3-
THIQ), 41.5 (ArCH2CH), 46.0 (C1-THIQ), 47.7 (C4-THIQ), 55.3 (OCH3), 107.4 (C7 or 
C5-THIQ), 115.5 (2 x ArCH, N-phenyl), 120.4 (C7 or C5-THIQ), 122.3 (C1CC8-THIQ), 
122.8 (ArCCl), 126.3 (ArCH), 126.9 (ArCH, C4-phenyl), 128.5 (2 x ArCH), 128.9 (2 x 
ArCH), 129.4 (2 x ArCH), 139.7 (C4CC5-THIQ), 140.3 (ArCCH2, C4-phenyl), 149.5 
(ArCN) and 156.0 (C8-THIQ) ppm. 
 
N-(4-Chlorophenyl)-N-(2-(3-methoxyphenyl)propyl)-2-phenylacetamide (231a) 
C24H24ClNO2, Mol. Wt.: 393.91 
 
Phenacetyl chloride (162 µL, 1.20 mmol) was added to a stirring solution of 225a 
(300 mg, 1.09 mmol) and Et3N (229 µL, 1.64 mmol) in DCM (3 mL) and the mixture 
was stirred overnight at rt under inert atmosphere. The mixture was then diluted with 
DCM (25 mL) washed with 1 N NaOH (3 x 25 mL), 1 N HCl (3 x 25 mL) and brine (25 
mL), then dried with MgSO4, filtered and evaporated to give a yellow oil (403 mg). The 
crude compound was purified by column chromatography (eluent: from 0% to 40% 
EtOAc in pet. ether) to give the product as a colourless oil (223 mg, 52%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 1.14 (3H, d, J = 7.0 Hz, CHCH3), 2.89 – 3.01 
(1H, m, CHCH3), 3.27 (2H, s, CH2CO), 3.67 (3H, s, OCH3), 3.68 – 3.73 (1H, m, 
CH2N), 3.93 (1H, dd, J = 6.9, 13.5 Hz, CH2N), 6.58 (2H, d, J = 7.4 Hz, 2 x ArCH, 
aniline), 6.59 – 6.61 (1H, m, ArCH, methoxyphenyl), 6.63 (1H, d, J = 7.9 Hz, ArCH, 
methoxyphenyl), 6.67 (1H, dd, J = 2.0, 7.9 Hz, ArCH, methoxyphenyl), 6.85 (2H, d, J = 
7.4 Hz, 2 x ArCH, aniline), 7.08 (1H, t, J = 7.9 Hz, ArCH, methoxyphenyl) and 7.10 – 
7.17 (5H, m, 5 x ArCH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 19.9 (CHCH3), 
38.3 (CHCH3), 41.4 (CH2CO), 55.2 (OCH3), 55.9 (CH2N), 112.1 (ArCH, 
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methoxyphenyl), 113.1 (ArCH, methoxyphenyl), 120.0 (ArCH, methoxyphenyl), 126.6 
(ArCH, phenyl), 128.4 (2 x ArCH, phenyl), 128.8 (2 x ArCH, aniline), 129.4 (ArCH, 
methoxyphenyl), 129.5 (ArCH, phenyl), 129.7 (2 x ArCH, aniline), 133.6 (ArCCl), 
135.2 (ArCCH2), 141.3 (ArCN), 145.7 (ArCCH), 159.7 (ArCO) and 170.9 (CON) ppm. 
 
N-(4-Chlorophenyl)-N-(2-(3-methoxyphenyl)butyl)-2-phenylacetamide (231b) 
C25H26ClNO2, Mol. Wt.: 407.93 
 
Phenacetyl chloride (154 µL, 1.14 mmol) was added to a stirring solution of 225b 
(300 mg, 1.04 mmol) and Et3N (218 µL, 1.56 mmol) in DCM (3 mL) and the mixture 
was stirred overnight at rt under inert atmosphere. The mixture was then diluted with 
DCM (25 mL) washed with 1 N NaOH (3 x 25 mL), 1 N HCl (3 x 25 mL) and brine (25 
mL), then dried with MgSO4, filtered and evaporated to give a yellow oil (426 mg). The 
crude compound was purified by column chromatography (eluent: from 0% to 40% 
EtOAc in pet. ether) to give the product as a colourless oil (361 mg, 85%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 0.68 (3H, t, J = 7.4 Hz, CH2CH3), 1.36 – 1.48 
(1H, m, CH2CH3), 1.54 – 1.63 (1H, m, CH2CH3), 2.64 – 2.79 (1H, m, CHCH2), 3.24 
(2H, s, CH2CO), 3.66 (3H, s, OCH3), 3.72 (1H, dd, J = 9.9, 13.5 Hz, CH2N), 3.98 (1H, 
dd, J = 6.1, 13.5 Hz, CH2N), 6.44 - 6.53 (2H, m, 2 x ArCH, aniline), 6.53 – 6.57 (1H, 
m, ArCH, methoxyphenyl), 6.58 (1H, d, J = 7.8 Hz, ArCH, methoxyphenyl), 6.68 (1H, 
dd, J = 2.1, 7.8 Hz, ArCH, methoxyphenyl), 6.80 – 6.85 (2H, m, 2 x ArCH, phenyl), 
7.07 (2H, t, J = 7.8 Hz, ArCH, methoxyphenyl) and 7.09 – 7.15 (5H, m, 3 x ArCH, 
phenyl, 2 x ArCH, aniline) ppm. 
13
C NMR (126 MHz, CDCl3) δ 11.8 (CH2CH3), 27.1 
(CH2CH3), 41.4 (CH2CO), 45.8 (CHCH2), 54.8 (CH2N), 55.2 (OCH3), 112.1 (ArCH, 
methoxyphenyl), 113.8 (ArCH, methoxyphenyl), 120.9 (ArCH, methoxyphenyl), 126.5 
(ArCH, phenyl), 128.3 (2 x ArCH), 128.8 (2 x ArCH), 129.2 (ArCH, methoxyphenyl), 
129.4 (2 x ArCH), 129.7 (2 x ArCH), 133.5 (ArCCl), 135.2 (ArCCH2), 141.4 (ArCN), 






C30H28ClNO2, Mol. Wt.: 470.00 
 
Phenacetyl chloride (127 µL, 0.938 mmol) was added to a stirring solution of 225c 
(300 mg, 0.853 mmol) and Et3N (179 µL, 1.28 mmol) in DCM (3 mL) and the mixture 
was stirred overnight at rt under inert atmosphere. The mixture was then diluted with 
DCM (25 mL) washed with 1 N NaOH (3 x 25 mL), 1 N HCl (3 x 25 mL) and brine (25 
mL), then dried with MgSO4, filtered and evaporated to give a yellow oil (387 mg). The 
crude compound was purified by column chromatography (eluent: from 0% to 40% 
EtOAc in pet. ether) to give the product as a colourless oil (153 mg, 38%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 2.77 (2H, dd, J = 8.4, 13.8 Hz, ArCH2CH), 2.83 
(2H, dd, J = 6.5, 13.8 Hz, ArCH2CH), 3.07 – 3.17 (1H, m, ArCH2CH), 3.23 (2H, s, 
ArCH2CO), 3.62 (3H, s, OCH3), 3.86 (1H, dd, J = 9.9, 13.6 Hz, CH2N), 4.00 (1H, dd, J 
= 6.1, 13.6 Hz, CH2N), 6.48 (2H, d, J = 7.4 Hz, 2 x ArCH, aniline), 6.49 – 6.52 (1H, m, 
ArCH, methoxyphenyl), 6.54 (1H, d, J = 7.8 Hz, ArCH, methoxyphenyl), 6.66 (1H, dd, 
J = 2.1, 7.8 Hz, ArCH, methoxyphenyl), 6.78 – 6.84 (2H, m, 2 x ArCH), 6.88 (2H, d, J 
= 7.0 Hz, 2 x ArCH), 7.03 (1H, t, J = 7.8 Hz, ArCH, methoxyphenyl) and 7.05 - 7.15 
(8H, m, 8 x ArCH) ppm. 
13
C NMR (126 MHz, CDCl3) δ 41.0 (ArCH2CH), 41.4 
(ArCH2CO), 45.6 (ArCH2CH), 54.0 (CH2N), 55.2 (OCH3), 112.4 (ArCH, 
methoxyphenyl), 113.7 (ArCH, methoxyphenyl), 120.8 (ArCH, methoxyphenyl), 126.0 
(ArCH), 126.6 (ArCH), 128.1 (2 x ArCH), 128.3 (2 x ArCH), 128.8 (2 x ArCH), 129.0 
(2 x ArCH), 129.3 (ArCH, methoxyphenyl), 129.4 (2 x ArCH), 129.7 (2 x ArCH), 133.6 
(ArCCl), 135.1 (ArCCH2CO), 139.4 (ArCCH2CH), 141.1 (ArCN), 143.3 (ArCCH), 






C24H24ClNO, Mol. Wt.: 377.91 
 
(Method K) 
The crude compound was purified by column chromatography (eluent: from 0% to 
10% EtOAc in pet. ether) to give the product as a yellow oil (22 mg, 36%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 1.32 (3H, d, J = 6.8 Hz, CHCH3), 3.02 (1H, dd, 
J = 5.5, 13.7 Hz, ArCH2CH), 3.04 – 3.14 (1H, m, H4-THIQ), 3.14 – 3.26 (2H, m, 
1 x ArCH2CH, 1 x H3-THIQ), 3.66 – 3.74 (1H, m, 1 x H3-THIQ), 3.79 (3H, s, OCH3), 
4.78 – 4.87 (1H, m, H1-THIQ), 6.61 (2H, d, J = 9.1 Hz, 2 x ArCH, N-phenyl), 6.68 (1H, 
dd, J = 2.6, 8.5 Hz, H7-THIQ), 6.82 (H, d, J = 2.6 Hz, H5-THIQ), 6.86 (H, d, J = 8.5 Hz, 
H8-THIQ), 7.05 (2H, d, J = 9.1 Hz, 2 x ArCH, N-phenyl), 7.10 – 7.15 (2H, m, 2 x 
ArCH, benzyl), 7.18 – 7.22 (2H, m, 2 x ArCH, benzyl) and 7.22 – 7.25 (1H, m, ArCH, 
benzyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 18.0 (CHCH3), 29.5 (C4-THIQ), 41.9 
(ArCH2CH), 48.0 (C3-THIQ), 55.2 (OCH3), 61.9 (C1-THIQ), 111.4 (C7-THIQ), 112.1 
(C5-THIQ), 116.5 (2 x ArCH, N-phenyl), 122.5 (ArCCl), 126.3(2 x ArCH, benzyl), 
128.3(ArCH, benzyl), 128.4(2 x ArCH, N-phenyl), 128.8(C8-THIQ), 129.0 (C1CC8-
THIQ), 129.6 (2 x ArCH, benzyl), 139.2 (ArCCH2), 140.9 (C4CC5-THIQ), 148.6 









The crude compound was purified by column chromatography (eluent: from 0% to 
10% EtOAc in pet. ether) to give the product as a yellow oil (87 mg, 46%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 1.03 (3H, t, J = 7.4 Hz, CH2CH3), 1.59 – 1.78 
(1H, m, CH2CH3), 1.90 – 2.04 (1H, m, CH2CH3), 2.92 – 3.05 (2H, m, H4-THIQ, 
ArCH2CH), 3.19 (1H, dd, J = 7.2, 13.4 Hz, ArCH2CH), 3.32 (1H, dd, J = 10.5, 13.6 Hz, 
H3-THIQ), 3.73 (1H, dd, J = 5.8, 13.6 Hz, H3-THIQ), 3.78 (3H, s, OCH3), 4.80 (1H, t, J 
= 6.5 Hz, H1-THIQ), 6.65 (1H, dd, J = 2.6, 8.6 Hz, H7-THIQ), 6.67 (2H, d, J = 8.8 Hz, 2 
x ArCH, N-phenyl), 6.77 (1H, d, J = 8.5 Hz, H8-THIQ), 6.81 (1H, d, J = 2.2 Hz, H5-
THIQ), 7.02 – 7.14 (4H, m, 2 x ArCH, N-phenyl, 2 x ArCH, phenyl), 7.15 – 7.21 (1H, 
m, ArCH, phenyl) and 7.21 – 7.25 (2H, m, 2 x ArCH, phenyl) ppm. 13C NMR (126 
MHz, CDCl3) δ 10.9 (CH2CH3), 25.8 (CH2CH3), 35.9 (C4-THIQ), 41.7 (ArCH2CH), 
45.8 (C3-THIQ), 55.2 (OCH3), 61.8 (C1-THIQ), 111.3 (C7-THIQ), 112.3 (C5-THIQ), 
116.9 (2 x ArCH, N-phenyl), 120.9 (ArCCl), 126.3 (ArCH, phenyl), 128.3 (2 x ArCH, 
phenyl), 128.6 (C8-THIQ), 128.9 (2 x ArCH, N-phenyl), 129.3 (C1CC8-THIQ), 129.7 (2 










The crude compound was purified by column chromatography (eluent: from 0% to 
10% EtOAc in pet. ether) to give the product as a colourless oil (11 mg, 46%) which 
showed: 
1
H NMR (400 MHz, CDCl3) δ 2.68 (1H, dd, J = 8.5, 13.5 Hz), 2.94 (1H, dd, 
J = 6.6, 13.6 Hz), 3.29 (4H, t, J = 10.7 Hz), 3.47 (1H, d, J = 7.6 Hz), 3.76 (3H, s), 4.80 
(1H, t, J = 6.3 Hz), 6.63 – 6.73 (3H, m), 6.78 (1H, d, J = 8.6 Hz), 6.85 (1H, d, 
J = 2.5 Hz), 7.01 (2H, d, J = 6.4 Hz), 7.07 (2H, d, J = 8.9 Hz), 7.14 – 7.24 (6H, m) and 






The crude compound was purified by column chromatography (eluent: from 0% to 
10% EtOAc in pet. ether) to give the product as a white solid (22mg, 12%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 1.04 (3H, t, J = 7.4 Hz, CH2CH3), 1.60 – 1.74 
(1H, m, CH2CH3), 1.97 – 2.13 (1H, m, CH2CH3), 2.99 – 3.12 (2H, m, ArCH2CH, H4-
THIQ), 3.19 (1H, dd, J = 3.0, 13.8 Hz, ArCH2CH), 3.51 (1H, dd, J = 11.5, 14.3 Hz, 
H3-THIQ), 3.82 (1H, dd, J = 6.6, 14.3 Hz, H3-THIQ), 3.89 (3H, s, OCH3), 5.05 (1H, d, J 
= 8.1 Hz, H1-THIQ), 6.50 (2H, d, J = 9.0 Hz, 2 x ArCH, N-phenyl), 6.72 (1H, d, J = 8.1 
Hz, H7-THIQ), 6.92 (1H, d, J = 7.8 Hz, H5-THIQ), 6.95 (2H, d, J = 9.0 Hz, 2 x ArCH, 
N-phenyl), 7.15 – 7.22 (2H, m, 1 x ArCH, phenyl, H6-THIQ) and 7.22 - 7.29 (4H, m, 4 
x ArCH, phenyl) ppm. 
13
C NMR (126 MHz, CDCl3) δ 10.8 (CH2CH3), 25.9 (CH2CH3), 
34.1 (C4-THIQ), 39.4 (ArCH2CH), 44.5 (C3-THIQ), 55.3 (OCH3), 58.0 (C1-THIQ), 
107.3 (C7-THIQ), 116.2 (2 x ArCH, N-phenyl), 119.5 (C5-THIQ), 122.0 (ArCCl), 126.0 
(ArCH, phenyl), 127.3 (C6-THIQ), 127.5 (C1CC8-THIQ), 128.2 (2 x ArCH, phenyl), 
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128.6 (2 x ArCH, N-phenyl), 129.4 (2 x ArCH, phenyl), 139.5 (C4CC5-THIQ), 140.5 




C30H28ClNO, Mol. Wt.: 454.00 
 
(Method K) 
The crude compound was purified by column chromatography (eluent: from 0% to 
10% EtOAc in pet. ether) to give the product as a colourless oil (2 mg, 8%) which 
showed: 
1
H NMR (500 MHz, CDCl3) δ 2.64 (1H, dd, J = 9.5, 13.8 Hz), 2.96 (1H, dd, J 
= 9.5, 13.7 Hz), 3.15 (1H, dd, J = 3.1, 13.8 Hz), 3.34 – 3.54 (3H, m), 3.90 (3H, s), 5.03 
(1H, d, J = 7.5 Hz), 6.25 – 6.34 (2H, m), 6.76 (1H, d, J = 8.1 Hz), 6.86 – 6.91 (2H, m), 
7.05 (1H, d, J = 7.4 Hz), 7.24 (6H, s), 7.24 – 7.29 (3H, m) and 7.35 (2H, dd, J = 6.4, 
13.9 Hz) ppm. 
 
2-(4-Chlorophenyl)-3-methyl-1,2,3,4-tetrahydroisoquinolin-6-ol hydrobromide  
(234a) 





Filtration afforded the product as a white precipitate (429 mg, 87%) which showed: 
1
H NMR (500 MHz, D6-DMSO) δ 0.91 (3H, d, J = 6.5 Hz, CHCH3), 2.59 (1H, dd, J 
= 1.6, 15.7 Hz, H4-THIQ), 3.06 (1H, dd, J = 5.3, 15.7 Hz, H4-THIQ), 4.03 (1H, d, J = 
15.3 Hz, H1-THIQ), 4.29 – 4.31 (1H, m, H3-THIQ), 4.32 (1H, d, J = 15.3 Hz, 
H1-THIQ), 6.60 (1H, d, J = 2.2 Hz, H5-THIQ), 6.63 (1H, dd, J = 2.2, 8.2 Hz, H7-THIQ), 
6.93 (2H, d, J = 9.1 Hz, 2 x ArCH, phenyl), 7.04 (1H, d, J = 8.2 Hz, H8-THIQ), 7.23 
(2H, d, J = 9.0 Hz, 2 x ArCH, phenyl) and 9.26 (1H, bs, OH) ppm. 
13
C NMR (126 MHz, 
D6-DMSO) δ 15.3 (CHCH3), 34.9 (C4-THIQ), 44.9 (C1-THIQ), 47.5 (C3-THIQ), 113.3 
(C7-THIQ), 115.0 (C5-THIQ), 115.1 (2 x ArCH, phenyl), 120.4 (ArCCl), 123.3 (C1CC8-
THIQ), 127.2 (C8-THIQ), 128.7 (2 x ArCH, phenyl), 133.8 (C1CC4-THI), 147.8 (ArCN) 




C16H17BrClNO, Mol. Wt.: 354.67 
 
(Method G) 
Filtration afforded the product as a yellow precipitate (178 mg, 58%) which showed: 
1
H NMR (500 MHz, D6-DMSO) δ 1.25 (3H, d, J = 6.9 Hz, CHCH3), 2.92 – 3.04 (1H, 
m, H4-THIQ), 3.21 (1H, dd, J = 6.6, 12.2 Hz, H3-THIQ), 3.47 (1H, dd, J = 4.4, 12.2 Hz, 
H3-THIQ), 4.20 (1H, d, J = 15.0 Hz, H1-THIQ), 4.28 (1H, d, J = 15.0 Hz, H1-THIQ), 
6.61 (1H, dd, J = 2.3, 8.3 Hz, H7-THIQ), 6.66 (1H, d, J = 2.3 Hz, H5-THIQ), 6.95 (2H, 
d, J = 9.0 Hz, 2 x ArCH, phenyl), 7.00 (1H, d, J = 8.3 Hz, H8-THIQ), 7.23 (2H, d, J = 
9.0 Hz, 2 x ArCH, phenyl) and 9.25 (1H, bs, OH) ppm. 
13
C NMR (126 MHz, D6-
DMSO) δ 19.3 (CHCH3), 32.3 (C4-THIQ), 49.0 (C1-THIQ), 52.2 (C3-THIQ), 113.2 (C5-
THIQ), 113.3 (C7-THIQ), 115.5 (2 x ArCH, phenyl), 120.8 (ArCCl), 123.7 (C1CC8-
THIQ), 127.3 (C8-THIQ), 128.6 (2 x Arch, phenyl), 140.7 (C4CC5-THIQ), 149.1 













+H) 276.0965, found 276.0967. 




C17H19BrClNO, Mol. Wt.: 368.70 
 
(Method G) 
Filtration afforded the product as a yellow precipitate (161 mg, 47%) which showed: 
1
H NMR (500 MHz, D6-DMSO) δ 0.97 (3H, t, J = 7.4 Hz, CH2CH3), 1.50 – 1.70 (2H, 
m, CH2CH3), 2.66 – 2.78 (1H, m, H4-THIQ), 3.27 (1H, dd, J = 3.9, 12.3 Hz, H3-THIQ), 
3.56 (1H, dd, J = 4.4, 12.3 Hz, H3-THIQ), 4.11 (1H, d, J = 15.0 Hz, H1-THIQ), 4.35 
(1H, d, J = 15.0 Hz, H1-THIQ), 6.58 – 6.67 (2H, m, H5, H7-THIQ), 6.94 (2H, d, J = 9.0 
Hz, 2 x ArCH, phenyl), 7.01 (1H, d, J = 8.9 Hz, H8-THIQ), 7.24 (2H, d, J = 9.0 Hz, 2 x 
ArCH, phenyl) and 9.25 (1H, bs, OH) ppm. 
13
C NMR (126 MHz, D6-DMSO) δ 11.8 
(CH2CH3), 26.6 (CH2CH3), 39.6 (C4-THIQ), 48.7 (C3-THIQ), 48.8 (C1-THIQ), 113.4 
(C5 or C7-THIQ), 114.0 (C5 or C7-THIQ), 115.1 (2 x ArCH, phenyl), 120.6 (ArCCl), 
123.7 (C1CC8-THIQ), 127.4 (C8-THIQ), 128.6 (2 x ArCH, phenyl), 139.6 (C4CC5-











+H) 290.1120, found 









Filtration afforded the product as a pale yellow precipitate (12 mg, 31%) which 
showed: 
1
H NMR (500 MHz, D6-DMSO) δ 0.86 (3H, d, J = 6.7 Hz, (CH3)2CH), 0.92 
(3H, d, J = 6.8 Hz, (CH3)2CH), 1.80 – 1.97 (1H, m, (CH3)2CH), 2.57 (1H, dt, J = 3.6, 
7.1 Hz, H4-THIQ), 3.15 (1H, dd, J = 3.7, 12.4 Hz, H3-THIQ), 3.75 (1H, dd, J = 3.9, 12.4 
Hz, H3-THIQ), 4.11 (1H, d, J = 15.1 Hz, H1-THIQ), 4.37 (1H, d, J = 15.0 Hz, H1-
THIQ), 6.62 (1H, d, J = 2.1 Hz, H5-THIQ), 6.64 (1H, dd, J = 2.4, 8.2 Hz, H7-THIQ), 
6.91 (2H, d, J = 9.0 Hz, 2 x ArCH, phenyl), 7.03 (1H, d, J = 8.2 Hz, H8-THIQ), 7.23 
(2H, d, J = 9.0 Hz, 2 x ArCH, phenyl) and 9.27 (1H, bs, OH) ppm. 
13
C NMR (126 MHz, 
D6-DMSO) δ 19.7 ((CH3)2CH), 21.1 ((CH3)2CH), 30.1 ((CH3)2CH), 44.8 (C4-THIQ), 
45.7 (C3-THIQ), 48.6 (C14-THIQ), 113.5 (C7-THIQ), 114.3 (2 x ArCH, phenyl), 114.8 
(C5-THIQ), 120.1 (ArCCl), 123.9 (C1CC8-THIQ), 127.5 (C8-THIQ), 128.6 (2 x ArCH, 
phenyl), 138.9 (C1CC4-THIQ), 148.5 (ArCN) and 155.3 (C6-THIQ) ppm. Mp 190-193 
°C. 
 
4-Benzyl-2-(4-chlorophenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol hydrobromide  
(234f) 
C22H21BrClNO, Mol. Wt.: 430.77 
 
(Method G) 
The crude compound was purified by reversed phase column chromatography 
(eluent: from 10% to 100% MeOH in water) to give the desired product as a yellow 
solid (201 mg, 66%) which showed: 
1
H NMR (500 MHz, D6-DMSO) δ 2.78 (1H, dd, J 
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= 10.2, 13.3 Hz, ArCH2, benzyl), 2.96 (1H, dd, J = 4.9, 13.5 Hz, ArCH2, benzyl), 3.05 
(1H, dd, J = 3.2, 12.1 Hz, H3-THIQ), 3.11 – 3.20 (1H, m, H4-THIQ), 3.38 (3H, dd, J = 
4.3, 12.1 Hz, H3-THIQ), 4.08 (1H, d, J = 15.0 Hz, H1-THIQ), 4.45 (1H, d, J = 15.0 Hz, 
H4-THIQ), 6.60 – 6.69 (2H, m, H5, H7-THIQ), 6.80 (2H, d, J = 8.9 Hz, 2 x ArCH, 
phenyl), 7.04 (1H, d, J = 8.9 Hz, H8-THIQ), 7.18 – 7.28 (5H, m, 3 x ArCH, benzyl, 2 x 
ArCH, phenyl), 7.32 (2H, t, J = 7.4 Hz, 2 x ArCH, benzyl) and 9.30 (1H, bs, OH) ppm. 




C17H19BrClNO, Mol. Wt.: 368.70 
 
(Method G) 
Filtration afforded the product as a white precipitate (81 mg, 85%) which showed: 
1
H 
NMR (500 MHz, D6-DMSO) δ 1.26 (6H, s, (CH3)2C), 3.22 (2H, s, H3-THIQ), 4.23 (2H, 
s, H1-THIQ), 6.61 (1H, dd, J = 2.3, 8.3 Hz, H7-THIQ), 6.77 (1H, d, J = 2.3 Hz, H5-
THIQ), 6.98 (1H, d, J = 8.3 Hz), 6.98 (2H, d, J = 9.1 Hz, 2 x ArCH, phenyl), 7.25 (2H, 
d, J = 9.1 Hz, 2 x ArCH, phenyl) and 9.20 (1H, bs, OH) ppm. 
13
C NMR (126 MHz, D6-
DMSO) δ 27.7 ((CH3)2C), 35.2 (C4-THIQ), 49.6 (C1-THIQ), 58.5 (C3-THIQ), 111.4 
(C5-THIQ), 113.4 (C7-THIQ), 115.6 (2 x ArCH, phenyl), 121.0 (ArCCl), 122.8 (C1CC8-
THIQ), 127.3 (C8-THIQ), 128.6 (2 x ArCH, phenyl), 144.5 (C4CC5-THIQ), 149.3 











+H) 290.1120, found 290.1141. 









Filtration afforded the product as a pale yellow precipitate (19 mg, 63%) which 
showed: 
1
H NMR (500 MHz, D6-DMSO) δ 1.15 (3H, d, J = 6.6 Hz, CHCH3), 2.74 – 
2.88 (1H, m, H4-THIQ), 2.91 (1H, dd, J = 4.5, 13.7 Hz, CH2CH), 3.03 (1H, dd, J = 9.4, 
13.7 Hz, CH2CH), 3.08 – 3.18 (1H, m, H3-THIQ), 3.65 (1H, dd, J = 5.5, 14.4 Hz, H3-
THIQ), 4.77 – 4.90 (1H, m, H1-THIQ), 6.44 – 6.53 (3H, m), 6.59 (2H, d, J = 8.9 Hz), 
6.88 – 6.96 (2H, m), 7.08 (2H, dd, J = 4.6, 10.9 Hz), 7.16 (3H, q, J = 7.3 Hz) and 9.19 
(2H, bs, OH) ppm. 
13
C NMR (126 MHz, D6-DMSO) δ 17.8 (CHCH3), 28.2 (C4-THIQ), 
41.5 (CH2CH), 46.2 (C3-THIQ), 60.4 (C1-THIQ), 113.0 (ArCH), 115.5 (2 x ArCH), 
120.1 (ArCCl), 126.0 (ArCH), 127.9 (C1CC8-THIQ), 128.0 (2 x ArCH), 128.3 (ArCH), 
128.5 (2 x ArCH), 128.6 (ArCH), 129.4 (2 x ArCH), 139.4 (ArCH2CH), 140.4 (C4CC5-











C24H25ClBrNO, Mol. Wt.: 458.82 
 
(Method G) 
Filtration afforded the product as a pale yellow precipitate (88 mg, 86%) which 
showed: 
1
H NMR (500 MHz, D6-DMSO) δ 0.97 (3H, t, J = 7.4 Hz, CH2CH3), 1.47 – 
1.72 (1H, m, CH2CH3), 1.82 – 2.01 (1H, m, CH2CH3), 2.80 – 2.93 (1H, m, H4-THIQ), 
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2.99 (1H, dd, J = 5.0, 13.7 Hz, ArCH2CH), 3.10 (1H, dd, J = 9.2, 13.7 Hz, ArCH2CH), 
3.32 (1H, dd, J = 11.6, 14.2 Hz, H3-THIQ), 3.76 (1H, dd, J = 5.8, 14.2 Hz, H3-THIQ), 
4.91 (1H, dd, J = 5.0, 8.6 Hz, H1-THIQ), 6.54 (1H, dd, J = 1.9, 8.3 Hz, H7-THIQ), 6.68 
(1H, d, J = 1.9 Hz, H5-THIQ), 6.71 (2H, d, J = 9.0 Hz, 2 x ArCH, N-phenyl), 6.95 (1H, 
d, J = 8.4 Hz, H8-THIQ), 7.05 (2H, d, J = 9.0 Hz, 2 x ArCH, N-phenyl), 7.12 - 7.19 (1H, 
m, ArCH, phenyl), 7.20 – 7.28 (4H, m, 4 x ArCH, phenyl) and 9.22 (1H, bs, OH) ppm. 
13
C NMR (126 MHz, D6-DMSO) δ 10.4 (CH2CH3), 25.0 (CH2CH3), 34.0 (C4-THIQ), 
41.3 (ArCH2CH), 43.6 (C3-THIQ), 60.2 (C1-THIQ), 112.8 (C7-THIQ), 113.0 (C5-
THIQ), 115.8 (2 x ArCH, N-phenyl), 120.2 (ArCCl), 126.0 (ArCH), 128.0 (2 x ArCH, 
phenyl), 128.3 (C1CC8-THIQ), 128.4 (C8-THIQ), 128.5 (2 x ArCH, N-phenyl), 129.4 (2 
x ArCH, phenyl), 138.8 (C4CC5-THIQ), 139.2 (ArCCH2CH), 148.5 (ArCN) and 155.8 




















C29H27ClBrNO, Mol. Wt.: 520.89 
 
(Method G) 
Filtration afforded the product as a white precipitate (12 mg, 45%) which showed: 
1
H 
NMR (500 MHz, D6-DMSO) δ 2.60 – 2.77 (1H, m, H3-THIQ), 2.95 (2H, ddd, J = 7.2, 
13.7, 18.8 Hz, CH2C1), 3.15 – 3.32 (4H, m, H3, H4-THIQ, CH2C4), 4.84 – 4.95 (1H, m, 
H1-THIQ), 6.50 (2H, d, J = 8.9 Hz, 2 x ArCH, N-phenyl), 6.57 (1H, d, J = 8.4 Hz, H7-
THIQ), 6.85 (1H, s, H5-THIQ), 6.96 (1H, d, J = 8.4 Hz, H8-THIQ), 7.01 (2H, d, J = 8.9 
Hz, 2 x ArCH, N-phenyl), 7.12 – 7.17 (3H, d, J = 7.5 Hz), 7.22 (2H, t, J = 7.4 Hz), 7.26 
(1H, dd, J = 6.0, 13.5 Hz), 7.32 (2H, d, J = 7.2 Hz), 7.36 (2H, t, J = 7.4 Hz) and 9.28 
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(1H, bs, OH) ppm. 
13
C NMR (126 MHz, D6-DMSO) δ 34.6 (C4-THIQ), 38.8 (C3-
THIQ), 41.1 (CH2C4), 44.2 (CH2C1), 60.2 (C1-THIQ), 113.1 (C7-THIQ), 113.4 (C5-
THIQ), 115.7 (2 x ArCH), 120.4 (ArCCl), 126.0 (ArCH), 126.2 (ArCH), 127.9 (2 x 
ArCH), 128.2 (C1CC8-THIQ), 128.3 (2 x ArCH), 128.4 (C8-THIQ), 128.5 (2 x ArCH), 
129.1 (2 x ArCH), 129.4 (2 x ArCH), 138.7 (C4CC5-THIQ), 139.0 (ArCCH2CH), 139.6 
















+H) 400.1439, found 400.1466. 




4.2. Biology: materials and methods 
All chemicals were purchased from Aldrich Chemical Co. (Gillingham, UK), or 
Fischer Scientific (Loughborough, UK). For purification of the His-17β-HSD1 protein 
an AKTA FPLC from Amersham Biosciences (GE Healthcare), HisTrap chelating HP 
column from Pharmacia (GE Healthcare) loaded with Ni
2+
 , and a Q-sepharose column 
Amersham Biosciences (GE Healthcare) were used. For enzyme and inhibitor assays 
Cell Titer 96 ® AQueous One solution was purchased from Promega (Southampton, 
UK). 
For the ERRα screening, the LanthaScreenTM Estrogen Related Receptor alpha TR-
FRET Co-activator assay kit was purchased from Invitrogent (catalogue number 
PV4663) and contained all the necessary components for the assay. As indicated by the 
protocol, the plates used were 384 well microplates Non-Binding Surface low volume, 
low flange, round bottom non-sterile black and were purchased from Fisher Scientific 
(Loughborough, UK) (product code HTS-120-040L). 
T47-D cells were kindly supplied by Dr. Atul Purohit, Imperial College of London, 
while the MCF-7 cells were kindly supplied by Prof. Rex Tyrell, University of Bath and 
all the media and additives were purchased from Aldrich Chemical Co. (Gillingham, 
UK). 
 
4.2.1.  Glycerol stock 
Cells were inoculated into 5 mL of LB medium with the appropriate antibiotic 
(Kanamycin and chloramphenicol; final conc. 30 mg/L and 34 mg/L, respectively) and 
incubated at 37 °C. Cell density was checked by a monochromator until OD600 ca. 0.8 
and then 1 mL of cell culture was mixed with 0.2 mL of sterile glycerol, and stored at –
80 °C. 
 
4.2.2.  Expression of His-17-βHSD1 
Cells were inoculated into 10 mL of LB medium with the appropriate antibiotic 
(Kanamycin and chloramphenicol; final conc. 30 mg/L and 34 mg/L, respectively) and 
incubated at 37 °C for 6 h. The 10 mL culture was transferred into 100 mL of fresh LB 
medium containing the same antibiotics and the cell were incubated overnight at 37 °C 
and shaken at 250 rpm. 10 mL of the overnight culture was transferred into 1 L of fresh 
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LB medium containing the same antibiotics and incubated at 37 °C until an OD600 = 0.6 
was measured. The culture was then cooled to 16 °C and IPTG was added to a final 
concentration of 12.5 µM. The culture was incubated overnight at 16 °C and shaken at 
250 rpm then harvested by centrifuging at 5000 rpm (2740 g) for 10 min. The 
supernatant was discarded and the pellet was suspended in ca. 30 mL of low imidazole 
Buffer A (buffer composition is described below) and frozen for four days. 
 
4.2.3.  Purification of His-17-βHSD1 
Buffer A (low imidazole): 40 mM Tris·HCl pH 8.0, 20% glycerol, 0.2 mM DTT, 0.4 
mM PMSF, 500 mM NaCl, 20 mM imidazole. 
Buffer B (High imidazole): 40 mM Tris·HCl pH 8.0, 20% glycerol, 0.2 mM DTT, 
0.4 mM PMSF, 500 mM NaCl, 500 mM imidazole. 
Buffer C (Low salt): 40 mM Tris·HCl pH 8.0, 20% glycerol, 0.2 mM DTT, 0.4 mM 
PMSF, 20 mM NaCl. 
Buffer D (High salt): 40 mM Tris·HCl pH 8.0, 20% glycerol, 0.2 mM DTT, 0.4 mM 
PMSF, 500 mM NaCl. 
 
4.2.3.1.  HisTrap column purification 
The pellet was defrosted and benzonase (5 units/mL of cells) was added prior to 
treatment with a One Shot Constant Cell Disruption System. The cell lysate was 
centrifuged at 10000 rpm (9600 g) for 30 min at 4 °C and the supernatant was steri-
filtered prior to further purification. The filtered supernatant was loaded onto an AKTA 
FPLC with a HisTrap chelating HP column that was previously activated by loading it 
with Nickel ions. The protein was loaded with 100% Buffer A and after rinsing with 5% 
Buffer B for 5 min at 3 mL/min the protein was eluted with a gradient of Buffer B from 
5% to 100% in 30 min, then 100% Buffer B for 10 min. The fractions containing the 
purified protein were identified by using SDS-PAGE gel electrophoresis and were 
subsequently dialysed at 5 °C for 3-4 h in low salt Buffer C (buffer composition 




4.2.3.2.  Q-sepharose column purification 
The dialysed protein was loaded onto an AKTA FPLC with a Q-sepharose column 
previously equilibrated with 100% Buffer C. The protein was loaded with 100% Buffer 
C and after rinsing with 5% Buffer D for 5 min at 3 mL/min the protein was eluted with 
a gradient of Buffer B from 5% to 100% in 30 min, then 100% Buffer B for 10 min. The 
fractions containing the purified protein were identified by using SDS-PAGE gel 
electrophoresis and were subsequently dialysed at 5 °C for 3-4 h in low salt Buffer E 
(40 mM Tris·HCl pH 7.5, 20% glycerol, 0.2 mM DTT, 1.0 mM EDTA) before leaving 
the dialysis cell in fresh Buffer E overnight. 
 
4.2.4.  SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was carried out using a Mini Protean II TM apparatus (Bio-Rad). A 3% 
stacking gel and 10%, 12.5% or 15% running gel were used along with gel running 
buffer containing 25 mM Tris, 0.2 M glycine and 0.5% (w/v) SDS. 
- Stacking gel: 30% (w/v) acrylamide and 0.8% (w/v) bisacrylamide solution (320 
μL), Tris-HCl (1 M, pH 6.8, 400 μL), 10% (w/v) SDS (32 μL), 1% (w/v) 
ammonium persulphate (160 μL), water (2.32 mL), TEMED (5 μL). 
- Running gel: 30% (w/v) acrylamide and 0.8% (w/v) bisacrylamide solution (2 
mL for 10%, 2.5 mL for 12.5%, 3 mL for 15%), Tris-HCl (0.75 M, pH 8.8, 3 
mL), 10% Pr(w/v) SDS (60 μL), 1% (w/v) ammonium persulphate (300 μL), 
water (750 μL for 10%, 200 μL for 12.5% and no water in 15%), TEMED (5 μL). 
- Sample loading buffer (2x): Tris-HCl (0.625 M, pH 6.8, 2.5 mL), glycerol (2.0 
mL), 10% (w/v) SDS solution (5.0 mL), β-mercaptoethanol (1.0 mL), water (9.5 
mL), 0.01% (w/v) bromophenol blue. 
- Gel staining solution: Comassie Brilliant Blue R-250 [0.25% (w/v)] with water in 
methanol [30% (v/v)] in water and acetic acid [10% (v/v)] in water. 
- Gel destaining solution: methanol [30% (v/v)] in water, acetic acid [10% (v/v)] in 
water. 
- Gel storing solution: methanol [30% (v/v)] in water, glycerol [3% (v/v)] in water. 
The protein sample (10 μL) and 5X SDS sample loading buffer (2 μL) were 
transferred into an Eppendorf tube. The sample was loaded onto a SDS-PAGE with a 
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3% stacking gel. The power supply was set at 40 mA per gel, 90V until the samples 
stacked, then 250 V until the end of the gel electrophoresis. Gels were stained and 
destained after electrophoresis using the above mentioned solutions. Standard molecular 
weight markers were used to calibrate the SDS-PAGE containing: 250 kDa, 148 kDa, 
98 kDa, 64 kDa, 50 kDa, 36 kDa, 22 kDa, 16 kDa and 4 kDa marker proteins. 
 
4.2.5.  Protein concentration determination 
Protein concentrations were determined by the method of Bradford and the test was 
performed in triplicates. The Bradford reagent was gently mixed and brought to room 
temperature. Protein standards in buffer ranging from 0.1-1.4 mg/ml were prepared 
using a bovine serum albumin (BSA) standard. 5 µL of the protein standard were added 
to separate wells in a 96 well plate. For the blank wells 5 µL of buffer were added. The 
unknown protein sample was prepared with approximate concentrations between 0.1-
1.4 mg/ml. To each well, 250 µL of the Bradford reagent was added and mixed on a 
shaker for approximately 30 s. The samples were left to incubate at room temperature 
for 5 to 45 min to construct a standard curve at 595 nm. The protein concentration was 
determined by comparing the absorbance values of the protein samples against the 
standard curve at 595 nm. 
 
4.2.6.  17β-HSD1 inhibition: MTS assay 
N-Octyl-β-D-glucopyranoside (to a final concentration of 0.6 mg/mL) was added to 
the purified protein solution prior to concentrating to approximately 1 mg/mL using a 
size filter falcon tube centrifuging at 5,500 rpm for 15 min. 
The 17β-HSD1 inhibition assay was performed measuring the oxidation of E2 to E1 
and using the MTS/PMS reagents (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium and phenazine methosulfate, 
respectively) as visual enhancer. The reaction was performed in triplicates and run in 
100 µL of solution made of 10 mM Tris·HCl pH 7.5, 25 µM NADP
+
, 10 µL of 17β-
HSD1 solution (1 mg/mL) 10% DMSO (or a solution of inhibitor in DMSO) and Milli-
Q water. The reaction was started by addition of a solution containing 10 µL of 
MTS/PES and 10 µL of E2 solution in DMSO (10 µM final concentration in assay). The 
reaction was followed using a Molecular Devices Versamax plate reader and reading the 
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absorbance at 490 nm at 10 seconds intervals for 2 min. The Vmax was extrapolated from 
the data using Graphpad and the inhibition was measured as ratio Vmaxinhib/Vmax0 and the 
results were given as percentage of inhibition 100 – (Vmaxinhib/Vmax0 x 100). 
 
4.2.7.  Crystallisation 
N-Octyl-β-D-glucopyranoside (to a final concentration of 0.6 mg/mL) was added to 
the purified protein solution prior to concentrating to approximately 10 mg/mL using a 
size filter falcon tube centrifuging at 5,500 rpm (g equivalence) for 15 min. Crystals of 
the enzyme were obtained using the vapour-diffusion method in a hanging-drop set-up. 
In a 24 well plate, 1 ml of the solutions described below was added into each well. A 1 
µL drop of enzyme solution was positioned on a glass lid and added of 1 µL of solution 
from the respective well, with or without mixing. Alternatively, 1 µL of solution 
containing NADP
+
, an inhibitor or both, was added to the drop on the glass lid. The lid 
was sealed on top of the respective well with the drop hanging on the top and the system 
was let to equilibrate. Apoenzyme crystals appeared in 3-4 days and were then soaked 
by slowly adding inhibitor to the drop. 
Crystallisation solution tested: 
- 100 mM Hepes buffer (pH 7.5), 0.16 mM MgCl2 and 20 % glycerol with: 5%, 
10%, 15%, 20%, 22%, 24%, 25%, 26%, 28% or 30% PEG 4000. 
- 0.3 mM MgAc2 and 0.1 M Sodium Cacobylate with: 10%, 15%, 20%, 25%, 30% 
or 35% PEG 8000. 
- 100 mM Hepes buffer (pH 7.5), 0.16 mM MgCl2 and 20 % glycerol with: 10%, 
15%, 20%, 25%, 30% or 35% PEG 6000. 
- 1.3 M, 1.4 M, 1.5 M, 1.6 M, 1.7 M or 1.8 M Sodium Citrate pH 6.5. 
- 25% PEG 4000, 100 mM Hepes buffer (pH 7.5), 0.16 mM MgCl2 and 20 % 
glycerol with: 0.1 M ammonium sulphate, 30% DMSO, 0.1 M glycine, 0.1 M 
guanidine hydrochloride, 30% glycerol, 7% 1-butanol, 30% MMD, 50% PEG 




4.2.8.  T-47D and MCF-7 cell culture  
The T-47D cells were cultured in RPMI-1640 medium supplemented with 10% (v/v) 
fetal bovine serum, 2mM L-glutamine, insulin, sodium pyruvate, 100 U/mL penicillin 
and 100 g/mL streptomycin, and incubated in a humidified atmosphere of 5% CO2 in 
air, at 37 °C.  
The MCF-7 cells supplied by Prof. R. Tyrell, University of Bath, were cultured in 
Dulbecco's modified Eagle's medium (DMEM) high glucose (4.5 g/L), supplemented 
with 10% (v/v) fetal bovine serum, 100 U/mL penicillin, 100 g/mL streptomycin, 
sodium pyruvate, L-glutamine, NaHCO3, and incubated in a humidified atmosphere of 
5% CO2 in air, at 37 °C. 
Cells were grown in T75 flasks and subcoltured approximately when 90% confluent. 
 
4.2.9.  T47D and MCF-7 growth inhibition assay 
The assay was performed to test the effect of the compounds on the cell growth 
stimulated by estrogens. After removing the medium the cells where rinsed with PBS 
and tripsinated at 37 °C for 5-10 min. The enzyme was stopped with the addition of 
fresh culture medium and the cell suspension was centrifuged at 1500 rpm for 10 min. 
The pellet was resuspended in PBS and centrifuged again at 1500 rpm for 10 min. The 
pellet was resuspended in the same growth medium supplemented with 10% charcoal-
stripped serum (CSS) or 10% normal fetal bovine serum (FBS) according to the 
experiment. The cells were counted and opportunely diluted and then 50 µL of cell 
suspension were transferred into each well of a 96 well plate. The seed density was 10
4
 
cells per well for T-47D and 500 cells per well for MCF-7. To each well were added 50 
µL of the same medium used for the seeding modified with the following additives 
accordingly to the experiment: 
Using T-47D cell line 
- E1 stimulated growth inhibition: E1 at 0.1 nM and the tested compound at 100 
µM, 10 µM, 1.0 µM or 0.1 µM in DMSO (1% in assay). The medium used 
supplemented with 10% CSS. 
- E2 stimulated growth inhibition: E2 at 0.1 nM and the tested compound at 100 
µM, 10 µM, 1.0 µM or 0.1 µM in DMSO (1% in assay). The medium used 
supplemented with 10% CSS. 
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- Testing compound growth stimulation: tested compound at 100 µM, 10 µM, 1.0 
µM or 0.1 µM in DMSO (1% in assay). The medium used supplemented with 
10% CSS. 
- Vehicle dependence growth curve: No vehicle, 1% DMSO or 1% EtOH in 
medium supplemented with 10% CSS. Cell density was analysed at day 0, 2, 4, 6, 
8 and 10. 
- Vehicle dependence growth curve: No vehicle, 1% DMSO or 1% EtOH in 
medium supplemented with 10% FBS. Cell density was analysed at day 0, 2, 4, 6, 
8 and 10. 
- E1 stimulated growth curve with EtOH as vehicle: with or without E1 at 0.1 nM 
in EtOH (1% in assay) in medium supplemented with 10% CSS. Cell density was 
analysed at day 0, 2, 4, 6, 8 and 10. 
- E2 stimulated growth curve with EtOH as vehicle: with or without E2 at 0.1 nM 
in EtOH (1% in assay) in medium supplemented with 10% CSS. Cell density was 
analysed at day 0, 2, 4, 6, 8 and 10. 
- E1 stimulated growth curve with EtOH as vehicle: with or without E1 at 0.1 nM 
in EtOH (1% in assay) in medium supplemented with 10% FBS. Cell density was 
analysed at day 0, 2, 4, 6, 8 and 10. 
- E2 stimulated growth curve with EtOH as vehicle: with or without E2 at 0.1 nM 
in EtOH (1% in assay) in medium supplemented with 10% FBS. Cell density was 
analysed at day 0, 2, 4, 6, 8 and 10. 
- Vehicle dependant growth inhibition or stimulation: 0.01%, 0.05, 0.1% 0.5, 1% 
of DMSO or EtOH in medium supplemented with 10% CSS. 
- Vehicle dependant growth inhibition or stimulation: 0.01%, 0.05, 0.1% 0.5, 1% 
of DMSO or EtOH in medium supplemented with 10% FBS. 
- E2 growth stimulation at different vehicle concentrations: E2 at 0.1, 1.0 or 10 nM 
in EtOH at final concentrations of 0.01%, 0.05, 0.1% 0.5 or 1% in medium 
supplemented with 10% CSS. 
- 4-Hydroxytamoxifen inhibition of E2 stimulated growth inhibition: 4-
Hydroxytamoxifen at 1 nM or 10 nM with or without E2 at 0.1 nM in EtOH (1% 
in assay). The medium used supplemented with 10% CSS. 
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- 4-Hydroxytamoxifen inhibition of E1 stimulated growth inhibition: 4-
Hydroxytamoxifen at 1 nM or 10 nM with or without E1 at 0.1 nM in EtOH (1% 
in assay). The medium used supplemented with 10% CSS. 
 
Using MCF-7 cell line 
- 4-Hydroxytamoxifen inhibition of E2 stimulated growth inhibition: 4-
Hydroxytamoxifen at 1 nM or 10 nM with or without E2 at 0.1 nM in EtOH (1% 
in assay). The medium used supplemented with 10% CSS. 
- 4-Hydroxytamoxifen inhibition of E1 stimulated growth inhibition: 4-
Hydroxytamoxifen at 1 nM or 10 nM with or without E1 at 0.1 nM in EtOH (1% 
in assay). The medium used supplemented with 10% CSS. 
- Vehicle dose response: no vehicle, 0.1% or 1% of DMSO or EtOH in medium 
used supplemented with 10% CSS. 
- E2 dose response: 0.01 nM, 0.1 nM, 1.0 nM, 10 nM, 100 nM, 1.0 µM of E2 in 
EtOH (1% final concentration in assay) in medium supplemented with 10% CSS. 
- E2 dose response: 0.01 nM, 0.1 nM, 1.0 nM, 10 nM, 100 nM, 1.0 µM of E2 in 
EtOH (1% final concentration in assay) in medium supplemented with 10% FBS. 
Cells were incubated in a humidified atmosphere of 5% CO2 in air, at 37 °C for 2-3 
h prior to the Day 0 reading. Cell density evaluation was performed by addition of 20 
µL of MTS/PES reagent and the plate was incubated at 37 °C for 2 h before the reading. 
For the T47-D cells the reading was repeated after further 2 h. Values are expressed as 
mean OD490nm of four replicates. Percentage of inhibitions are calculated arbitrarily 
setting to 100% growth the control with no inhibitor and expressing the percentage of 
inhibition as (mean ODinhib)/(mean ODno-inhib)x100 %. 
 
4.2.10.  Inhibition of ERRα  
The inhibition of ERRα mas measured using a kit commercially available from 
Invitrogen. The standard protocol supplied with the kit was modified only to obtain 
percentage of inhibition instead of curves of inhibition. The complete TR-FRET 
co-regulator Buffer G (complete Buffer G) was prepare by addition of a 1 M DTT 
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solution to TR-FRET co-regulator Buffer G to a final concentration of 5 mM. One 
quarter of the complete Buffer G was stored on ice while the rest was stored at rt. 
Step 1: in a 96 well plate was prepared a solution of 1 µL inverse agonist (10 mM 
stock solution), XCT790 (inhibitor control, 1 mM stock solution) or DMSO (no 
inhibitor control) and 49 µL of complete Buffer G. The solution from each well of the 
96 well plate, was transferred into four wells of a 384 well plate in 10-µL aliquots 
(Figure 120).  
 
Figure 120. Scheme of the transfer of aliquots from the 96 well plate to the 384 well plate. 
Step 2: in a 96 well plate, 25 µL of a solution of ERRα-LBD in ice cold complete 
Buffer G was prepared at 4X the final concentration recommended in the Certificate of 
Analysis. 5 µL aliquots were transferred from the 96 well plate into each well of the 384 
well plate (Figure 120). 
Step 3: in a 96 well plate, 25 µL of a solution of 2 µM Fluorescein-PDC1a and 20 
nM Tb anti-GST antibody in complete buffer G were prepared and 5 µL aliquots were 
transferred from the 96 well plate into each well of the 384 well plate (Figure 120). 
The plate was incubated at rt and read after 1 h and 2 h. Every point is reported as 
ratio of the emissions 520:495 nm and the percentage of activity (inverse agonism) is 
calculated as a ratio (520:495)inverse agonist / (520:495)XCT790 X 100. 
 
4.2.11.  OUTSOURCED ASSAYS 
4.2.11.1. 17β-HSD1 inhibition: whole cell radio-assay 
The assay was performed by the Ipsen laboratories. T-47D human breast cancer cells 
were incubated with 
3
H-E1 at a concentration of 2 nM per well, in a 24 well tissue 
culture plate, in the absence or presence of the inhibitor (0.1 nM – 10 µM). After 
incubation of the substrate with or without the inhibitor for 30 min at 37 ºC, the 
products were isolated from the mixture by extraction with diethyl ether (4 ml), using 
14
C-E2 (5000 dpm) to monitor procedural losses. Separation of 
3
H-E2 from the mixture 
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was achieved using TLC (DCM/EtOAc, 4:1 v/v) and the mass of 
3
H-E2 produced was 
calculated from the 
3




4.2.11.2. 17β-HSD1 inhibition: cell homogenate radio-assay 
The assay was performed by Prof. Lanisnik laboratories. Inhibition assays were 
carried out in 100 mM phosphate buffer (pH 6.5) in the presence of 1% acetonitrile as 
the cosolvent. The inhibitor stock solutions were prepared in DMSO, and diluted with 





H(N)] and unlabelled E1) in the reaction solution was 62 nM, and the 
concentration of NADPH was 100μM. The reactions were carried out at 37 °C and 
stopped with EtOAc after the time needed to convert approximately 30% of the 
substrate in a control assay (in the absence of inhibitor). Substrate and product were 
extracted from the reaction mixture in ethyl acetate. The organic phase was removed, 
the residue was dissolved in acetonitrile and separated on a reverse-phase (C18) HPLC 
column with a mobile phase of acetonitrile and water (45:55, v/v) at 1mL/min. The 
assays were performed in duplicates and the results are expressed as the mean values. 
Detection and quantification of the radioactive steroids were performed using a 
radioflow detector. 
 
4.2.11.3. Nuclear receptors screening from DiscoveRx 
Cell Handling 
1. PathHunter NHRPro cell lines were expanded from freezer stocks in T25 flasks 
according to standard procedures and maintained in selective growth media prior to the 
assay. 
2. Once it was established that the cells were healthy and growing normally, cells 
were passaged from flasks using cell dissociation reagent and seeded into white-walled, 
clear-bottom 384-well micro-plates for compound profiling. 
3. For profiling, cells were seeded at a density of 10,000 cells per well in a total 
volume of 20 µL and were allowed to adhere and recover overnight prior to compound 





1. Intermediate dilution of compound stocks were generated such that 5 µL of 5X 
compound could be added to each well with a final vehicle concentration of 1% of the 
total volume. 
2. For profiling compound in agonist mode, the cells were incubated in the presence 
of the compound at 37°C for 5 hours.  
Inverse Agonist Format 
1. Intermediate dilution of the compound stocks were generated such that 5 µL of 5X 
compound could be added to each well with a final vehicle concentration of 1% of the 
total volume. 
2. For profiling compound in inverse agonist mode, the cells were incubated in the 
presence of compound at 37°C for 5 hours. 
Antagonist Format 
1. For antagonist determination, cells were pre-incubated with antagonist followed 
by agonist challenge at the EC 80 concentration: 2.5 µL of 5X compound was added to 
the cells and incubated at 37˚C for 1 hour. 
3. 5 µL of 6X EC 80 agonist was added to the cells and incubated at 37˚C for 5 
hours. 
Signal Detection  
1. After appropriate compound incubation, assay signal was generated through a 
single addition of 12.5 or 15 µL (50% v/v) of PathHunter Detection reagent cocktail for 
agonist and antagonist assays, respectively, followed by a one hour incubation at room 
temperature. 
2. Microplates were read following signal generation with a PerkinElmer Envision 
TM instrument for chemiluminescent signal detection. 
Data Analysis 




2. For agonist mode assays, percentage activity was calculated using the following 
formula: % Activity =100% x (Mean RLU of test sample — mean RLU of vehicle 
control) / (mean MAX RLU control ligand — mean RLU of vehicle control). 
3. For antagonist mode assays, percentage inhibition was calculated using the 
following formula: % Inhibition =100% x (1 — (Mean RLU of test sample — mean 
RLU of vehicle control) / (mean RLU of EC 80 control — mean RLU of vehicle 
control)). 
 
4.2.11.4. Eli Lilly 





CGRP Receptor Antagonist 
Primary Assays: - hCGRP cAMP antagonist SK-N-MC cells SP (% Inhibition) 
- hCGRP cAMP antagonist SK-N-MC cells CRC (IC50) 
Secondary Assays: - hCGRP Arrestin CHO cells CRC (IC50) 
- hCGRP Bndg CRC SK-N-MC cells SP/CRC (%Efficacy) / 
(IC50) 
- Main peak confirmation HPLC 
Confirmatory Assay: - Profiling Biochemical Activity rCGRP (spleen homo), hCT, 
hAMY, hADM Bndg SPA CHO CRC (Ki) 
mGlu2 Receptor Allosteric Antagonist 
Primary Assays: - hmGlu2R cAMP/FLIPR antagonist AV12 cells SP (% Inhibition) 
- rMGluR2 Calcium Moblzn Antag SP (% Inhibition) 
- hmGlu2R cAMP antagonist AV12 cells CRC (IC50) 
- hmGlu3R cAMP antagonist AV12 cells CRC (IC50) 
Secondary Assay: - hmGlu6R cAMP antagonist AV12 cells CRC (IC50) 
Confirmatory Assay: - mGlu2R Binding CRC (Ki) 
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GPR 119 Receptor Agonist 
Primary Assays: - hGPR119 cAMP agonist HEK293 cells SP (% Efficacy) 
- hGPR119 cAMP agonist HEK293 cells CRC (EC50) 
- Parental cAMP agonist HEK293 cells CRC (EC50) 
Secondary Assays: - Profiling Biochemical Activity Kinase Panel (Ki, % Efficacy) 
- PDE profiling (IC50) 
- mGPR119 cAMP agonist HEK293 cells CRC (EC50) 
Confirmatory Assays: - mGPR119 cAMP agonist HEK293 cells CRC (EC50) 
- GLP-1 Secretion Glutag cells (EC50) 
- GLP-1 Secretion STC-1 cells (EC50) 
 
EZH2 Inhibitor (Enhancer of Zeste Homolog 2) 
Primary Assays: - hPRC2 (EZH2) H3 SPA ( % Inhibition) 
- hPRC2 (EZH2) H3 SPA CRC (IC50) 
Secondary assays: - hPRC2 MS MOA CRC (IC50) 
- Main peak confirmation HPLC 
Confirmatory Assays: - EZH2 H3K27Me3 Cell Based CRC (IC50) 





GLP – 1 Secretion 
Primary Assays: - GLP-1 Secretion NCI SP / CRC ( % Efficacy) / (EC50) 
- GLP-1 Secretion STC-1 CRC (EC50) 
- GLP-1 Secretion Glu-Tag CRC (EC50) 
Secondary assays: - Growth Hormone Secretion Primary Rat Hepatocyte SP / CRC 
(% Efficacy / EC50) 
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- Profiling Biochemical Activity - CSR Panel (Ki , % Efficacy) 
- PDE Profiling (IC50) 
- cAMP NCI (EC50) 
- Calcium Moblzn NCI (EC50) 
Confirmatory Assays: - GPCR Profiling (EC50) 
PCSK9 Synthesis Inhibition 
Primary assays: - HepG2 PCSK9 Secretion SP / CRC (% Efficacy / IC50) 
Secondary assays: - mLuciferase PCSK9 Reporter CRC (IC50) 
- Nuclear Hormone Receptor Assays (PPARa, LXRa/b, FXR) 
CRC (% Efficacy / EC50) 
- Profiling Biochemical Activity - Kinase panel (% Efficacy) 
- Cytolethality Primary Rat Hepatocyte CRC (IC50) 
Confirmatory assays: - HepG2 PCSK9 transcription CRC (EC50) 
Wnt Pathway Activator 
Primary Assays: - β-Catenin Levels C2C12 cells SP / CRC (% Efficacy / EC50) 
- Alkaline Phosphatase C2C12 cells CRC (EC50) 
Secondary assays: - G2/M Counterscreen – DNA Content HeLa cells (IC50) 
- Profiling Biochemical Activity - GSK-3 (% Efficacy) 
- Cytolethality Primary Rat Hepatocyte CRC (IC50) 
Confirmatory assays: - β-Catenin Levels hADSC cells CRC (EC50) 
- Alkaline Phosphatase hADSC cells CRC (EC50) 
 
4.2.11.5. National Cancer Institute of America (NCI) – Developmental 
Therapeutics Program (DTP) 
The screening is a two-stage process, beginning with the evaluation of all compounds 
against the 60 cell lines at a single dose of 10 µM. The output from the single dose 
screen is reported as a mean graph and is available for analysis by the COMPARE 
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program. Compounds which exhibit significant growth inhibition are evaluated against 
the 60 cell panel at five concentration levels. 
The human tumour cell lines of the cancer screening panel are grown in RPMI 1640 
medium containing 5% fetal bovine serum and 2 mM L-glutamine. For a typical 
screening experiment, cells are inoculated into 96 well microtiter plates in 100 µL at 
plating densities ranging from 5,000 to 40,000 cells/well depending on the doubling 
time of individual cell lines. After cell inoculation, the microtiter plates are incubated at 
37 °C, 5% CO2, 95% air and 100% relative humidity for 24 h prior to addition of 
experimental drugs.  
After 24 h, two plates of each cell line are fixed in situ with TCA, to represent a 
measurement of the cell population for each cell line at the time of drug addition (Tz). 
Experimental drugs are solubilised in dimethyl sulfoxide at 400-fold the desired final 
maximum test concentration and stored frozen prior to use. At the time of drug addition, 
an aliquot of frozen concentrate is thawed and diluted to twice the desired final 
maximum test concentration with complete medium containing 50 µg/ml gentamicin. 
Additional four, 10-fold or ½ log serial dilutions are made to provide a total of five drug 
concentrations plus control. Aliquots of 100 µl of these different drug dilutions are 
added to the appropriate microtiter wells already containing 100 µl of medium, resulting 
in the required final drug concentrations.  
Following drug addition, the plates are incubated for an additional 48 h at 37 °C, 5% 
CO2, 95% air, and 100% relative humidity. For adherent cells, the assay is terminated 
by the addition of cold TCA. Cells are fixed in situ by the gentle addition of 50 µl of 
cold 50% (w/v) TCA (final concentration, 10% TCA) and incubated for 60 minutes at 
4°C. The supernatant is discarded, and the plates are washed five times with tap water 
and air dried. Sulforhodamine B (SRB) solution (100 µl) at 0.4% (w/v) in 1% acetic 
acid is added to each well, and plates are incubated for 10 minutes at room temperature. 
After staining, unbound dye is removed by washing five times with 1% acetic acid and 
the plates are air dried. Bound stain is subsequently solubilised with 10 mM trizma 
base, and the absorbance is read on an automated plate reader at a wavelength of 515 
nm. For suspension cells, the methodology is the same except that the assay is 
terminated by fixing settled cells at the bottom of the wells by gently adding 50 µl of 80 
% TCA (final concentration, 16 % TCA). Using the seven absorbance measurements 
[time zero, (Tz), control growth, (C), and test growth in the presence of drug at the five 
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concentration levels (Ti)], the percentage growth is calculated at each of the drug 
concentrations levels. Percentage growth inhibition is calculated as:  
[(Ti-Tz)/(C-Tz)] x 100 for concentrations for which Ti>/=Tz  
[(Ti-Tz)/Tz] x 100 for concentrations for which Ti<Tz.  
Three dose response parameters are calculated for each experimental agent. Growth 
inhibition of 50% (GI50) is calculated from [(Ti-Tz)/(C-Tz)] x 100 = 50, which is the 
drug concentration resulting in a 50% reduction in the net protein increase (as measured 
by SRB staining) in control cells during the drug incubation. The drug concentration 
resulting in total growth inhibition (TGI) is calculated from Ti = Tz. The LC50 
(concentration of drug resulting in a 50% reduction in the measured protein at the end of 
the drug treatment as compared to that at the beginning) indicating a net loss of cells 
following treatment is calculated from [(Ti-Tz)/Tz] x 100 = -50. Values are calculated 
for each of these three parameters if the level of activity is reached; however, if the 
effect is not reached or is exceeded, the value for that parameter is expressed as greater 
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Crystallographic data for compound 164j 
 
Table 1.  Crystal data and structure refinement for 1. 
 Identification code k12farm2 
 Empirical formula C16 H16 Cl N O 
 Formula weight 273.75 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal system Orthorhombic 
 Space group P21cn 
 Unit cell dimensions a = 6.5270(1)Å alpha = 90
o
 
       b = 8.1320(1)Å beta = 90
o
 
       c = 26.0040(4)Å gamma = 90
o
 
 Volume 1380.23(3) Å
3
 
 Z 4 
 Density (calculated) 1.317 Mg/m
3
 
 Absorption coefficient 0.268 mm
-1
 
 F(000) 576 
 Crystal size 0.50 x 0.25 x 0.20 mm 
 Theta range for data collection 4.00 to 27.50
o
. 
 Index ranges -7<=h<=8; -10<=k<=10; -33<=l<=33 
 Reflections collected 15160 
 Independent reflections 3094 [R(int) = 0.0505] 
 Reflections observed (>2sigma) 2704 
 Data Completeness 0.997 
 Absorption correction Semi-empirical from equivalents 
 Max. and min. transmission 0.925 and 0.857 
 Refinement method Full-matrix least-squares on F
2
 
 Data / restraints / parameters 3094 / 1 / 174 
 Goodness-of-fit on F
2
 1.039 
 Final R indices [I>2sigma(I)] R1 = 0.0359   wR2 = 0.0827 
 R indices (all data) R1 = 0.0458  wR2 = 0.0879 
 Absolute structure parameter 0.14(6) 
 Largest diff. peak and hole 0.257 and -0.176 eÅ
-3
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 Table 2.  Atomic coordinates ( x 10
4





) for 1.U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor.                                                                                                                        
  Atom   x   y   z  U(eq) 
                                                                                                                          
Cl(1) 3053(1) 5163(1) -1546(1) 41(1) 
O(1) 7675(3) 10123(2) 2348(1) 42(1) 
N(2) 2499(2) 8397(2) 503(1) 30(1) 
C(1) 4054(3) 7980(2) 883(1) 30(1) 
C(3) 534(3) 8813(3) 739(1) 37(1) 
C(4) 695(3) 10373(3) 1050(1) 37(1) 
C(5) 2653(3) 11364(2) 1834(1) 34(1) 
C(6) 4335(3) 11363(2) 2156(1) 34(1) 
C(7) 5915(3) 10255(2) 2064(1) 32(1) 
C(8) 5772(3) 9167(2) 1652(1) 29(1) 
C(9) 4088(3) 9179(2) 1329(1) 27(1) 
C(10) 2493(3) 10289(2) 1414(1) 31(1) 
C(11) 8019(4) 11336(3) 2736(1) 45(1) 
C(1') 2552(3) 7537(2) 32(1) 27(1) 
C(2') 1147(3) 7910(2) -360(1) 31(1) 
C(3') 1269(3) 7144(2) -837(1) 32(1) 
C(4') 2804(3) 6016(2) -932(1) 31(1) 
C(5') 4196(3) 5611(2) -553(1) 33(1) 
C(6') 4056(3) 6347(2) -71(1) 31(1) 
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 Table 3.   Bond lengths [Å] and angles [
o
] for 1. 
  Cl(1)-C(4') 1.7505(17) O(1)-C(7) 1.371(2) 
O(1)-C(11) 1.427(2) N(2)-C(1') 1.410(2) 
N(2)-C(1) 1.457(2) N(2)-C(3) 1.461(3) 
C(1)-C(9) 1.515(2) C(3)-C(4) 1.509(3) 
C(4)-C(10) 1.509(3 C(5)-C(6) 1.381(3) 
C(5)-C(10) 1.403(3 C(6)-C(7) 1.390(3) 
C(7)-C(8) 1.392(3) C(8)-C(9) 1.382(3) 
C(9)-C(10) 1.396(3)  C(1')-C(2') 1.404(3) 
C(1')-C(6') 1.404(3) C(2')-C(3') 1.390(3) 
C(3')-C(4') 1.380(3) C(4')-C(5') 1.380(3) 
C(5')-C(6') 1.392(3)   
      
C(7)-O(1)-C(11) 117.28(16) C(1')-N(2)-C(1) 117.18(14) 
C(1')-N(2)-C(3) 120.04(15) C(1)-N(2)-C(3) 112.35(14) 
N(2)-C(1)-C(9) 112.34(15) N(2)-C(3)-C(4) 111.04(17) 
C(10)-C(4)-C(3) 110.71(17) C(6)-C(5)-C(10) 122.10(17) 
C(5)-C(6)-C(7) 118.99(17) O(1)-C(7)-C(6) 125.34(17) 
O(1)-C(7)-C(8) 114.96(17) C(6)-C(7)-C(8) 119.70(18) 
C(9)-C(8)-C(7) 121.04(18) C(8)-C(9)-C(10) 120.08(16) 
C(8)-C(9)-C(1) 118.13(16) C(10)-C(9)-C(1) 121.78(17) 
C(9)-C(10)-C(5) 118.09(17) C(9)-C(10)-C(4) 120.63(17) 
C(5)-C(10)-C(4) 121.23(17) C(2')-C(1')-C(6') 117.86(16) 
C(2')-C(1')-N(2) 120.47(16) C(6')-C(1')-N(2) 121.60(16) 
C(3')-C(2')-C(1') 120.89(18) C(4')-C(3')-C(2') 119.88(17) 
C(5')-C(4')-C(3') 120.61(17) C(5')-C(4')-Cl(1) 119.77(15) 
C(3')-C(4')-Cl(1) 119.55(14) C(4')-C(5')-C(6') 119.82(18) 
C(5')-C(6')-C(1') 120.88(17)   
   
Symmetry transformations used to generate equivalent atoms: 
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) for 1.  The anisotropic 






 U11 + ... + 2 h k a* b* 
U12 ] 
  Atom  U11  U22  U33  U23  U13  U12 
                                                                                                                            
Cl(1) 54(1) 39(1) 30(1) -5(1) -7(1) -1(1) 
O(1) 46(1) 40(1) 39(1) -9(1) -12(1) 5(1) 
N(2) 27(1) 35(1) 27(1) -1(1) -2(1) 4(1) 
C(1) 30(1) 31(1) 28(1) 0(1) 0(1) 6(1) 
C(3) 30(1) 40(1) 41(1) -6(1) 0(1) 2(1) 
C(4) 32(1) 39(1) 41(1) -1(1) 1(1) 9(1) 
C(5) 35(1) 33(1) 35(1) -2(1) 8(1) 7(1) 
C(6) 42(1) 30(1) 28(1) -2(1) 5(1) -3(1) 
C(7) 38(1) 30(1) 27(1) 3(1) -3(1) -1(1) 
C(8) 33(1) 25(1) 30(1) 1(1) 1(1) 2(1) 
C(9) 30(1) 25(1) 26(1) 3(1) 2(1) 0(1) 
C(10) 30(1) 33(1) 30(1) 3(1) 5(1) 0(1) 
C(11) 50(1) 46(1) 37(1) -10(1) -8(1) -1(1) 
C(1') 28(1) 26(1) 28(1) 4(1) 1(1) -3(1) 
C(2') 31(1) 30(1) 32(1) 4(1) -4(1) 1(1) 
C(3') 32(1) 33(1) 31(1) 6(1) -7(1) -3(1) 
C(4') 40(1) 27(1) 27(1) 1(1) -4(1) -6(1) 
C(5') 38(1) 28(1) 33(1) 1(1) -2(1) 5(1) 
C(6') 33(1) 30(1) 29(1) 2(1) -7(1) 4(1) 
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 Table 5.   Hydrogen coordinates ( x 10
4





) for 1. 
  Atom   x   y   z  U(eq) 
                                                                                                                         
H(1A) 5415 7972 716 36 
H(1B) 3785 6860 1016 36 
H(3A) 89 7900 964 45 
H(3B) -511 8957 467 45 
H(4A) 864 11323 817 45 
H(4B) -583 10535 1249 45 
H(5) 1570 12116 1900 41 
H(6) 4412 12108 2437 40 
H(8) 6848 8405 1591 35 
H(11A) 6978 11228 3005 67 
H(11B) 7932 12435 2582 67 
H(11C) 9382 11180 2885 67 
H(2') 99 8696 -298 37 
H(3') 298 7397 -1098 39 
H(5') 5247 4833 -621 40 





Table 6.   Dihedral angles [
o
] for 1. 
  Atom1  -  Atom2  -  Atom3  -  Atom4  Dihedral 
                                                                                                                          
C(1') - N(2) - C(1) - C(9) 169.66(16) 
C(3) - N(2) - C(1) - C(9) -45.3(2) 
C(1') - N(2) - C(3) - C(4) -150.30(17) 
C(1) - N(2) - C(3) - C(4) 65.8(2) 
N(2) - C(3) - C(4) - C(10) -50.4(2) 
C(10) - C(5) - C(6) - C(7) -0.5(3) 
C(11) - O(1) - C(7) - C(6) -7.3(3) 
C(11) - O(1) - C(7) - C(8) 172.51(17) 
C(5) - C(6) - C(7) - O(1) 179.54(18) 
C(5) - C(6) - C(7) - C(8) -0.2(3) 
O(1) - C(7) - C(8) - C(9) -179.27(16) 
C(6) - C(7) - C(8) - C(9) 0.5(3) 
C(7) - C(8) - C(9) - C(10) -0.1(3) 
C(7) - C(8) - C(9) - C(1) 178.97(17) 
N(2) - C(1) - C(9) - C(8) -164.97(16) 
N(2) - C(1) - C(9) - C(10) 14.1(2) 
C(8) - C(9) - C(10) - C(5) -0.5(3) 
C(1) - C(9) - C(10) - C(5) -179.61(17) 
C(8) - C(9) - C(10) - C(4) 176.98(17) 
C(1) - C(9) - C(10) - C(4) -2.1(3) 
C(6) - C(5) - C(10) - C(9) 0.8(3) 
C(6) - C(5) - C(10) - C(4) -176.66(18) 
C(3) - C(4) - C(10) - C(9) 19.8(3) 
C(3) - C(4) - C(10) - C(5) -162.75(18) 
C(1) - N(2) - C(1') - C(2') -177.84(17) 
C(3) - N(2) - C(1') - C(2') 39.9(2) 
C(1) - N(2) - C(1') - C(6') -1.0(2) 
C(3) - N(2) - C(1') - C(6') -143.22(19) 
C(6') - C(1') - C(2') - C(3') -1.2(3) 
N(2) - C(1') - C(2') - C(3') 175.83(17) 
C(1') - C(2') - C(3') - C(4') -0.8(3) 
C(2') - C(3') - C(4') - C(5') 1.5(3) 
C(2') - C(3') - C(4') - Cl(1) -175.66(15) 
C(3') - C(4') - C(5') - C(6') -0.1(3) 
Cl(1) - C(4') - C(5') - C(6') 177.04(15) 
C(4') - C(5') - C(6') - C(1') -2.0(3) 
C(2') - C(1') - C(6') - C(5') 2.6(3) 
N(2) - C(1') - C(6') - C(5') -174.40(18) 
 










163e 163i 163q 163s 170e 170i 170q 170s
Type of cancer Cell line
Leukemia CCRF-CEM 0,7 -2,3 4,2 -0,5 5,5 12,7 5,5 6,5
Leukemia HL-60(TB) 20,4 18,8 19,6 11,0 6,1 7,7 9,2 1,5
Leukemia K-562 22,2 19,7 22,2 15,6 18,0 23,9 4,1 5,2
Leukemia MOLT-4 8,4 19,1 9,6 11,5 11,5 32,4 5,9 11,9
Leukemia RPMI-8226 -6,2 3,4 8,0 5,3 2,9 5,8 2,7 7,5
Leukemia SR 8,2 9,0 6,8 2,2 2,7 6,6 0,8 2,4
Non-Small Cell Lung Cancer A549/ATCC 4,4 1,4 4,4 6,0 7,7 7,8 3,7
Non-Small Cell Lung Cancer EKVX -1,6 19,9 3,9 13,4 4,7 9,5 -0,6 -6,3
Non-Small Cell Lung Cancer HOP-62 -2,1 -13,1 -7,2 1,6 -3,5 -7,6 -9,8 -6,1
Non-Small Cell Lung Cancer HOP-92 27,2 9,4
Non-Small Cell Lung Cancer NCI-H226 -10,6 -2,7 -9,9 5,2 3,2 -2,0 1,0 -2,6
Non-Small Cell Lung Cancer NCI-H23 4,6 8,7 3,4 -1,4 -3,1 2,0 -5,7 11,8
Non-Small Cell Lung Cancer NCI-H322M -3,3 -4,0 1,6 6,0 0,8 13,9 1,8 -9,8
Non-Small Cell Lung Cancer NCI-H460 -14,5 -3,5 -6,0 -4,4 -1,8 -6,2 2,4 -2,5
Non-Small Cell Lung Cancer NCI-H522 13,5 34,7 27,7 23,1 18,5 20,3 6,7 31,7
Colon Cancer COLO 205 -17,6 -14,5 -10,9 -5,2 -15,9 -9,3 -10,1 -13,6
Colon Cancer HCC-2998
Colon Cancer HCT-116 -6,7 7,5 8,8 2,0 -5,0 -2,0 -1,5 9,4
Colon Cancer HCT-15 5,9 4,8 2,1 3,9 -2,4 6,3 -1,0 10,7
Colon Cancer HT29 19,4 25,6 23,0 19,7 -0,2 10,1 4,8 6,1
Colon Cancer KM12 1,0 -5,9 -10,2 7,8 3,5 -7,2 -5,7 12,1
Colon Cancer SW-620 0,9 6,5 3,1 8,0 -3,4 2,5 3,5 3,0
CNS Cancer SF-268 -5,1 -11,8 -6,7 1,9 -1,1 6,8 0,5 -2,1
CNS Cancer SF-295 9,2 0,7 6,7 1,5 4,8 -2,8 0,6 -4,1
CNS Cancer SF-539 -6,8 -5,8 -8,8 -11,8 -2,6 0,3 -12,8 25,7
CNS Cancer SNB-19 -1,2 2,4 -4,6 -3,2 6,0 0,8 6,5 -2,2
CNS Cancer SNB-75 8,4 7,5 -6,7 8,3 13,4 16,5 -0,5 5,5
CNS Cancer U251 4,6 24,4 2,9 3,0 2,0 0,4 -0,9
Melanoma LOX IMVI 4,2 0,1 -2,6 0,0 -0,9 1,5 1,0 11,1
Melanoma M14 1,8 -1,8 -3,2 -2,7 -6,0 -8,2 -8,0 2,6
Melanoma MALME-3M
Melanoma MDA-MB-435 9,6 3,8 6,4 0,4 -0,1 -1,9 0,3 5,5
Melanoma SK-MEL-2
Melanoma SK-MEL-28 -9,1 -7,8 -13,6 -3,5 -4,7 -11,2 -11,5 -8,8
Melanoma SK-MEL-5 -0,7 6,3 7,2 12,3 2,6 3,5 -0,3 15,9
Melanoma UACC-257 -3,8 -7,4 -3,1 -5,3 -7,9 -1,8 24,4 18,0
Melanoma UACC-62 3,4 13,1 7,9 6,7 0,9 8,0 0,1 16,4
Ovarian Cancer IGROV1 -4,7 -0,9 -2,0 -2,9 -11,6 0,4 -11,3 -16,0
Ovarian Cancer NCI/ADR-RES -1,9 -2,9 -2,6 1,1 -1,8 -7,6 -7,0 19,6
Ovarian Cancer OVCAR-3 -4,3 -12,0 -11,1 -0,2 -2,8 -13,4 -4,8 -15,2
Ovarian Cancer OVCAR-4 6,4 6,2 -2,1 5,0 -6,6 2,8 -4,7 6,6
Ovarian Cancer OVCAR-5 -3,9 10,0 5,4 2,6 -0,8 5,3 -11,7 -7,1
Ovarian Cancer OVCAR-8 -0,5 1,5 -1,5 -6,1 4,1 -8,3
Ovarian Cancer SK-OV-3 -4,7 -3,5 -1,2 4,9 -7,1 -11,3 -13,2 -8,5
Renal Cancer 786-0 7,7 12,7 9,5 9,3 7,0 11,4 7,7 11,8
Renal Cancer A498 9,0 34,0 28,6 28,8 3,5 39,1 6,6 12,4
Renal Cancer ACHN -12,3 -3,7 -5,8 -6,5 -3,0 -3,4 -20,8 70,3
Renal Cancer CAKI-1 4,5 9,2 18,7 12,4 2,3 3,0 -2,0 42,2
Renal Cancer RXF 393 -0,7 -0,9 -21,0 0,0 -1,9 10,5 -6,3 -3,5
Renal Cancer SN12C 6,6 2,1 -1,5 1,4 -1,2 0,8 -12,6 0,4
Renal Cancer TK-10 7,4 24,0 26,7 26,3 12,6 18,7 7,1 4,5
Renal Cancer UO-31 7,1 10,7 8,4 16,5 11,0 27,2 5,0 8,1
Prostate Cancer DU-145 -4,0 -2,1 -4,2 1,0 5,5 -5,9 -7,1 5,5
Prostate Cancer PC-3 -9,2 8,8 3,2 11,6 -1,6 10,1 -5,5 23,8
Breast Cancer BT-549 1,7 4,2 4,3 4,8 6,9 -4,1 -3,8 22,1
Breast Cancer HS 578T -6,6 -23,5 7,8 11,0 -7,5 0,0 -2,2 -30,3
Breast Cancer MCF7 -0,2 1,2 -0,7 -0,7 -10,8 -4,3 -5,2 -0,8
Breast Cancer MDA-MB-231/ATCC -2,6 -2,5 -13,8 -17,2 -14,1 4,2 -7,0 20,5
Breast Cancer MDA-MB-468 -10,6 -12,6 7,8 20,1 -4,9 2,5 7,1 1,0










163u 163w 163t 163v 164j 165j 163aa 143z
Type of cancer Cell line
Leukemia CCRF-CEM -9,9 0,7 72,8 1,5 16,0 2,3 -2,0
Leukemia HL-60(TB) 1,9 20,1 46,4 12,8 112,8 4,6 18,6 41,7
Leukemia K-562 13,7 30,5 51,7 39,6 47,1 7,8 20,0 24,8
Leukemia MOLT-4 12,4 13,0 71,0 12,2 130,7 20,6 11,8 12,6
Leukemia RPMI-8226 1,0 6,9 14,3 6,4 15,5 6,5 17,6 6,3
Leukemia SR 8,9 22,2 56,9 22,7 121,4 36,2 8,6 17,1
Non-Small Cell Lung Cancer A549/ATCC -1,5 8,8 1,9 6,1 9,8 1,4 8,5 -0,1
Non-Small Cell Lung Cancer EKVX
Non-Small Cell Lung Cancer HOP-62 -6,3 -6,0 -2,8 -20,3 -3,7 -0,4 -4,6 -9,2
Non-Small Cell Lung Cancer HOP-92 -3,1 9,4 -7,7 2,1 6,0 14,0 9,3 -20,1
Non-Small Cell Lung Cancer NCI-H226
Non-Small Cell Lung Cancer NCI-H23 2,8 -1,3 13,4 7,0 20,6 11,3 16,5 5,1
Non-Small Cell Lung Cancer NCI-H322M 2,1 5,7 1,3 -2,8 15,4 10,1 7,9 8,2
Non-Small Cell Lung Cancer NCI-H460 -5,4 -3,9 -1,7 -10,2 37,9 0,6 1,6 -13,4
Non-Small Cell Lung Cancer NCI-H522
Colon Cancer COLO 205 0,0 -11,2 -4,4 -9,0 -9,4 5,3 0,8 -18,3
Colon Cancer HCC-2998 -10,3 0,1 -0,7 2,2 -8,9 1,4 -0,9 2,6
Colon Cancer HCT-116 -9,4 -1,3 1,0 -9,0 92,6 6,5 8,7 -2,4
Colon Cancer HCT-15 1,1 1,1 9,3 7,4 35,2 1,8 12,0 4,5
Colon Cancer HT29 -9,2 4,6 14,1 4,7 94,5 5,6 17,2 4,9
Colon Cancer KM12 6,1 -4,5 24,2 4,5 131,2 7,5 9,8 3,0
Colon Cancer SW-620 -2,4 -4,5 16,9 -0,5 182,6 9,3 4,4 -7,6
CNS Cancer SF-268 6,0 5,2 -0,9 3,7 93,9 19,0 -3,3 -5,3
CNS Cancer SF-295 6,5 10,1 -36,1 7,7 9,8 4,0 14,1 22,0
CNS Cancer SF-539 5,3 12,1 2,7 6,9 1,2 9,8 1,8 0,0
CNS Cancer SNB-19
CNS Cancer SNB-75 -7,1 -18,0 -8,1 -11,3 -20,5 -11,1 -31,1 -3,8
CNS Cancer U251 -3,1 4,8 1,8 3,8 34,3 2,9 12,8 2,7
Melanoma LOX IMVI -5,9 -6,1 7,4 3,6 160,6 11,4 5,2 0,5
Melanoma M14 -6,8 -7,8 -0,8 -6,0 3,5 3,2 1,8 -16,7
Melanoma MALME-3M 6,1 9,8 4,9 -2,7 27,3 7,1 20,0 14,1
Melanoma MDA-MB-435 -1,7 -1,3 53,9 7,1 179,9 -0,9 1,3 2,4
Melanoma SK-MEL-2
Melanoma SK-MEL-28 -9,1 -8,0 1,2 -1,6 -9,7 -2,3 -10,0 -16,7
Melanoma SK-MEL-5 6,5 -9,0 4,8 8,3 -1,1 8,2 -8,8 1,4
Melanoma UACC-257 21,7 13,6 14,6 12,0 12,9 89,3 7,6 10,5
Melanoma UACC-62 2,3 8,0 9,5 8,7 14,1 13,7 19,1 9,3
Ovarian Cancer IGROV1 5,0 -0,6 -7,9 -4,6 12,1 14,6 15,8 8,0
Ovarian Cancer NCI/ADR-RES -2,6 -6,0 -6,1 -7,2 21,5 -1,5 -3,6 -9,4
Ovarian Cancer OVCAR-3 -6,1 -12,9 -1,4 -4,0 188,8 -1,3 0,3 -6,5
Ovarian Cancer OVCAR-4 -8,2 -10,6 -2,4 -8,0 1,4 1,0 4,5 0,8
Ovarian Cancer OVCAR-5 4,5 2,8 8,2 15,1 12,5 4,6 3,7 9,2
Ovarian Cancer OVCAR-8 0,0 -2,7 10,0 2,3 117,1 2,2 -12,0 -10,0
Ovarian Cancer SK-OV-3 2,1 -3,2 -4,0 -9,0 3,4 -0,8 10,9 -5,1
Renal Cancer 786-0 -2,6 1,1 -4,8 3,6 4,8 -1,3 2,0 -2,0
Renal Cancer A498 8,3 30,6 7,8 1,2 19,9 15,7 1,9 10,0
Renal Cancer ACHN -4,6 -4,5 2,4 -2,3 16,2 1,8 0,2 1,2
Renal Cancer CAKI-1 1,6 4,0 -2,4 13,8 28,5 17,3 9,3 4,7
Renal Cancer RXF 393 5,8 25,5 -29,1 3,6 4,0 -4,0 -5,4 -4,1
Renal Cancer SN12C 1,1 5,9 -7,4 -6,9 5,0 -5,6 5,6 4,5
Renal Cancer TK-10
Renal Cancer UO-31 20,9 6,9 27,9 13,9 42,7 21,7 26,4 21,1
Prostate Cancer DU-145 -4,9 -3,7 -1,5 -1,2 64,5 2,8 0,6 -4,6
Prostate Cancer PC-3 -2,8 -1,0 -5,8 3,1 100,0 16,9 9,3 6,0
Breast Cancer BT-549 -15,3 0,0 -3,6 -4,7 -3,2 7,6 -0,9 -14,7
Breast Cancer HS 578T -0,7 -10,1 -2,6 -5,3 -8,2 7,7 -4,7 -14,9
Breast Cancer MCF7 -1,8 -8,1 3,2 -19,9 -1,2 5,7 11,9 -3,4
Breast Cancer MDA-MB-231/ATCC 0,0 -7,1 15,7 3,7 11,1 11,4 7,7 -0,9
Breast Cancer MDA-MB-468 0,4 1,4 11,1 7,7 0,0 -3,8 21,3 3,9









166i 170aa 170t 170u 146x 167 168 166s
Type of cancer Cell line
Leukemia CCRF-CEM 5,2 68,1 22,6 -15,1 -0,3 -9,6 -1,2
Leukemia HL-60(TB) 25,6 62,4 36,1 -3,8 -2,3 6,5 17,8 21,8
Leukemia K-562 42,6 50,1 76,5 4,6 10,9 3,6 27,6 23,3
Leukemia MOLT-4 21,6 66,8 36,2 -5,1 1,8 -4,5 -8,4 8,9
Leukemia RPMI-8226 27,7 27,6 2,8 -10,3 -15,7 -1,5 3,7 8,1
Leukemia SR 20,7 29,9 35,5 -16,4 9,7 8,2 26,3 -1,7
Non-Small Cell Lung Cancer A549/ATCC 2,1 16,8 -3,5 -6,1 -1,0 1,4 2,6 -0,7
Non-Small Cell Lung Cancer EKVX
Non-Small Cell Lung Cancer HOP-62 -11,0 -2,9 -1,4 -10,2 -8,4 -9,1 -5,9 -3,3
Non-Small Cell Lung Cancer HOP-92 -1,9 16,3 -6,6 -24,9 -10,6 -9,5 6,8 -15,5
Non-Small Cell Lung Cancer NCI-H226
Non-Small Cell Lung Cancer NCI-H23 4,3 10,3 0,6 1,6 -3,0 -1,9 -5,0 7,0
Non-Small Cell Lung Cancer NCI-H322M 3,2 14,5 5,9 -11,9 6,9 0,1 2,1 6,8
Non-Small Cell Lung Cancer NCI-H460 -8,0 2,6 -6,2 -14,0 -12,6 -7,8 -7,3 -14,9
Non-Small Cell Lung Cancer NCI-H522
Colon Cancer COLO 205 -11,5 -20,6 -16,4 -11,0 -20,8 -18,6 -12,1 -13,5
Colon Cancer HCC-2998 -4,2 3,1 -13,9 -6,5 -10,7 2,3 -2,1 -17,6
Colon Cancer HCT-116 -4,4 17,8 -9,8 -10,6 -8,5 -5,4 -4,1 -2,7
Colon Cancer HCT-15 2,5 14,3 8,8 2,5 0,8 -3,1 0,9 0,8
Colon Cancer HT29 15,6 -2,5 5,2 -4,0 -1,4 8,0 3,4 2,7
Colon Cancer KM12 7,6 12,4 23,2 1,4 6,2 4,5 2,0 1,7
Colon Cancer SW-620 -0,9 5,3 2,0 -8,3 -14,0 -6,5 -6,3 -2,8
CNS Cancer SF-268 6,6 23,7 7,0 2,3 2,1 9,5 -6,9 -2,9
CNS Cancer SF-295 16,4 3,5 -37,6 1,3 13,6 13,4 27,4 10,1
CNS Cancer SF-539 6,7 9,2 1,5 5,2 -1,7 0,1 3,1 1,0
CNS Cancer SNB-19
CNS Cancer SNB-75 -6,9 -12,0 7,4 11,6 -6,2 -1,5 -1,6 -2,1
CNS Cancer U251 -1,6 9,6 0,4 -1,2 -1,9 -2,3 -0,3 0,1
Melanoma LOX IMVI -6,8 10,9 0,5 1,6 -7,7 -4,2 -5,7 -0,6
Melanoma M14 -19,9 -6,6 -2,2 -13,8 -12,3 -9,0 -9,3 -11,5
Melanoma MALME-3M 0,6 3,2 -0,7 -3,2 5,1 -8,0 10,5 18,3
Melanoma MDA-MB-435 4,6 6,2 83,3 -2,9 1,7 -5,3 5,5 -5,6
Melanoma SK-MEL-2
Melanoma SK-MEL-28 -11,0 -14,5 -6,4 -11,9 -11,4 -20,0 -3,4 -11,1
Melanoma SK-MEL-5 10,4 -1,1 33,4 -9,2 1,4 8,0 26,0 6,8
Melanoma UACC-257 2,9 16,9 -4,0 3,3 7,7 3,1 8,6 9,9
Melanoma UACC-62 9,0 27,2 4,0 -1,0 -3,5 -1,6 8,4 7,1
Ovarian Cancer IGROV1 4,8 15,3 -20,6 -7,2 -0,8 -10,2 0,0 7,9
Ovarian Cancer NCI/ADR-RES -10,0 2,8 -3,7 -6,5 -8,8 -7,4 -4,0 -9,5
Ovarian Cancer OVCAR-3 1,4 -3,0 -7,1 -2,7 -11,1 -9,6 -11,1 -3,2
Ovarian Cancer OVCAR-4 -5,3 2,9 -2,4 -11,9 -6,0 -4,7 -9,9 -6,0
Ovarian Cancer OVCAR-5 8,8 -0,3 2,0 4,9 -3,5 1,4 6,9 2,8
Ovarian Cancer OVCAR-8 -0,2 8,1 -3,7 -0,4 -6,8 -4,0 -20,0 -5,7
Ovarian Cancer SK-OV-3 -9,4 -6,7 0,1 -3,6 -0,6 -3,8 0,1 3,9
Renal Cancer 786-0 -2,8 4,2 -6,9 -5,7 -0,5 -3,1 1,6 -9,4
Renal Cancer A498 -20,3 -3,1 -0,3 -15,5 11,7 10,4 29,4 3,9
Renal Cancer ACHN -6,9 6,9 3,5 1,2 -2,1 -4,8 -3,9 -4,9
Renal Cancer CAKI-1 9,9 8,0 8,6 6,7 12,3 -1,5 8,5 0,6
Renal Cancer RXF 393 7,6 -35,5 -18,6 -0,5 -15,3 -6,2 0,9 -10,5
Renal Cancer SN12C 1,9 14,3 -3,8 -10,6 -1,4 -8,3 0,9 0,6
Renal Cancer TK-10
Renal Cancer UO-31 30,2 43,6 31,1 20,9 16,4 -0,1 15,1 17,4
Prostate Cancer DU-145 -2,8 2,5 -10,0 -8,4 -6,9 0,5 -7,7 -10,0
Prostate Cancer PC-3 9,0 32,8 -10,9 -7,5 -2,6 6,1 7,7 8,5
Breast Cancer BT-549 -15,1 6,3 -4,2 -8,7 -10,8 2,6 -1,2 -14,9
Breast Cancer HS 578T -9,7 -2,4 4,6 -1,1 -21,2 -20,2 -15,4 -2,1
Breast Cancer MCF7 -0,4 13,6 -0,3 -10,1 -1,0 -9,8 -8,5 -0,8
Breast Cancer MDA-MB-231/ATCC -10,4 29,4 19,6 1,4 0,4 -11,3 -5,1 -5,6
Breast Cancer MDA-MB-468 1,3 16,1 -2,4 -2,2 2,9 1,9 5,9 0,8










176x 181a 181e 181f 191a 191e 190f 181c
Type of cancer Cell line
Leukemia CCRF-CEM 21,0 2,6 4,1 7,9 13,6 1,3 30,0
Leukemia HL-60(TB) 91,0 1,5 34,6 36,3 6,0 -8,6 -0,5 50,0
Leukemia K-562 69,0 28,9 51,3 45,5 24,8 12,2 33,0 34,6
Leukemia MOLT-4 31,6 20,0 35,0 25,7 32,7 17,1 13,7 24,9
Leukemia RPMI-8226 73,6 21,7 48,5 44,5 -6,3 5,2 10,2 65,3
Leukemia SR 54,1 19,5 27,6 33,9 14,0 7,8 30,5 36,3
Non-Small Cell Lung Cancer A549/ATCC 31,6 7,7 0,2 -0,8 3,5 4,2 0,1 12,2
Non-Small Cell Lung Cancer EKVX
Non-Small Cell Lung Cancer HOP-62 12,8 -1,6 -1,4 -10,3 -8,6 2,1 2,6 12,7
Non-Small Cell Lung Cancer HOP-92 48,3 19,6 1,2 2,1 1,3 6,8 8,5 37,0
Non-Small Cell Lung Cancer NCI-H226 14,0
Non-Small Cell Lung Cancer NCI-H23 29,0 7,5 11,5 12,0 0,8 0,8 9,4 36,9
Non-Small Cell Lung Cancer NCI-H322M 3,2 -0,7 -3,6 -6,0 13,3 -0,3 8,6 5,4
Non-Small Cell Lung Cancer NCI-H460 12,3 -2,4 2,6 -7,0 -9,2 -4,3 4,4 7,0
Non-Small Cell Lung Cancer NCI-H522 35,6
Colon Cancer COLO 205 46,8 -18,3 -4,0 -3,6 -12,5 -9,3 1,7 5,9
Colon Cancer HCC-2998 37,6 6,8 1,9 1,4 -10,2 -12,5 -1,1 4,5
Colon Cancer HCT-116 21,7 3,8 12,2 19,8 3,8 5,1 27,2 27,0
Colon Cancer HCT-15 -0,9 -1,4 9,1 7,0 3,5 -6,1 9,0 -0,8
Colon Cancer HT29 12,5 9,5 24,0 25,6 -15,2 4,9 20,6 14,5
Colon Cancer KM12 73,8 -0,7 3,4 8,1 7,9 5,3 27,0 21,7
Colon Cancer SW-620 22,2 -0,8 0,0 5,1 -12,0 -10,5 9,6 10,0
CNS Cancer SF-268 43,6 1,5 4,0 6,8 16,2 16,9 9,2 12,7
CNS Cancer SF-295 25,8 6,0 -40,5 6,4 3,1 7,5 1,2 5,7
CNS Cancer SF-539 16,1 3,3 0,3 4,0 5,1 4,4 9,8 9,5
CNS Cancer SNB-19 11,0
CNS Cancer SNB-75 8,6 -3,0 -4,6 -0,9 2,7 3,8 1,2 10,2
CNS Cancer U251 37,9 4,6 4,3 1,0 1,0 0,5 6,7 32,9
Melanoma LOX IMVI 9,7 -4,6 -0,6 -1,9 2,7 0,2 2,2 14,3
Melanoma M14 5,6 -11,3 -1,6 -7,9 -8,2 -2,4 6,0 2,7
Melanoma MALME-3M 42,6 12,7 11,8 5,3 10,5 -4,3 7,5 21,3
Melanoma MDA-MB-435 59,2 -6,5 8,7 2,0 -1,0 -10,9 -5,2 17,3
Melanoma SK-MEL-2 10,6
Melanoma SK-MEL-28 18,5 -17,9 -6,5 -9,4 -10,5 -10,9 -4,6 2,4
Melanoma SK-MEL-5 6,2 -2,3 6,9 2,5 3,7 104,6 0,2 4,2
Melanoma UACC-257 11,0 1,7 6,5 14,3 -3,5 10,6
Melanoma UACC-62 48,5 15,8 8,1 12,3 5,3 -2,4 14,3 22,8
Ovarian Cancer IGROV1 36,8 6,8 -15,8 8,1 3,7 5,8 24,0 23,8
Ovarian Cancer NCI/ADR-RES -8,1 -6,2 -8,5 -8,0 -7,5 -3,2 -4,3 3,7
Ovarian Cancer OVCAR-3 66,9 -7,5 7,0 17,3 -7,8 5,9 14,3 31,3
Ovarian Cancer OVCAR-4 31,7 0,1 1,5 0,5 3,4 5,4 7,3 11,0
Ovarian Cancer OVCAR-5 8,6 0,1 4,4 11,2 1,1 0,0 4,5 6,1
Ovarian Cancer OVCAR-8 22,6 0,1 -3,4 -6,2 -2,9 -1,4 -19,6 23,3
Ovarian Cancer SK-OV-3 4,7 4,8 -1,9 -3,8 -11,9 -1,6 3,4 -7,2
Renal Cancer 786-0 2,4 -0,2 -2,7 3,2 -1,0 -5,5 2,4 1,2
Renal Cancer A498 2,8 6,7 -2,9 4,2 11,3 2,5 -18,9 19,4
Renal Cancer ACHN -0,8 -6,3 -1,0 -5,1 1,5 -0,2 3,6 0,5
Renal Cancer CAKI-1 3,4 0,4 1,1 7,7 20,7 -0,5 9,4 9,0
Renal Cancer RXF 393 18,0 -15,1 -14,2 14,3 -8,2 -7,7 -3,1 -7,7
Renal Cancer SN12C 28,9 0,7 -2,1 -7,5 2,5 -5,6 2,0 13,3
Renal Cancer TK-10 -7,8
Renal Cancer UO-31 21,7 9,2 32,0 19,5 35,0 12,9 25,3 39,0
Prostate Cancer DU-145 25,8 -3,1 -2,6 -2,7 -0,1 3,6 -3,4 0,1
Prostate Cancer PC-3 62,9 2,1 -7,3 7,1 4,1 12,7 6,6 36,6
Breast Cancer BT-549 46,0 -3,6 -7,5 -10,2 -5,0 -4,0 -14,9 36,3
Breast Cancer HS 578T 13,3 -8,4 -5,4 -10,5 -4,9 -10,6 -9,5
Breast Cancer MCF7 52,2 -6,5 -16,2 -13,1 -19,3 -19,5 1,9 5,0
Breast Cancer MDA-MB-231/ATCC 12,9 -6,7 -8,5 -5,4 10,7 -10,0 4,5 19,9
Breast Cancer MDA-MB-468 94,4 -2,2 6,8 22,1 -1,4 -6,7 0,2 59,6









191b 191c 191f 173 174 143n 175n 145h
Type of cancer Cell line
Leukemia CCRF-CEM 15,7 14,0 5,8 21,6 30,1 -0,3 116,7 -4,3
Leukemia HL-60(TB) 19,4 19,9 21,8 15,0 9,7 9,5 103,0 15,7
Leukemia K-562 15,1 11,7 15,7 18,2 -4,1 84,3 -4,8
Leukemia MOLT-4 28,4 27,4 3,6 10,0 1,9 109,3 1,4
Leukemia RPMI-8226 32,0 29,4 14,3 11,1 -0,3 -6,0 109,5 -4,4
Leukemia SR 31,2 22,2 6,9 -21,7 5,5 -6,8 125,4 11,1
Non-Small Cell Lung Cancer A549/ATCC 27,1 22,1 22,4 11,1 12,1 7,9 37,5 12,6
Non-Small Cell Lung Cancer EKVX
Non-Small Cell Lung Cancer HOP-62 5,4 2,4 -5,5 6,8 -1,1 -10,0 26,9 -1,0
Non-Small Cell Lung Cancer HOP-92 32,7 33,4 10,9 5,6 110,9 -7,6
Non-Small Cell Lung Cancer NCI-H226 -1,5 15,7 8,5 1,5 7,7 0,0 26,0 8,7
Non-Small Cell Lung Cancer NCI-H23 18,0 30,4 15,9 13,2 2,2 3,5 109,9 5,7
Non-Small Cell Lung Cancer NCI-H322M -0,4 6,2 8,3 10,2 -5,4 0,0 21,1 0,1
Non-Small Cell Lung Cancer NCI-H460 3,5 6,0 2,1 -0,8 -3,8 -3,1 87,5 1,4
Non-Small Cell Lung Cancer NCI-H522 10,2 24,5 20,6 61,4 31,0 4,0 90,1 1,3
Colon Cancer COLO 205 -7,3 -7,8 -5,4 -6,2 -2,6 -2,9 90,0 1,0
Colon Cancer HCC-2998 -6,1 -1,7 4,0 4,5 -2,2 -1,5 55,5 -7,6
Colon Cancer HCT-116 14,8 28,4 15,1 -6,0 14,0 6,5 159,8 9,5
Colon Cancer HCT-15 4,6 17,3 14,9 15,9 6,1 1,7 147,0 0,3
Colon Cancer HT29 3,2 21,3 8,8 3,3 9,7 -15,0 149,5 3,3
Colon Cancer KM12 18,2 12,5 6,6 20,3 -5,4 -15,1 142,0 -0,6
Colon Cancer SW-620 11,2 4,7 3,2 0,1 0,8 -6,0 171,4 2,7
CNS Cancer SF-268 8,5 5,1 6,8 5,1 28,9 -17,0 95,5 -5,3
CNS Cancer SF-295 -3,4 0,7 5,6 5,2 1,1 0,1 23,7 -3,8
CNS Cancer SF-539 7,4 9,6 0,0 15,5 10,0 -11,8 33,4 -4,1
CNS Cancer SNB-19 -11,9 -10,6 -0,2 3,6 0,2 -1,2 30,5 8,7
CNS Cancer SNB-75 16,0 25,2 11,9 13,2 39,6 1,0 47,8 12,7
CNS Cancer U251 7,1 9,3 9,0 9,0 11,7 11,5 153,5 8,7
Melanoma LOX IMVI 8,0 9,8 10,3 20,0 5,5 3,1 154,2 4,7
Melanoma M14 6,9 5,3 0,9 0,6 9,8 -6,8 73,2 -6,9
Melanoma MALME-3M 6,0 19,8 8,9 8,8 0,8 -6,1 128,8 1,8
Melanoma MDA-MB-435 10,4 10,4 2,8 7,3 8,5 -0,3 167,7 -7,1
Melanoma SK-MEL-2 6,3 1,6 -9,0 0,5 0,3 -9,1 56,9 -8,7
Melanoma SK-MEL-28 5,5 1,7 -10,1 -6,0 3,6 -18,3 122,2 -8,8
Melanoma SK-MEL-5 -3,3 8,6 -1,6 2,6 -0,4 -4,0 7,5 0,9
Melanoma UACC-257 6,3 1,6 -9,0 0,5 0,3 -9,1 56,9 -8,7
Melanoma UACC-62 17,1 10,4 17,4 7,9 -2,3 5,4 77,7 1,3
Ovarian Cancer IGROV1 -14,9 8,0 3,6 -15,5 -3,4 -1,8 81,9 0,6
Ovarian Cancer NCI/ADR-RES 6,0 12,5 4,1 7,7 0,3 -0,2 70,0 -4,5
Ovarian Cancer OVCAR-3 2,3 0,0 -1,6 -7,2 25,3 -18,9 176,0 -13,3
Ovarian Cancer OVCAR-4 19,8 26,3 8,2 2,9 16,4 -9,0 67,9 4,3
Ovarian Cancer OVCAR-5 2,5 1,2 -5,8 -6,3 -13,6 -26,4 25,2 -9,7
Ovarian Cancer OVCAR-8 8,1 13,4 4,4 4,6 7,3 2,6 119,2 2,2
Ovarian Cancer SK-OV-3 -16,3 -10,0 -22,9 -9,1 -0,7 0,3 35,2 -10,9
Renal Cancer 786-0 5,0 5,6 5,4 -0,7 13,1 2,9 68,1 -12,2
Renal Cancer A498 11,6 0,7 32,6 21,5 40,7 45,2 73,4 25,1
Renal Cancer ACHN -10,6 1,4 4,1 14,8 12,0 -5,5 109,7 -1,7
Renal Cancer CAKI-1 7,0 2,9 7,3 16,8 4,0 -0,1 87,0 6,3
Renal Cancer RXF 393 0,4 7,8 5,9 0,9 60,2 -1,2 56,7 -14,3
Renal Cancer SN12C 11,1 19,4 6,9 2,1 18,2 -3,5 88,2 5,6
Renal Cancer TK-10 9,6 -20,4 -1,3 -3,3 -3,1 -13,4 64,0 -21,0
Renal Cancer UO-31 27,6 39,7 32,9 23,3 30,3 27,2 99,7 38,3
Prostate Cancer DU-145 -9,5 -1,0 -3,3 11,3 -3,8 -10,2 39,8 -9,0
Prostate Cancer PC-3 22,4 25,3 18,2 12,7 3,1 -0,4 89,0 18,9
Breast Cancer BT-549 7,4 -10,5 -7,6 13,2 -0,5 -2,2 99,2 -0,4
Breast Cancer HS 578T 9,5 4,9 -13,8 9,9 -2,5 61,9 -4,9
Breast Cancer MCF7 -8,2 15,2 -2,0 8,5 15,2 3,5 75,3 13,9
Breast Cancer MDA-MB-231/ATCC 9,5 9,2 3,7 16,7 15,9 -0,7 122,8 14,7
Breast Cancer MDA-MB-468 -7,7 -6,1 9,1 10,7 12,9 11,2 104,2 -21,4











144h 181g 181i 228a 228b 228d 234e 234a
Type of cancer Cell line
Leukemia CCRF-CEM 8,6 13,8 26,9 9,5 11,6 9,0 15,6 5,7
Leukemia HL-60(TB) 12,3 23,8 57,0 20,1 25,2 17,3 15,8 23,6
Leukemia K-562 -3,9 30,5 -9,1 14,0 7,3 22,3 3,3
Leukemia MOLT-4 -3,3 6,2 -1,6 3,8 2,7 4,5 3,9
Leukemia RPMI-8226 -2,0 23,2 53,6 6,3 8,5 4,9 6,8 11,0
Leukemia SR 7,4 12,3 51,3 0,4 13,6 7,9 5,7 1,7
Non-Small Cell Lung Cancer A549/ATCC 19,2 12,9 10,6 3,3 10,0 9,2 6,5 12,5
Non-Small Cell Lung Cancer EKVX
Non-Small Cell Lung Cancer HOP-62 -1,6 1,6 -18,6 -7,0 -5,7 -6,1 -11,0 -16,3
Non-Small Cell Lung Cancer HOP-92 11,0 11,5 22,2 5,5 24,8 -1,3
Non-Small Cell Lung Cancer NCI-H226 12,8 13,9 10,1 7,5 3,8 6,8 1,5 -0,7
Non-Small Cell Lung Cancer NCI-H23 6,8 17,8 35,6 15,6 6,8 18,7 4,0 8,8
Non-Small Cell Lung Cancer NCI-H322M 1,0 -11,5 -10,6 -18,7 -10,2 -3,5 0,8 -2,7
Non-Small Cell Lung Cancer NCI-H460 -3,1 0,0 2,6 -4,0 -1,6 -2,6 -3,5 -1,2
Non-Small Cell Lung Cancer NCI-H522 10,8 20,5 29,5 25,7 25,7 10,2 19,2 10,9
Colon Cancer COLO 205 -4,7 4,4 16,1 -4,6 2,3 5,1 -2,3 -1,0
Colon Cancer HCC-2998 -11,5 -4,9 15,4 -3,4 -3,5 -0,9 -8,9 -6,2
Colon Cancer HCT-116 5,8 30,2 32,8 15,8 25,6 28,8 -3,3 15,7
Colon Cancer HCT-15 4,1 13,6 14,4 17,2 13,8 15,8 3,0 11,3
Colon Cancer HT29 -10,7 36,8 36,1 23,2 25,2 21,4 -2,7 19,5
Colon Cancer KM12 -6,8 -4,6 5,3 -2,2 -9,0 -5,8 -2,5 -7,7
Colon Cancer SW-620 -3,6 10,1 10,6 3,8 0,3 5,7 -0,9 3,4
CNS Cancer SF-268 -10,2 -1,2 0,4 -7,5 -2,0 -17,4 3,4 -12,2
CNS Cancer SF-295 -7,1 -3,4 5,7 3,7 2,1 -1,0 0,7 -2,1
CNS Cancer SF-539 -2,2 1,3 2,0 -6,6 -3,8 -6,1 2,4 -5,1
CNS Cancer SNB-19 4,3 6,6 5,8 4,4 0,4 -0,1 -4,7 7,5
CNS Cancer SNB-75 12,0 14,2 15,0 -2,9 15,1 4,9 16,2 -2,2
CNS Cancer U251 11,6 7,0 15,2 1,4 10,4 7,6 5,8 7,9
Melanoma LOX IMVI 7,2 11,0 7,5 0,4 -0,1 3,3 2,6 -1,6
Melanoma M14 0,3 -1,1 4,1 -3,7 6,5 -1,7 -10,3 -12,4
Melanoma MALME-3M 0,1 5,1 14,3 6,5 -3,1 -3,7 1,5 6,2
Melanoma MDA-MB-435 0,6 -1,2 12,4 7,1 2,1 4,7 -0,5 4,8
Melanoma SK-MEL-2 -7,9 -4,5 -4,8 -1,5 5,9 0,7 -12,9 -2,0
Melanoma SK-MEL-28 -8,9 -5,6 -0,8 -0,7 -9,9 -16,1 -3,8 -3,8
Melanoma SK-MEL-5 2,2 -2,2 1,3 5,4 12,1
Melanoma UACC-257 -7,9 -4,5 -4,8 -1,5 5,9 0,7 -12,9 -2,0
Melanoma UACC-62 1,7 5,0 18,8 13,5 12,3 23,3 4,4 16,7
Ovarian Cancer IGROV1 -10,4 9,0 12,4 -19,1 -1,2 14,5 -11,6 -1,7
Ovarian Cancer NCI/ADR-RES -5,7 5,0 3,4 -6,7 -0,9 2,6 -5,1 -5,1
Ovarian Cancer OVCAR-3 -15,0 -19,1 1,8 -17,2 -14,1 -25,4 -12,6 -20,1
Ovarian Cancer OVCAR-4 -9,4 8,6 40,2 13,7 21,3 17,2 7,4 9,6
Ovarian Cancer OVCAR-5 11,7 2,7 -4,7 -2,2 -1,0 -20,1 -4,4 -12,1
Ovarian Cancer OVCAR-8 4,7 6,8 3,9 -1,0 3,8 0,6 0,8 7,4
Ovarian Cancer SK-OV-3 0,4 0,7 -3,7 -8,8 -9,1 7,2 -10,6 -16,0
Renal Cancer 786-0 -12,2 -4,1 5,2 0,4 6,0 0,7 -2,6 -1,6
Renal Cancer A498 31,2 38,2 44,5 44,5 26,9 31,3 15,0 40,4
Renal Cancer ACHN 5,7 3,6 -5,3 -9,4 1,8 -2,8 5,1 -4,2
Renal Cancer CAKI-1 9,5 9,6 -0,6 0,1 4,6 12,3 3,3 -1,8
Renal Cancer RXF 393 -3,9 -1,5 18,8 -4,6 -0,2 -3,9 -2,1 -16,2
Renal Cancer SN12C 12,3 7,0 0,8 -2,9 1,0 8,9 6,6 7,7
Renal Cancer TK-10 -8,3 -16,0 -7,2 -4,3 -13,2 -23,4 -12,7 5,8
Renal Cancer UO-31 19,2 28,2 15,7 14,4 12,8 9,4 15,4 15,5
Prostate Cancer DU-145 -12,7 -12,4 -4,7 -7,2 -7,0 -14,7 -10,1 -9,4
Prostate Cancer PC-3 19,1 7,6 12,2 6,7 4,8 -1,2 10,5 22,3
Breast Cancer BT-549 -4,9 -14,1 12,5 -9,8 -12,4 -2,2 -18,4 -2,4
Breast Cancer HS 578T -3,9 -2,4 0,6 -12,1 -10,3 -4,5 -3,3 -0,1
Breast Cancer MCF7 13,9 4,0 7,6 3,1 4,0 9,6 -6,8 -1,0
Breast Cancer MDA-MB-231/ATCC 19,7 8,1 0,1 -2,9 5,4 1,4 -5,5 5,7
Breast Cancer MDA-MB-468 2,9 0,7 79,4 -9,1 1,4 12,0 -22,7 -2,5




234c 234f 234h 191g 191h 191i
Type of cancer Cell line
Leukemia CCRF-CEM 3,6 6,5 -3,4 5,5 7,5 -3,9
Leukemia HL-60(TB) 14,1 16,5 20,4 9,7 11,3 21,5
Leukemia K-562 12,2 -11,4 2,2 5,0 -1,6
Leukemia MOLT-4 3,3 -3,2 1,9 7,3 -15,2
Leukemia RPMI-8226 3,5 26,3 0,0 17,9 17,7 9,3
Leukemia SR -13,9 8,1 -14,9 -12,6 -20,2 -26,8
Non-Small Cell Lung Cancer A549/ATCC 20,1 22,3 -1,4 7,6 24,8 10,9
Non-Small Cell Lung Cancer EKVX
Non-Small Cell Lung Cancer HOP-62 -8,3 -19,7 -15,4 -8,1 -14,0 -13,4
Non-Small Cell Lung Cancer HOP-92 12,5 11,4 5,5 28,5
Non-Small Cell Lung Cancer NCI-H226 12,6 -1,1 3,0 11,7 9,5 -0,5
Non-Small Cell Lung Cancer NCI-H23 2,7 9,3 -6,8 19,4 11,8 1,6
Non-Small Cell Lung Cancer NCI-H322M 1,6 9,8 -9,1 -5,5 -4,3 -8,5
Non-Small Cell Lung Cancer NCI-H460 -2,8 0,5 -2,7 8,0 3,4 -2,8
Non-Small Cell Lung Cancer NCI-H522 2,8 12,0 -5,0 29,9 15,3 1,3
Colon Cancer COLO 205 -11,1 -14,9 -17,0 -8,2 -5,2 -7,0
Colon Cancer HCC-2998 -17,1 -8,5 -4,6 -7,0 -4,6 -9,4
Colon Cancer HCT-116 2,2 13,2 -6,1 40,0 18,1 1,5
Colon Cancer HCT-15 3,3 7,7 2,7 17,4 9,4 -2,0
Colon Cancer HT29 -8,7 -4,1 -7,7 20,6 8,1 -23,2
Colon Cancer KM12 -7,6 -2,3 -14,0 5,8 2,3 -18,7
Colon Cancer SW-620 -4,5 3,9 -2,1 12,0 2,4 -10,2
CNS Cancer SF-268 -9,4 -8,2 -12,9 0,3 -4,0 -23,7
CNS Cancer SF-295 -11,8 -5,8 1,2 -0,9 -2,8 -4,6
CNS Cancer SF-539 -1,3 -1,3 -0,3 -3,2 -2,5 -11,2
CNS Cancer SNB-19 4,5 3,1 -4,3 0,5 2,2 7,9
CNS Cancer SNB-75 13,6 12,9 -0,4 20,3 24,4 14,7
CNS Cancer U251 17,9 1,5 -0,3 1,9 12,6 3,5
Melanoma LOX IMVI 4,5 5,6 0,5 5,2 0,7 0,0
Melanoma M14 -9,4 -6,8 -14,1 -6,9 6,6 -14,0
Melanoma MALME-3M -17,3 -6,1 -10,2 7,8 4,6 -11,6
Melanoma MDA-MB-435 1,0 5,8 -3,3 6,0 9,1 1,9
Melanoma SK-MEL-2 -15,3 -6,3 -24,4 1,3 0,7 -18,2
Melanoma SK-MEL-28 -5,6 -3,2 -17,3 -2,8 -3,7 -31,9
Melanoma SK-MEL-5
Melanoma UACC-257 -15,3 -6,3 -24,4 1,3 0,7 -18,2
Melanoma UACC-62 12,7 15,9 0,2 27,2 29,6 8,6
Ovarian Cancer IGROV1 -11,6 -5,5 -18,1 -9,4 3,0 -20,0
Ovarian Cancer NCI/ADR-RES -8,5 8,2 -8,7 -0,2 1,9 1,1
Ovarian Cancer OVCAR-3 -17,5 -17,7 -19,6 -9,2 -8,2 -17,3
Ovarian Cancer OVCAR-4 -4,3 10,1 -2,1 20,2 5,4 -17,1
Ovarian Cancer OVCAR-5 -7,1 -5,0 -2,2 10,8 10,2 -20,5
Ovarian Cancer OVCAR-8 4,9 9,3 2,1 3,4 11,0 7,8
Ovarian Cancer SK-OV-3 -12,8 -16,2 -27,0 -22,0 -17,9 -14,9
Renal Cancer 786-0 -6,2 -2,5 -8,9 -3,0 3,8 -15,5
Renal Cancer A498 30,6 9,5 29,9 18,2 27,9 58,7
Renal Cancer ACHN 4,9 4,9 -0,9 0,1 8,1 -1,8
Renal Cancer CAKI-1 13,8 8,7 -1,5 18,6 13,7 -4,8
Renal Cancer RXF 393 -2,1 0,6 0,7 -3,4 7,8 -20,3
Renal Cancer SN12C 8,7 1,2 -7,1 11,0 8,4 8,8
Renal Cancer TK-10 -24,9 -11,9 -14,4 -6,1 -20,2 -49,4
Renal Cancer UO-31 12,2 18,9 9,6 26,6 20,1 12,1
Prostate Cancer DU-145 -18,6 -16,7 -13,8 -6,6 -10,9 -18,0
Prostate Cancer PC-3 19,0 13,8 1,4 16,0 21,1 12,4
Breast Cancer BT-549 -12,2 -11,4 -29,1 -16,7 -19,0 2,1
Breast Cancer HS 578T -6,2 2,5 0,4 -2,1 2,5 -11,8
Breast Cancer MCF7 10,0 4,7 -8,0 -3,5 -8,0 -10,0
Breast Cancer MDA-MB-231/ATCC 13,4 10,8 -8,5 16,0 9,1 9,3
Breast Cancer MDA-MB-468 11,3 -4,1 2,9 -17,3 7,2 15,9
Breast Cancer T-47D 25,5 22,9 -0,3 26,7 30,9 -3,7
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Graphic data by cancer type 
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